[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$foBTRnE8ZmO_0NMcBtfCW0k0yd9h8iIyWAYEm-ZJ9884":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":88,"rows":95},"Fred Hutchinson Cancer Center",[4],532,false,94,29,178757,75,184,[14,17,20,23,26,28,31,34],{"name":15,"count":16},"Leukemia",59,{"name":18,"count":19},"Recurrent Adult Acute Myeloid Leukemia",37,{"name":21,"count":22},"Recurrent Small Lymphocytic Lymphoma",36,{"name":24,"count":25},"Recurrent Mantle Cell Lymphoma",35,{"name":27,"count":25},"Refractory Chronic Lymphocytic Leukemia",{"name":29,"count":30},"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",34,{"name":32,"count":33},"Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",33,{"name":35,"count":36},"Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",31,[38,43,48,53,58,63,68,73,78,83],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT03277729","A Phase I\u002FII Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas","2024-03-29","Chimeric Antigen Receptor T-Cell Therapy",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT04195945","CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients","2025-06-06","Liposome-encapsulated Daunorubicin-Cytarabine",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT03399773","Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes","2025-06-09","Dilanubicel",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT05359211","NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","2025-09-04","Cyclophosphamide",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT04198922","Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease","2025-09-29","Acalabrutinib",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT04572815","Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant","2025-10-27","Ustekinumab",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT00716066","Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases","2025-12-30","Anti-Thymocyte Globulin",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT04994808","Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia","2026-01-22","Clofarabine",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT06752694","Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia","2026-01-23","Cyclosporine",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT04384692","Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis","2026-04-03","Busulfan",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,138,167,185,203,653,1641,2336,2746,3080,3244,3481,3603,3637,3826,3982,4135,4190,4255,4301,4331,4373,4555,4589,4625,4710,4732,4767,4789,4811,4833,4864,4886,4908,4961,5049,5139,5182,5230,5256,5278,5304,5326,5344,5370,5394,5419,5437,5460,5478,5498,5516,5541,5559,5583,5601,5619,5637,5655,5673,5691,5714,5732,5750,5768,5858,5912,5934,5956,5974,5992,6010,6041,6059,6077,6095,6139,6164,6188,6213,6231,6249,6267,6285,6311,6334,6368,6411,6445,6478,6504,6530,6571,6600,6639,6667,6696,6714,6740,6758,6782,6800,6818,6836,6854,6904,6958,7006,7051,7090,7124,7154,7184,7220,7260,7290,7342,7368,7396,7434,7461,7483,7505,7527,7555,7582,7609,7631,7653,7675,7700,7725,7747,7769,7791,7813,7846,7873,7895,7932,7954,7976,7994,8018,8036,8060,8083,8106,8130,8154,8172,8198,8222,8240,8258,8276,8300,8318,8342,8360,8378,8396,8414,8432,8456,8478,8496,8517,8535,8553,8571,8589,8607,8625,8647,8665,8690,8713,8731,8760,8778,8803,8821,8848,8866,8901,8919,8937,8961,8979,8997,9015,9040,9067,9093,9111,9134,9152,9170,9188,9206,9224,9242,9260,9286,9304,9322,9340,9358,9382,9400,9418,9443,9469,9487,9505,9523,9541,9559,9577,9595,9613,9638,9656,9674,9698,9716,9734,9752,9775,9815,9833,9862,9886,10007,10098,10168,10206,10232,10258,10284,10306,10333,10359,10377,10402,10420,10438,10456,10480,10498,10520,10543,10565],{"intervention":97,"totalTrials":98,"cells":99},"Recombinant Human Papillomavirus Nonavalent Vaccine",2,{"EARLY_PHASE1":100,"PHASE1":103,"PHASE2":105,"PHASE3":107,"PHASE4":109,"NA":136},{"trials":101,"activeCount":102},[],0,{"trials":104,"activeCount":102},[],{"trials":106,"activeCount":102},[],{"trials":108,"activeCount":102},[],{"trials":110,"activeCount":135,"soonestReadout":128},[111,123],{"nctId":112,"briefTitle":113,"status":114,"phases":115,"primaryCompletion":116,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":122},"NCT03051516","HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions","TERMINATED",[93],"2022-12-31","2017-08-01",188,[120,121],"High Grade Anal Canal Intraepithelial Neoplasia","High Grade Vulvar Squamous Intraepithelial Lesion",[97],{"nctId":124,"briefTitle":125,"status":126,"phases":127,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":134},"NCT04265950","Establishing Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV, OPTIMO Trial","ACTIVE_NOT_RECRUITING",[93],"2026-06-30","2026-07-31","2022-03-10",97,[133],"HIV Infection",[97],1,{"trials":137,"activeCount":102},[],{"intervention":139,"totalTrials":135,"cells":140},"Nicotine Gum",{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":163,"NA":165},{"trials":142,"activeCount":102},[],{"trials":144,"activeCount":102},[],{"trials":146,"activeCount":102},[],{"trials":148,"activeCount":135,"soonestReadout":154},[149],{"nctId":150,"briefTitle":151,"status":152,"phases":153,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":160},"NCT06811038","iCanQuit Smoking Cessation Among Hispanic Adults","NOT_YET_RECRUITING",[92],"2029-07-01","2030-07-01","2026-06-01",854,[159],"Cigarette Smoking-Related Carcinoma",[139,161,162],"Nicotine Patch","Nicotine Lozenge",{"trials":164,"activeCount":102},[],{"trials":166,"activeCount":102},[],{"intervention":161,"totalTrials":135,"cells":168},{"EARLY_PHASE1":169,"PHASE1":171,"PHASE2":173,"PHASE3":175,"PHASE4":181,"NA":183},{"trials":170,"activeCount":102},[],{"trials":172,"activeCount":102},[],{"trials":174,"activeCount":102},[],{"trials":176,"activeCount":135,"soonestReadout":154},[177],{"nctId":150,"briefTitle":151,"status":152,"phases":178,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":179,"interventions":180},[92],[159],[139,161,162],{"trials":182,"activeCount":102},[],{"trials":184,"activeCount":102},[],{"intervention":162,"totalTrials":135,"cells":186},{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":191,"PHASE3":193,"PHASE4":199,"NA":201},{"trials":188,"activeCount":102},[],{"trials":190,"activeCount":102},[],{"trials":192,"activeCount":102},[],{"trials":194,"activeCount":135,"soonestReadout":154},[195],{"nctId":150,"briefTitle":151,"status":152,"phases":196,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":197,"interventions":198},[92],[159],[139,161,162],{"trials":200,"activeCount":102},[],{"trials":202,"activeCount":102},[],{"intervention":204,"totalTrials":36,"cells":205},"Fludarabine",{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":396,"PHASE3":637,"PHASE4":639,"NA":641},{"trials":207,"activeCount":102},[],{"trials":209,"activeCount":395,"soonestReadout":56},[210,223,237,265,276,289,302,313,327,340,353,379],{"nctId":211,"briefTitle":212,"status":213,"phases":214,"primaryCompletion":215,"completion":215,"start":216,"enrollment":217,"conditions":218,"interventions":220},"NCT06043713","Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations","RECRUITING",[90],"2028-01-01","2023-12-15",24,[219],"Metastatic Malignant Solid Neoplasm",[221,57,204,222],"Bendamustine","T-cell Receptor-engineered T-cells",{"nctId":224,"briefTitle":225,"status":226,"phases":227,"primaryCompletion":228,"completion":229,"start":230,"enrollment":231,"conditions":232,"interventions":235},"NCT03338972","Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma","COMPLETED",[90],"2021-05-03","2022-03-22","2017-11-29",28,[233,234],"Recurrent Plasma Cell Myeloma","Refractory Plasma Cell Myeloma",[236,57,204],"Autologous Anti-BCMA-CAR-expressing CD4+\u002FCD8+ T-lymphocytes FCARH143",{"nctId":238,"briefTitle":239,"status":114,"phases":240,"primaryCompletion":241,"completion":242,"start":243,"enrollment":244,"conditions":245,"interventions":263},"NCT03103971","huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia",[90],"2023-03-23","2024-03-23","2017-11-03",55,[246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262],"Recurrent Adult Acute Lymphoblastic Leukemia","Recurrent B-Cell Non-Hodgkin Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma","Refractory Adult Acute Lymphoblastic Leukemia","Refractory B-Cell Non-Hodgkin Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma","Recurrent Transformed Non-Hodgkin Lymphoma","Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","Recurrent B Acute Lymphoblastic Leukemia","Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Refractory B Acute Lymphoblastic Leukemia","Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",[264,57,204],"Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+\u002FCD8+ T-lymphocytes",{"nctId":266,"briefTitle":267,"status":114,"phases":268,"primaryCompletion":269,"completion":269,"start":270,"enrollment":271,"conditions":272,"interventions":273},"NCT03502577","BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma",[90],"2022-04-20","2018-05-23",19,[233,234],[274,57,204,275],"BCMA-specific CAR-expressing T Lymphocytes","Gamma-Secretase Inhibitor LY3039478",{"nctId":277,"briefTitle":278,"status":213,"phases":279,"primaryCompletion":280,"completion":280,"start":281,"enrollment":282,"conditions":283,"interventions":287},"NCT07227571","Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent\u002FProgressive Osteosarcoma, FIERCe Trial",[90],"2044-01-31","2026-01-16",30,[284,285,286],"Advanced Osteosarcoma","Recurrent Osteosarcoma","Refractory Osteosarcoma",[288,204,57],"FH FOLR1 ST CAR T-cells",{"nctId":290,"briefTitle":291,"status":213,"phases":292,"primaryCompletion":293,"completion":294,"start":295,"enrollment":296,"conditions":297,"interventions":300},"NCT06609928","FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia",[90],"2027-10-01","2042-10-01","2025-02-24",12,[298,299],"Recurrent Childhood Acute Myeloid Leukemia","Refractory Childhood Acute Myeloid Leukemia",[301,57,204],"FOLR1 CAR T-cells",{"nctId":303,"briefTitle":304,"status":114,"phases":305,"primaryCompletion":306,"completion":306,"start":307,"enrollment":282,"conditions":308,"interventions":310},"NCT02706405","JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",[90],"2021-05-28","2016-11-15",[309,248,249,252,256,253],"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",[311,57,312,204],"Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+\u002FCD8+ Central Memory T-lymphocytes JCAR014","Durvalumab",{"nctId":54,"briefTitle":55,"status":126,"phases":314,"primaryCompletion":56,"completion":315,"start":316,"enrollment":317,"conditions":318,"interventions":324},[90],"2026-09-04","2022-12-08",27,[248,258,319,320,252,261,321,322,323],"Recurrent Grade 3b Follicular Lymphoma","Recurrent Primary Mediastinal Large B-Cell Lymphoma","Refractory Grade 3b Follicular Lymphoma","Refractory Primary Mediastinal Large B-Cell Lymphoma","Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma",[57,204,325,326],"Lisocabtagene Maraleucel","Polymer-conjugated IL-15 Receptor Agonist NKTR-255",{"nctId":328,"briefTitle":329,"status":114,"phases":330,"primaryCompletion":331,"completion":332,"start":333,"enrollment":334,"conditions":335,"interventions":338},"NCT04809766","Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma",[90],"2024-10-24","2025-01-15","2021-12-14",9,[336,337],"Metastatic Pancreatic Ductal Adenocarcinoma","Stage IV Pancreatic Cancer AJCC v8",[339,57,204,221],"Autologous Mesothelin-specific TCR-T Cells",{"nctId":341,"briefTitle":342,"status":343,"phases":344,"primaryCompletion":345,"completion":345,"start":346,"enrollment":102,"conditions":347,"interventions":352},"NCT06094842","Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer","WITHDRAWN",[90],"2028-03-15","2025-04-15",[348,349,350,351],"Prostate Carcinoma","Prostate Small Cell Neuroendocrine Carcinoma","Stage III Prostate Cancer AJCC v8","Stage IV Prostate Cancer AJCC v8",[221,57,204,222],{"nctId":354,"briefTitle":355,"status":213,"phases":356,"primaryCompletion":357,"completion":358,"start":359,"enrollment":360,"conditions":361,"interventions":371},"NCT04375631","CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia",[90],"2027-02-28","2027-03-17","2020-12-03",120,[362,363,364,365,366,367,368,369,370],"Recurrent Acute Myeloid Leukemia","Recurrent Chronic Myelomonocytic Leukemia","Recurrent Myelodysplastic Syndrome","Refractory Acute Myeloid Leukemia","Refractory Chronic Myelomonocytic Leukemia","Refractory Mixed Phenotype Acute Leukemia","Refractory Myelodysplastic Syndrome","Refractory Acute Leukemia of Ambiguous Lineage","Refractory Acute Undifferentiated Leukemia",[372,57,82,373,374,375,376,377,378,204,373],"Cladribine","Cytarabine","Filgrastim","Mitoxantrone","Mycophenolate Mofetil","Mycophenolate Sodium","Idarubicin",{"nctId":380,"briefTitle":381,"status":126,"phases":382,"primaryCompletion":383,"completion":384,"start":385,"enrollment":282,"conditions":386,"interventions":392},"NCT06034470","Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms",[90],"2026-05-31","2029-05-31","2023-12-18",[387,388,389,390,391],"Acute Myeloid Leukemia","Mixed Phenotype Acute Leukemia","Myelodysplastic Syndrome","Myelodysplastic\u002FMyeloproliferative Neoplasm","Myeloproliferative Neoplasm",[373,204,393,378,394],"Granulocyte Colony-Stimulating Factor","Pivekimab Sunirine",6,{"trials":397,"activeCount":636,"soonestReadout":51},[398,410,419,443,456,469,482,492,506,519,540,548,565,582,592,604,613,622],{"nctId":49,"briefTitle":50,"status":126,"phases":399,"primaryCompletion":51,"completion":400,"start":401,"enrollment":36,"conditions":402,"interventions":408},[91],"2027-04-02","2022-05-10",[403,404,405,406,389,407],"Acute Biphenotypic Leukemia","Acute Lymphoblastic Leukemia","Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Hematopoietic and Lymphoid Cell Neoplasm","Myelodysplastic Syndrome With Excess Blasts",[52,57,204,409],"Thiotepa",{"nctId":79,"briefTitle":80,"status":126,"phases":411,"primaryCompletion":81,"completion":412,"start":413,"enrollment":135,"conditions":414,"interventions":416},[91],"2026-10-15","2025-09-25",[415],"Aplastic Anemia",[82,204,393,376,417,418],"Ruxolitinib","Sirolimus",{"nctId":420,"briefTitle":421,"status":213,"phases":422,"primaryCompletion":423,"completion":423,"start":424,"enrollment":425,"conditions":426,"interventions":440},"NCT03779854","Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant",[91],"2028-12-31","2019-08-29",68,[403,427,428,404,429,430,431,432,433,388,434,435,436,437,438,439,391],"Acute Leukemia","Acute Leukemia of Ambiguous Lineage","Acute Undifferentiated Leukemia","Allogeneic Hematopoietic Stem Cell Transplantation Recipient","Blastic Plasmacytoid Dendritic Cell Neoplasm","Blasts Under 25 Percent of Bone Marrow Nucleated Cells","Blasts Under 5 Percent of Bone Marrow Nucleated Cells","Myelodysplastic Syndrome With Excess Blasts-1","Myelodysplastic Syndrome\u002FAcute Myeloid Leukemia","Burkitt Leukemia","Chronic Monocytic Leukemia","Lymphoblastic Lymphoma","Mast Cell Leukemia",[409,204,57,87,441,442],"Tacrolimus","Methotrexate",{"nctId":444,"briefTitle":445,"status":213,"phases":446,"primaryCompletion":447,"completion":448,"start":449,"enrollment":22,"conditions":450,"interventions":454},"NCT06928662","Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse",[90,91],"2028-03-09","2028-11-29","2025-09-23",[387,429,388,362,451,363,452,364,365,370,366,367,368,453],"Recurrent Acute Undifferentiated Leukemia","Recurrent Mixed Phenotype Acute Leukemia","Secondary Acute Myeloid Leukemia",[455,373,374,204,378],"Decitabine",{"nctId":457,"briefTitle":458,"status":213,"phases":459,"primaryCompletion":460,"completion":461,"start":462,"enrollment":463,"conditions":464,"interventions":466},"NCT07046078","Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer",[91],"2027-06-30","2029-06-30","2025-09-26",20,[428,387,465,389],"Chronic Myelomonocytic Leukemia",[373,204,378,467,468],"Peripheral Blood Stem Cell","Recombinant Granulocyte Colony-Stimulating Factor",{"nctId":470,"briefTitle":471,"status":226,"phases":472,"primaryCompletion":473,"start":474,"enrollment":475,"conditions":476,"interventions":478},"NCT00004485","Bone Marrow Transplantation in Treating Children With Sickle Cell Disease",[90,91],"2007-08","1999-12",50,[477],"Sickle Cell Anemia",[479,480,481],"cyclosporine","fludarabine","mycophenolate mofetil",{"nctId":84,"briefTitle":85,"status":126,"phases":483,"primaryCompletion":86,"completion":484,"start":485,"enrollment":486,"conditions":487,"interventions":490},[91],"2030-04-23","2020-12-18",53,[488,489],"Primary Myelofibrosis","Secondary Myelofibrosis",[87,57,204,491,442,376,417,441],"Melphalan",{"nctId":493,"briefTitle":494,"status":114,"phases":495,"primaryCompletion":496,"completion":496,"start":497,"enrollment":463,"conditions":498,"interventions":503},"NCT01434472","High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma",[91],"2020-05-06","2011-11-16",[499,500,247,501,251,502,252],"Post-Transplant Lymphoproliferative Disorder","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Burkitt Lymphoma","Refractory Burkitt Lymphoma",[82,504,376,505,204],"Fludarabine Phosphate","Rituximab",{"nctId":507,"briefTitle":508,"status":114,"phases":509,"primaryCompletion":510,"completion":511,"start":512,"enrollment":135,"conditions":513,"interventions":518},"NCT04083170","Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers",[91],"2022-11-11","2022-11-30","2022-10-06",[514,404,515,387,405,406,133,389,407,516,517],"Acute Erythroid Leukemia","Acute Megakaryoblastic Leukemia","Non-Hodgkin Lymphoma","Refractory Anemia",[204,57,409,52],{"nctId":520,"briefTitle":521,"status":226,"phases":522,"primaryCompletion":523,"completion":524,"start":525,"enrollment":526,"conditions":527,"interventions":539},"NCT00719888","Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease",[91],"2023-12-22","2024-12-19","2005-11-18",135,[403,404,387,528,529,405,530,531,438,532,533,534,389,535,516,536,537,517,538],"Burkitt Lymphoma","Chronic Lymphocytic Leukemia","Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Follicular Lymphoma","Lymphoplasmacytic Lymphoma","Mantle Cell Lymphoma","Marginal Zone Lymphoma","Myelofibrosis","Plasma Cell Myeloma","Prolymphocytic Leukemia","Small Lymphocytic Lymphoma",[57,82,204,376,409],{"nctId":74,"briefTitle":75,"status":126,"phases":541,"primaryCompletion":76,"completion":542,"start":543,"enrollment":544,"conditions":545,"interventions":546},[91],"2026-07-16","2023-08-11",23,[387,389],[77,204,547],"Treosulfan",{"nctId":549,"briefTitle":550,"status":213,"phases":551,"primaryCompletion":552,"completion":553,"start":554,"enrollment":555,"conditions":556,"interventions":564},"NCT04195633","Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies",[91],"2027-04-15","2029-03-12","2021-01-25",60,[427,404,387,557,558,528,559,465,560,438,532,533,388,389,537,27,561,562,563],"Adult Diffuse Large Cell Lymphoma","Anaplastic Large Cell Lymphoma","Chronic Myeloid Leukemia, BCR-ABL1 Positive","Hodgkin Lymphoma","Refractory Follicular Lymphoma","Refractory Marginal Zone Lymphoma","Refractory Small Lymphocytic Lymphoma",[57,82,374,204,376,377,547],{"nctId":566,"briefTitle":567,"status":114,"phases":568,"primaryCompletion":569,"completion":570,"start":571,"enrollment":135,"conditions":572,"interventions":578},"NCT04639245","Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer",[90,91],"2022-08-04","2022-08-16","2021-07-19",[573,574,219,575,576,577],"Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Lung Non-Small Cell Carcinoma","Metastatic Triple-Negative Breast Carcinoma","Metastatic Urothelial Carcinoma","Stage IV Lung Cancer AJCC v8",[579,57,204,580,581],"Atezolizumab","MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells","PD1 Inhibitor",{"nctId":583,"briefTitle":584,"status":213,"phases":585,"primaryCompletion":586,"completion":587,"start":588,"enrollment":360,"conditions":589,"interventions":590},"NCT03970096","Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)",[91],"2027-12-31","2029-12-31","2019-11-19",[427,404,387,389,391],[409,204,441,591,442,57,467,82,418,87],"Allogeneic CD34+-enriched and CD45RA-depleted PBSCs",{"nctId":593,"briefTitle":594,"status":213,"phases":595,"primaryCompletion":596,"completion":596,"start":597,"enrollment":598,"conditions":599,"interventions":601},"NCT04083183","Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases",[90,91],"2028-01-09","2020-06-16",40,[600],"Non-Malignant Neoplasm",[602,204,57,603,376,418],"Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10","Lapine T-Lymphocyte Immune Globulin",{"nctId":605,"briefTitle":606,"status":213,"phases":607,"primaryCompletion":608,"completion":608,"start":609,"enrollment":475,"conditions":610,"interventions":611},"NCT07228624","Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome\u002FMyeloproliferative Neoplasm Overlap Syndromes",[91],"2030-09-01","2026-02-04",[390,488,489],[417,87,57,204,612,491,442,441],"JAK Inhibitor",{"nctId":614,"briefTitle":615,"status":213,"phases":616,"primaryCompletion":617,"completion":618,"start":619,"enrollment":463,"conditions":620,"interventions":621},"NCT04370301","Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis",[91],"2027-04-30","2029-08-31","2021-02-09",[488,489],[57,612,204,468,491,376,441],{"nctId":623,"briefTitle":624,"status":213,"phases":625,"primaryCompletion":626,"completion":626,"start":627,"enrollment":628,"conditions":629,"interventions":633},"NCT06236139","Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer",[90,91],"2027-03-30","2024-11-26",48,[630,631,632],"Castration-Resistant Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8",[634,57,635,204],"Anti-STEAP1 CAR T-cells","Enzalutamide",13,{"trials":638,"activeCount":102},[],{"trials":640,"activeCount":102},[],{"trials":642,"activeCount":102},[643],{"nctId":644,"briefTitle":645,"status":226,"phases":646,"primaryCompletion":647,"start":648,"enrollment":463,"conditions":649,"interventions":652},"NCT00010361","Study of Total Body Irradiation and Fludarabine Followed By Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation in Combination With Cyclosporine and Mycophenolate Mofetil in Patients With Inherited Disorders",[94],"2007-04","2000-11",[650,651],"Metabolism, Inborn Errors","Granulomatous Disease, Chronic",[479,480,481],{"intervention":57,"totalTrials":654,"cells":655},90,{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":987,"PHASE3":1582,"PHASE4":1616,"NA":1618},{"trials":657,"activeCount":102},[],{"trials":659,"activeCount":395,"soonestReadout":56},[660,664,676,693,703,723,742,764,768,782,786,790,801,812,816,825,835,839,843,853,857,861,938,949,961,965,969,978],{"nctId":211,"briefTitle":212,"status":213,"phases":661,"primaryCompletion":215,"completion":215,"start":216,"enrollment":217,"conditions":662,"interventions":663},[90],[219],[221,57,204,222],{"nctId":665,"briefTitle":666,"status":226,"phases":667,"start":668,"enrollment":25,"conditions":669,"interventions":671},"NCT00014755","Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis",[90],"1997-12",[670],"Multiple Sclerosis",[672,673,674,675],"anti-thymocyte globulin","cyclophosphamide","filgrastim","prednisone",{"nctId":677,"briefTitle":678,"status":114,"phases":679,"primaryCompletion":680,"completion":680,"start":681,"enrollment":682,"conditions":683,"interventions":686},"NCT03864419","Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda",[90],"2023-07-26","2019-10-24",18,[528,684,685],"KSHV-associated Multicentric Castleman Disease","Diffuse Large B-Cell Lymphoma",[687,57,688,442,689,690,691,692,505],"Rituximab and Hyaluronidase Human","Vincristine","Doxorubicin","Doxorubicin Hydrochloride","Prednisone","Etoposide",{"nctId":694,"briefTitle":695,"status":152,"phases":696,"primaryCompletion":586,"completion":423,"start":156,"enrollment":282,"conditions":697,"interventions":701},"NCT04579523","²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma",[90],[698,699,700],"Multiple Myeloma","Recurrent Multiple Myeloma","Refractory Multiple Myeloma",[702,57,504],"Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10",{"nctId":704,"briefTitle":705,"status":226,"phases":706,"primaryCompletion":707,"start":473,"enrollment":296,"conditions":708,"interventions":717},"NCT00621452","Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma",[90],"2014-01",[709,710,711,712,713,24,714,21,27,715,716],"B-cell Chronic Lymphocytic Leukemia","Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","Nodal Marginal Zone B-cell Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Marginal Zone Lymphoma","Splenic Marginal Zone Lymphoma","Waldenström Macroglobulinemia",[718,673,719,720,721,722],"therapeutic autologous lymphocytes","aldesleukin","polymerase chain reaction","gene rearrangement analysis","genetically engineered lymphocyte therapy",{"nctId":724,"briefTitle":725,"status":114,"phases":726,"primaryCompletion":727,"completion":728,"start":729,"enrollment":730,"conditions":731,"interventions":741},"NCT00589316","Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome",[90],"2016-10-01","2021-10-01","2007-10-05",26,[732,733,734,735,465,736,737,738,739,740],"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","Adult Acute Lymphoblastic Leukemia in Remission","Adult Acute Myeloid Leukemia in Remission","CD45-Positive Neoplastic Cells Present","Previously Treated Myelodysplastic Syndrome","Refractory Anemia With Excess Blasts","Refractory Anemia With Ring Sideroblasts","Refractory Cytopenia With Multilineage Dysplasia","Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts",[57,504,376,441],{"nctId":743,"briefTitle":744,"status":226,"phases":745,"primaryCompletion":746,"completion":746,"start":747,"enrollment":748,"conditions":749,"interventions":762},"NCT03518242","Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer",[90],"2022-05-04","2018-06-06",100,[750,751,752,753,754,755,756,757,758,759,760,761],"Breast Cancer Female","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Invasive Breast Carcinoma","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8",[57,442,763],"Capecitabine",{"nctId":224,"briefTitle":225,"status":226,"phases":765,"primaryCompletion":228,"completion":229,"start":230,"enrollment":231,"conditions":766,"interventions":767},[90],[233,234],[236,57,204],{"nctId":769,"briefTitle":770,"status":343,"phases":771,"primaryCompletion":772,"completion":772,"start":773,"enrollment":102,"conditions":774,"interventions":780},"NCT02059850","NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid\u002FRound Cell Liposarcoma",[90],"2016-01","2014-07",[775,776,777,778,779],"Adult Synovial Sarcoma","Myxoid\u002FRound Cell Liposarcoma","Recurrent Adult Soft Tissue Sarcoma","Stage III Adult Soft Tissue Sarcoma","Stage IV Adult Soft Tissue Sarcoma",[781,57],"Autologous NY-ESO-1-specific CD8-positive T Lymphocytes",{"nctId":238,"briefTitle":239,"status":114,"phases":783,"primaryCompletion":241,"completion":242,"start":243,"enrollment":244,"conditions":784,"interventions":785},[90],[246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262],[264,57,204],{"nctId":266,"briefTitle":267,"status":114,"phases":787,"primaryCompletion":269,"completion":269,"start":270,"enrollment":271,"conditions":788,"interventions":789},[90],[233,234],[274,57,204,275],{"nctId":791,"briefTitle":792,"status":226,"phases":793,"completion":794,"start":795,"conditions":796,"interventions":800},"NCT00062140","Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer",[90],"2004-07","2003-04",[15,797,798,799],"Lymphoma","Myelodysplastic Syndromes","Myelodysplastic\u002FMyeloproliferative Diseases",[673],{"nctId":802,"briefTitle":803,"status":226,"phases":804,"primaryCompletion":805,"start":806,"enrollment":807,"conditions":808,"interventions":810},"NCT00317876","Cyclophosphamide in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Fanconi's Anemia",[90],"2003-07","1998-06",25,[809],"Fanconi Anemia",[673,479,811],"methotrexate",{"nctId":277,"briefTitle":278,"status":213,"phases":813,"primaryCompletion":280,"completion":280,"start":281,"enrollment":282,"conditions":814,"interventions":815},[90],[284,285,286],[288,204,57],{"nctId":817,"briefTitle":818,"status":114,"phases":819,"primaryCompletion":820,"start":821,"enrollment":296,"conditions":822,"interventions":824},"NCT01106235","Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma",[90],"2011-11","2010-04",[823],"Stage IV Melanoma",[718,719,673],{"nctId":826,"briefTitle":827,"status":226,"phases":828,"primaryCompletion":829,"start":830,"enrollment":395,"conditions":831,"interventions":833},"NCT01477021","Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery",[90],"2013-09","2012-01",[832,775,777,778,779],"Adult Liposarcoma",[673,834],"NY-ESO-1-specific T cells",{"nctId":290,"briefTitle":291,"status":213,"phases":836,"primaryCompletion":293,"completion":294,"start":295,"enrollment":296,"conditions":837,"interventions":838},[90],[298,299],[301,57,204],{"nctId":303,"briefTitle":304,"status":114,"phases":840,"primaryCompletion":306,"completion":306,"start":307,"enrollment":282,"conditions":841,"interventions":842},[90],[309,248,249,252,256,253],[311,57,312,204],{"nctId":844,"briefTitle":845,"status":226,"phases":846,"primaryCompletion":847,"start":848,"enrollment":296,"conditions":849,"interventions":851},"NCT01339663","Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma",[90],"2012-12","2012-03",[850,823],"Recurrent Melanoma",[673,719,852,720,718],"autologous tumor cell vaccine",{"nctId":54,"briefTitle":55,"status":126,"phases":854,"primaryCompletion":56,"completion":315,"start":316,"enrollment":317,"conditions":855,"interventions":856},[90],[248,258,319,320,252,261,321,322,323],[57,204,325,326],{"nctId":328,"briefTitle":329,"status":114,"phases":858,"primaryCompletion":331,"completion":332,"start":333,"enrollment":334,"conditions":859,"interventions":860},[90],[336,337],[339,57,204,221],{"nctId":862,"briefTitle":863,"status":226,"phases":864,"primaryCompletion":865,"start":866,"enrollment":544,"conditions":867,"interventions":936},"NCT00343798","A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies",[90],"2013-07","2006-04",[868,869,733,734,29,870,35,871,32,872,873,558,874,875,876,877,878,879,880,881,882,883,884,885,886,887,888,889,890,710,711,891,892,893,894,895,896,897,898,537,899,500,900,901,902,903,904,905,906,907,712,713,908,24,714,21,517,737,909,27,700,453,910,715,911,912,913,914,915,916,917,918,919,920,921,922,923,924,925,926,927,928,929,930,931,932,933,934,935],"Accelerated Phase Chronic Myelogenous Leukemia","Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome","Adult Acute Myeloid Leukemia With Del(5q)","Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)","Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)","Adult Nasal Type Extranodal NK\u002FT-cell Lymphoma","Childhood Acute Lymphoblastic Leukemia in Remission","Childhood Acute Myeloid Leukemia in Remission","Childhood Burkitt Lymphoma","Childhood Chronic Myelogenous Leukemia","Childhood Diffuse Large Cell Lymphoma","Childhood Immunoblastic Large Cell Lymphoma","Childhood Myelodysplastic Syndromes","Childhood Nasal Type Extranodal NK\u002FT-cell Lymphoma","Chronic Phase Chronic Myelogenous Leukemia","Contiguous Stage II Adult Burkitt Lymphoma","Contiguous Stage II Adult Diffuse Large Cell Lymphoma","Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma","Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma","Contiguous Stage II Adult Lymphoblastic Lymphoma","Contiguous Stage II Grade 3 Follicular Lymphoma","Contiguous Stage II Mantle Cell Lymphoma","de Novo Myelodysplastic Syndromes","Noncontiguous Stage II Adult Burkitt Lymphoma","Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma","Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma","Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma","Noncontiguous Stage II Adult Lymphoblastic Lymphoma","Noncontiguous Stage II Grade 3 Follicular Lymphoma","Noncontiguous Stage II Mantle Cell Lymphoma","Previously Treated Myelodysplastic Syndromes","Recurrent Adult Burkitt Lymphoma","Recurrent Adult Diffuse Mixed Cell Lymphoma","Recurrent Adult Grade III Lymphomatoid Granulomatosis","Recurrent Adult Immunoblastic Large Cell Lymphoma","Recurrent Adult Lymphoblastic Lymphoma","Recurrent Childhood Anaplastic Large Cell Lymphoma","Recurrent Childhood Grade III Lymphomatoid Granulomatosis","Recurrent Childhood Large Cell Lymphoma","Recurrent Childhood Lymphoblastic Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Refractory Anemia With Excess Blasts in Transformation","Secondary Myelodysplastic Syndromes","Stage I Adult Burkitt Lymphoma","Stage I Adult Diffuse Large Cell Lymphoma","Stage I Adult Diffuse Mixed Cell Lymphoma","Stage I Adult Immunoblastic Large Cell Lymphoma","Stage I Adult Lymphoblastic Lymphoma","Stage I Childhood Lymphoblastic Lymphoma","Stage I Grade 3 Follicular Lymphoma","Stage I Mantle Cell Lymphoma","Stage II Childhood Lymphoblastic Lymphoma","Stage III Adult Burkitt Lymphoma","Stage III Adult Diffuse Large Cell Lymphoma","Stage III Adult Diffuse Mixed Cell Lymphoma","Stage III Adult Immunoblastic Large Cell Lymphoma","Stage III Adult Lymphoblastic Lymphoma","Stage III Childhood Lymphoblastic Lymphoma","Stage III Grade 3 Follicular Lymphoma","Stage III Mantle Cell Lymphoma","Stage IV Adult Burkitt Lymphoma","Stage IV Adult Diffuse Large Cell Lymphoma","Stage IV Adult Diffuse Mixed Cell Lymphoma","Stage IV Adult Immunoblastic Large Cell Lymphoma","Stage IV Adult Lymphoblastic Lymphoma","Stage IV Childhood Lymphoblastic Lymphoma","Stage IV Grade 3 Follicular Lymphoma","Stage IV Mantle Cell Lymphoma",[673,937,479,481],"fludarabine phosphate",{"nctId":939,"briefTitle":940,"status":226,"phases":941,"completion":942,"start":943,"enrollment":944,"conditions":945,"interventions":946},"NCT00002788","High-Dose Chemotherapy Followed by Total-Body Irradiation and Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia",[90],"2002-09","1995-10",15,[15],[674,673,947,948],"dexamethasone","etoposide",{"nctId":950,"briefTitle":951,"status":226,"phases":952,"completion":953,"start":954,"conditions":955,"interventions":957},"NCT00003899","Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors",[90],"2001-11","1999-01",[956],"Unspecified Adult Solid Tumor, Protocol Specific",[674,673,958,959,960],"melphalan","paclitaxel","thiotepa",{"nctId":341,"briefTitle":342,"status":343,"phases":962,"primaryCompletion":345,"completion":345,"start":346,"enrollment":102,"conditions":963,"interventions":964},[90],[348,349,350,351],[221,57,204,222],{"nctId":354,"briefTitle":355,"status":213,"phases":966,"primaryCompletion":357,"completion":358,"start":359,"enrollment":360,"conditions":967,"interventions":968},[90],[362,363,364,365,366,367,368,369,370],[372,57,82,373,374,375,376,377,378,204,373],{"nctId":970,"briefTitle":971,"status":226,"phases":972,"completion":973,"start":974,"enrollment":296,"conditions":975,"interventions":976},"NCT00012207","Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",[90],"2010-07","2000-09",[15,797],[719,718,673,675,977],"vincristine sulfate",{"nctId":979,"briefTitle":980,"status":114,"phases":981,"primaryCompletion":982,"start":983,"enrollment":282,"conditions":984,"interventions":985},"NCT00354419","Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant",[90],"2010-12","2006-02",[415],[673,672,479,481,986,674],"DNA analysis",{"trials":988,"activeCount":296,"soonestReadout":41},[989,993,1047,1056,1078,1087,1100,1119,1130,1139,1154,1158,1167,1178,1187,1194,1207,1220,1224,1237,1244,1248,1252,1259,1267,1274,1292,1301,1318,1333,1337,1343,1354,1367,1374,1378,1382,1392,1400,1407,1416,1420,1427,1436,1461,1475,1484,1492,1500,1504,1521,1525,1536,1547,1561,1568,1578],{"nctId":49,"briefTitle":50,"status":126,"phases":990,"primaryCompletion":51,"completion":400,"start":401,"enrollment":36,"conditions":991,"interventions":992},[91],[403,404,405,406,389,407],[52,57,204,409],{"nctId":994,"briefTitle":995,"status":226,"phases":996,"primaryCompletion":997,"completion":998,"start":999,"enrollment":486,"conditions":1000,"interventions":1042},"NCT00049504","Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer",[91],"2011-03","2014-02","2002-01",[868,733,734,29,870,35,871,32,872,873,558,1001,874,875,876,877,880,881,1002,890,710,1003,1004,1005,711,1006,1007,898,899,500,900,1008,901,1009,902,903,1010,904,905,906,907,1011,1012,712,713,908,24,714,1013,21,1014,27,700,1015,910,1016,715,1017,920,921,922,1018,1019,923,924,1020,1021,1022,1023,1024,1025,926,927,1026,1027,1028,1029,928,929,930,1030,1031,931,932,1032,1033,1034,1035,1036,1037,934,935,1038,1039,1040,1041,716],"Angioimmunoblastic T-cell Lymphoma","Cutaneous B-cell Non-Hodgkin Lymphoma","Hematopoietic\u002FLymphoid Cancer","Hepatosplenic T-cell Lymphoma","Intraocular Lymphoma","Peripheral T-cell Lymphoma","Post-transplant Lymphoproliferative Disorder","Recurrent Adult Diffuse Small Cleaved Cell Lymphoma","Recurrent Adult Hodgkin Lymphoma","Recurrent Adult T-cell Leukemia\u002FLymphoma","Recurrent Childhood Small Noncleaved Cell Lymphoma","Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma","Recurrent Mycosis Fungoides\u002FSezary Syndrome","Recurrent\u002FRefractory Childhood Hodgkin Lymphoma","Relapsing Chronic Myelogenous Leukemia","Small Intestine Lymphoma","Stage II Multiple Myeloma","Stage III Adult Diffuse Small Cleaved Cell Lymphoma","Stage III Adult Hodgkin Lymphoma","Stage III Adult T-cell Leukemia\u002FLymphoma","Stage III Childhood Hodgkin Lymphoma","Stage III Chronic Lymphocytic Leukemia","Stage III Cutaneous T-cell Non-Hodgkin Lymphoma","Stage III Grade 1 Follicular Lymphoma","Stage III Grade 2 Follicular Lymphoma","Stage III Marginal Zone Lymphoma","Stage III Multiple Myeloma","Stage III Mycosis Fungoides\u002FSezary Syndrome","Stage III Small Lymphocytic Lymphoma","Stage IV Adult Diffuse Small Cleaved Cell Lymphoma","Stage IV Adult Hodgkin Lymphoma","Stage IV Adult T-cell Leukemia\u002FLymphoma","Stage IV Childhood Hodgkin Lymphoma","Stage IV Chronic Lymphocytic Leukemia","Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma","Stage IV Grade 1 Follicular Lymphoma","Stage IV Grade 2 Follicular Lymphoma","Stage IV Marginal Zone Lymphoma","Stage IV Mycosis Fungoides\u002FSezary Syndrome","Stage IV Small Lymphocytic Lymphoma","Testicular Lymphoma",[673,937,1043,481,720,1044,1045,1046],"tacrolimus","fluorescence in situ hybridization","polymorphism analysis","gene expression analysis",{"nctId":1048,"briefTitle":1049,"status":226,"phases":1050,"primaryCompletion":1051,"completion":1052,"start":983,"enrollment":1053,"conditions":1054,"interventions":1055},"NCT00343785","Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant",[91],"2012-05","2012-08",21,[415],[673,672,479,811,986,1045],{"nctId":1057,"briefTitle":1058,"status":114,"phases":1059,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":1062,"conditions":1063,"interventions":1075},"NCT02408016","Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma",[90,91],"2020-06-30","2015-05-22",11,[1064,1065,1066,1067,1068,1069,1070,1071,1072,1073,1074],"Advanced Pleural Malignant Mesothelioma","HLA-A*0201 Positive Cells Present","Recurrent Non-Small Cell Lung Carcinoma","Recurrent Pleural Malignant Mesothelioma","Stage III Non-Small Cell Lung Cancer AJCC v7","Stage III Pleural Malignant Mesothelioma AJCC v7","Stage IIIA Non-Small Cell Lung Cancer AJCC v7","Stage IIIB Non-Small Cell Lung Cancer AJCC v7","Stage IV Non-Small Cell Lung Cancer AJCC v7","Stage IV Pleural Malignant Mesothelioma AJCC v7","WT1 Positive",[1076,1077,57],"Aldesleukin","Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm\u002FTn Lymphocytes",{"nctId":1079,"briefTitle":1080,"status":226,"phases":1081,"primaryCompletion":1082,"completion":848,"start":1083,"enrollment":1084,"conditions":1085,"interventions":1086},"NCT00553306","Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma",[90,91],"2010-08","2007-09",10,[850,823],[718,719,673,720],{"nctId":1088,"briefTitle":1089,"status":1090,"phases":1091,"primaryCompletion":1092,"start":1093,"enrollment":1094,"conditions":1095,"interventions":1097},"NCT00438841","Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma","UNKNOWN",[91],"2008-12","2006-08",43,[1096],"Multiple Myeloma and Plasma Cell Neoplasm",[1098,673,947,1099],"bortezomib","thalidomide",{"nctId":1101,"briefTitle":1102,"status":226,"phases":1103,"primaryCompletion":1104,"completion":1105,"start":1106,"enrollment":1094,"conditions":1107,"interventions":1117},"NCT01427881","Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies",[91],"2014-06","2015-07","2011-09",[868,733,1108,734,1109,873,1110,558,1001,1111,1112,874,1113,875,876,877,878,879,880,881,465,882,1002,890,710,1004,1005,711,1114,1006,1115,1007,898,246,18,899,500,900,1008,901,1009,902,903,1010,1116,298,904,905,906,907,1011,1012,712,713,908,24,714,1013,21,1014,1015,453,910,1016,715,1027,1041,716],"Adult Acute Megakaryoblastic Leukemia (M7)","Adult Erythroleukemia (M6a)","Adult Pure Erythroid Leukemia (M6b)","Blastic Phase Chronic Myelogenous Leukemia","Childhood Acute Erythroleukemia (M6)","Childhood Acute Megakaryocytic Leukemia (M7)","Noncutaneous Extranodal Lymphoma","Philadelphia Chromosome Negative Chronic Myelogenous Leukemia","Recurrent Childhood Acute Lymphoblastic Leukemia",[673,479,937,1118],"busulfan",{"nctId":1120,"briefTitle":1121,"status":226,"phases":1122,"primaryCompletion":1123,"completion":1123,"start":1124,"conditions":1125,"interventions":1129},"NCT00005804","Bone Marrow Transplantation in Treating Patients With Hematologic Cancer",[91],"2002-08","1999-10",[1126,15,797,1096,798,1127,1128],"Chronic Myeloproliferative Disorders","Precancerous\u002FNonmalignant Condition","Small Intestine Cancer",[673],{"nctId":1131,"briefTitle":1132,"status":226,"phases":1133,"completion":1134,"start":1135,"conditions":1136,"interventions":1138},"NCT00054340","Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder",[90,91],"2006-09","2002-10",[1126,1137,15,798,799],"Graft Versus Host Disease",[672,1118,673,479,811],{"nctId":1140,"briefTitle":1141,"status":114,"phases":1142,"primaryCompletion":1143,"completion":1143,"start":1144,"enrollment":1145,"conditions":1146,"interventions":1153},"NCT03246906","Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation",[91],"2025-05-03","2017-09-11",150,[404,387,1147,529,685,533,389,390,537,1148,1149,1150,233,21,1151,1152,431],"Aggressive Non-Hodgkin Lymphoma","Recurrent Chronic Lymphocytic Leukemia","Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Recurrent Hodgkin Lymphoma","Recurrent Waldenstrom Macroglobulinemia","Hematologic and Lymphocytic Disorder",[57,82,376,418],{"nctId":420,"briefTitle":421,"status":213,"phases":1155,"primaryCompletion":423,"completion":423,"start":424,"enrollment":425,"conditions":1156,"interventions":1157},[91],[403,427,428,404,429,430,431,432,433,388,434,435,436,437,438,439,391],[409,204,57,87,441,442],{"nctId":1159,"briefTitle":1160,"status":226,"phases":1161,"primaryCompletion":1162,"completion":76,"start":1163,"enrollment":1164,"conditions":1165,"interventions":1166},"NCT02251821","JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis",[91],"2022-12-28","2014-10-20",61,[488,489],[87,57,504,491,442,376,417,441],{"nctId":1168,"briefTitle":1169,"status":114,"phases":1170,"primaryCompletion":1171,"completion":1172,"start":1173,"enrollment":98,"conditions":1174,"interventions":1176},"NCT01570348","Crohn's Allogeneic Transplant Study",[91],"2019-02-03","2019-10-30","2012-07-17",[1175],"Crohn Disease",[57,504,376,1177,441],"Mycophenolic Acid",{"nctId":1179,"briefTitle":1180,"status":226,"phases":1181,"primaryCompletion":1182,"start":1183,"enrollment":475,"conditions":1184,"interventions":1185},"NCT00317785","Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases",[91],"2007-11","2005-05",[15,797,798],[673,479,811,481,1186,1043],"sirolimus",{"nctId":1188,"briefTitle":1189,"status":226,"phases":1190,"primaryCompletion":795,"completion":795,"start":1191,"enrollment":463,"conditions":1192,"interventions":1193},"NCT00002792","Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders",[91],"1996-06",[1126,15,799],[1118,673,479,811,1043],{"nctId":1195,"briefTitle":1196,"status":226,"phases":1197,"primaryCompletion":1198,"completion":1198,"start":1199,"enrollment":598,"conditions":1200,"interventions":1205},"NCT00918723","Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[90,91],"2016-10","2009-06",[529,1201,1202,1203,1204,1022,1029,1034,1040],"Stage I Chronic Lymphocytic Leukemia","Stage I Small Lymphocytic Lymphoma","Stage II Chronic Lymphocytic Leukemia","Stage II Small Lymphocytic Lymphoma",[504,57,505,1206],"Vorinostat",{"nctId":1208,"briefTitle":1209,"status":114,"phases":1210,"primaryCompletion":1211,"completion":1212,"start":1213,"enrollment":1214,"conditions":1215,"interventions":1219},"NCT00358657","Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders",[91],"2018-08-17","2019-05-25","2006-05-24",14,[1216,1217,1218],"Immunodeficiency Syndrome","Severe Aplastic Anemia","Genetic Disorder",[57,504,376,418,441],{"nctId":84,"briefTitle":85,"status":126,"phases":1221,"primaryCompletion":86,"completion":484,"start":485,"enrollment":486,"conditions":1222,"interventions":1223},[91],[488,489],[87,57,204,491,442,376,417,441],{"nctId":1225,"briefTitle":1226,"status":226,"phases":1227,"primaryCompletion":1228,"completion":1228,"start":1229,"enrollment":1230,"conditions":1231,"interventions":1235},"NCT00789776","Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer",[90,91],"2017-05","2008-10-13",41,[404,387,1147,685,736,1148,1149,1232,24,233,21,27,1233,234,563,1234],"Recurrent Indolent Adult Non-Hodgkin Lymphoma","Refractory Hodgkin Lymphoma","Waldenstrom Macroglobulinemia",[57,504,376,1236,441],"Natural Killer Cell Therapy",{"nctId":1238,"briefTitle":1239,"status":226,"phases":1240,"primaryCompletion":1241,"start":1124,"enrollment":682,"conditions":1242,"interventions":1243},"NCT00005940","Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission",[91],"2006-01",[734,29,870,35,871,32,872],[1118,673,479,811],{"nctId":507,"briefTitle":508,"status":114,"phases":1245,"primaryCompletion":510,"completion":511,"start":512,"enrollment":135,"conditions":1246,"interventions":1247},[91],[514,404,515,387,405,406,133,389,407,516,517],[204,57,409,52],{"nctId":520,"briefTitle":521,"status":226,"phases":1249,"primaryCompletion":523,"completion":524,"start":525,"enrollment":526,"conditions":1250,"interventions":1251},[91],[403,404,387,528,529,405,530,531,438,532,533,534,389,535,516,536,537,517,538],[57,82,204,376,409],{"nctId":1253,"briefTitle":1254,"status":226,"phases":1255,"primaryCompletion":474,"completion":474,"start":1256,"enrollment":282,"conditions":1257,"interventions":1258},"NCT00002554","Monoclonal Antibody Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia in Remission or First Relapse",[91],"1993-11",[15],[1118,673,811],{"nctId":1260,"briefTitle":1261,"status":226,"phases":1262,"completion":1263,"start":1264,"enrollment":475,"conditions":1265,"interventions":1266},"NCT00002553","Chemotherapy Plus Radiation Therapy and Biological Therapy in Treating Patients With Hematologic Cancer",[91],"2003-06","1990-08",[15,797],[673],{"nctId":1268,"briefTitle":1269,"status":226,"phases":1270,"completion":473,"start":1271,"conditions":1272,"interventions":1273},"NCT00024050","Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome",[91],"2001-02",[15,798],[1118,673,479,811],{"nctId":1275,"briefTitle":1276,"status":226,"phases":1277,"primaryCompletion":772,"completion":1278,"start":1279,"enrollment":1280,"conditions":1281,"interventions":1289},"NCT00005803","Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma",[90,91],"2018-10","1999-09",76,[537,1009,1282,1283,1148,1284,21,1285,27,1233,1286,563,1287,1288],"Recurrent Childhood Hodgkin Lymphoma","Recurrent Childhood Non-Hodgkin Lymphoma","Recurrent Non-Hodgkin Lymphoma","Refractory Childhood Hodgkin Lymphoma","Refractory Non-Hodgkin Lymphoma","T-Cell Chronic Lymphocytic Leukemia","T-Cell Prolymphocytic Leukemia",[1290,57,82,373,692,504,491,376,1291],"Carmustine","Therapeutic Autologous Lymphocytes",{"nctId":1293,"briefTitle":1294,"status":114,"phases":1295,"primaryCompletion":1296,"completion":1297,"start":1298,"enrollment":636,"conditions":1299,"interventions":1300},"NCT00719849","Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease",[91],"2008-11","2009-12","2005-11",[15,797,1096,798,799],[672,673,479,937,481],{"nctId":39,"briefTitle":40,"status":126,"phases":1302,"primaryCompletion":41,"completion":1303,"start":1304,"enrollment":486,"conditions":1305,"interventions":1317},[90,91],"2039-03","2017-12-05",[247,1148,248,1306,1307,24,714,251,252,561,1308,1309,1310,1311,1312,562,1313,1314,21,27,563,1315,1316],"Recurrent Follicular Lymphoma","Recurrent Lymphoplasmacytic Lymphoma","Refractory Lymphoplasmacytic Lymphoma","Refractory Mantle Cell Lymphoma","Refractory Transformed Non-Hodgkin Lymphoma","Recurrent Transformed B-Cell Non-Hodgkin Lymphoma","Recurrent Transformed Chronic Lymphocytic Leukemia","Refractory Transformed B-Cell Non-Hodgkin Lymphoma","Refractory Transformed Chronic Lymphocytic Leukemia","Recurrent Central Nervous System Lymphoma","Refractory Central Nervous System Lymphoma",[42,57,504],{"nctId":1319,"briefTitle":1320,"status":226,"phases":1321,"primaryCompletion":1322,"completion":1322,"start":1323,"enrollment":1062,"conditions":1324,"interventions":1331},"NCT01807182","Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma",[91],"2021-08-26","2013-08-20",[1325,1326,1327,1328,1329,1330],"Stage III Cutaneous Melanoma AJCC v7","Stage IIIA Cutaneous Melanoma AJCC v7","Stage IIIB Cutaneous Melanoma AJCC v7","Stage IIIC Cutaneous Melanoma AJCC v7","Stage IV Cutaneous Melanoma AJCC v6 and v7","Metastatic Melanoma",[1076,57,504,1332],"Therapeutic Tumor Infiltrating Lymphocytes",{"nctId":549,"briefTitle":550,"status":213,"phases":1334,"primaryCompletion":552,"completion":553,"start":554,"enrollment":555,"conditions":1335,"interventions":1336},[91],[427,404,387,557,558,528,559,465,560,438,532,533,388,389,537,27,561,562,563],[57,82,374,204,376,377,547],{"nctId":1338,"briefTitle":1121,"status":226,"phases":1339,"completion":1340,"start":474,"conditions":1341,"interventions":1342},"NCT00005854",[91],"2000-10",[15,797,1096,798],[673,479,811],{"nctId":1344,"briefTitle":1345,"status":213,"phases":1346,"primaryCompletion":1347,"completion":1348,"start":1349,"enrollment":1350,"conditions":1351,"interventions":1353},"NCT06013423","Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases",[91],"2031-10-31","2032-10-31","2024-07-23",54,[428,404,387,431,1352,388,389,391,516,559],"Hematopoietic and Lymphatic System Neoplasm",[57,82,504,376,409],{"nctId":1355,"briefTitle":1356,"status":114,"phases":1357,"primaryCompletion":1358,"completion":1358,"start":1359,"enrollment":1360,"conditions":1361,"interventions":1365},"NCT01640301","Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant",[90,91],"2020-03-20","2012-12-06",47,[18,298,453,1362,1363,1364,1065,362],"Therapy-Related Acute Myeloid Leukemia","Donor","Hematopoietic Cell Transplant Recipient",[1076,57,504,1366],"WT1-Sensitized Allogeneic T-Lymphocytes",{"nctId":1368,"briefTitle":1369,"status":226,"phases":1370,"primaryCompletion":953,"completion":953,"start":1371,"enrollment":598,"conditions":1372,"interventions":1373},"NCT00003870","Monoclonal Antibody Therapy, Cyclophosphamide, and Total-Body Irradiation Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Recurrent Acute Lymphocytic Leukemia",[91],"1999-02",[15],[673,811],{"nctId":566,"briefTitle":567,"status":114,"phases":1375,"primaryCompletion":569,"completion":570,"start":571,"enrollment":135,"conditions":1376,"interventions":1377},[90,91],[573,574,219,575,576,577],[579,57,204,580,581],{"nctId":583,"briefTitle":584,"status":213,"phases":1379,"primaryCompletion":586,"completion":587,"start":588,"enrollment":360,"conditions":1380,"interventions":1381},[91],[427,404,387,389,391],[409,204,441,591,442,57,467,82,418,87],{"nctId":1383,"briefTitle":1384,"status":226,"phases":1385,"primaryCompletion":1386,"completion":1386,"start":1387,"enrollment":1388,"conditions":1389,"interventions":1390},"NCT00003913","Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease",[91],"2005-08","1998-12",390,[15,797,798,799],[672,674,1118,673,1391],"methylprednisolone",{"nctId":1393,"briefTitle":1394,"status":226,"phases":1395,"primaryCompletion":1396,"completion":1396,"start":1371,"enrollment":1397,"conditions":1398,"interventions":1399},"NCT00073918","Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",[91],"2011-10-02",111,[558,1002,710,711,899,500,900,1008,902,903,712,713,908,24,714,715,716],[673,948],{"nctId":1401,"briefTitle":1402,"status":226,"phases":1403,"primaryCompletion":1404,"completion":1404,"start":1371,"enrollment":598,"conditions":1405,"interventions":1406},"NCT00003868","Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia",[91],"2005-03",[15],[673,811],{"nctId":1408,"briefTitle":1409,"status":226,"phases":1410,"completion":1182,"start":1411,"conditions":1412,"interventions":1414},"NCT00027937","Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma",[91],"2001-08",[797,956,1413],"Unspecified Childhood Solid Tumor, Protocol Specific",[719,674,1415,1118,673,958,959,960],"sargramostim",{"nctId":593,"briefTitle":594,"status":213,"phases":1417,"primaryCompletion":596,"completion":596,"start":597,"enrollment":598,"conditions":1418,"interventions":1419},[90,91],[600],[602,204,57,603,376,418],{"nctId":1421,"briefTitle":1422,"status":226,"phases":1423,"primaryCompletion":1424,"start":999,"enrollment":282,"conditions":1425,"interventions":1426},"NCT00049634","Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder",[90,91],"2007-02",[1126,15,798,799],[1118,673,479,811],{"nctId":1428,"briefTitle":1429,"status":226,"phases":1430,"primaryCompletion":1431,"completion":1431,"start":1424,"enrollment":395,"conditions":1432,"interventions":1435},"NCT00453388","Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia",[91],"2013-06",[1433,1434,809,736],"Acute Myeloid Leukemia in Remission","de Novo Myelodysplastic Syndrome",[57,82,504,376],{"nctId":1437,"briefTitle":1438,"status":114,"phases":1439,"primaryCompletion":1440,"completion":1440,"start":1441,"enrollment":1442,"conditions":1443,"interventions":1460},"NCT01028716","Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies",[91],"2021-10-07","2010-05-19",46,[403,1444,1445,1446,1447,1433,1448,1449,1450,1451,429,1452,1453,1454,528,1455,1456,1457,389,1458,433,1306,1150,24,714,233,234,453,1459,1364],"Acute Erythroid Leukemia in Remission","Acute Leukemia in Remission","Acute Lymphoblastic Leukemia in Remission","Acute Myeloid Leukaemia With Prior Myelodysplastic Syndrome","Acute Myeloid Leukemia With FLT3\u002FITD Mutation","Acute Myeloid Leukemia With Inv(3)(Q21Q26.2); RPN1-EVI1","Acute Myeloid Leukemia With Multilineage Dysplasia","Acute Myeloid Leukemia With t(6;9)","Adult Acute Lymphoblastic Leukemia in Complete Remission","B Acute Lymphoblastic Leukemia With T(1;19)(Q23;P13.3); E2A-PBX1 (TCF3-PBX1)","Ph+ ALL","Childhood Acute Lymphoblastic Leukemia in Complete Remission","DS Stage II Plasma Cell Myeloma","DS Stage III Plasma Cell Myeloma","Recurrent Anaplastic Large Cell Lymphoma","T Lymphoblastic Lymphoma",[57,374,504,376,441],{"nctId":1462,"briefTitle":1463,"status":226,"phases":1464,"primaryCompletion":1465,"completion":1465,"start":1466,"enrollment":1467,"conditions":1468,"interventions":1474},"NCT00723099","Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer",[91],"2018-07-31","2008-06-25",73,[404,387,1147,1469,882,1470,797,388,389,391,1148,1306,1307,24,714,233,21,1471,27,1472,561,1233,1308,1309,563,1473],"Chronic Myelogenous Leukemia","Indolent Non-Hodgkin Lymphoma","Recurrent T-Cell Non-Hodgkin Lymphoma","Refractory Chronic Myelogenous Leukemia","T-Cell Non-Hodgkin Lymphoma",[57,82,504,376],{"nctId":1476,"briefTitle":1477,"status":343,"phases":1478,"primaryCompletion":1479,"completion":1479,"start":1480,"enrollment":102,"conditions":1481,"interventions":1483},"NCT03602898","Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation",[91],"2023-09-17","2021-06-01",[1446,732,465,530,1482,389,535,391,362,1150,1284,365,1362],"Hematopoietic and Lymphoid System Neoplasm",[72,87,57,82,504,442,441],{"nctId":1485,"briefTitle":1486,"status":226,"phases":1487,"start":1488,"enrollment":463,"conditions":1489,"interventions":1491},"NCT00016458","Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis",[91],"2000-06",[1490],"Systemic Sclerosis",[672,673],{"nctId":1493,"briefTitle":1494,"status":114,"phases":1495,"primaryCompletion":1496,"start":1083,"enrollment":135,"conditions":1497,"interventions":1498},"NCT00555048","Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer",[90,91],"2010-10",[1137,15,798,799],[1499,1118,673,811,1043],"alemtuzumab",{"nctId":605,"briefTitle":606,"status":213,"phases":1501,"primaryCompletion":608,"completion":608,"start":609,"enrollment":475,"conditions":1502,"interventions":1503},[91],[390,488,489],[417,87,57,204,612,491,442,441],{"nctId":1505,"briefTitle":1506,"status":226,"phases":1507,"primaryCompletion":1508,"completion":1508,"start":1509,"enrollment":1510,"conditions":1511,"interventions":1520},"NCT01008462","Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia",[91],"2018-06-30","2010-03-18",16,[1512,1513,1514,1515,1516,1009,1517,1282,1283,1148,233,21,1285,27,1286,234,563,1518,1519,1288,1234],"B-Cell Prolymphocytic Leukemia","Hypodiploidy","Loss of Chromosome 17p","Plasma Cell Leukemia","Progression of Multiple Myeloma or Plasma Cell Leukemia","Recurrent Adult Non-Hodgkin Lymphoma","t(14;16)","t(4;14)",[1290,57,373,692,504,491,376,441],{"nctId":614,"briefTitle":615,"status":213,"phases":1522,"primaryCompletion":617,"completion":618,"start":619,"enrollment":463,"conditions":1523,"interventions":1524},[91],[488,489],[57,612,204,468,491,376,441],{"nctId":1526,"briefTitle":1527,"status":213,"phases":1528,"primaryCompletion":1529,"completion":1530,"start":1531,"enrollment":282,"conditions":1532,"interventions":1535},"NCT03670966","211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome",[90,91],"2028-01-28","2029-10-20","2019-07-10",[1446,732,1433,465,407,1533,362,1534,365,452,367,406],"Recurrent Acute Lymphoblastic Leukemia","Refractory Acute Lymphoblastic Leukemia",[602,57,376,468,504,441],{"nctId":1537,"briefTitle":1538,"status":226,"phases":1539,"primaryCompletion":1540,"completion":1541,"start":1542,"enrollment":1053,"conditions":1543,"interventions":1545},"NCT01413100","Scleroderma Treatment With Autologous Transplant (STAT) Study",[91],"2023-09-15","2024-09-11","2011-09-15",[1544],"Systemic Scleroderma",[72,57,374,376,1546],"Plerixafor",{"nctId":1548,"briefTitle":1549,"status":226,"phases":1550,"primaryCompletion":1551,"completion":1552,"start":1553,"enrollment":1554,"conditions":1555,"interventions":1560},"NCT02220985","Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD",[91],"2025-04-01","2025-05-01","2015-03-23",84,[1556,403,428,429,1557,1558,431,874,875,1363,438,407,434,1559,1533,362,1116,298,1149,1534,365,1446,1433],"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Allogeneic Hematopoietic Stem Cell Transplant Recipient","Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Myelodysplastic Syndrome With Excess Blasts-2",[57,504,442,376,441,409],{"nctId":1562,"briefTitle":1563,"status":226,"phases":1564,"primaryCompletion":1135,"completion":1135,"start":1565,"conditions":1566,"interventions":1567},"NCT00025545","Filgrastim-Treated Donor Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia\u003C\u002Fp>",[91],"1996-03",[15],[673,811],{"nctId":1569,"briefTitle":1570,"status":226,"phases":1571,"primaryCompletion":829,"completion":1572,"start":1573,"enrollment":1084,"conditions":1574,"interventions":1575},"NCT00871481","Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma",[90,91],"2013-10","2009-02",[850,823],[1576,673,719,720,1577],"ipilimumab","therapeutic cytotoxic T lymphocytes",{"nctId":623,"briefTitle":624,"status":213,"phases":1579,"primaryCompletion":626,"completion":626,"start":627,"enrollment":628,"conditions":1580,"interventions":1581},[90,91],[630,631,632],[634,57,635,204],{"trials":1583,"activeCount":102},[1584,1596,1608],{"nctId":1585,"briefTitle":1586,"status":226,"phases":1587,"primaryCompletion":1588,"completion":1589,"start":1241,"enrollment":807,"conditions":1590,"interventions":1594},"NCT00322101","Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia",[92],"2012-04","2014-10",[869,1591,734,29,870,35,871,32,872,875,880,890,1592,1593,898,18,298,453,910],"Acute Myeloid Leukemia\u002FTransient Myeloproliferative Disorder","Myelodysplastic Syndrome With Isolated Del(5q)","Myelodysplastic\u002FMyeloproliferative Neoplasm, Unclassifiable",[673,481,1118,479,937,1595,1044,1045,1043,811],"cytogenetic analysis",{"nctId":1597,"briefTitle":1598,"status":226,"phases":1599,"primaryCompletion":1600,"completion":1600,"start":1601,"enrollment":1602,"conditions":1603,"interventions":1605},"NCT00003972","Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer",[92],"2003-03","1998-07",280,[1604],"Breast Cancer",[674,1415,1118,1606,673,958,959,1607,960],"carboplatin","tamoxifen citrate",{"nctId":1609,"briefTitle":1610,"status":226,"phases":1611,"primaryCompletion":1612,"completion":1612,"start":1613,"enrollment":748,"conditions":1614,"interventions":1615},"NCT00002789","Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myeloid Leukemia",[92],"2001-09","1996-05",[15],[1118,673,479,811],{"trials":1617,"activeCount":102},[],{"trials":1619,"activeCount":102},[1620,1628],{"nctId":1621,"briefTitle":1622,"status":1623,"phases":1624,"primaryCompletion":1496,"start":1199,"conditions":1625,"interventions":1627},"NCT01005537","Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma","NO_LONGER_AVAILABLE",[],[1626],"Melanoma (Skin)",[719,718,673],{"nctId":1629,"briefTitle":1630,"status":226,"phases":1631,"primaryCompletion":1632,"completion":1431,"start":1633,"enrollment":1634,"conditions":1635,"interventions":1640},"NCT00445744","Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome",[94],"2011-06","2006-12",52,[734,29,870,35,871,32,872,875,880,890,1636,1592,1637,898,488,18,298,453,910,489,1638,1639],"Essential Thrombocythemia","Polycythemia Vera","Untreated Adult Acute Myeloid Leukemia","Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies",[673,1118,1043,811,1595],{"intervention":376,"totalTrials":1642,"cells":1643},77,{"EARLY_PHASE1":1644,"PHASE1":1646,"PHASE2":1727,"PHASE3":2249,"PHASE4":2275,"NA":2277},{"trials":1645,"activeCount":102},[],{"trials":1647,"activeCount":135,"soonestReadout":357},[1648,1657,1661,1668,1684,1695,1699,1703,1707,1716],{"nctId":1649,"briefTitle":1650,"status":226,"phases":1651,"primaryCompletion":1652,"completion":1653,"start":1654,"enrollment":944,"conditions":1655,"interventions":1656},"NCT01503242","90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma",[90],"2017-06-06","2019-12-06","2012-01-09",[536,234],[82,504,376],{"nctId":724,"briefTitle":725,"status":114,"phases":1658,"primaryCompletion":727,"completion":728,"start":729,"enrollment":730,"conditions":1659,"interventions":1660},[90],[732,733,734,735,465,736,737,738,739,740],[57,504,376,441],{"nctId":1662,"briefTitle":1663,"status":226,"phases":1664,"primaryCompletion":1083,"start":1665,"enrollment":98,"conditions":1666,"interventions":1667},"NCT00093743","Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia",[90],"2000-01",[734,29,870,35,871,32,872,875,880,809,898],[937,479,481],{"nctId":1669,"briefTitle":1670,"status":226,"phases":1671,"primaryCompletion":1672,"completion":1673,"start":1674,"enrollment":395,"conditions":1675,"interventions":1683},"NCT00008450","Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant",[90],"2011-10-25","2018-12-26","1997-08-11",[1676,1677,1678,1679,1680,1681,1682],"Adenosine Deaminase Deficiency","Autosomal Recessive Disorder","Immune System Disorder","Purine-Nucleoside Phosphorylase Deficiency","Severe Combined Immunodeficiency","Severe Combined Immunodeficiency With Absence of T and B Cells","X-Linked Severe Combined Immunodeficiency",[82,376],{"nctId":1685,"briefTitle":1686,"status":226,"phases":1687,"primaryCompletion":1688,"start":1689,"enrollment":1690,"conditions":1691,"interventions":1693},"NCT00988715","Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome",[90],"2015-01","2010-04-21",17,[465,1593,736,246,18,737,739,1692,453],"Refractory Cytopenia With Multilineage Dysplasia and Ringed Sideroblasts",[1694,82,376,504],"Pretargeted Radioimmunotherapy",{"nctId":862,"briefTitle":863,"status":226,"phases":1696,"primaryCompletion":865,"start":866,"enrollment":544,"conditions":1697,"interventions":1698},[90],[868,869,733,734,29,870,35,871,32,872,873,558,874,875,876,877,878,879,880,881,882,883,884,885,886,887,888,889,890,710,711,891,892,893,894,895,896,897,898,537,899,500,900,901,902,903,904,905,906,907,712,713,908,24,714,21,517,737,909,27,700,453,910,715,911,912,913,914,915,916,917,918,919,920,921,922,923,924,925,926,927,928,929,930,931,932,933,934,935],[673,937,479,481],{"nctId":354,"briefTitle":355,"status":213,"phases":1700,"primaryCompletion":357,"completion":358,"start":359,"enrollment":360,"conditions":1701,"interventions":1702},[90],[362,363,364,365,366,367,368,369,370],[372,57,82,373,374,375,376,377,378,204,373],{"nctId":979,"briefTitle":980,"status":114,"phases":1704,"primaryCompletion":982,"start":983,"enrollment":282,"conditions":1705,"interventions":1706},[90],[415],[673,672,479,481,986,674],{"nctId":1708,"briefTitle":1709,"status":226,"phases":1710,"primaryCompletion":1711,"completion":1712,"start":830,"enrollment":1510,"conditions":1713,"interventions":1714},"NCT01300572","Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS",[90],"2017-10-29","2019-11-22",[465,736,246,18,737,453],[82,504,1715,376],"Indium In 111 Anti-CD45 Monoclonal Antibody BC8",{"nctId":1717,"briefTitle":1718,"status":226,"phases":1719,"primaryCompletion":1720,"completion":1721,"start":1722,"enrollment":1723,"conditions":1724,"interventions":1726},"NCT00008177","Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes",[90],"2009-03-21","2010-12-15","1999-07-27",79,[734,29,870,35,871,32,872,465,890,898,18,737,909,1725,739,910,1638],"Refractory Anemia With Ringed Sideroblasts",[937,479,481],{"trials":1728,"activeCount":2248,"soonestReadout":81},[1729,1736,1747,1781,1785,1795,1805,1813,1823,1831,1835,1847,1851,1855,1866,1874,1878,1882,1916,1925,1942,1946,1950,1954,1958,1968,1972,1976,1987,1995,2005,2019,2027,2036,2040,2044,2053,2057,2061,2069,2078,2082,2086,2090,2094,2104,2112,2121,2129,2138,2142,2152,2160,2179,2183,2187,2195,2240,2244],{"nctId":1730,"briefTitle":1731,"status":226,"phases":1732,"completion":1182,"start":1733,"enrollment":11,"conditions":1734,"interventions":1735},"NCT00119340","Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous Leukemia",[90,91],"2005-04",[15],[479,937,481],{"nctId":1737,"briefTitle":1738,"status":226,"phases":1739,"primaryCompletion":1740,"completion":1741,"start":1742,"enrollment":1743,"conditions":1744,"interventions":1745},"NCT00119392","Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",[91],"2009-07","2016-04-23","2004-06",42,[709,711,899,500,900,1008,901,902,903,712,713,908,24,714,21,715,716],[1746,479,937,481],"rituximab",{"nctId":1748,"briefTitle":1749,"status":226,"phases":1750,"primaryCompletion":1241,"start":1751,"enrollment":19,"conditions":1752,"interventions":1780},"NCT00078858","Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant",[90,91],"2003-09",[868,733,734,29,870,35,871,32,872,1753,873,558,1001,874,875,876,877,878,1754,879,880,881,1755,465,882,1756,883,884,885,886,887,888,889,890,710,1004,1757,1593,711,891,892,893,894,895,896,897,1114,1006,1007,898,246,18,899,500,900,1008,901,1009,902,903,1010,1116,298,904,905,906,907,1011,1012,712,713,908,24,714,1013,1758,21,1014,517,1725,27,1759,700,1015,715,911,912,913,914,915,1760,1761,1762,916,1763,917,918,1764,1765,1766,919,1767,920,921,922,923,924,1020,1768,1769,925,1770,926,927,928,929,930,931,932,1032,1771,1772,933,1773,934,935,1774,1775,1776,1777,1778,1638,1779,1639,716],"Adult Grade III Lymphomatoid Granulomatosis","Childhood Grade III Lymphomatoid Granulomatosis","Childhood Renal Cell Carcinoma","Clear Cell Renal Cell Carcinoma","Juvenile Myelomonocytic Leukemia","Recurrent Renal Cell Cancer","Refractory Hairy Cell Leukemia","Stage I Adult T-cell Leukemia\u002FLymphoma","Stage I Childhood Anaplastic Large Cell Lymphoma","Stage I Childhood Large Cell Lymphoma","Stage I Childhood Small Noncleaved Cell Lymphoma","Stage II Adult T-cell Leukemia\u002FLymphoma","Stage II Childhood Anaplastic Large Cell Lymphoma","Stage II Childhood Large Cell Lymphoma","Stage II Childhood Small Noncleaved Cell Lymphoma","Stage III Childhood Anaplastic Large Cell Lymphoma","Stage III Childhood Large Cell Lymphoma","Stage III Childhood Small Noncleaved Cell Lymphoma","Stage IV Childhood Anaplastic Large Cell Lymphoma","Stage IV Childhood Large Cell Lymphoma","Stage IV Childhood Small Noncleaved Cell Lymphoma","Stage IV Renal Cell Cancer","T-cell Large Granular Lymphocyte Leukemia","Type 1 Papillary Renal Cell Carcinoma","Type 2 Papillary Renal Cell Carcinoma","Untreated Adult Acute Lymphoblastic Leukemia","Untreated Childhood Acute Lymphoblastic Leukemia",[937,479,481],{"nctId":994,"briefTitle":995,"status":226,"phases":1782,"primaryCompletion":997,"completion":998,"start":999,"enrollment":486,"conditions":1783,"interventions":1784},[91],[868,733,734,29,870,35,871,32,872,873,558,1001,874,875,876,877,880,881,1002,890,710,1003,1004,1005,711,1006,1007,898,899,500,900,1008,901,1009,902,903,1010,904,905,906,907,1011,1012,712,713,908,24,714,1013,21,1014,27,700,1015,910,1016,715,1017,920,921,922,1018,1019,923,924,1020,1021,1022,1023,1024,1025,926,927,1026,1027,1028,1029,928,929,930,1030,1031,931,932,1032,1033,1034,1035,1036,1037,934,935,1038,1039,1040,1041,716],[673,937,1043,481,720,1044,1045,1046],{"nctId":1786,"briefTitle":1787,"status":226,"phases":1788,"primaryCompletion":1789,"completion":1790,"start":1791,"enrollment":1792,"conditions":1793,"interventions":1794},"NCT01252667","Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant",[91],"2019-01-25","2019-03","2011-01-25",44,[387],[77,82,376],{"nctId":1796,"briefTitle":1797,"status":226,"phases":1798,"primaryCompletion":1278,"completion":1799,"start":1800,"enrollment":1360,"conditions":1801,"interventions":1803},"NCT01527045","Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies",[91],"2019-04","2012-09-25",[1147,433,529,1514,390,516,537,246,18,1802,1116,298,1148,1149,248,1150,24,1284,233,21,1234],"Recurrent Aggressive Adult Non-Hodgkin Lymphoma",[1804,82,504,376],"Atorvastatin Calcium",{"nctId":1806,"briefTitle":1807,"status":226,"phases":1808,"completion":1809,"start":1665,"conditions":1810,"interventions":1811},"NCT00006233","Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma",[91],"2003-12",[1626],[1812,479,937,481],"therapeutic allogeneic lymphocytes",{"nctId":1814,"briefTitle":1815,"status":226,"phases":1816,"primaryCompletion":1817,"completion":1817,"start":1818,"conditions":1819,"interventions":1822},"NCT00005941","Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer",[91],"2005-06","1999-11",[1820,1821],"Cervical Cancer","Vaginal Cancer",[1812,479,937,481],{"nctId":1824,"briefTitle":1825,"status":226,"phases":1826,"primaryCompletion":1827,"start":1828,"conditions":1829,"interventions":1830},"NCT00096096","Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation",[91],"2006-05","2004-08",[1126,1137,15,797,1096,798,799],[481,1043],{"nctId":1140,"briefTitle":1141,"status":114,"phases":1832,"primaryCompletion":1143,"completion":1143,"start":1144,"enrollment":1145,"conditions":1833,"interventions":1834},[91],[404,387,1147,529,685,533,389,390,537,1148,1149,1150,233,21,1151,1152,431],[57,82,376,418],{"nctId":1836,"briefTitle":1837,"status":226,"phases":1838,"primaryCompletion":1839,"completion":1840,"start":1411,"enrollment":1841,"conditions":1842,"interventions":1846},"NCT00027820","Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer",[90,91],"2004-09","2004-09-05",106,[734,874,875,1843,1755,465,1756,1434,1844,736,1516,246,18,1009,903,1517,1116,298,907,1283,517,1725,1285,27,1845,1776,1777,1778,1638,1779],"Childhood Myelodysplastic Syndrome","Metastatic Renal Cell Cancer","Renal Medullary Carcinoma",[504,82,376],{"nctId":79,"briefTitle":80,"status":126,"phases":1848,"primaryCompletion":81,"completion":412,"start":413,"enrollment":135,"conditions":1849,"interventions":1850},[91],[415],[82,204,393,376,417,418],{"nctId":1159,"briefTitle":1160,"status":226,"phases":1852,"primaryCompletion":1162,"completion":76,"start":1163,"enrollment":1164,"conditions":1853,"interventions":1854},[91],[488,489],[87,57,504,491,442,376,417,441],{"nctId":1856,"briefTitle":1857,"status":226,"phases":1858,"primaryCompletion":1859,"completion":1860,"start":1241,"enrollment":1642,"conditions":1861,"interventions":1865},"NCT00397813","Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders",[91],"2017-09","2018-03",[1862,465,1434,1636,391,1863,1637,1864,488,517,737,738,739,740],"Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative","Paroxysmal Nocturnal Hemoglobinuria","Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase",[82,504,376],{"nctId":1867,"briefTitle":1868,"status":226,"phases":1869,"primaryCompletion":1870,"completion":1871,"start":1600,"enrollment":1053,"conditions":1872,"interventions":1873},"NCT00060424","Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia",[91],"2010-09","2010-09-22",[1512,529,537,1148,21,27,1288],[82,504,376],{"nctId":1168,"briefTitle":1169,"status":114,"phases":1875,"primaryCompletion":1171,"completion":1172,"start":1173,"enrollment":98,"conditions":1876,"interventions":1877},[91],[1175],[57,504,376,1177,441],{"nctId":1179,"briefTitle":1180,"status":226,"phases":1879,"primaryCompletion":1182,"start":1183,"enrollment":475,"conditions":1880,"interventions":1881},[91],[15,797,798],[673,479,811,481,1186,1043],{"nctId":1883,"briefTitle":1884,"status":226,"phases":1885,"primaryCompletion":1886,"completion":1887,"start":1888,"enrollment":1145,"conditions":1889,"interventions":1915},"NCT00089011","Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer",[91],"2014-03","2018-07","2004-04",[868,733,734,29,870,35,871,32,872,873,558,1001,1111,874,875,876,877,878,879,880,881,882,883,884,885,1890,886,887,1891,1892,888,889,1893,1894,1002,890,1636,710,1004,1005,711,891,892,893,1895,894,895,1896,1897,896,897,1898,1899,1114,1006,1637,1007,898,488,537,246,18,899,500,900,1008,901,1009,902,903,1010,1116,298,904,905,906,907,1011,1012,712,713,908,24,714,1013,21,1014,27,1759,700,1015,1016,715,911,912,913,1900,914,915,1760,1761,1762,916,1763,1201,1901,1902,1903,917,918,1904,1905,1202,1906,1907,1764,1765,1766,919,1767,1203,1908,1017,1909,1910,920,921,922,1018,923,924,1020,1768,1769,925,1770,1022,1023,1024,1025,926,927,1026,1027,1029,1911,1912,928,929,930,1030,931,932,1032,1771,1772,933,1773,1034,1035,1036,1037,934,935,1038,1040,1913,1914,1041,1778,1638,1779,1639,716],"Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma","Contiguous Stage II Grade 1 Follicular Lymphoma","Contiguous Stage II Grade 2 Follicular Lymphoma","Contiguous Stage II Marginal Zone Lymphoma","Contiguous Stage II Small Lymphocytic Lymphoma","Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma","Noncontiguous Stage II Grade 1 Follicular Lymphoma","Noncontiguous Stage II Grade 2 Follicular Lymphoma","Noncontiguous Stage II Marginal Zone Lymphoma","Noncontiguous Stage II Small Lymphocytic Lymphoma","Stage I Adult Diffuse Small Cleaved Cell Lymphoma","Stage I Cutaneous T-cell Non-Hodgkin Lymphoma","Stage I Grade 1 Follicular Lymphoma","Stage I Grade 2 Follicular Lymphoma","Stage I Marginal Zone Lymphoma","Stage I Multiple Myeloma","Stage IA Mycosis Fungoides\u002FSezary Syndrome","Stage IB Mycosis Fungoides\u002FSezary Syndrome","Stage II Cutaneous T-cell Non-Hodgkin Lymphoma","Stage IIA Mycosis Fungoides\u002FSezary Syndrome","Stage IIB Mycosis Fungoides\u002FSezary Syndrome","Stage IIIA Mycosis Fungoides\u002FSezary Syndrome","Stage IIIB Mycosis Fungoides\u002FSezary Syndrome","Stage IVA Mycosis Fungoides\u002FSezary Syndrome","Stage IVB Mycosis Fungoides\u002FSezary Syndrome",[937,481,1043],{"nctId":1917,"briefTitle":1918,"status":226,"phases":1919,"primaryCompletion":1297,"completion":1297,"start":953,"enrollment":555,"conditions":1920,"interventions":1924},"NCT00040846","Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies",[91],[29,870,35,871,32,872,873,558,1001,876,877,878,879,881,882,1890,1891,1892,1893,1894,710,1004,1593,711,1895,1896,1897,1898,1899,1006,898,1921,18,899,500,900,1008,901,1009,902,903,1010,1116,298,904,906,907,1011,1012,712,713,908,24,714,1013,21,1014,27,1759,700,1015,715,1900,1761,1762,1901,1902,1903,918,1904,1922,1202,1765,1766,1908,1923,921,1018,1768,1769,1023,1024,1025,927,1026,1028,1029,929,1030,1771,1772,1035,1036,1037,935,1038,1039,1040,1775,716],"Progressive Hairy Cell Leukemia, Initial Treatment","Stage I Mycosis Fungoides\u002FSezary Syndrome","Stage II Mycosis Fungoides\u002FSezary Syndrome",[1499,937,481,479],{"nctId":1926,"briefTitle":1927,"status":226,"phases":1928,"primaryCompletion":773,"completion":1929,"start":1930,"enrollment":231,"conditions":1931,"interventions":1937},"NCT00036738","Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib",[91],"2018-05","2001-07-13",[733,1932,1933,874,1934,405,1935,246,1116,1936],"Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Blastic Phase","Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Chronic Phase of Disease","Recurrent Disease",[82,1938,504,1939,376,1940,1941],"Dasatinib","Imatinib Mesylate","Nilotinib","Therapeutic Allogeneic Lymphocytes",{"nctId":470,"briefTitle":471,"status":226,"phases":1943,"primaryCompletion":473,"start":474,"enrollment":475,"conditions":1944,"interventions":1945},[90,91],[477],[479,480,481],{"nctId":1208,"briefTitle":1209,"status":114,"phases":1947,"primaryCompletion":1211,"completion":1212,"start":1213,"enrollment":1214,"conditions":1948,"interventions":1949},[91],[1216,1217,1218],[57,504,376,418,441],{"nctId":84,"briefTitle":85,"status":126,"phases":1951,"primaryCompletion":86,"completion":484,"start":485,"enrollment":486,"conditions":1952,"interventions":1953},[91],[488,489],[87,57,204,491,442,376,417,441],{"nctId":493,"briefTitle":494,"status":114,"phases":1955,"primaryCompletion":496,"completion":496,"start":497,"enrollment":463,"conditions":1956,"interventions":1957},[91],[499,500,247,501,251,502,252],[82,504,376,505,204],{"nctId":1959,"briefTitle":1960,"status":226,"phases":1961,"primaryCompletion":1962,"start":1963,"enrollment":9,"conditions":1964,"interventions":1966},"NCT00553098","Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders",[91],"2015-03","2006-06",[1216,1965],"Non-Cancer Diagnosis",[1967,82,504,376],"Alemtuzumab",{"nctId":1225,"briefTitle":1226,"status":226,"phases":1969,"primaryCompletion":1228,"completion":1228,"start":1229,"enrollment":1230,"conditions":1970,"interventions":1971},[90,91],[404,387,1147,685,736,1148,1149,1232,24,233,21,27,1233,234,563,1234],[57,504,376,1236,441],{"nctId":520,"briefTitle":521,"status":226,"phases":1973,"primaryCompletion":523,"completion":524,"start":525,"enrollment":526,"conditions":1974,"interventions":1975},[91],[403,404,387,528,529,405,530,531,438,532,533,534,389,535,516,536,537,517,538],[57,82,204,376,409],{"nctId":1977,"briefTitle":1978,"status":226,"phases":1979,"primaryCompletion":1980,"start":1981,"enrollment":1053,"conditions":1982,"interventions":1985},"NCT00006251","Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer",[90,91],"2005-09","2000-05",[429,873,558,1001,876,878,1754,879,880,881,465,1002,890,710,1004,1005,1757,439,1593,1983,711,1114,1006,1007,898,1984,246,18,899,500,900,1008,901,1009,902,903,1010,1116,298,904,905,906,907,1011,1012,712,713,908,24,714,1013,1758,21,1014,27,1759,700,1016,715,1017,1027,1775,1041,716],"Myeloid\u002FNK-cell Acute Leukemia","Primary Systemic Amyloidosis",[937,479,481,1986],"donor lymphocytes",{"nctId":1988,"briefTitle":1989,"status":226,"phases":1990,"primaryCompletion":1991,"completion":1991,"start":1340,"conditions":1992,"interventions":1993},"NCT00008151","Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome",[91],"2002-07",[15,798],[479,937,1994,811,481],"gemtuzumab ozogamicin",{"nctId":1996,"briefTitle":1997,"status":226,"phases":1998,"completion":1999,"start":2000,"enrollment":598,"conditions":2001,"interventions":2002},"NCT00110058","Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia",[91],"2006-07","2005-02",[15],[2003,1812,479,937,2004,481],"recombinant interferon alfa","imatinib mesylate",{"nctId":2006,"briefTitle":2007,"status":226,"phases":2008,"primaryCompletion":2009,"completion":2009,"start":2010,"enrollment":1690,"conditions":2011,"interventions":2018},"NCT00045435","Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission",[91],"2009-01","2002-04",[869,1108,2012,2013,2014,2015,2016,734,29,870,35,32,872,2017,1109,1110,453],"Adult Acute Minimally Differentiated Myeloid Leukemia (M0)","Adult Acute Monoblastic Leukemia (M5a)","Adult Acute Monocytic Leukemia (M5b)","Adult Acute Myeloblastic Leukemia With Maturation (M2)","Adult Acute Myeloblastic Leukemia Without Maturation (M1)","Adult Acute Myelomonocytic Leukemia (M4)",[937,479,481],{"nctId":2020,"briefTitle":2021,"status":226,"phases":2022,"primaryCompletion":2023,"start":2024,"enrollment":598,"conditions":2025,"interventions":2026},"NCT00003954","Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma",[90,91],"2002-12","1999-03",[700,1905,1017,1027],[958,479,481,1812],{"nctId":2028,"briefTitle":2029,"status":226,"phases":2030,"primaryCompletion":333,"completion":333,"start":2031,"enrollment":2032,"conditions":2033,"interventions":2035},"NCT00796068","Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant",[91],"2009-02-24",130,[403,1446,1433,433,405,530,2034],"Myelodysplastic Syndrome (MDS)",[82,504,376,547],{"nctId":1275,"briefTitle":1276,"status":226,"phases":2037,"primaryCompletion":772,"completion":1278,"start":1279,"enrollment":1280,"conditions":2038,"interventions":2039},[90,91],[537,1009,1282,1283,1148,1284,21,1285,27,1233,1286,563,1287,1288],[1290,57,82,373,692,504,491,376,1291],{"nctId":1293,"briefTitle":1294,"status":114,"phases":2041,"primaryCompletion":1296,"completion":1297,"start":1298,"enrollment":636,"conditions":2042,"interventions":2043},[91],[15,797,1096,798,799],[672,673,479,937,481],{"nctId":2045,"briefTitle":2046,"status":226,"phases":2047,"primaryCompletion":1198,"completion":1198,"start":2048,"enrollment":2049,"conditions":2050,"interventions":2051},"NCT00793572","Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma",[91],"2008-10",32,[234],[2052,82,82,504,491,376],"Bortezomib",{"nctId":549,"briefTitle":550,"status":213,"phases":2054,"primaryCompletion":552,"completion":553,"start":554,"enrollment":555,"conditions":2055,"interventions":2056},[91],[427,404,387,557,558,528,559,465,560,438,532,533,388,389,537,27,561,562,563],[57,82,374,204,376,377,547],{"nctId":1344,"briefTitle":1345,"status":213,"phases":2058,"primaryCompletion":1347,"completion":1348,"start":1349,"enrollment":1350,"conditions":2059,"interventions":2060},[91],[428,404,387,431,1352,388,389,391,516,559],[57,82,504,376,409],{"nctId":2062,"briefTitle":2063,"status":213,"phases":2064,"primaryCompletion":460,"completion":2065,"start":2066,"enrollment":11,"conditions":2067,"interventions":2068},"NCT03128034","211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia",[90,91],"2029-03-31","2017-10-24",[404,732,387,465,407,362,1534,1533,452,365,367,388],[82,504,376],{"nctId":2070,"briefTitle":2071,"status":114,"phases":2072,"primaryCompletion":2073,"completion":2074,"start":2075,"enrollment":682,"conditions":2076,"interventions":2077},"NCT00119366","Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome",[91],"2014-08","2019-05-08","2003-05",[29,870,35,871,32,872,880,465,898,18,298,737,909,1725,739,453,910],[937,479,481],{"nctId":593,"briefTitle":594,"status":213,"phases":2079,"primaryCompletion":596,"completion":596,"start":597,"enrollment":598,"conditions":2080,"interventions":2081},[90,91],[600],[602,204,57,603,376,418],{"nctId":1428,"briefTitle":1429,"status":226,"phases":2083,"primaryCompletion":1431,"completion":1431,"start":1424,"enrollment":395,"conditions":2084,"interventions":2085},[91],[1433,1434,809,736],[57,82,504,376],{"nctId":1437,"briefTitle":1438,"status":114,"phases":2087,"primaryCompletion":1440,"completion":1440,"start":1441,"enrollment":1442,"conditions":2088,"interventions":2089},[91],[403,1444,1445,1446,1447,1433,1448,1449,1450,1451,429,1452,1453,1454,528,1455,1456,1457,389,1458,433,1306,1150,24,714,233,234,453,1459,1364],[57,374,504,376,441],{"nctId":1462,"briefTitle":1463,"status":226,"phases":2091,"primaryCompletion":1465,"completion":1465,"start":1466,"enrollment":1467,"conditions":2092,"interventions":2093},[91],[404,387,1147,1469,882,1470,797,388,389,391,1148,1306,1307,24,714,233,21,1471,27,1472,561,1233,1308,1309,563,1473],[57,82,504,376],{"nctId":2095,"briefTitle":2096,"status":226,"phases":2097,"primaryCompletion":2098,"completion":2098,"start":2099,"enrollment":2100,"conditions":2101,"interventions":2103},"NCT00104858","Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[91],"2018-03-30","2004-12",66,[529,537,21,27,1022,1029,1034,1040,2102],"T-Cell Large Granular Lymphocyte Leukemia",[82,504,376,505],{"nctId":2105,"briefTitle":2106,"status":226,"phases":2107,"primaryCompletion":2108,"completion":2109,"start":1135,"enrollment":1510,"conditions":2110,"interventions":2111},"NCT00054353","Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma",[90,91],"2009-10","2012-10-14",[700],[937,958,481,479],{"nctId":2113,"briefTitle":2114,"status":226,"phases":2115,"primaryCompletion":2116,"completion":2117,"start":2075,"enrollment":22,"conditions":2118,"interventions":2119},"NCT00096161","Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant",[91],"2015-02","2015-08",[404,387,529,405,1137,560,390,516,536,1234],[82,376,2120,1941],"Pentostatin",{"nctId":2122,"briefTitle":2123,"status":226,"phases":2124,"primaryCompletion":794,"completion":2125,"start":2126,"enrollment":1062,"conditions":2127,"interventions":2128},"NCT00005851","Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer",[90,91],"2018-09-27","2000-02",[1758,1774],[937,479,481,1812],{"nctId":2130,"briefTitle":2131,"status":226,"phases":2132,"primaryCompletion":1404,"start":2133,"enrollment":682,"conditions":2134,"interventions":2137},"NCT00003145","Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia",[91],"1997-08",[2135,2136,405,1935,1936],"Accelerated Phase of Disease","Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive",[504,82,376,1941],{"nctId":1505,"briefTitle":1506,"status":226,"phases":2139,"primaryCompletion":1508,"completion":1508,"start":1509,"enrollment":1510,"conditions":2140,"interventions":2141},[91],[1512,1513,1514,1515,1516,1009,1517,1282,1283,1148,233,21,1285,27,1286,234,563,1518,1519,1288,1234],[1290,57,373,692,504,491,376,441],{"nctId":2143,"briefTitle":2144,"status":226,"phases":2145,"primaryCompletion":2146,"completion":2146,"start":2147,"enrollment":2148,"conditions":2149,"interventions":2151},"NCT00919503","Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders",[91],"2020-06-10","2009-07-31",98,[2150],"Non-Neoplastic Hematologic and Lymphocytic Disorder",[72,82,504,442,376,441,547],{"nctId":2153,"briefTitle":2154,"status":226,"phases":2155,"primaryCompletion":973,"completion":2156,"start":1404,"enrollment":296,"conditions":2157,"interventions":2158},"NCT00118352","Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer",[91],"2015-05-26",[429,733,734,873,558,1001,1862,874,875,876,877,878,879,880,881,465,882,1002,710,1004,1005,1757,439,1593,711,1114,1006,898,246,18,899,500,900,1008,901,1009,902,903,1010,1116,298,904,905,906,907,1011,1012,712,713,908,24,714,1013,21,1014,27,1759,700,1015,910,1016,715,1041,716],[1499,937,479,481,2159],"graft versus host disease prophylaxis\u002Ftherapy",{"nctId":2161,"briefTitle":2162,"status":226,"phases":2163,"primaryCompletion":2164,"completion":2165,"start":2166,"enrollment":1642,"conditions":2167,"interventions":2178},"NCT01251575","Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant",[91],"2018-11-23","2019-02-11","2010-12-01",[2168,2169,2170,2171,2172,1147,2173,2174,2175,1843,2176,529,2177,530,406,533,536,537,1148,27,1288,1234,248,1150],"Adult Acute Lymphoblastic Leukemia","Adult Acute Myeloid Leukemia","Adult Diffuse Large B-Cell Lymphoma","Adult Myelodysplastic Syndrome","Adult Non-Hodgkin Lymphoma","Childhood Acute Lymphoblastic Leukemia","Childhood Acute Myeloid Leukemia","Childhood Diffuse Large B-Cell Lymphoma","Childhood Non-Hodgkin Lymphoma","Chronic Lymphocytic Leukemia in Remission",[82,504,376,418],{"nctId":614,"briefTitle":615,"status":213,"phases":2180,"primaryCompletion":617,"completion":618,"start":619,"enrollment":463,"conditions":2181,"interventions":2182},[91],[488,489],[57,612,204,468,491,376,441],{"nctId":1526,"briefTitle":1527,"status":213,"phases":2184,"primaryCompletion":1529,"completion":1530,"start":1531,"enrollment":282,"conditions":2185,"interventions":2186},[90,91],[1446,732,1433,465,407,1533,362,1534,365,452,367,406],[602,57,376,468,504,441],{"nctId":2188,"briefTitle":2189,"status":226,"phases":2190,"completion":794,"start":2191,"conditions":2192,"interventions":2193},"NCT00027547","Combination Chemotherapy and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia",[90,91],"2001-07",[15],[1812,479,2194,937,811,481],"cytarabine",{"nctId":2196,"briefTitle":2197,"status":226,"phases":2198,"primaryCompletion":2199,"completion":2200,"start":2201,"enrollment":2202,"conditions":2203,"interventions":2239},"NCT00105001","Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer",[91],"2011-05","2015-05-08","2004-11",210,[1593,736,27,234,1234,1556,733,734,2204,2205,2206,2207,1862,1558,874,875,876,2136,878,2208,1843,2209,2210,2211,2212,2213,2214,2215,2216,2217,2218,2219,2220,2221,2222,2223,2224,2225,2226,2227,2228,1204,246,18,899,500,900,1008,1009,2229,903,1116,298,904,906,907,2230,712,713,908,24,714,21,1282,1149,2231,911,912,913,2232,915,1761,1762,916,2233,1902,1903,917,918,1904,1202,1765,919,2234,920,921,922,1018,2235,924,1768,1769,925,2236,1024,1025,926,927,1026,1029,928,929,930,1030,2237,932,1771,1772,933,2238,1036,1037,934,935,1038,1040],"Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL","Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11","Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA","Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1","Childhood Immunoblastic Lymphoma","Stage II Contiguous Adult Burkitt Lymphoma","Stage II Contiguous Adult Diffuse Large Cell Lymphoma","Stage II Contiguous Adult Diffuse Mixed Cell Lymphoma","Stage II Contiguous Adult Diffuse Small Cleaved Cell Lymphoma","Stage II Adult Contiguous Immunoblastic Lymphoma","Stage II Contiguous Adult Lymphoblastic Lymphoma","Stage II Grade 1 Contiguous Follicular Lymphoma","Stage II Grade 2 Contiguous Follicular Lymphoma","Stage II Grade 3 Contiguous Follicular Lymphoma","Stage II Contiguous Mantle Cell Lymphoma","Stage II Non-Contiguous Adult Burkitt Lymphoma","Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma","Stage II Non-Contiguous Adult Diffuse Mixed Cell Lymphoma","Stage II Non-Contiguous Adult Diffuse Small Cleaved Cell Lymphoma","Stage II Adult Non-Contiguous Immunoblastic Lymphoma","Stage II Non-Contiguous Adult Lymphoblastic Lymphoma","Stage II Grade 1 Non-Contiguous Follicular Lymphoma","Stage II Grade 2 Non-Contiguous Follicular Lymphoma","Stage II Grade 3 Non-Contiguous Follicular Lymphoma","Stage II Non-Contiguous Mantle Cell Lymphoma","Recurrent Adult Immunoblastic Lymphoma","Recurrent Childhood Burkitt Lymphoma","Secondary Myelodysplastic Syndrome","Stage I Adult Immunoblastic Lymphoma","Stage I Childhood Burkitt Lymphoma","Stage II Childhood Burkitt Lymphoma","Stage III Adult Immunoblastic Lymphoma","Stage III Childhood Burkitt Lymphoma","Stage IV Adult Immunoblastic Lymphoma","Stage IV Childhood Burkitt Lymphoma",[504,441,376,418],{"nctId":1537,"briefTitle":1538,"status":226,"phases":2241,"primaryCompletion":1540,"completion":1541,"start":1542,"enrollment":1053,"conditions":2242,"interventions":2243},[91],[1544],[72,57,374,376,1546],{"nctId":1548,"briefTitle":1549,"status":226,"phases":2245,"primaryCompletion":1551,"completion":1552,"start":1553,"enrollment":1554,"conditions":2246,"interventions":2247},[91],[1556,403,428,429,1557,1558,431,874,875,1363,438,407,434,1559,1533,362,1116,298,1149,1534,365,1446,1433],[57,504,442,376,441,409],8,{"trials":2250,"activeCount":102},[2251,2262,2266],{"nctId":2252,"briefTitle":2253,"status":226,"phases":2254,"primaryCompletion":2255,"completion":2256,"start":2257,"enrollment":2258,"conditions":2259,"interventions":2261},"NCT01231412","Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant",[92],"2016-10-08","2017-06-30","2010-11",174,[404,387,1147,529,685,406,1470,533,389,391,537,1148,233,27,2260,1233,538,1287,1234],"Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive",[82,504,376,418],{"nctId":1585,"briefTitle":1586,"status":226,"phases":2263,"primaryCompletion":1588,"completion":1589,"start":1241,"enrollment":807,"conditions":2264,"interventions":2265},[92],[869,1591,734,29,870,35,871,32,872,875,880,890,1592,1593,898,18,298,453,910],[673,481,1118,479,937,1595,1044,1045,1043,811],{"nctId":2267,"briefTitle":2268,"status":226,"phases":2269,"primaryCompletion":998,"completion":2270,"start":2271,"enrollment":2272,"conditions":2273,"interventions":2274},"NCT00075478","Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer",[92],"2014-02-02","2003-10",87,[1446,1433,1147,530,685,406,1470,533,390,536,27,1233,1234],[504,376,82],{"trials":2276,"activeCount":102},[],{"trials":2278,"activeCount":102},[2279,2288,2296,2303,2332],{"nctId":2280,"briefTitle":2281,"status":226,"phases":2282,"primaryCompletion":2010,"completion":2010,"start":2283,"enrollment":2284,"conditions":2285,"interventions":2286},"NCT00003196","Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma",[94],"1997-09",63,[873,558,1001,1002,710,1004,1005,711,1114,1006,246,899,500,900,1008,901,902,903,1010,1012,712,713,908,24,714,1013,21,27,1759,700,1016,715,1017,1027,1041,716],[2287,479,481,1812],"chemotherapy",{"nctId":2289,"briefTitle":2290,"status":226,"phases":2291,"primaryCompletion":2000,"start":2292,"enrollment":2293,"conditions":2294,"interventions":2295},"NCT00014235","Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies",[94],"2000-12",160,[1591,429,733,734,29,870,35,871,32,872,873,558,1001,431,874,875,876,878,879,880,881,465,1002,890,710,1004,1005,1757,439,1593,711,1114,1006,1007,898,1984,246,18,899,500,900,1008,901,1009,902,903,1010,1116,298,904,905,906,907,1011,1012,712,713,908,24,714,1013,21,1014,27,1759,700,1016,715,1017,1027,1775,1041,1778,1638,1779,1639,716],[937,479,481],{"nctId":2297,"briefTitle":2298,"status":226,"phases":2299,"primaryCompletion":1991,"start":1818,"enrollment":244,"conditions":2300,"interventions":2302},"NCT00005799","Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer",[94],[868,733,734,29,870,35,871,32,872,709,874,875,877,880,1755,882,1756,890,710,711,898,246,18,1008,1009,1116,298,1012,712,713,714,1013,21,1014,27,1759,700,1015,715,2301,1774,1775,1776,1777,716],"Stage III Renal Cell Cancer",[937,1812,479,481],{"nctId":2304,"briefTitle":2305,"status":226,"phases":2306,"primaryCompletion":2307,"start":1818,"enrollment":2308,"conditions":2309,"interventions":2331},"NCT00112593","Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer",[94],"2014-11",5,[868,429,733,734,29,870,35,871,32,872,1753,873,2310,2311,2312,2313,2314,2315,2316,2317,2318,558,1001,1111,874,875,876,877,878,1754,879,880,881,2319,465,2320,882,883,884,885,1890,886,887,1891,1892,888,889,1893,1894,1002,1636,2321,710,1004,133,2322,1005,2323,1757,439,2324,1593,1983,711,891,892,893,1895,894,895,1896,1897,896,897,1898,1899,1114,1006,1637,1007,898,2325,488,1984,1921,537,453,910,1016,715,2326,911,912,913,1900,2327,914,915,1760,1761,2328,1762,916,1763,1201,1901,1902,1903,917,918,1904,1905,1202,1906,1907,2329,1764,1765,2330,1766,919,1767,1203,1908,1017,1909,1910,920,921,922,1018,1019,923,924,1020,1768,1021,1769,925,1770,1022,1023,1024,1025,926,927,1026,1027,1029,1911,1912,928,929,930,1030,1031,931,932,1032,1771,1033,1772,933,1773,1034,1035,1036,1037,934,935,1038,1040,1913,1914,1775,1041,956,1413,716],"Aggressive NK-cell Leukemia","AIDS-related Diffuse Large Cell Lymphoma","AIDS-related Diffuse Mixed Cell Lymphoma","AIDS-related Diffuse Small Cleaved Cell Lymphoma","AIDS-related Immunoblastic Large Cell Lymphoma","AIDS-related Lymphoblastic Lymphoma","AIDS-related Peripheral\u002FSystemic Lymphoma","AIDS-related Primary CNS Lymphoma","AIDS-related Small Noncleaved Cell Lymphoma","Chronic Eosinophilic Leukemia","Chronic Neutrophilic Leukemia","Extramedullary Plasmacytoma","HIV-associated Hodgkin Lymphoma","Isolated Plasmacytoma of Bone","Meningeal Chronic Myelogenous Leukemia","Primary Central Nervous System Lymphoma","Stage 0 Chronic Lymphocytic Leukemia","Stage I Adult Hodgkin Lymphoma","Stage I Childhood Hodgkin Lymphoma","Stage II Adult Hodgkin Lymphoma","Stage II Childhood Hodgkin Lymphoma",[937,479,481],{"nctId":644,"briefTitle":645,"status":226,"phases":2333,"primaryCompletion":647,"start":648,"enrollment":463,"conditions":2334,"interventions":2335},[94],[650,651],[479,480,481],{"intervention":504,"totalTrials":2337,"cells":2338},80,{"EARLY_PHASE1":2339,"PHASE1":2341,"PHASE2":2389,"PHASE3":2716,"PHASE4":2730,"NA":2732},{"trials":2340,"activeCount":102},[],{"trials":2342,"activeCount":135,"soonestReadout":586},[2343,2347,2351,2355,2359,2365,2373,2377,2381,2385],{"nctId":694,"briefTitle":695,"status":152,"phases":2344,"primaryCompletion":586,"completion":423,"start":156,"enrollment":282,"conditions":2345,"interventions":2346},[90],[698,699,700],[702,57,504],{"nctId":1649,"briefTitle":1650,"status":226,"phases":2348,"primaryCompletion":1652,"completion":1653,"start":1654,"enrollment":944,"conditions":2349,"interventions":2350},[90],[536,234],[82,504,376],{"nctId":724,"briefTitle":725,"status":114,"phases":2352,"primaryCompletion":727,"completion":728,"start":729,"enrollment":730,"conditions":2353,"interventions":2354},[90],[732,733,734,735,465,736,737,738,739,740],[57,504,376,441],{"nctId":1662,"briefTitle":1663,"status":226,"phases":2356,"primaryCompletion":1083,"start":1665,"enrollment":98,"conditions":2357,"interventions":2358},[90],[734,29,870,35,871,32,872,875,880,809,898],[937,479,481],{"nctId":2360,"briefTitle":2361,"status":226,"phases":2362,"completion":2048,"start":2075,"enrollment":296,"conditions":2363,"interventions":2364},"NCT00317759","Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma",[90],[1626],[718,937],{"nctId":2366,"briefTitle":2367,"status":226,"phases":2368,"primaryCompletion":1632,"start":2369,"enrollment":2370,"conditions":2371,"interventions":2372},"NCT00110071","Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma",[90],"2005-01",38,[710,711,899,500,900,1008,902,903,712,713,908,24,714,715,716],[937,720],{"nctId":1685,"briefTitle":1686,"status":226,"phases":2374,"primaryCompletion":1688,"start":1689,"enrollment":1690,"conditions":2375,"interventions":2376},[90],[465,1593,736,246,18,737,739,1692,453],[1694,82,376,504],{"nctId":862,"briefTitle":863,"status":226,"phases":2378,"primaryCompletion":865,"start":866,"enrollment":544,"conditions":2379,"interventions":2380},[90],[868,869,733,734,29,870,35,871,32,872,873,558,874,875,876,877,878,879,880,881,882,883,884,885,886,887,888,889,890,710,711,891,892,893,894,895,896,897,898,537,899,500,900,901,902,903,904,905,906,907,712,713,908,24,714,21,517,737,909,27,700,453,910,715,911,912,913,914,915,916,917,918,919,920,921,922,923,924,925,926,927,928,929,930,931,932,933,934,935],[673,937,479,481],{"nctId":1708,"briefTitle":1709,"status":226,"phases":2382,"primaryCompletion":1711,"completion":1712,"start":830,"enrollment":1510,"conditions":2383,"interventions":2384},[90],[465,736,246,18,737,453],[82,504,1715,376],{"nctId":1717,"briefTitle":1718,"status":226,"phases":2386,"primaryCompletion":1720,"completion":1721,"start":1722,"enrollment":1723,"conditions":2387,"interventions":2388},[90],[734,29,870,35,871,32,872,465,890,898,18,737,909,1725,739,910,1638],[937,479,481],{"trials":2390,"activeCount":2308,"soonestReadout":41},[2391,2395,2399,2403,2407,2417,2421,2428,2432,2436,2440,2444,2451,2455,2471,2475,2479,2488,2495,2499,2503,2507,2511,2515,2522,2526,2530,2541,2545,2549,2553,2557,2561,2565,2569,2573,2577,2581,2585,2589,2593,2597,2601,2610,2620,2624,2628,2632,2636,2640,2644,2654,2658,2668,2672,2676,2680,2684,2688,2692,2696,2700,2704,2708],{"nctId":1730,"briefTitle":1731,"status":226,"phases":2392,"completion":1182,"start":1733,"enrollment":11,"conditions":2393,"interventions":2394},[90,91],[15],[479,937,481],{"nctId":1737,"briefTitle":1738,"status":226,"phases":2396,"primaryCompletion":1740,"completion":1741,"start":1742,"enrollment":1743,"conditions":2397,"interventions":2398},[91],[709,711,899,500,900,1008,901,902,903,712,713,908,24,714,21,715,716],[1746,479,937,481],{"nctId":1748,"briefTitle":1749,"status":226,"phases":2400,"primaryCompletion":1241,"start":1751,"enrollment":19,"conditions":2401,"interventions":2402},[90,91],[868,733,734,29,870,35,871,32,872,1753,873,558,1001,874,875,876,877,878,1754,879,880,881,1755,465,882,1756,883,884,885,886,887,888,889,890,710,1004,1757,1593,711,891,892,893,894,895,896,897,1114,1006,1007,898,246,18,899,500,900,1008,901,1009,902,903,1010,1116,298,904,905,906,907,1011,1012,712,713,908,24,714,1013,1758,21,1014,517,1725,27,1759,700,1015,715,911,912,913,914,915,1760,1761,1762,916,1763,917,918,1764,1765,1766,919,1767,920,921,922,923,924,1020,1768,1769,925,1770,926,927,928,929,930,931,932,1032,1771,1772,933,1773,934,935,1774,1775,1776,1777,1778,1638,1779,1639,716],[937,479,481],{"nctId":994,"briefTitle":995,"status":226,"phases":2404,"primaryCompletion":997,"completion":998,"start":999,"enrollment":486,"conditions":2405,"interventions":2406},[91],[868,733,734,29,870,35,871,32,872,873,558,1001,874,875,876,877,880,881,1002,890,710,1003,1004,1005,711,1006,1007,898,899,500,900,1008,901,1009,902,903,1010,904,905,906,907,1011,1012,712,713,908,24,714,1013,21,1014,27,700,1015,910,1016,715,1017,920,921,922,1018,1019,923,924,1020,1021,1022,1023,1024,1025,926,927,1026,1027,1028,1029,928,929,930,1030,1031,931,932,1032,1033,1034,1035,1036,1037,934,935,1038,1039,1040,1041,716],[673,937,1043,481,720,1044,1045,1046],{"nctId":2408,"briefTitle":2409,"status":114,"phases":2410,"primaryCompletion":2411,"completion":2412,"start":2413,"enrollment":1230,"conditions":2414,"interventions":2415},"NCT00914940","Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD",[91],"2019-12-01","2020-05-26","2009-12-17",[1137,15,798],[504,441,409,2416],"T Cell-Depleted Hematopoietic Stem Cell Transplantation",{"nctId":1796,"briefTitle":1797,"status":226,"phases":2418,"primaryCompletion":1278,"completion":1799,"start":1800,"enrollment":1360,"conditions":2419,"interventions":2420},[91],[1147,433,529,1514,390,516,537,246,18,1802,1116,298,1148,1149,248,1150,24,1284,233,21,1234],[1804,82,504,376],{"nctId":2422,"briefTitle":2423,"status":226,"phases":2424,"primaryCompletion":2075,"completion":2075,"start":2425,"conditions":2426,"interventions":2427},"NCT00027924","Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic Syndrome",[91],"2001-10",[15,798],[1118,479,937,811],{"nctId":1806,"briefTitle":1807,"status":226,"phases":2429,"completion":1809,"start":1665,"conditions":2430,"interventions":2431},[91],[1626],[1812,479,937,481],{"nctId":1814,"briefTitle":1815,"status":226,"phases":2433,"primaryCompletion":1817,"completion":1817,"start":1818,"conditions":2434,"interventions":2435},[91],[1820,1821],[1812,479,937,481],{"nctId":1101,"briefTitle":1102,"status":226,"phases":2437,"primaryCompletion":1104,"completion":1105,"start":1106,"enrollment":1094,"conditions":2438,"interventions":2439},[91],[868,733,1108,734,1109,873,1110,558,1001,1111,1112,874,1113,875,876,877,878,879,880,881,465,882,1002,890,710,1004,1005,711,1114,1006,1115,1007,898,246,18,899,500,900,1008,901,1009,902,903,1010,1116,298,904,905,906,907,1011,1012,712,713,908,24,714,1013,21,1014,1015,453,910,1016,715,1027,1041,716],[673,479,937,1118],{"nctId":1836,"briefTitle":1837,"status":226,"phases":2441,"primaryCompletion":1839,"completion":1840,"start":1411,"enrollment":1841,"conditions":2442,"interventions":2443},[90,91],[734,874,875,1843,1755,465,1756,1434,1844,736,1516,246,18,1009,903,1517,1116,298,907,1283,517,1725,1285,27,1845,1776,1777,1778,1638,1779],[504,82,376],{"nctId":2445,"briefTitle":2446,"status":226,"phases":2447,"primaryCompletion":1386,"completion":2448,"start":1839,"enrollment":544,"conditions":2449,"interventions":2450},"NCT01056614","Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies",[91],"2016-04",[868,734,29,870,35,871,32,872,1111,875,877,880,882,890,1003,1593,898,18,298,1015],[937,1118,672,1043,811],{"nctId":1159,"briefTitle":1160,"status":226,"phases":2452,"primaryCompletion":1162,"completion":76,"start":1163,"enrollment":1164,"conditions":2453,"interventions":2454},[91],[488,489],[87,57,504,491,442,376,417,441],{"nctId":2456,"briefTitle":2457,"status":226,"phases":2458,"primaryCompletion":2459,"completion":2459,"start":2460,"enrollment":598,"conditions":2461,"interventions":2470},"NCT04965597","Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)",[91],"2026-02-18","2022-04-19",[2462,2463,2464,2465,1863,2466,2467,2468,2469],"Bone Marrow Failure Syndrome","Congenital Amegakaryocytic Thrombocytopenia","Diamond-Blackfan Anemia","Hereditary Sideroblastic Anemia","Shwachman-Diamond Syndrome","Hematologic Neoplasm With Germline GATA2 Mutation","Hematologic Neoplasm With Germline SAMD9 Mutation","Hematologic Neoplasm With Germline SAMD9L Mutation",[547,504,441,442,603],{"nctId":1856,"briefTitle":1857,"status":226,"phases":2472,"primaryCompletion":1859,"completion":1860,"start":1241,"enrollment":1642,"conditions":2473,"interventions":2474},[91],[1862,465,1434,1636,391,1863,1637,1864,488,517,737,738,739,740],[82,504,376],{"nctId":1867,"briefTitle":1868,"status":226,"phases":2476,"primaryCompletion":1870,"completion":1871,"start":1600,"enrollment":1053,"conditions":2477,"interventions":2478},[91],[1512,529,537,1148,21,27,1288],[82,504,376],{"nctId":2480,"briefTitle":2481,"status":226,"phases":2482,"primaryCompletion":2483,"start":1573,"enrollment":2484,"conditions":2485,"interventions":2486},"NCT00860574","Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia",[91],"2013-02",96,[868,733,734,29,870,35,871,32,872,1111,874,875,877,880,465,890,898,246,18,1116,298,910,1778,1779],[2487,937,1043,811],"treosulfan",{"nctId":2489,"briefTitle":2490,"status":226,"phases":2491,"completion":2492,"start":795,"enrollment":463,"conditions":2493,"interventions":2494},"NCT00112567","Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer",[90,91],"2007-07",[15,798],[937,960],{"nctId":1168,"briefTitle":1169,"status":114,"phases":2496,"primaryCompletion":1171,"completion":1172,"start":1173,"enrollment":98,"conditions":2497,"interventions":2498},[91],[1175],[57,504,376,1177,441],{"nctId":1883,"briefTitle":1884,"status":226,"phases":2500,"primaryCompletion":1886,"completion":1887,"start":1888,"enrollment":1145,"conditions":2501,"interventions":2502},[91],[868,733,734,29,870,35,871,32,872,873,558,1001,1111,874,875,876,877,878,879,880,881,882,883,884,885,1890,886,887,1891,1892,888,889,1893,1894,1002,890,1636,710,1004,1005,711,891,892,893,1895,894,895,1896,1897,896,897,1898,1899,1114,1006,1637,1007,898,488,537,246,18,899,500,900,1008,901,1009,902,903,1010,1116,298,904,905,906,907,1011,1012,712,713,908,24,714,1013,21,1014,27,1759,700,1015,1016,715,911,912,913,1900,914,915,1760,1761,1762,916,1763,1201,1901,1902,1903,917,918,1904,1905,1202,1906,1907,1764,1765,1766,919,1767,1203,1908,1017,1909,1910,920,921,922,1018,923,924,1020,1768,1769,925,1770,1022,1023,1024,1025,926,927,1026,1027,1029,1911,1912,928,929,930,1030,931,932,1032,1771,1772,933,1773,1034,1035,1036,1037,934,935,1038,1040,1913,1914,1041,1778,1638,1779,1639,716],[937,481,1043],{"nctId":1917,"briefTitle":1918,"status":226,"phases":2504,"primaryCompletion":1297,"completion":1297,"start":953,"enrollment":555,"conditions":2505,"interventions":2506},[91],[29,870,35,871,32,872,873,558,1001,876,877,878,879,881,882,1890,1891,1892,1893,1894,710,1004,1593,711,1895,1896,1897,1898,1899,1006,898,1921,18,899,500,900,1008,901,1009,902,903,1010,1116,298,904,906,907,1011,1012,712,713,908,24,714,1013,21,1014,27,1759,700,1015,715,1900,1761,1762,1901,1902,1903,918,1904,1922,1202,1765,1766,1908,1923,921,1018,1768,1769,1023,1024,1025,927,1026,1028,1029,929,1030,1771,1772,1035,1036,1037,935,1038,1039,1040,1775,716],[1499,937,481,479],{"nctId":1926,"briefTitle":1927,"status":226,"phases":2508,"primaryCompletion":773,"completion":1929,"start":1930,"enrollment":231,"conditions":2509,"interventions":2510},[91],[733,1932,1933,874,1934,405,1935,246,1116,1936],[82,1938,504,1939,376,1940,1941],{"nctId":1195,"briefTitle":1196,"status":226,"phases":2512,"primaryCompletion":1198,"completion":1198,"start":1199,"enrollment":598,"conditions":2513,"interventions":2514},[90,91],[529,1201,1202,1203,1204,1022,1029,1034,1040],[504,57,505,1206],{"nctId":2516,"briefTitle":2517,"status":226,"phases":2518,"completion":1182,"start":2519,"enrollment":598,"conditions":2520,"interventions":2521},"NCT00346359","Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer",[91],"2006-03",[1126,1137,15,798,799],[672,1118,937,811,1043],{"nctId":1208,"briefTitle":1209,"status":114,"phases":2523,"primaryCompletion":1211,"completion":1212,"start":1213,"enrollment":1214,"conditions":2524,"interventions":2525},[91],[1216,1217,1218],[57,504,376,418,441],{"nctId":493,"briefTitle":494,"status":114,"phases":2527,"primaryCompletion":496,"completion":496,"start":497,"enrollment":463,"conditions":2528,"interventions":2529},[91],[499,500,247,501,251,502,252],[82,504,376,505,204],{"nctId":2531,"briefTitle":2532,"status":1090,"phases":2533,"primaryCompletion":2534,"completion":2535,"start":2536,"enrollment":2537,"conditions":2538,"interventions":2540},"NCT01894477","Treo\u002FFlu\u002FTBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia",[91],"2017-01-09","2022-06","2013-11",102,[1433,465,2539,389,390,1593],"Minimal Residual Disease",[504,547],{"nctId":1959,"briefTitle":1960,"status":226,"phases":2542,"primaryCompletion":1962,"start":1963,"enrollment":9,"conditions":2543,"interventions":2544},[91],[1216,1965],[1967,82,504,376],{"nctId":1225,"briefTitle":1226,"status":226,"phases":2546,"primaryCompletion":1228,"completion":1228,"start":1229,"enrollment":1230,"conditions":2547,"interventions":2548},[90,91],[404,387,1147,685,736,1148,1149,1232,24,233,21,27,1233,234,563,1234],[57,504,376,1236,441],{"nctId":1977,"briefTitle":1978,"status":226,"phases":2550,"primaryCompletion":1980,"start":1981,"enrollment":1053,"conditions":2551,"interventions":2552},[90,91],[429,873,558,1001,876,878,1754,879,880,881,465,1002,890,710,1004,1005,1757,439,1593,1983,711,1114,1006,1007,898,1984,246,18,899,500,900,1008,901,1009,902,903,1010,1116,298,904,905,906,907,1011,1012,712,713,908,24,714,1013,1758,21,1014,27,1759,700,1016,715,1017,1027,1775,1041,716],[937,479,481,1986],{"nctId":1988,"briefTitle":1989,"status":226,"phases":2554,"primaryCompletion":1991,"completion":1991,"start":1340,"conditions":2555,"interventions":2556},[91],[15,798],[479,937,1994,811,481],{"nctId":1996,"briefTitle":1997,"status":226,"phases":2558,"completion":1999,"start":2000,"enrollment":598,"conditions":2559,"interventions":2560},[91],[15],[2003,1812,479,937,2004,481],{"nctId":2006,"briefTitle":2007,"status":226,"phases":2562,"primaryCompletion":2009,"completion":2009,"start":2010,"enrollment":1690,"conditions":2563,"interventions":2564},[91],[869,1108,2012,2013,2014,2015,2016,734,29,870,35,32,872,2017,1109,1110,453],[937,479,481],{"nctId":2028,"briefTitle":2029,"status":226,"phases":2566,"primaryCompletion":333,"completion":333,"start":2031,"enrollment":2032,"conditions":2567,"interventions":2568},[91],[403,1446,1433,433,405,530,2034],[82,504,376,547],{"nctId":1275,"briefTitle":1276,"status":226,"phases":2570,"primaryCompletion":772,"completion":1278,"start":1279,"enrollment":1280,"conditions":2571,"interventions":2572},[90,91],[537,1009,1282,1283,1148,1284,21,1285,27,1233,1286,563,1287,1288],[1290,57,82,373,692,504,491,376,1291],{"nctId":1293,"briefTitle":1294,"status":114,"phases":2574,"primaryCompletion":1296,"completion":1297,"start":1298,"enrollment":636,"conditions":2575,"interventions":2576},[91],[15,797,1096,798,799],[672,673,479,937,481],{"nctId":2045,"briefTitle":2046,"status":226,"phases":2578,"primaryCompletion":1198,"completion":1198,"start":2048,"enrollment":2049,"conditions":2579,"interventions":2580},[91],[234],[2052,82,82,504,491,376],{"nctId":39,"briefTitle":40,"status":126,"phases":2582,"primaryCompletion":41,"completion":1303,"start":1304,"enrollment":486,"conditions":2583,"interventions":2584},[90,91],[247,1148,248,1306,1307,24,714,251,252,561,1308,1309,1310,1311,1312,562,1313,1314,21,27,563,1315,1316],[42,57,504],{"nctId":1319,"briefTitle":1320,"status":226,"phases":2586,"primaryCompletion":1322,"completion":1322,"start":1323,"enrollment":1062,"conditions":2587,"interventions":2588},[91],[1325,1326,1327,1328,1329,1330],[1076,57,504,1332],{"nctId":1344,"briefTitle":1345,"status":213,"phases":2590,"primaryCompletion":1347,"completion":1348,"start":1349,"enrollment":1350,"conditions":2591,"interventions":2592},[91],[428,404,387,431,1352,388,389,391,516,559],[57,82,504,376,409],{"nctId":1355,"briefTitle":1356,"status":114,"phases":2594,"primaryCompletion":1358,"completion":1358,"start":1359,"enrollment":1360,"conditions":2595,"interventions":2596},[90,91],[18,298,453,1362,1363,1364,1065,362],[1076,57,504,1366],{"nctId":2062,"briefTitle":2063,"status":213,"phases":2598,"primaryCompletion":460,"completion":2065,"start":2066,"enrollment":11,"conditions":2599,"interventions":2600},[90,91],[404,732,387,465,407,362,1534,1533,452,365,367,388],[82,504,376],{"nctId":2602,"briefTitle":2603,"status":226,"phases":2604,"primaryCompletion":1404,"completion":1404,"start":2605,"conditions":2606,"interventions":2607},"NCT00005802","Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia",[90,91],"1999-06",[15],[719,674,1812,2194,948,937,811,2608,2609],"mitoxantrone hydrochloride","therapeutic hydrocortisone",{"nctId":2611,"briefTitle":2612,"status":226,"phases":2613,"primaryCompletion":2614,"completion":117,"start":2615,"enrollment":2616,"conditions":2617,"interventions":2619},"NCT00622895","Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis",[90,91],"2011-11-01","2006-09-01",3,[1544,2618],"Severe Systemic Sclerosis",[937,1177,1043],{"nctId":2070,"briefTitle":2071,"status":114,"phases":2621,"primaryCompletion":2073,"completion":2074,"start":2075,"enrollment":682,"conditions":2622,"interventions":2623},[91],[29,870,35,871,32,872,880,465,898,18,298,737,909,1725,739,453,910],[937,479,481],{"nctId":1428,"briefTitle":1429,"status":226,"phases":2625,"primaryCompletion":1431,"completion":1431,"start":1424,"enrollment":395,"conditions":2626,"interventions":2627},[91],[1433,1434,809,736],[57,82,504,376],{"nctId":1437,"briefTitle":1438,"status":114,"phases":2629,"primaryCompletion":1440,"completion":1440,"start":1441,"enrollment":1442,"conditions":2630,"interventions":2631},[91],[403,1444,1445,1446,1447,1433,1448,1449,1450,1451,429,1452,1453,1454,528,1455,1456,1457,389,1458,433,1306,1150,24,714,233,234,453,1459,1364],[57,374,504,376,441],{"nctId":1462,"briefTitle":1463,"status":226,"phases":2633,"primaryCompletion":1465,"completion":1465,"start":1466,"enrollment":1467,"conditions":2634,"interventions":2635},[91],[404,387,1147,1469,882,1470,797,388,389,391,1148,1306,1307,24,714,233,21,1471,27,1472,561,1233,1308,1309,563,1473],[57,82,504,376],{"nctId":2095,"briefTitle":2096,"status":226,"phases":2637,"primaryCompletion":2098,"completion":2098,"start":2099,"enrollment":2100,"conditions":2638,"interventions":2639},[91],[529,537,21,27,1022,1029,1034,1040,2102],[82,504,376,505],{"nctId":1476,"briefTitle":1477,"status":343,"phases":2641,"primaryCompletion":1479,"completion":1479,"start":1480,"enrollment":102,"conditions":2642,"interventions":2643},[91],[1446,732,465,530,1482,389,535,391,362,1150,1284,365,1362],[72,87,57,82,504,442,441],{"nctId":2645,"briefTitle":2646,"status":226,"phases":2647,"primaryCompletion":2648,"completion":2649,"start":2650,"enrollment":463,"conditions":2651,"interventions":2653},"NCT01858740","Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children",[91],"2023-01-30","2023-07-30","2014-04-10",[1556,403,428,429,733,734,1558,874,875,405,434,1559,246,18,1116,298,250,2652],"Refractory Childhood Acute Lymphoblastic Leukemia",[504,442,2416,441,409],{"nctId":2105,"briefTitle":2106,"status":226,"phases":2655,"primaryCompletion":2108,"completion":2109,"start":1135,"enrollment":1510,"conditions":2656,"interventions":2657},[90,91],[700],[937,958,481,479],{"nctId":2659,"briefTitle":2660,"status":213,"phases":2661,"primaryCompletion":2662,"completion":2662,"start":2663,"enrollment":598,"conditions":2664,"interventions":2666},"NCT03980769","Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders",[91],"2028-07-01","2021-05-05",[2665],"Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder",[409,547,504,2667],"Rabbit Anti-Thymocyte Globulin",{"nctId":2122,"briefTitle":2123,"status":226,"phases":2669,"primaryCompletion":794,"completion":2125,"start":2126,"enrollment":1062,"conditions":2670,"interventions":2671},[90,91],[1758,1774],[937,479,481,1812],{"nctId":2130,"briefTitle":2131,"status":226,"phases":2673,"primaryCompletion":1404,"start":2133,"enrollment":682,"conditions":2674,"interventions":2675},[91],[2135,2136,405,1935,1936],[504,82,376,1941],{"nctId":1505,"briefTitle":1506,"status":226,"phases":2677,"primaryCompletion":1508,"completion":1508,"start":1509,"enrollment":1510,"conditions":2678,"interventions":2679},[91],[1512,1513,1514,1515,1516,1009,1517,1282,1283,1148,233,21,1285,27,1286,234,563,1518,1519,1288,1234],[1290,57,373,692,504,491,376,441],{"nctId":2143,"briefTitle":2144,"status":226,"phases":2681,"primaryCompletion":2146,"completion":2146,"start":2147,"enrollment":2148,"conditions":2682,"interventions":2683},[91],[2150],[72,82,504,442,376,441,547],{"nctId":2153,"briefTitle":2154,"status":226,"phases":2685,"primaryCompletion":973,"completion":2156,"start":1404,"enrollment":296,"conditions":2686,"interventions":2687},[91],[429,733,734,873,558,1001,1862,874,875,876,877,878,879,880,881,465,882,1002,710,1004,1005,1757,439,1593,711,1114,1006,898,246,18,899,500,900,1008,901,1009,902,903,1010,1116,298,904,905,906,907,1011,1012,712,713,908,24,714,1013,21,1014,27,1759,700,1015,910,1016,715,1041,716],[1499,937,479,481,2159],{"nctId":2161,"briefTitle":2162,"status":226,"phases":2689,"primaryCompletion":2164,"completion":2165,"start":2166,"enrollment":1642,"conditions":2690,"interventions":2691},[91],[2168,2169,2170,2171,2172,1147,2173,2174,2175,1843,2176,529,2177,530,406,533,536,537,1148,27,1288,1234,248,1150],[82,504,376,418],{"nctId":1526,"briefTitle":1527,"status":213,"phases":2693,"primaryCompletion":1529,"completion":1530,"start":1531,"enrollment":282,"conditions":2694,"interventions":2695},[90,91],[1446,732,1433,465,407,1533,362,1534,365,452,367,406],[602,57,376,468,504,441],{"nctId":2188,"briefTitle":2189,"status":226,"phases":2697,"completion":794,"start":2191,"conditions":2698,"interventions":2699},[90,91],[15],[1812,479,2194,937,811,481],{"nctId":2196,"briefTitle":2197,"status":226,"phases":2701,"primaryCompletion":2199,"completion":2200,"start":2201,"enrollment":2202,"conditions":2702,"interventions":2703},[91],[1593,736,27,234,1234,1556,733,734,2204,2205,2206,2207,1862,1558,874,875,876,2136,878,2208,1843,2209,2210,2211,2212,2213,2214,2215,2216,2217,2218,2219,2220,2221,2222,2223,2224,2225,2226,2227,2228,1204,246,18,899,500,900,1008,1009,2229,903,1116,298,904,906,907,2230,712,713,908,24,714,21,1282,1149,2231,911,912,913,2232,915,1761,1762,916,2233,1902,1903,917,918,1904,1202,1765,919,2234,920,921,922,1018,2235,924,1768,1769,925,2236,1024,1025,926,927,1026,1029,928,929,930,1030,2237,932,1771,1772,933,2238,1036,1037,934,935,1038,1040],[504,441,376,418],{"nctId":1548,"briefTitle":1549,"status":226,"phases":2705,"primaryCompletion":1551,"completion":1552,"start":1553,"enrollment":1554,"conditions":2706,"interventions":2707},[91],[1556,403,428,429,1557,1558,431,874,875,1363,438,407,434,1559,1533,362,1116,298,1149,1534,365,1446,1433],[57,504,442,376,441,409],{"nctId":2709,"briefTitle":2710,"status":114,"phases":2711,"primaryCompletion":973,"completion":973,"start":1633,"enrollment":135,"conditions":2712,"interventions":2713},"NCT00450983","Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases",[91],[1137,15,798],[2714,2715,937,811,960,1046],"muromonab-CD3","natural killer cell therapy",{"trials":2717,"activeCount":102},[2718,2722,2726],{"nctId":2252,"briefTitle":2253,"status":226,"phases":2719,"primaryCompletion":2255,"completion":2256,"start":2257,"enrollment":2258,"conditions":2720,"interventions":2721},[92],[404,387,1147,529,685,406,1470,533,389,391,537,1148,233,27,2260,1233,538,1287,1234],[82,504,376,418],{"nctId":1585,"briefTitle":1586,"status":226,"phases":2723,"primaryCompletion":1588,"completion":1589,"start":1241,"enrollment":807,"conditions":2724,"interventions":2725},[92],[869,1591,734,29,870,35,871,32,872,875,880,890,1592,1593,898,18,298,453,910],[673,481,1118,479,937,1595,1044,1045,1043,811],{"nctId":2267,"briefTitle":2268,"status":226,"phases":2727,"primaryCompletion":998,"completion":2270,"start":2271,"enrollment":2272,"conditions":2728,"interventions":2729},[92],[1446,1433,1147,530,685,406,1470,533,390,536,27,1233,1234],[504,376,82],{"trials":2731,"activeCount":102},[],{"trials":2733,"activeCount":102},[2734,2738,2742],{"nctId":2289,"briefTitle":2290,"status":226,"phases":2735,"primaryCompletion":2000,"start":2292,"enrollment":2293,"conditions":2736,"interventions":2737},[94],[1591,429,733,734,29,870,35,871,32,872,873,558,1001,431,874,875,876,878,879,880,881,465,1002,890,710,1004,1005,1757,439,1593,711,1114,1006,1007,898,1984,246,18,899,500,900,1008,901,1009,902,903,1010,1116,298,904,905,906,907,1011,1012,712,713,908,24,714,1013,21,1014,27,1759,700,1016,715,1017,1027,1775,1041,1778,1638,1779,1639,716],[937,479,481],{"nctId":2297,"briefTitle":2298,"status":226,"phases":2739,"primaryCompletion":1991,"start":1818,"enrollment":244,"conditions":2740,"interventions":2741},[94],[868,733,734,29,870,35,871,32,872,709,874,875,877,880,1755,882,1756,890,710,711,898,246,18,1008,1009,1116,298,1012,712,713,714,1013,21,1014,27,1759,700,1015,715,2301,1774,1775,1776,1777,716],[937,1812,479,481],{"nctId":2304,"briefTitle":2305,"status":226,"phases":2743,"primaryCompletion":2307,"start":1818,"enrollment":2308,"conditions":2744,"interventions":2745},[94],[868,429,733,734,29,870,35,871,32,872,1753,873,2310,2311,2312,2313,2314,2315,2316,2317,2318,558,1001,1111,874,875,876,877,878,1754,879,880,881,2319,465,2320,882,883,884,885,1890,886,887,1891,1892,888,889,1893,1894,1002,1636,2321,710,1004,133,2322,1005,2323,1757,439,2324,1593,1983,711,891,892,893,1895,894,895,1896,1897,896,897,1898,1899,1114,1006,1637,1007,898,2325,488,1984,1921,537,453,910,1016,715,2326,911,912,913,1900,2327,914,915,1760,1761,2328,1762,916,1763,1201,1901,1902,1903,917,918,1904,1905,1202,1906,1907,2329,1764,1765,2330,1766,919,1767,1203,1908,1017,1909,1910,920,921,922,1018,1019,923,924,1020,1768,1021,1769,925,1770,1022,1023,1024,1025,926,927,1026,1027,1029,1911,1912,928,929,930,1030,1031,931,932,1032,1771,1033,1772,933,1773,1034,1035,1036,1037,934,935,1038,1040,1913,1914,1775,1041,956,1413,716],[937,479,481],{"intervention":479,"totalTrials":1642,"cells":2747},{"EARLY_PHASE1":2748,"PHASE1":2750,"PHASE2":2792,"PHASE3":3031,"PHASE4":3056,"NA":3058},{"trials":2749,"activeCount":102},[],{"trials":2751,"activeCount":135,"soonestReadout":357},[2752,2756,2760,2764,2768,2772,2776,2780,2784,2788],{"nctId":1649,"briefTitle":1650,"status":226,"phases":2753,"primaryCompletion":1652,"completion":1653,"start":1654,"enrollment":944,"conditions":2754,"interventions":2755},[90],[536,234],[82,504,376],{"nctId":1662,"briefTitle":1663,"status":226,"phases":2757,"primaryCompletion":1083,"start":1665,"enrollment":98,"conditions":2758,"interventions":2759},[90],[734,29,870,35,871,32,872,875,880,809,898],[937,479,481],{"nctId":1669,"briefTitle":1670,"status":226,"phases":2761,"primaryCompletion":1672,"completion":1673,"start":1674,"enrollment":395,"conditions":2762,"interventions":2763},[90],[1676,1677,1678,1679,1680,1681,1682],[82,376],{"nctId":802,"briefTitle":803,"status":226,"phases":2765,"primaryCompletion":805,"start":806,"enrollment":807,"conditions":2766,"interventions":2767},[90],[809],[673,479,811],{"nctId":1685,"briefTitle":1686,"status":226,"phases":2769,"primaryCompletion":1688,"start":1689,"enrollment":1690,"conditions":2770,"interventions":2771},[90],[465,1593,736,246,18,737,739,1692,453],[1694,82,376,504],{"nctId":862,"briefTitle":863,"status":226,"phases":2773,"primaryCompletion":865,"start":866,"enrollment":544,"conditions":2774,"interventions":2775},[90],[868,869,733,734,29,870,35,871,32,872,873,558,874,875,876,877,878,879,880,881,882,883,884,885,886,887,888,889,890,710,711,891,892,893,894,895,896,897,898,537,899,500,900,901,902,903,904,905,906,907,712,713,908,24,714,21,517,737,909,27,700,453,910,715,911,912,913,914,915,916,917,918,919,920,921,922,923,924,925,926,927,928,929,930,931,932,933,934,935],[673,937,479,481],{"nctId":354,"briefTitle":355,"status":213,"phases":2777,"primaryCompletion":357,"completion":358,"start":359,"enrollment":360,"conditions":2778,"interventions":2779},[90],[362,363,364,365,366,367,368,369,370],[372,57,82,373,374,375,376,377,378,204,373],{"nctId":979,"briefTitle":980,"status":114,"phases":2781,"primaryCompletion":982,"start":983,"enrollment":282,"conditions":2782,"interventions":2783},[90],[415],[673,672,479,481,986,674],{"nctId":1708,"briefTitle":1709,"status":226,"phases":2785,"primaryCompletion":1711,"completion":1712,"start":830,"enrollment":1510,"conditions":2786,"interventions":2787},[90],[465,736,246,18,737,453],[82,504,1715,376],{"nctId":1717,"briefTitle":1718,"status":226,"phases":2789,"primaryCompletion":1720,"completion":1721,"start":1722,"enrollment":1723,"conditions":2790,"interventions":2791},[90],[734,29,870,35,871,32,872,465,890,898,18,737,909,1725,739,910,1638],[937,479,481],{"trials":2793,"activeCount":2308,"soonestReadout":81},[2794,2798,2802,2806,2810,2814,2818,2822,2826,2830,2834,2838,2842,2846,2850,2854,2858,2862,2866,2870,2878,2882,2886,2892,2896,2900,2904,2908,2912,2916,2920,2924,2928,2932,2936,2940,2944,2948,2952,2956,2960,2964,2968,2972,2976,2980,2984,2988,2992,2996,3000,3004,3008,3012,3016,3020,3027],{"nctId":1730,"briefTitle":1731,"status":226,"phases":2795,"completion":1182,"start":1733,"enrollment":11,"conditions":2796,"interventions":2797},[90,91],[15],[479,937,481],{"nctId":1737,"briefTitle":1738,"status":226,"phases":2799,"primaryCompletion":1740,"completion":1741,"start":1742,"enrollment":1743,"conditions":2800,"interventions":2801},[91],[709,711,899,500,900,1008,901,902,903,712,713,908,24,714,21,715,716],[1746,479,937,481],{"nctId":1748,"briefTitle":1749,"status":226,"phases":2803,"primaryCompletion":1241,"start":1751,"enrollment":19,"conditions":2804,"interventions":2805},[90,91],[868,733,734,29,870,35,871,32,872,1753,873,558,1001,874,875,876,877,878,1754,879,880,881,1755,465,882,1756,883,884,885,886,887,888,889,890,710,1004,1757,1593,711,891,892,893,894,895,896,897,1114,1006,1007,898,246,18,899,500,900,1008,901,1009,902,903,1010,1116,298,904,905,906,907,1011,1012,712,713,908,24,714,1013,1758,21,1014,517,1725,27,1759,700,1015,715,911,912,913,914,915,1760,1761,1762,916,1763,917,918,1764,1765,1766,919,1767,920,921,922,923,924,1020,1768,1769,925,1770,926,927,928,929,930,931,932,1032,1771,1772,933,1773,934,935,1774,1775,1776,1777,1778,1638,1779,1639,716],[937,479,481],{"nctId":1048,"briefTitle":1049,"status":226,"phases":2807,"primaryCompletion":1051,"completion":1052,"start":983,"enrollment":1053,"conditions":2808,"interventions":2809},[91],[415],[673,672,479,811,986,1045],{"nctId":1786,"briefTitle":1787,"status":226,"phases":2811,"primaryCompletion":1789,"completion":1790,"start":1791,"enrollment":1792,"conditions":2812,"interventions":2813},[91],[387],[77,82,376],{"nctId":1796,"briefTitle":1797,"status":226,"phases":2815,"primaryCompletion":1278,"completion":1799,"start":1800,"enrollment":1360,"conditions":2816,"interventions":2817},[91],[1147,433,529,1514,390,516,537,246,18,1802,1116,298,1148,1149,248,1150,24,1284,233,21,1234],[1804,82,504,376],{"nctId":2422,"briefTitle":2423,"status":226,"phases":2819,"primaryCompletion":2075,"completion":2075,"start":2425,"conditions":2820,"interventions":2821},[91],[15,798],[1118,479,937,811],{"nctId":1806,"briefTitle":1807,"status":226,"phases":2823,"completion":1809,"start":1665,"conditions":2824,"interventions":2825},[91],[1626],[1812,479,937,481],{"nctId":1814,"briefTitle":1815,"status":226,"phases":2827,"primaryCompletion":1817,"completion":1817,"start":1818,"conditions":2828,"interventions":2829},[91],[1820,1821],[1812,479,937,481],{"nctId":1101,"briefTitle":1102,"status":226,"phases":2831,"primaryCompletion":1104,"completion":1105,"start":1106,"enrollment":1094,"conditions":2832,"interventions":2833},[91],[868,733,1108,734,1109,873,1110,558,1001,1111,1112,874,1113,875,876,877,878,879,880,881,465,882,1002,890,710,1004,1005,711,1114,1006,1115,1007,898,246,18,899,500,900,1008,901,1009,902,903,1010,1116,298,904,905,906,907,1011,1012,712,713,908,24,714,1013,21,1014,1015,453,910,1016,715,1027,1041,716],[673,479,937,1118],{"nctId":1131,"briefTitle":1132,"status":226,"phases":2835,"completion":1134,"start":1135,"conditions":2836,"interventions":2837},[90,91],[1126,1137,15,798,799],[672,1118,673,479,811],{"nctId":1140,"briefTitle":1141,"status":114,"phases":2839,"primaryCompletion":1143,"completion":1143,"start":1144,"enrollment":1145,"conditions":2840,"interventions":2841},[91],[404,387,1147,529,685,533,389,390,537,1148,1149,1150,233,21,1151,1152,431],[57,82,376,418],{"nctId":1836,"briefTitle":1837,"status":226,"phases":2843,"primaryCompletion":1839,"completion":1840,"start":1411,"enrollment":1841,"conditions":2844,"interventions":2845},[90,91],[734,874,875,1843,1755,465,1756,1434,1844,736,1516,246,18,1009,903,1517,1116,298,907,1283,517,1725,1285,27,1845,1776,1777,1778,1638,1779],[504,82,376],{"nctId":79,"briefTitle":80,"status":126,"phases":2847,"primaryCompletion":81,"completion":412,"start":413,"enrollment":135,"conditions":2848,"interventions":2849},[91],[415],[82,204,393,376,417,418],{"nctId":1856,"briefTitle":1857,"status":226,"phases":2851,"primaryCompletion":1859,"completion":1860,"start":1241,"enrollment":1642,"conditions":2852,"interventions":2853},[91],[1862,465,1434,1636,391,1863,1637,1864,488,517,737,738,739,740],[82,504,376],{"nctId":1867,"briefTitle":1868,"status":226,"phases":2855,"primaryCompletion":1870,"completion":1871,"start":1600,"enrollment":1053,"conditions":2856,"interventions":2857},[91],[1512,529,537,1148,21,27,1288],[82,504,376],{"nctId":1179,"briefTitle":1180,"status":226,"phases":2859,"primaryCompletion":1182,"start":1183,"enrollment":475,"conditions":2860,"interventions":2861},[91],[15,797,798],[673,479,811,481,1186,1043],{"nctId":1917,"briefTitle":1918,"status":226,"phases":2863,"primaryCompletion":1297,"completion":1297,"start":953,"enrollment":555,"conditions":2864,"interventions":2865},[91],[29,870,35,871,32,872,873,558,1001,876,877,878,879,881,882,1890,1891,1892,1893,1894,710,1004,1593,711,1895,1896,1897,1898,1899,1006,898,1921,18,899,500,900,1008,901,1009,902,903,1010,1116,298,904,906,907,1011,1012,712,713,908,24,714,1013,21,1014,27,1759,700,1015,715,1900,1761,1762,1901,1902,1903,918,1904,1922,1202,1765,1766,1908,1923,921,1018,1768,1769,1023,1024,1025,927,1026,1028,1029,929,1030,1771,1772,1035,1036,1037,935,1038,1039,1040,1775,716],[1499,937,481,479],{"nctId":1188,"briefTitle":1189,"status":226,"phases":2867,"primaryCompletion":795,"completion":795,"start":1191,"enrollment":463,"conditions":2868,"interventions":2869},[91],[1126,15,799],[1118,673,479,811,1043],{"nctId":2871,"briefTitle":2872,"status":114,"phases":2873,"primaryCompletion":848,"completion":848,"start":2874,"enrollment":395,"conditions":2875,"interventions":2876},"NCT01342887","Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",[90,91],"2011-04",[1108,2012,2013,2014,2015,2016,29,870,35,32,872,2017,1109,1110,18],[479,2877,2608,948],"pravastatin sodium",{"nctId":1926,"briefTitle":1927,"status":226,"phases":2879,"primaryCompletion":773,"completion":1929,"start":1930,"enrollment":231,"conditions":2880,"interventions":2881},[91],[733,1932,1933,874,1934,405,1935,246,1116,1936],[82,1938,504,1939,376,1940,1941],{"nctId":470,"briefTitle":471,"status":226,"phases":2883,"primaryCompletion":473,"start":474,"enrollment":475,"conditions":2884,"interventions":2885},[90,91],[477],[479,480,481],{"nctId":2887,"briefTitle":2888,"status":343,"phases":2889,"start":1565,"enrollment":102,"conditions":2890,"interventions":2891},"NCT00002790","Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant",[90,91],[1137,15,798],[479,811,1186],{"nctId":493,"briefTitle":494,"status":114,"phases":2893,"primaryCompletion":496,"completion":496,"start":497,"enrollment":463,"conditions":2894,"interventions":2895},[91],[499,500,247,501,251,502,252],[82,504,376,505,204],{"nctId":1959,"briefTitle":1960,"status":226,"phases":2897,"primaryCompletion":1962,"start":1963,"enrollment":9,"conditions":2898,"interventions":2899},[91],[1216,1965],[1967,82,504,376],{"nctId":1238,"briefTitle":1239,"status":226,"phases":2901,"primaryCompletion":1241,"start":1124,"enrollment":682,"conditions":2902,"interventions":2903},[91],[734,29,870,35,871,32,872],[1118,673,479,811],{"nctId":520,"briefTitle":521,"status":226,"phases":2905,"primaryCompletion":523,"completion":524,"start":525,"enrollment":526,"conditions":2906,"interventions":2907},[91],[403,404,387,528,529,405,530,531,438,532,533,534,389,535,516,536,537,517,538],[57,82,204,376,409],{"nctId":1977,"briefTitle":1978,"status":226,"phases":2909,"primaryCompletion":1980,"start":1981,"enrollment":1053,"conditions":2910,"interventions":2911},[90,91],[429,873,558,1001,876,878,1754,879,880,881,465,1002,890,710,1004,1005,1757,439,1593,1983,711,1114,1006,1007,898,1984,246,18,899,500,900,1008,901,1009,902,903,1010,1116,298,904,905,906,907,1011,1012,712,713,908,24,714,1013,1758,21,1014,27,1759,700,1016,715,1017,1027,1775,1041,716],[937,479,481,1986],{"nctId":1988,"briefTitle":1989,"status":226,"phases":2913,"primaryCompletion":1991,"completion":1991,"start":1340,"conditions":2914,"interventions":2915},[91],[15,798],[479,937,1994,811,481],{"nctId":1996,"briefTitle":1997,"status":226,"phases":2917,"completion":1999,"start":2000,"enrollment":598,"conditions":2918,"interventions":2919},[91],[15],[2003,1812,479,937,2004,481],{"nctId":2006,"briefTitle":2007,"status":226,"phases":2921,"primaryCompletion":2009,"completion":2009,"start":2010,"enrollment":1690,"conditions":2922,"interventions":2923},[91],[869,1108,2012,2013,2014,2015,2016,734,29,870,35,32,872,2017,1109,1110,453],[937,479,481],{"nctId":2020,"briefTitle":2021,"status":226,"phases":2925,"primaryCompletion":2023,"start":2024,"enrollment":598,"conditions":2926,"interventions":2927},[90,91],[700,1905,1017,1027],[958,479,481,1812],{"nctId":2028,"briefTitle":2029,"status":226,"phases":2929,"primaryCompletion":333,"completion":333,"start":2031,"enrollment":2032,"conditions":2930,"interventions":2931},[91],[403,1446,1433,433,405,530,2034],[82,504,376,547],{"nctId":1268,"briefTitle":1269,"status":226,"phases":2933,"completion":473,"start":1271,"conditions":2934,"interventions":2935},[91],[15,798],[1118,673,479,811],{"nctId":1275,"briefTitle":1276,"status":226,"phases":2937,"primaryCompletion":772,"completion":1278,"start":1279,"enrollment":1280,"conditions":2938,"interventions":2939},[90,91],[537,1009,1282,1283,1148,1284,21,1285,27,1233,1286,563,1287,1288],[1290,57,82,373,692,504,491,376,1291],{"nctId":1293,"briefTitle":1294,"status":114,"phases":2941,"primaryCompletion":1296,"completion":1297,"start":1298,"enrollment":636,"conditions":2942,"interventions":2943},[91],[15,797,1096,798,799],[672,673,479,937,481],{"nctId":2045,"briefTitle":2046,"status":226,"phases":2945,"primaryCompletion":1198,"completion":1198,"start":2048,"enrollment":2049,"conditions":2946,"interventions":2947},[91],[234],[2052,82,82,504,491,376],{"nctId":549,"briefTitle":550,"status":213,"phases":2949,"primaryCompletion":552,"completion":553,"start":554,"enrollment":555,"conditions":2950,"interventions":2951},[91],[427,404,387,557,558,528,559,465,560,438,532,533,388,389,537,27,561,562,563],[57,82,374,204,376,377,547],{"nctId":1338,"briefTitle":1121,"status":226,"phases":2953,"completion":1340,"start":474,"conditions":2954,"interventions":2955},[91],[15,797,1096,798],[673,479,811],{"nctId":1344,"briefTitle":1345,"status":213,"phases":2957,"primaryCompletion":1347,"completion":1348,"start":1349,"enrollment":1350,"conditions":2958,"interventions":2959},[91],[428,404,387,431,1352,388,389,391,516,559],[57,82,504,376,409],{"nctId":2062,"briefTitle":2063,"status":213,"phases":2961,"primaryCompletion":460,"completion":2065,"start":2066,"enrollment":11,"conditions":2962,"interventions":2963},[90,91],[404,732,387,465,407,362,1534,1533,452,365,367,388],[82,504,376],{"nctId":2070,"briefTitle":2071,"status":114,"phases":2965,"primaryCompletion":2073,"completion":2074,"start":2075,"enrollment":682,"conditions":2966,"interventions":2967},[91],[29,870,35,871,32,872,880,465,898,18,298,737,909,1725,739,453,910],[937,479,481],{"nctId":583,"briefTitle":584,"status":213,"phases":2969,"primaryCompletion":586,"completion":587,"start":588,"enrollment":360,"conditions":2970,"interventions":2971},[91],[427,404,387,389,391],[409,204,441,591,442,57,467,82,418,87],{"nctId":1421,"briefTitle":1422,"status":226,"phases":2973,"primaryCompletion":1424,"start":999,"enrollment":282,"conditions":2974,"interventions":2975},[90,91],[1126,15,798,799],[1118,673,479,811],{"nctId":1428,"briefTitle":1429,"status":226,"phases":2977,"primaryCompletion":1431,"completion":1431,"start":1424,"enrollment":395,"conditions":2978,"interventions":2979},[91],[1433,1434,809,736],[57,82,504,376],{"nctId":1462,"briefTitle":1463,"status":226,"phases":2981,"primaryCompletion":1465,"completion":1465,"start":1466,"enrollment":1467,"conditions":2982,"interventions":2983},[91],[404,387,1147,1469,882,1470,797,388,389,391,1148,1306,1307,24,714,233,21,1471,27,1472,561,1233,1308,1309,563,1473],[57,82,504,376],{"nctId":2095,"briefTitle":2096,"status":226,"phases":2985,"primaryCompletion":2098,"completion":2098,"start":2099,"enrollment":2100,"conditions":2986,"interventions":2987},[91],[529,537,21,27,1022,1029,1034,1040,2102],[82,504,376,505],{"nctId":1476,"briefTitle":1477,"status":343,"phases":2989,"primaryCompletion":1479,"completion":1479,"start":1480,"enrollment":102,"conditions":2990,"interventions":2991},[91],[1446,732,465,530,1482,389,535,391,362,1150,1284,365,1362],[72,87,57,82,504,442,441],{"nctId":2105,"briefTitle":2106,"status":226,"phases":2993,"primaryCompletion":2108,"completion":2109,"start":1135,"enrollment":1510,"conditions":2994,"interventions":2995},[90,91],[700],[937,958,481,479],{"nctId":2113,"briefTitle":2114,"status":226,"phases":2997,"primaryCompletion":2116,"completion":2117,"start":2075,"enrollment":22,"conditions":2998,"interventions":2999},[91],[404,387,529,405,1137,560,390,516,536,1234],[82,376,2120,1941],{"nctId":2122,"briefTitle":2123,"status":226,"phases":3001,"primaryCompletion":794,"completion":2125,"start":2126,"enrollment":1062,"conditions":3002,"interventions":3003},[90,91],[1758,1774],[937,479,481,1812],{"nctId":2130,"briefTitle":2131,"status":226,"phases":3005,"primaryCompletion":1404,"start":2133,"enrollment":682,"conditions":3006,"interventions":3007},[91],[2135,2136,405,1935,1936],[504,82,376,1941],{"nctId":2143,"briefTitle":2144,"status":226,"phases":3009,"primaryCompletion":2146,"completion":2146,"start":2147,"enrollment":2148,"conditions":3010,"interventions":3011},[91],[2150],[72,82,504,442,376,441,547],{"nctId":2153,"briefTitle":2154,"status":226,"phases":3013,"primaryCompletion":973,"completion":2156,"start":1404,"enrollment":296,"conditions":3014,"interventions":3015},[91],[429,733,734,873,558,1001,1862,874,875,876,877,878,879,880,881,465,882,1002,710,1004,1005,1757,439,1593,711,1114,1006,898,246,18,899,500,900,1008,901,1009,902,903,1010,1116,298,904,905,906,907,1011,1012,712,713,908,24,714,1013,21,1014,27,1759,700,1015,910,1016,715,1041,716],[1499,937,479,481,2159],{"nctId":2161,"briefTitle":2162,"status":226,"phases":3017,"primaryCompletion":2164,"completion":2165,"start":2166,"enrollment":1642,"conditions":3018,"interventions":3019},[91],[2168,2169,2170,2171,2172,1147,2173,2174,2175,1843,2176,529,2177,530,406,533,536,537,1148,27,1288,1234,248,1150],[82,504,376,418],{"nctId":3021,"briefTitle":3022,"status":226,"phases":3023,"completion":2519,"start":3024,"conditions":3025,"interventions":3026},"NCT00089050","Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia",[91],"2004-05",[15],[479,1994],{"nctId":2188,"briefTitle":2189,"status":226,"phases":3028,"completion":794,"start":2191,"conditions":3029,"interventions":3030},[90,91],[15],[1812,479,2194,937,811,481],{"trials":3032,"activeCount":102},[3033,3037,3041,3045,3049],{"nctId":2252,"briefTitle":2253,"status":226,"phases":3034,"primaryCompletion":2255,"completion":2256,"start":2257,"enrollment":2258,"conditions":3035,"interventions":3036},[92],[404,387,1147,529,685,406,1470,533,389,391,537,1148,233,27,2260,1233,538,1287,1234],[82,504,376,418],{"nctId":1585,"briefTitle":1586,"status":226,"phases":3038,"primaryCompletion":1588,"completion":1589,"start":1241,"enrollment":807,"conditions":3039,"interventions":3040},[92],[869,1591,734,29,870,35,871,32,872,875,880,890,1592,1593,898,18,298,453,910],[673,481,1118,479,937,1595,1044,1045,1043,811],{"nctId":2267,"briefTitle":2268,"status":226,"phases":3042,"primaryCompletion":998,"completion":2270,"start":2271,"enrollment":2272,"conditions":3043,"interventions":3044},[92],[1446,1433,1147,530,685,406,1470,533,390,536,27,1233,1234],[504,376,82],{"nctId":1609,"briefTitle":1610,"status":226,"phases":3046,"primaryCompletion":1612,"completion":1612,"start":1613,"enrollment":748,"conditions":3047,"interventions":3048},[92],[15],[1118,673,479,811],{"nctId":3050,"briefTitle":3051,"status":226,"phases":3052,"completion":2010,"start":3053,"conditions":3054,"interventions":3055},"NCT00002456","Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation",[92],"1986-05",[1137,15,797],[479,811],{"trials":3057,"activeCount":102},[],{"trials":3059,"activeCount":102},[3060,3064,3068,3072,3076],{"nctId":2280,"briefTitle":2281,"status":226,"phases":3061,"primaryCompletion":2010,"completion":2010,"start":2283,"enrollment":2284,"conditions":3062,"interventions":3063},[94],[873,558,1001,1002,710,1004,1005,711,1114,1006,246,899,500,900,1008,901,902,903,1010,1012,712,713,908,24,714,1013,21,27,1759,700,1016,715,1017,1027,1041,716],[2287,479,481,1812],{"nctId":2289,"briefTitle":2290,"status":226,"phases":3065,"primaryCompletion":2000,"start":2292,"enrollment":2293,"conditions":3066,"interventions":3067},[94],[1591,429,733,734,29,870,35,871,32,872,873,558,1001,431,874,875,876,878,879,880,881,465,1002,890,710,1004,1005,1757,439,1593,711,1114,1006,1007,898,1984,246,18,899,500,900,1008,901,1009,902,903,1010,1116,298,904,905,906,907,1011,1012,712,713,908,24,714,1013,21,1014,27,1759,700,1016,715,1017,1027,1775,1041,1778,1638,1779,1639,716],[937,479,481],{"nctId":2297,"briefTitle":2298,"status":226,"phases":3069,"primaryCompletion":1991,"start":1818,"enrollment":244,"conditions":3070,"interventions":3071},[94],[868,733,734,29,870,35,871,32,872,709,874,875,877,880,1755,882,1756,890,710,711,898,246,18,1008,1009,1116,298,1012,712,713,714,1013,21,1014,27,1759,700,1015,715,2301,1774,1775,1776,1777,716],[937,1812,479,481],{"nctId":2304,"briefTitle":2305,"status":226,"phases":3073,"primaryCompletion":2307,"start":1818,"enrollment":2308,"conditions":3074,"interventions":3075},[94],[868,429,733,734,29,870,35,871,32,872,1753,873,2310,2311,2312,2313,2314,2315,2316,2317,2318,558,1001,1111,874,875,876,877,878,1754,879,880,881,2319,465,2320,882,883,884,885,1890,886,887,1891,1892,888,889,1893,1894,1002,1636,2321,710,1004,133,2322,1005,2323,1757,439,2324,1593,1983,711,891,892,893,1895,894,895,1896,1897,896,897,1898,1899,1114,1006,1637,1007,898,2325,488,1984,1921,537,453,910,1016,715,2326,911,912,913,1900,2327,914,915,1760,1761,2328,1762,916,1763,1201,1901,1902,1903,917,918,1904,1905,1202,1906,1907,2329,1764,1765,2330,1766,919,1767,1203,1908,1017,1909,1910,920,921,922,1018,1019,923,924,1020,1768,1021,1769,925,1770,1022,1023,1024,1025,926,927,1026,1027,1029,1911,1912,928,929,930,1030,1031,931,932,1032,1771,1033,1772,933,1773,1034,1035,1036,1037,934,935,1038,1040,1913,1914,1775,1041,956,1413,716],[937,479,481],{"nctId":644,"briefTitle":645,"status":226,"phases":3077,"primaryCompletion":647,"start":648,"enrollment":463,"conditions":3078,"interventions":3079},[94],[650,651],[479,480,481],{"intervention":441,"totalTrials":25,"cells":3081},{"EARLY_PHASE1":3082,"PHASE1":3084,"PHASE2":3090,"PHASE3":3230,"PHASE4":3236,"NA":3238},{"trials":3083,"activeCount":102},[],{"trials":3085,"activeCount":102},[3086],{"nctId":724,"briefTitle":725,"status":114,"phases":3087,"primaryCompletion":727,"completion":728,"start":729,"enrollment":730,"conditions":3088,"interventions":3089},[90],[732,733,734,735,465,736,737,738,739,740],[57,504,376,441],{"trials":3091,"activeCount":395,"soonestReadout":86},[3092,3096,3100,3104,3108,3112,3116,3120,3124,3128,3132,3136,3140,3150,3154,3158,3162,3166,3172,3176,3180,3184,3188,3192,3196,3200,3204,3208,3214,3218,3222,3226],{"nctId":994,"briefTitle":995,"status":226,"phases":3093,"primaryCompletion":997,"completion":998,"start":999,"enrollment":486,"conditions":3094,"interventions":3095},[91],[868,733,734,29,870,35,871,32,872,873,558,1001,874,875,876,877,880,881,1002,890,710,1003,1004,1005,711,1006,1007,898,899,500,900,1008,901,1009,902,903,1010,904,905,906,907,1011,1012,712,713,908,24,714,1013,21,1014,27,700,1015,910,1016,715,1017,920,921,922,1018,1019,923,924,1020,1021,1022,1023,1024,1025,926,927,1026,1027,1028,1029,928,929,930,1030,1031,931,932,1032,1033,1034,1035,1036,1037,934,935,1038,1039,1040,1041,716],[673,937,1043,481,720,1044,1045,1046],{"nctId":2408,"briefTitle":2409,"status":114,"phases":3097,"primaryCompletion":2411,"completion":2412,"start":2413,"enrollment":1230,"conditions":3098,"interventions":3099},[91],[1137,15,798],[504,441,409,2416],{"nctId":1824,"briefTitle":1825,"status":226,"phases":3101,"primaryCompletion":1827,"start":1828,"conditions":3102,"interventions":3103},[91],[1126,1137,15,797,1096,798,799],[481,1043],{"nctId":2445,"briefTitle":2446,"status":226,"phases":3105,"primaryCompletion":1386,"completion":2448,"start":1839,"enrollment":544,"conditions":3106,"interventions":3107},[91],[868,734,29,870,35,871,32,872,1111,875,877,880,882,890,1003,1593,898,18,298,1015],[937,1118,672,1043,811],{"nctId":420,"briefTitle":421,"status":213,"phases":3109,"primaryCompletion":423,"completion":423,"start":424,"enrollment":425,"conditions":3110,"interventions":3111},[91],[403,427,428,404,429,430,431,432,433,388,434,435,436,437,438,439,391],[409,204,57,87,441,442],{"nctId":1159,"briefTitle":1160,"status":226,"phases":3113,"primaryCompletion":1162,"completion":76,"start":1163,"enrollment":1164,"conditions":3114,"interventions":3115},[91],[488,489],[87,57,504,491,442,376,417,441],{"nctId":2456,"briefTitle":2457,"status":226,"phases":3117,"primaryCompletion":2459,"completion":2459,"start":2460,"enrollment":598,"conditions":3118,"interventions":3119},[91],[2462,2463,2464,2465,1863,2466,2467,2468,2469],[547,504,441,442,603],{"nctId":2480,"briefTitle":2481,"status":226,"phases":3121,"primaryCompletion":2483,"start":1573,"enrollment":2484,"conditions":3122,"interventions":3123},[91],[868,733,734,29,870,35,871,32,872,1111,874,875,877,880,465,890,898,246,18,1116,298,910,1778,1779],[2487,937,1043,811],{"nctId":1168,"briefTitle":1169,"status":114,"phases":3125,"primaryCompletion":1171,"completion":1172,"start":1173,"enrollment":98,"conditions":3126,"interventions":3127},[91],[1175],[57,504,376,1177,441],{"nctId":1179,"briefTitle":1180,"status":226,"phases":3129,"primaryCompletion":1182,"start":1183,"enrollment":475,"conditions":3130,"interventions":3131},[91],[15,797,798],[673,479,811,481,1186,1043],{"nctId":1883,"briefTitle":1884,"status":226,"phases":3133,"primaryCompletion":1886,"completion":1887,"start":1888,"enrollment":1145,"conditions":3134,"interventions":3135},[91],[868,733,734,29,870,35,871,32,872,873,558,1001,1111,874,875,876,877,878,879,880,881,882,883,884,885,1890,886,887,1891,1892,888,889,1893,1894,1002,890,1636,710,1004,1005,711,891,892,893,1895,894,895,1896,1897,896,897,1898,1899,1114,1006,1637,1007,898,488,537,246,18,899,500,900,1008,901,1009,902,903,1010,1116,298,904,905,906,907,1011,1012,712,713,908,24,714,1013,21,1014,27,1759,700,1015,1016,715,911,912,913,1900,914,915,1760,1761,1762,916,1763,1201,1901,1902,1903,917,918,1904,1905,1202,1906,1907,1764,1765,1766,919,1767,1203,1908,1017,1909,1910,920,921,922,1018,923,924,1020,1768,1769,925,1770,1022,1023,1024,1025,926,927,1026,1027,1029,1911,1912,928,929,930,1030,931,932,1032,1771,1772,933,1773,1034,1035,1036,1037,934,935,1038,1040,1913,1914,1041,1778,1638,1779,1639,716],[937,481,1043],{"nctId":1188,"briefTitle":1189,"status":226,"phases":3137,"primaryCompletion":795,"completion":795,"start":1191,"enrollment":463,"conditions":3138,"interventions":3139},[91],[1126,15,799],[1118,673,479,811,1043],{"nctId":3141,"briefTitle":3142,"status":226,"phases":3143,"primaryCompletion":2257,"start":647,"enrollment":3144,"conditions":3145,"interventions":3148},"NCT00489203","Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer",[91],140,[1003,868,733,734,29,35,871,32,872,3146,1111,874,875,877,880,2319,465,2320,882,883,884,885,1890,886,887,1891,1892,888,889,1893,1894,890,1636,2321,710,1137,2323,1757,2324,3147,711,891,892,1895,894,895,1896,1897,896,897,1898,1899,898,488,246,18,899,500,900,1008,901,1009,903,1010,1012,712,713,908,24,714,1013,21,1014,27,1759,1015,910,911,912,913,1900,2327,914,915,1760,2328,1201,1901,1902,1903,917,918,1904,1905,1922,1202,2329,1764,1203,1908,1017,1923,920,921,922,1018,1019,923,924,1020,1022,1023,1024,1025,926,927,1026,1027,1028,1029,928,929,930,1030,1031,931,932,1032,1034,1035,1036,1037,934,1038,1039,1040],"Atypical Chronic Myeloid Leukemia","Myelodysplastic\u002FMyeloproliferative Disease, Unclassifiable",[3149,1043,811],"beclomethasone dipropionate",{"nctId":2516,"briefTitle":2517,"status":226,"phases":3151,"completion":1182,"start":2519,"enrollment":598,"conditions":3152,"interventions":3153},[91],[1126,1137,15,798,799],[672,1118,937,811,1043],{"nctId":1208,"briefTitle":1209,"status":114,"phases":3155,"primaryCompletion":1211,"completion":1212,"start":1213,"enrollment":1214,"conditions":3156,"interventions":3157},[91],[1216,1217,1218],[57,504,376,418,441],{"nctId":84,"briefTitle":85,"status":126,"phases":3159,"primaryCompletion":86,"completion":484,"start":485,"enrollment":486,"conditions":3160,"interventions":3161},[91],[488,489],[87,57,204,491,442,376,417,441],{"nctId":1225,"briefTitle":1226,"status":226,"phases":3163,"primaryCompletion":1228,"completion":1228,"start":1229,"enrollment":1230,"conditions":3164,"interventions":3165},[90,91],[404,387,1147,685,736,1148,1149,1232,24,233,21,27,1233,234,563,1234],[57,504,376,1236,441],{"nctId":3167,"briefTitle":3168,"status":226,"phases":3169,"primaryCompletion":1733,"completion":1733,"start":1263,"conditions":3170,"interventions":3171},"NCT00089037","Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation",[90,91],[1126,1137,15,797,1096,798,799],[811,1186,1043],{"nctId":2611,"briefTitle":2612,"status":226,"phases":3173,"primaryCompletion":2614,"completion":117,"start":2615,"enrollment":2616,"conditions":3174,"interventions":3175},[90,91],[1544,2618],[937,1177,1043],{"nctId":583,"briefTitle":584,"status":213,"phases":3177,"primaryCompletion":586,"completion":587,"start":588,"enrollment":360,"conditions":3178,"interventions":3179},[91],[427,404,387,389,391],[409,204,441,591,442,57,467,82,418,87],{"nctId":1437,"briefTitle":1438,"status":114,"phases":3181,"primaryCompletion":1440,"completion":1440,"start":1441,"enrollment":1442,"conditions":3182,"interventions":3183},[91],[403,1444,1445,1446,1447,1433,1448,1449,1450,1451,429,1452,1453,1454,528,1455,1456,1457,389,1458,433,1306,1150,24,714,233,234,453,1459,1364],[57,374,504,376,441],{"nctId":1476,"briefTitle":1477,"status":343,"phases":3185,"primaryCompletion":1479,"completion":1479,"start":1480,"enrollment":102,"conditions":3186,"interventions":3187},[91],[1446,732,465,530,1482,389,535,391,362,1150,1284,365,1362],[72,87,57,82,504,442,441],{"nctId":2645,"briefTitle":2646,"status":226,"phases":3189,"primaryCompletion":2648,"completion":2649,"start":2650,"enrollment":463,"conditions":3190,"interventions":3191},[91],[1556,403,428,429,733,734,1558,874,875,405,434,1559,246,18,1116,298,250,2652],[504,442,2416,441,409],{"nctId":1493,"briefTitle":1494,"status":114,"phases":3193,"primaryCompletion":1496,"start":1083,"enrollment":135,"conditions":3194,"interventions":3195},[90,91],[1137,15,798,799],[1499,1118,673,811,1043],{"nctId":605,"briefTitle":606,"status":213,"phases":3197,"primaryCompletion":608,"completion":608,"start":609,"enrollment":475,"conditions":3198,"interventions":3199},[91],[390,488,489],[417,87,57,204,612,491,442,441],{"nctId":1505,"briefTitle":1506,"status":226,"phases":3201,"primaryCompletion":1508,"completion":1508,"start":1509,"enrollment":1510,"conditions":3202,"interventions":3203},[91],[1512,1513,1514,1515,1516,1009,1517,1282,1283,1148,233,21,1285,27,1286,234,563,1518,1519,1288,1234],[1290,57,373,692,504,491,376,441],{"nctId":2143,"briefTitle":2144,"status":226,"phases":3205,"primaryCompletion":2146,"completion":2146,"start":2147,"enrollment":2148,"conditions":3206,"interventions":3207},[91],[2150],[72,82,504,442,376,441,547],{"nctId":3209,"briefTitle":3210,"status":226,"phases":3211,"primaryCompletion":2492,"start":1980,"enrollment":463,"conditions":3212,"interventions":3213},"NCT00313625","Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma",[91],[1096],[1118,958,811,1043],{"nctId":614,"briefTitle":615,"status":213,"phases":3215,"primaryCompletion":617,"completion":618,"start":619,"enrollment":463,"conditions":3216,"interventions":3217},[91],[488,489],[57,612,204,468,491,376,441],{"nctId":1526,"briefTitle":1527,"status":213,"phases":3219,"primaryCompletion":1529,"completion":1530,"start":1531,"enrollment":282,"conditions":3220,"interventions":3221},[90,91],[1446,732,1433,465,407,1533,362,1534,365,452,367,406],[602,57,376,468,504,441],{"nctId":2196,"briefTitle":2197,"status":226,"phases":3223,"primaryCompletion":2199,"completion":2200,"start":2201,"enrollment":2202,"conditions":3224,"interventions":3225},[91],[1593,736,27,234,1234,1556,733,734,2204,2205,2206,2207,1862,1558,874,875,876,2136,878,2208,1843,2209,2210,2211,2212,2213,2214,2215,2216,2217,2218,2219,2220,2221,2222,2223,2224,2225,2226,2227,2228,1204,246,18,899,500,900,1008,1009,2229,903,1116,298,904,906,907,2230,712,713,908,24,714,21,1282,1149,2231,911,912,913,2232,915,1761,1762,916,2233,1902,1903,917,918,1904,1202,1765,919,2234,920,921,922,1018,2235,924,1768,1769,925,2236,1024,1025,926,927,1026,1029,928,929,930,1030,2237,932,1771,1772,933,2238,1036,1037,934,935,1038,1040],[504,441,376,418],{"nctId":1548,"briefTitle":1549,"status":226,"phases":3227,"primaryCompletion":1551,"completion":1552,"start":1553,"enrollment":1554,"conditions":3228,"interventions":3229},[91],[1556,403,428,429,1557,1558,431,874,875,1363,438,407,434,1559,1533,362,1116,298,1149,1534,365,1446,1433],[57,504,442,376,441,409],{"trials":3231,"activeCount":102},[3232],{"nctId":1585,"briefTitle":1586,"status":226,"phases":3233,"primaryCompletion":1588,"completion":1589,"start":1241,"enrollment":807,"conditions":3234,"interventions":3235},[92],[869,1591,734,29,870,35,871,32,872,875,880,890,1592,1593,898,18,298,453,910],[673,481,1118,479,937,1595,1044,1045,1043,811],{"trials":3237,"activeCount":102},[],{"trials":3239,"activeCount":102},[3240],{"nctId":1629,"briefTitle":1630,"status":226,"phases":3241,"primaryCompletion":1632,"completion":1431,"start":1633,"enrollment":1634,"conditions":3242,"interventions":3243},[94],[734,29,870,35,871,32,872,875,880,890,1636,1592,1637,898,488,18,298,453,910,489,1638,1639],[673,1118,1043,811,1595],{"intervention":373,"totalTrials":317,"cells":3245},{"EARLY_PHASE1":3246,"PHASE1":3248,"PHASE2":3298,"PHASE3":3455,"PHASE4":3457,"NA":3459},{"trials":3247,"activeCount":102},[],{"trials":3249,"activeCount":98,"soonestReadout":383},[3250,3257,3270,3281,3290,3294],{"nctId":3251,"briefTitle":3252,"status":226,"phases":3253,"primaryCompletion":3254,"start":1387,"conditions":3255,"interventions":3256},"NCT00107354","Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant",[90],"2009-08",[15,798],[719,1812,718,2194,948,2608],{"nctId":3258,"briefTitle":3259,"status":114,"phases":3260,"primaryCompletion":3261,"completion":3262,"start":3263,"enrollment":2616,"conditions":3264,"interventions":3267},"NCT02483000","Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies",[90],"2019-11-17","2020-09-02","2017-02-01",[528,3265,685,1470,533,247,3266],"CD20-Positive Neoplastic Cells Present","Refractory Mature B-Cell Non-Hodgkin Lymphoma",[3268,1290,3269,373,692,491],"Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein","Clearing Agent",{"nctId":3271,"briefTitle":3272,"status":343,"phases":3273,"primaryCompletion":3274,"completion":293,"start":3275,"enrollment":102,"conditions":3276,"interventions":3279},"NCT05228249","Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma",[90],"2025-10-01","2023-04",[248,258,259,249,3277,252,261,262,253,3278],"Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma",[1290,373,692,3280,491],"Loncastuximab Tesirine",{"nctId":3282,"briefTitle":3283,"status":226,"phases":3284,"completion":3285,"start":2369,"conditions":3286,"interventions":3287},"NCT00107523","Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia",[90],"2005-10",[15],[2194,3288,3289],"idarubicin","pravastatin",{"nctId":354,"briefTitle":355,"status":213,"phases":3291,"primaryCompletion":357,"completion":358,"start":359,"enrollment":360,"conditions":3292,"interventions":3293},[90],[362,363,364,365,366,367,368,369,370],[372,57,82,373,374,375,376,377,378,204,373],{"nctId":380,"briefTitle":381,"status":126,"phases":3295,"primaryCompletion":383,"completion":384,"start":385,"enrollment":282,"conditions":3296,"interventions":3297},[90],[387,388,389,390,391],[373,204,393,378,394],{"trials":3299,"activeCount":3454,"soonestReadout":46},[3300,3306,3315,3325,3332,3339,3350,3360,3364,3374,3378,3382,3386,3395,3405,3414,3421,3425,3450],{"nctId":44,"briefTitle":45,"status":126,"phases":3301,"primaryCompletion":46,"completion":586,"start":3302,"enrollment":555,"conditions":3303,"interventions":3305},[91],"2020-05-27",[387,3304],"Myeloid Neoplasm",[47,372,373,468,375],{"nctId":3307,"briefTitle":3308,"status":114,"phases":3309,"primaryCompletion":865,"completion":829,"start":3310,"enrollment":3311,"conditions":3312,"interventions":3313},"NCT01607645","Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS",[91],"2012-07",7,[1108,2013,2014,2015,2016,29,35,32,872,2017,1109,1110,898,18,737],[3314,3288,2194],"decitabine",{"nctId":3316,"briefTitle":3317,"status":226,"phases":3318,"primaryCompletion":3319,"completion":3320,"start":3321,"enrollment":317,"conditions":3322,"interventions":3324},"NCT00992446","Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma",[91],"2015-06-17","2019-10-29","2010-09-02",[2170,3323,531,533,516,1473],"B-Cell Non-Hodgkin Lymphoma",[2052,1290,373,692,491,505,1206],{"nctId":3326,"briefTitle":3327,"status":226,"phases":3328,"completion":3329,"start":1981,"conditions":3330,"interventions":3331},"NCT00006367","Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis",[91],"2004-01",[1126],[674,1118,2194,3288],{"nctId":3333,"briefTitle":3334,"status":226,"phases":3335,"primaryCompletion":1431,"completion":1431,"start":1051,"enrollment":30,"conditions":3336,"interventions":3337},"NCT01567059","Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",[91],[1450,29,870,871,890,898,453,910,1638],[3338,2194,3314],"tosedostat",{"nctId":3340,"briefTitle":3341,"status":226,"phases":3342,"primaryCompletion":3343,"completion":3344,"start":3345,"enrollment":3346,"conditions":3347,"interventions":3348},"NCT02044796","Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed\u002FRefractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes",[90,91],"2018-03-09","2018-04-16","2014-01-23",199,[403,1434,736,18,1638,453],[372,373,374,3349],"Mitoxantrone Hydrochloride",{"nctId":3351,"briefTitle":3352,"status":226,"phases":3353,"primaryCompletion":3354,"completion":3355,"start":3356,"enrollment":2100,"conditions":3357,"interventions":3358},"NCT03531918","Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm",[90,91],"2021-07-01","2021-11-01","2018-09-14",[387],[372,373,3359,468,3349],"Gemtuzumab Ozogamicin",{"nctId":444,"briefTitle":445,"status":213,"phases":3361,"primaryCompletion":447,"completion":448,"start":449,"enrollment":22,"conditions":3362,"interventions":3363},[90,91],[387,429,388,362,451,363,452,364,365,370,366,367,368,453],[455,373,374,204,378],{"nctId":3365,"briefTitle":3366,"status":226,"phases":3367,"primaryCompletion":3368,"completion":3369,"start":3370,"enrollment":463,"conditions":3371,"interventions":3373},"NCT01921387","Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies",[90,91],"2017-07-26","2020-07-26","2013-10-09",[247,1150,24,1471,251,1233,1309,3372],"Refractory T-Cell Non-Hodgkin Lymphoma",[1290,373,692,491],{"nctId":457,"briefTitle":458,"status":213,"phases":3375,"primaryCompletion":460,"completion":461,"start":462,"enrollment":463,"conditions":3376,"interventions":3377},[91],[428,387,465,389],[373,204,378,467,468],{"nctId":1275,"briefTitle":1276,"status":226,"phases":3379,"primaryCompletion":772,"completion":1278,"start":1279,"enrollment":1280,"conditions":3380,"interventions":3381},[90,91],[537,1009,1282,1283,1148,1284,21,1285,27,1233,1286,563,1287,1288],[1290,57,82,373,692,504,491,376,1291],{"nctId":2602,"briefTitle":2603,"status":226,"phases":3383,"primaryCompletion":1404,"completion":1404,"start":2605,"conditions":3384,"interventions":3385},[90,91],[15],[719,674,1812,2194,948,937,811,2608,2609],{"nctId":3387,"briefTitle":3388,"status":226,"phases":3389,"primaryCompletion":3390,"completion":3391,"start":3392,"enrollment":1634,"conditions":3393,"interventions":3394},"NCT01729845","Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes",[90,91],"2016-08-25","2017-04-03","2012-12-20",[736,18],[373,455,692,3349],{"nctId":3396,"briefTitle":3397,"status":226,"phases":3398,"primaryCompletion":3399,"completion":3399,"start":3400,"enrollment":231,"conditions":3401,"interventions":3404},"NCT02921061","Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS",[90,91],"2018-10-24","2016-11-17",[388,736,18,3402,365,3403,1638],"Recurrent High Risk Myelodysplastic Syndrome","Refractory High Risk Myelodysplastic Syndrome",[372,373,455,374,3349],{"nctId":3406,"briefTitle":3407,"status":226,"phases":3408,"primaryCompletion":3409,"completion":3409,"start":3410,"enrollment":282,"conditions":3411,"interventions":3412},"NCT00002674","Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia",[91],"2000-03","1994-10",[15],[674,2194,948,3413,2608],"hydroxyurea",{"nctId":3415,"briefTitle":3416,"status":226,"phases":3417,"primaryCompletion":847,"completion":847,"start":1296,"enrollment":25,"conditions":3418,"interventions":3419},"NCT00839982","Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS",[90,91],[29,870,35,32,872,1592,898,18],[3420,2194],"clofarabine",{"nctId":1505,"briefTitle":1506,"status":226,"phases":3422,"primaryCompletion":1508,"completion":1508,"start":1509,"enrollment":1510,"conditions":3423,"interventions":3424},[91],[1512,1513,1514,1515,1516,1009,1517,1282,1283,1148,233,21,1285,27,1286,234,563,1518,1519,1288,1234],[1290,57,373,692,504,491,376,441],{"nctId":69,"briefTitle":70,"status":126,"phases":3426,"primaryCompletion":71,"completion":3427,"start":3428,"enrollment":486,"conditions":3429,"interventions":3449},[91],"2030-01-31","2008-06",[3430,3431,3432,3433,3434,3435,3436,3437,3438,3439,3440,3441,3442,3443,3444,3445,3446,3447,3448],"Autoimmune Disease","Neurologic Autoimmune Disease","Autologous Transplant Autoimmune","Multiple Sclerosis Transplant","MS Stem Cell Transplant","Multiple Sclerosis Stem Cell Transplant","Stiff Person Syndrome","HCT for Neurologic Autoimmune Disorders","CIDP Transplant","Myasthenia Gravis Transplant","Autoimmune Nervous System Disorder","Central Nervous System Vasculitis","Cerebellar Degeneration","Chronic Inflammatory Demyelinating Polyneuropathy","Lambert Eaton Myasthenic Syndrome","Myasthenia Gravis","Neuromyelitis Optica","Opsoclonus Myoclonus Syndrome","Rasmussen Subacute Encephalitis",[72,1290,373,692,491,691],{"nctId":2188,"briefTitle":2189,"status":226,"phases":3451,"completion":794,"start":2191,"conditions":3452,"interventions":3453},[90,91],[15],[1812,479,2194,937,811,481],4,{"trials":3456,"activeCount":102},[],{"trials":3458,"activeCount":102},[],{"trials":3460,"activeCount":102},[3461,3474],{"nctId":3462,"briefTitle":3463,"status":343,"phases":3464,"primaryCompletion":3465,"start":2116,"enrollment":102,"conditions":3466,"interventions":3471},"NCT01769911","Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma",[94],"2019-02",[873,2311,2312,2313,2314,2315,2316,2318,558,1001,1002,710,1004,2322,1005,711,1114,1006,899,500,900,1008,901,1009,902,903,1010,1012,712,713,908,24,714,1013,21,1759,1016,715,3467,3468,3469,3470,1775,1041,716],"Stage I AIDS-related Lymphoma","Stage II AIDS-related Lymphoma","Stage III AIDS-related Lymphoma","Stage IV AIDS-related Lymphoma",[3472,2194,958,948,3473],"carmustine","O6-benzylguanine",{"nctId":3475,"briefTitle":3476,"status":226,"phases":3477,"primaryCompletion":2116,"completion":772,"start":3478,"enrollment":217,"conditions":3479,"interventions":3480},"NCT01831232","Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes",[94],"2013-05",[1108,2012,2013,2014,2015,2016,29,870,35,32,872,2017,1109,1110,465,890,1593,737,1638],[2877,3288,2194],{"intervention":409,"totalTrials":463,"cells":3482},{"EARLY_PHASE1":3483,"PHASE1":3485,"PHASE2":3517,"PHASE3":3593,"PHASE4":3599,"NA":3601},{"trials":3484,"activeCount":102},[],{"trials":3486,"activeCount":102},[3487,3497,3505,3509],{"nctId":3488,"briefTitle":3489,"status":226,"phases":3490,"primaryCompletion":3491,"completion":3491,"start":3492,"conditions":3493,"interventions":3495},"NCT00003080","Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer",[90],"2001-05","1996-09",[3494],"Ovarian Cancer",[3496,958,2608,1607,960],"endocrine-modulating drug therapy",{"nctId":3498,"briefTitle":3499,"status":226,"phases":3500,"primaryCompletion":999,"completion":999,"start":3501,"enrollment":1510,"conditions":3502,"interventions":3504},"NCT00003081","Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Ewing's Sarcoma, Peripheral Primitive Neuroectodermal Tumor, or Rhabdomyosarcoma",[90],"1998-03",[3503],"Sarcoma",[674,1118,958,960],{"nctId":950,"briefTitle":951,"status":226,"phases":3506,"completion":953,"start":954,"conditions":3507,"interventions":3508},[90],[956],[674,673,958,959,960],{"nctId":3510,"briefTitle":3511,"status":226,"phases":3512,"primaryCompletion":953,"start":3513,"enrollment":3514,"conditions":3515,"interventions":3516},"NCT00002977","Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission",[90],"1997-01",45,[3494],[674,958,960],{"trials":3518,"activeCount":2308,"soonestReadout":51},[3519,3523,3527,3531,3535,3539,3543,3547,3551,3555,3563,3567,3581,3585,3589],{"nctId":49,"briefTitle":50,"status":126,"phases":3520,"primaryCompletion":51,"completion":400,"start":401,"enrollment":36,"conditions":3521,"interventions":3522},[91],[403,404,405,406,389,407],[52,57,204,409],{"nctId":2408,"briefTitle":2409,"status":114,"phases":3524,"primaryCompletion":2411,"completion":2412,"start":2413,"enrollment":1230,"conditions":3525,"interventions":3526},[91],[1137,15,798],[504,441,409,2416],{"nctId":420,"briefTitle":421,"status":213,"phases":3528,"primaryCompletion":423,"completion":423,"start":424,"enrollment":425,"conditions":3529,"interventions":3530},[91],[403,427,428,404,429,430,431,432,433,388,434,435,436,437,438,439,391],[409,204,57,87,441,442],{"nctId":2489,"briefTitle":2490,"status":226,"phases":3532,"completion":2492,"start":795,"enrollment":463,"conditions":3533,"interventions":3534},[90,91],[15,798],[937,960],{"nctId":507,"briefTitle":508,"status":114,"phases":3536,"primaryCompletion":510,"completion":511,"start":512,"enrollment":135,"conditions":3537,"interventions":3538},[91],[514,404,515,387,405,406,133,389,407,516,517],[204,57,409,52],{"nctId":520,"briefTitle":521,"status":226,"phases":3540,"primaryCompletion":523,"completion":524,"start":525,"enrollment":526,"conditions":3541,"interventions":3542},[91],[403,404,387,528,529,405,530,531,438,532,533,534,389,535,516,536,537,517,538],[57,82,204,376,409],{"nctId":1344,"briefTitle":1345,"status":213,"phases":3544,"primaryCompletion":1347,"completion":1348,"start":1349,"enrollment":1350,"conditions":3545,"interventions":3546},[91],[428,404,387,431,1352,388,389,391,516,559],[57,82,504,376,409],{"nctId":583,"briefTitle":584,"status":213,"phases":3548,"primaryCompletion":586,"completion":587,"start":588,"enrollment":360,"conditions":3549,"interventions":3550},[91],[427,404,387,389,391],[409,204,441,591,442,57,467,82,418,87],{"nctId":1408,"briefTitle":1409,"status":226,"phases":3552,"completion":1182,"start":1411,"conditions":3553,"interventions":3554},[91],[797,956,1413],[719,674,1415,1118,673,958,959,960],{"nctId":3556,"briefTitle":3557,"status":226,"phases":3558,"primaryCompletion":3559,"completion":3559,"start":3560,"conditions":3561,"interventions":3562},"NCT00003146","Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma",[91],"2001-06","1997-11",[1096],[1118,958,960],{"nctId":2645,"briefTitle":2646,"status":226,"phases":3564,"primaryCompletion":2648,"completion":2649,"start":2650,"enrollment":463,"conditions":3565,"interventions":3566},[91],[1556,403,428,429,733,734,1558,874,875,405,434,1559,246,18,1116,298,250,2652],[504,442,2416,441,409],{"nctId":3568,"briefTitle":3569,"status":226,"phases":3570,"primaryCompletion":1297,"completion":1297,"start":3560,"enrollment":475,"conditions":3571,"interventions":3580},"NCT00003199","Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer",[91],[3572,3573,3574,3575,3576,3577,3578,3579],"Estrogen Receptor-negative Breast Cancer","Estrogen Receptor-positive Breast Cancer","Inflammatory Breast Cancer","Male Breast Cancer","Progesterone Receptor-negative Breast Cancer","Progesterone Receptor-positive Breast Cancer","Stage IIIB Breast Cancer","Stage IV Breast Cancer",[1607,1118,960,958,719,1415],{"nctId":2659,"briefTitle":2660,"status":213,"phases":3582,"primaryCompletion":2662,"completion":2662,"start":2663,"enrollment":598,"conditions":3583,"interventions":3584},[91],[2665],[409,547,504,2667],{"nctId":1548,"briefTitle":1549,"status":226,"phases":3586,"primaryCompletion":1551,"completion":1552,"start":1553,"enrollment":1554,"conditions":3587,"interventions":3588},[91],[1556,403,428,429,1557,1558,431,874,875,1363,438,407,434,1559,1533,362,1116,298,1149,1534,365,1446,1433],[57,504,442,376,441,409],{"nctId":2709,"briefTitle":2710,"status":114,"phases":3590,"primaryCompletion":973,"completion":973,"start":1633,"enrollment":135,"conditions":3591,"interventions":3592},[91],[1137,15,798],[2714,2715,937,811,960,1046],{"trials":3594,"activeCount":102},[3595],{"nctId":1597,"briefTitle":1598,"status":226,"phases":3596,"primaryCompletion":1600,"completion":1600,"start":1601,"enrollment":1602,"conditions":3597,"interventions":3598},[92],[1604],[674,1415,1118,1606,673,958,959,1607,960],{"trials":3600,"activeCount":102},[],{"trials":3602,"activeCount":102},[],{"intervention":468,"totalTrials":2308,"cells":3604},{"EARLY_PHASE1":3605,"PHASE1":3607,"PHASE2":3609,"PHASE3":3631,"PHASE4":3633,"NA":3635},{"trials":3606,"activeCount":102},[],{"trials":3608,"activeCount":102},[],{"trials":3610,"activeCount":3454,"soonestReadout":46},[3611,3615,3619,3623,3627],{"nctId":44,"briefTitle":45,"status":126,"phases":3612,"primaryCompletion":46,"completion":586,"start":3302,"enrollment":555,"conditions":3613,"interventions":3614},[91],[387,3304],[47,372,373,468,375],{"nctId":3351,"briefTitle":3352,"status":226,"phases":3616,"primaryCompletion":3354,"completion":3355,"start":3356,"enrollment":2100,"conditions":3617,"interventions":3618},[90,91],[387],[372,373,3359,468,3349],{"nctId":457,"briefTitle":458,"status":213,"phases":3620,"primaryCompletion":460,"completion":461,"start":462,"enrollment":463,"conditions":3621,"interventions":3622},[91],[428,387,465,389],[373,204,378,467,468],{"nctId":614,"briefTitle":615,"status":213,"phases":3624,"primaryCompletion":617,"completion":618,"start":619,"enrollment":463,"conditions":3625,"interventions":3626},[91],[488,489],[57,612,204,468,491,376,441],{"nctId":1526,"briefTitle":1527,"status":213,"phases":3628,"primaryCompletion":1529,"completion":1530,"start":1531,"enrollment":282,"conditions":3629,"interventions":3630},[90,91],[1446,732,1433,465,407,1533,362,1534,365,452,367,406],[602,57,376,468,504,441],{"trials":3632,"activeCount":102},[],{"trials":3634,"activeCount":102},[],{"trials":3636,"activeCount":102},[],{"intervention":811,"totalTrials":1094,"cells":3638},{"EARLY_PHASE1":3639,"PHASE1":3641,"PHASE2":3655,"PHASE3":3804,"PHASE4":3818,"NA":3820},{"trials":3640,"activeCount":102},[],{"trials":3642,"activeCount":102},[3643,3647,3651],{"nctId":677,"briefTitle":678,"status":114,"phases":3644,"primaryCompletion":680,"completion":680,"start":681,"enrollment":682,"conditions":3645,"interventions":3646},[90],[528,684,685],[687,57,688,442,689,690,691,692,505],{"nctId":743,"briefTitle":744,"status":226,"phases":3648,"primaryCompletion":746,"completion":746,"start":747,"enrollment":748,"conditions":3649,"interventions":3650},[90],[750,751,752,753,754,755,756,757,758,759,760,761],[57,442,763],{"nctId":802,"briefTitle":803,"status":226,"phases":3652,"primaryCompletion":805,"start":806,"enrollment":807,"conditions":3653,"interventions":3654},[90],[809],[673,479,811],{"trials":3656,"activeCount":3454,"soonestReadout":86},[3657,3661,3665,3669,3673,3677,3681,3685,3689,3693,3700,3704,3708,3712,3716,3720,3724,3728,3732,3736,3740,3744,3748,3752,3756,3760,3764,3768,3772,3776,3780,3784,3788,3792,3796,3800],{"nctId":1048,"briefTitle":1049,"status":226,"phases":3658,"primaryCompletion":1051,"completion":1052,"start":983,"enrollment":1053,"conditions":3659,"interventions":3660},[91],[415],[673,672,479,811,986,1045],{"nctId":2422,"briefTitle":2423,"status":226,"phases":3662,"primaryCompletion":2075,"completion":2075,"start":2425,"conditions":3663,"interventions":3664},[91],[15,798],[1118,479,937,811],{"nctId":1131,"briefTitle":1132,"status":226,"phases":3666,"completion":1134,"start":1135,"conditions":3667,"interventions":3668},[90,91],[1126,1137,15,798,799],[672,1118,673,479,811],{"nctId":2445,"briefTitle":2446,"status":226,"phases":3670,"primaryCompletion":1386,"completion":2448,"start":1839,"enrollment":544,"conditions":3671,"interventions":3672},[91],[868,734,29,870,35,871,32,872,1111,875,877,880,882,890,1003,1593,898,18,298,1015],[937,1118,672,1043,811],{"nctId":420,"briefTitle":421,"status":213,"phases":3674,"primaryCompletion":423,"completion":423,"start":424,"enrollment":425,"conditions":3675,"interventions":3676},[91],[403,427,428,404,429,430,431,432,433,388,434,435,436,437,438,439,391],[409,204,57,87,441,442],{"nctId":1159,"briefTitle":1160,"status":226,"phases":3678,"primaryCompletion":1162,"completion":76,"start":1163,"enrollment":1164,"conditions":3679,"interventions":3680},[91],[488,489],[87,57,504,491,442,376,417,441],{"nctId":2456,"briefTitle":2457,"status":226,"phases":3682,"primaryCompletion":2459,"completion":2459,"start":2460,"enrollment":598,"conditions":3683,"interventions":3684},[91],[2462,2463,2464,2465,1863,2466,2467,2468,2469],[547,504,441,442,603],{"nctId":2480,"briefTitle":2481,"status":226,"phases":3686,"primaryCompletion":2483,"start":1573,"enrollment":2484,"conditions":3687,"interventions":3688},[91],[868,733,734,29,870,35,871,32,872,1111,874,875,877,880,465,890,898,246,18,1116,298,910,1778,1779],[2487,937,1043,811],{"nctId":1179,"briefTitle":1180,"status":226,"phases":3690,"primaryCompletion":1182,"start":1183,"enrollment":475,"conditions":3691,"interventions":3692},[91],[15,797,798],[673,479,811,481,1186,1043],{"nctId":3694,"briefTitle":3695,"status":226,"phases":3696,"primaryCompletion":473,"start":1827,"enrollment":486,"conditions":3697,"interventions":3699},"NCT00357084","Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant",[91],[3698],"Cancer",[811,1391,675],{"nctId":1188,"briefTitle":1189,"status":226,"phases":3701,"primaryCompletion":795,"completion":795,"start":1191,"enrollment":463,"conditions":3702,"interventions":3703},[91],[1126,15,799],[1118,673,479,811,1043],{"nctId":3141,"briefTitle":3142,"status":226,"phases":3705,"primaryCompletion":2257,"start":647,"enrollment":3144,"conditions":3706,"interventions":3707},[91],[1003,868,733,734,29,35,871,32,872,3146,1111,874,875,877,880,2319,465,2320,882,883,884,885,1890,886,887,1891,1892,888,889,1893,1894,890,1636,2321,710,1137,2323,1757,2324,3147,711,891,892,1895,894,895,1896,1897,896,897,1898,1899,898,488,246,18,899,500,900,1008,901,1009,903,1010,1012,712,713,908,24,714,1013,21,1014,27,1759,1015,910,911,912,913,1900,2327,914,915,1760,2328,1201,1901,1902,1903,917,918,1904,1905,1922,1202,2329,1764,1203,1908,1017,1923,920,921,922,1018,1019,923,924,1020,1022,1023,1024,1025,926,927,1026,1027,1028,1029,928,929,930,1030,1031,931,932,1032,1034,1035,1036,1037,934,1038,1039,1040],[3149,1043,811],{"nctId":2887,"briefTitle":2888,"status":343,"phases":3709,"start":1565,"enrollment":102,"conditions":3710,"interventions":3711},[90,91],[1137,15,798],[479,811,1186],{"nctId":2516,"briefTitle":2517,"status":226,"phases":3713,"completion":1182,"start":2519,"enrollment":598,"conditions":3714,"interventions":3715},[91],[1126,1137,15,798,799],[672,1118,937,811,1043],{"nctId":84,"briefTitle":85,"status":126,"phases":3717,"primaryCompletion":86,"completion":484,"start":485,"enrollment":486,"conditions":3718,"interventions":3719},[91],[488,489],[87,57,204,491,442,376,417,441],{"nctId":1238,"briefTitle":1239,"status":226,"phases":3721,"primaryCompletion":1241,"start":1124,"enrollment":682,"conditions":3722,"interventions":3723},[91],[734,29,870,35,871,32,872],[1118,673,479,811],{"nctId":1253,"briefTitle":1254,"status":226,"phases":3725,"primaryCompletion":474,"completion":474,"start":1256,"enrollment":282,"conditions":3726,"interventions":3727},[91],[15],[1118,673,811],{"nctId":3167,"briefTitle":3168,"status":226,"phases":3729,"primaryCompletion":1733,"completion":1733,"start":1263,"conditions":3730,"interventions":3731},[90,91],[1126,1137,15,797,1096,798,799],[811,1186,1043],{"nctId":1988,"briefTitle":1989,"status":226,"phases":3733,"primaryCompletion":1991,"completion":1991,"start":1340,"conditions":3734,"interventions":3735},[91],[15,798],[479,937,1994,811,481],{"nctId":1268,"briefTitle":1269,"status":226,"phases":3737,"completion":473,"start":1271,"conditions":3738,"interventions":3739},[91],[15,798],[1118,673,479,811],{"nctId":1338,"briefTitle":1121,"status":226,"phases":3741,"completion":1340,"start":474,"conditions":3742,"interventions":3743},[91],[15,797,1096,798],[673,479,811],{"nctId":2602,"briefTitle":2603,"status":226,"phases":3745,"primaryCompletion":1404,"completion":1404,"start":2605,"conditions":3746,"interventions":3747},[90,91],[15],[719,674,1812,2194,948,937,811,2608,2609],{"nctId":1368,"briefTitle":1369,"status":226,"phases":3749,"primaryCompletion":953,"completion":953,"start":1371,"enrollment":598,"conditions":3750,"interventions":3751},[91],[15],[673,811],{"nctId":583,"briefTitle":584,"status":213,"phases":3753,"primaryCompletion":586,"completion":587,"start":588,"enrollment":360,"conditions":3754,"interventions":3755},[91],[427,404,387,389,391],[409,204,441,591,442,57,467,82,418,87],{"nctId":1401,"briefTitle":1402,"status":226,"phases":3757,"primaryCompletion":1404,"completion":1404,"start":1371,"enrollment":598,"conditions":3758,"interventions":3759},[91],[15],[673,811],{"nctId":1421,"briefTitle":1422,"status":226,"phases":3761,"primaryCompletion":1424,"start":999,"enrollment":282,"conditions":3762,"interventions":3763},[90,91],[1126,15,798,799],[1118,673,479,811],{"nctId":1476,"briefTitle":1477,"status":343,"phases":3765,"primaryCompletion":1479,"completion":1479,"start":1480,"enrollment":102,"conditions":3766,"interventions":3767},[91],[1446,732,465,530,1482,389,535,391,362,1150,1284,365,1362],[72,87,57,82,504,442,441],{"nctId":2645,"briefTitle":2646,"status":226,"phases":3769,"primaryCompletion":2648,"completion":2649,"start":2650,"enrollment":463,"conditions":3770,"interventions":3771},[91],[1556,403,428,429,733,734,1558,874,875,405,434,1559,246,18,1116,298,250,2652],[504,442,2416,441,409],{"nctId":1493,"briefTitle":1494,"status":114,"phases":3773,"primaryCompletion":1496,"start":1083,"enrollment":135,"conditions":3774,"interventions":3775},[90,91],[1137,15,798,799],[1499,1118,673,811,1043],{"nctId":605,"briefTitle":606,"status":213,"phases":3777,"primaryCompletion":608,"completion":608,"start":609,"enrollment":475,"conditions":3778,"interventions":3779},[91],[390,488,489],[417,87,57,204,612,491,442,441],{"nctId":2143,"briefTitle":2144,"status":226,"phases":3781,"primaryCompletion":2146,"completion":2146,"start":2147,"enrollment":2148,"conditions":3782,"interventions":3783},[91],[2150],[72,82,504,442,376,441,547],{"nctId":3209,"briefTitle":3210,"status":226,"phases":3785,"primaryCompletion":2492,"start":1980,"enrollment":463,"conditions":3786,"interventions":3787},[91],[1096],[1118,958,811,1043],{"nctId":2188,"briefTitle":2189,"status":226,"phases":3789,"completion":794,"start":2191,"conditions":3790,"interventions":3791},[90,91],[15],[1812,479,2194,937,811,481],{"nctId":1548,"briefTitle":1549,"status":226,"phases":3793,"primaryCompletion":1551,"completion":1552,"start":1553,"enrollment":1554,"conditions":3794,"interventions":3795},[91],[1556,403,428,429,1557,1558,431,874,875,1363,438,407,434,1559,1533,362,1116,298,1149,1534,365,1446,1433],[57,504,442,376,441,409],{"nctId":2709,"briefTitle":2710,"status":114,"phases":3797,"primaryCompletion":973,"completion":973,"start":1633,"enrollment":135,"conditions":3798,"interventions":3799},[91],[1137,15,798],[2714,2715,937,811,960,1046],{"nctId":1562,"briefTitle":1563,"status":226,"phases":3801,"primaryCompletion":1135,"completion":1135,"start":1565,"conditions":3802,"interventions":3803},[91],[15],[673,811],{"trials":3805,"activeCount":102},[3806,3810,3814],{"nctId":1585,"briefTitle":1586,"status":226,"phases":3807,"primaryCompletion":1588,"completion":1589,"start":1241,"enrollment":807,"conditions":3808,"interventions":3809},[92],[869,1591,734,29,870,35,871,32,872,875,880,890,1592,1593,898,18,298,453,910],[673,481,1118,479,937,1595,1044,1045,1043,811],{"nctId":1609,"briefTitle":1610,"status":226,"phases":3811,"primaryCompletion":1612,"completion":1612,"start":1613,"enrollment":748,"conditions":3812,"interventions":3813},[92],[15],[1118,673,479,811],{"nctId":3050,"briefTitle":3051,"status":226,"phases":3815,"completion":2010,"start":3053,"conditions":3816,"interventions":3817},[92],[1137,15,797],[479,811],{"trials":3819,"activeCount":102},[],{"trials":3821,"activeCount":102},[3822],{"nctId":1629,"briefTitle":1630,"status":226,"phases":3823,"primaryCompletion":1632,"completion":1431,"start":1633,"enrollment":1634,"conditions":3824,"interventions":3825},[94],[734,29,870,35,871,32,872,875,880,890,1636,1592,1637,898,488,18,298,453,910,489,1638,1639],[673,1118,1043,811,1595],{"intervention":1118,"totalTrials":2049,"cells":3827},{"EARLY_PHASE1":3828,"PHASE1":3830,"PHASE2":3836,"PHASE3":3960,"PHASE4":3974,"NA":3976},{"trials":3829,"activeCount":102},[],{"trials":3831,"activeCount":102},[3832],{"nctId":3498,"briefTitle":3499,"status":226,"phases":3833,"primaryCompletion":999,"completion":999,"start":3501,"enrollment":1510,"conditions":3834,"interventions":3835},[90],[3503],[674,1118,958,960],{"trials":3837,"activeCount":3454,"soonestReadout":86},[3838,3842,3846,3850,3854,3860,3864,3870,3874,3878,3882,3890,3894,3898,3902,3906,3910,3920,3924,3928,3932,3936,3940,3944,3948,3952,3956],{"nctId":2422,"briefTitle":2423,"status":226,"phases":3839,"primaryCompletion":2075,"completion":2075,"start":2425,"conditions":3840,"interventions":3841},[91],[15,798],[1118,479,937,811],{"nctId":3326,"briefTitle":3327,"status":226,"phases":3843,"completion":3329,"start":1981,"conditions":3844,"interventions":3845},[91],[1126],[674,1118,2194,3288],{"nctId":1101,"briefTitle":1102,"status":226,"phases":3847,"primaryCompletion":1104,"completion":1105,"start":1106,"enrollment":1094,"conditions":3848,"interventions":3849},[91],[868,733,1108,734,1109,873,1110,558,1001,1111,1112,874,1113,875,876,877,878,879,880,881,465,882,1002,890,710,1004,1005,711,1114,1006,1115,1007,898,246,18,899,500,900,1008,901,1009,902,903,1010,1116,298,904,905,906,907,1011,1012,712,713,908,24,714,1013,21,1014,1015,453,910,1016,715,1027,1041,716],[673,479,937,1118],{"nctId":1131,"briefTitle":1132,"status":226,"phases":3851,"completion":1134,"start":1135,"conditions":3852,"interventions":3853},[90,91],[1126,1137,15,798,799],[672,1118,673,479,811],{"nctId":3855,"briefTitle":3856,"status":226,"phases":3857,"primaryCompletion":2425,"completion":2425,"start":1665,"conditions":3858,"interventions":3859},"NCT00005948","Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous Leukemia",[91],[15],[719,2003,1415,1118],{"nctId":2445,"briefTitle":2446,"status":226,"phases":3861,"primaryCompletion":1386,"completion":2448,"start":1839,"enrollment":544,"conditions":3862,"interventions":3863},[91],[868,734,29,870,35,871,32,872,1111,875,877,880,882,890,1003,1593,898,18,298,1015],[937,1118,672,1043,811],{"nctId":3865,"briefTitle":3866,"status":226,"phases":3867,"completion":648,"start":668,"conditions":3868,"interventions":3869},"NCT00003195","Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma",[91],[1096],[2003,1118],{"nctId":420,"briefTitle":421,"status":213,"phases":3871,"primaryCompletion":423,"completion":423,"start":424,"enrollment":425,"conditions":3872,"interventions":3873},[91],[403,427,428,404,429,430,431,432,433,388,434,435,436,437,438,439,391],[409,204,57,87,441,442],{"nctId":1159,"briefTitle":1160,"status":226,"phases":3875,"primaryCompletion":1162,"completion":76,"start":1163,"enrollment":1164,"conditions":3876,"interventions":3877},[91],[488,489],[87,57,504,491,442,376,417,441],{"nctId":1188,"briefTitle":1189,"status":226,"phases":3879,"primaryCompletion":795,"completion":795,"start":1191,"enrollment":463,"conditions":3880,"interventions":3881},[91],[1126,15,799],[1118,673,479,811,1043],{"nctId":3883,"briefTitle":3884,"status":226,"phases":3885,"primaryCompletion":3886,"completion":3886,"start":3887,"enrollment":282,"conditions":3888,"interventions":3889},"NCT00003875","Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia",[91],"2015-06-11","1998-10-13",[734,29,870,871,32,875,18,298],[1118,948,719],{"nctId":2516,"briefTitle":2517,"status":226,"phases":3891,"completion":1182,"start":2519,"enrollment":598,"conditions":3892,"interventions":3893},[91],[1126,1137,15,798,799],[672,1118,937,811,1043],{"nctId":84,"briefTitle":85,"status":126,"phases":3895,"primaryCompletion":86,"completion":484,"start":485,"enrollment":486,"conditions":3896,"interventions":3897},[91],[488,489],[87,57,204,491,442,376,417,441],{"nctId":1238,"briefTitle":1239,"status":226,"phases":3899,"primaryCompletion":1241,"start":1124,"enrollment":682,"conditions":3900,"interventions":3901},[91],[734,29,870,35,871,32,872],[1118,673,479,811],{"nctId":1253,"briefTitle":1254,"status":226,"phases":3903,"primaryCompletion":474,"completion":474,"start":1256,"enrollment":282,"conditions":3904,"interventions":3905},[91],[15],[1118,673,811],{"nctId":1268,"briefTitle":1269,"status":226,"phases":3907,"completion":473,"start":1271,"conditions":3908,"interventions":3909},[91],[15,798],[1118,673,479,811],{"nctId":3911,"briefTitle":3912,"status":343,"phases":3913,"primaryCompletion":3914,"completion":3915,"start":3916,"enrollment":102,"conditions":3917,"interventions":3919},"NCT03515707","Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia",[91],"2022-04-15","2022-07-30","2018-07-10",[387,3918],"Minimal Residual Disease Negativity",[87,692],{"nctId":583,"briefTitle":584,"status":213,"phases":3921,"primaryCompletion":586,"completion":587,"start":588,"enrollment":360,"conditions":3922,"interventions":3923},[91],[427,404,387,389,391],[409,204,441,591,442,57,467,82,418,87],{"nctId":1383,"briefTitle":1384,"status":226,"phases":3925,"primaryCompletion":1386,"completion":1386,"start":1387,"enrollment":1388,"conditions":3926,"interventions":3927},[91],[15,797,798,799],[672,674,1118,673,1391],{"nctId":1408,"briefTitle":1409,"status":226,"phases":3929,"completion":1182,"start":1411,"conditions":3930,"interventions":3931},[91],[797,956,1413],[719,674,1415,1118,673,958,959,960],{"nctId":1421,"briefTitle":1422,"status":226,"phases":3933,"primaryCompletion":1424,"start":999,"enrollment":282,"conditions":3934,"interventions":3935},[90,91],[1126,15,798,799],[1118,673,479,811],{"nctId":3556,"briefTitle":3557,"status":226,"phases":3937,"primaryCompletion":3559,"completion":3559,"start":3560,"conditions":3938,"interventions":3939},[91],[1096],[1118,958,960],{"nctId":1476,"briefTitle":1477,"status":343,"phases":3941,"primaryCompletion":1479,"completion":1479,"start":1480,"enrollment":102,"conditions":3942,"interventions":3943},[91],[1446,732,465,530,1482,389,535,391,362,1150,1284,365,1362],[72,87,57,82,504,442,441],{"nctId":3568,"briefTitle":3569,"status":226,"phases":3945,"primaryCompletion":1297,"completion":1297,"start":3560,"enrollment":475,"conditions":3946,"interventions":3947},[91],[3572,3573,3574,3575,3576,3577,3578,3579],[1607,1118,960,958,719,1415],{"nctId":1493,"briefTitle":1494,"status":114,"phases":3949,"primaryCompletion":1496,"start":1083,"enrollment":135,"conditions":3950,"interventions":3951},[90,91],[1137,15,798,799],[1499,1118,673,811,1043],{"nctId":605,"briefTitle":606,"status":213,"phases":3953,"primaryCompletion":608,"completion":608,"start":609,"enrollment":475,"conditions":3954,"interventions":3955},[91],[390,488,489],[417,87,57,204,612,491,442,441],{"nctId":3209,"briefTitle":3210,"status":226,"phases":3957,"primaryCompletion":2492,"start":1980,"enrollment":463,"conditions":3958,"interventions":3959},[91],[1096],[1118,958,811,1043],{"trials":3961,"activeCount":102},[3962,3966,3970],{"nctId":1585,"briefTitle":1586,"status":226,"phases":3963,"primaryCompletion":1588,"completion":1589,"start":1241,"enrollment":807,"conditions":3964,"interventions":3965},[92],[869,1591,734,29,870,35,871,32,872,875,880,890,1592,1593,898,18,298,453,910],[673,481,1118,479,937,1595,1044,1045,1043,811],{"nctId":1597,"briefTitle":1598,"status":226,"phases":3967,"primaryCompletion":1600,"completion":1600,"start":1601,"enrollment":1602,"conditions":3968,"interventions":3969},[92],[1604],[674,1415,1118,1606,673,958,959,1607,960],{"nctId":1609,"briefTitle":1610,"status":226,"phases":3971,"primaryCompletion":1612,"completion":1612,"start":1613,"enrollment":748,"conditions":3972,"interventions":3973},[92],[15],[1118,673,479,811],{"trials":3975,"activeCount":102},[],{"trials":3977,"activeCount":102},[3978],{"nctId":1629,"briefTitle":1630,"status":226,"phases":3979,"primaryCompletion":1632,"completion":1431,"start":1633,"enrollment":1634,"conditions":3980,"interventions":3981},[94],[734,29,870,35,871,32,872,875,880,890,1636,1592,1637,898,488,18,298,453,910,489,1638,1639],[673,1118,1043,811,1595],{"intervention":958,"totalTrials":282,"cells":3983},{"EARLY_PHASE1":3984,"PHASE1":3986,"PHASE2":4020,"PHASE3":4105,"PHASE4":4127,"NA":4129},{"trials":3985,"activeCount":102},[],{"trials":3987,"activeCount":102},[3988,3992,3996,4004,4008,4012,4016],{"nctId":3258,"briefTitle":3259,"status":114,"phases":3989,"primaryCompletion":3261,"completion":3262,"start":3263,"enrollment":2616,"conditions":3990,"interventions":3991},[90],[528,3265,685,1470,533,247,3266],[3268,1290,3269,373,692,491],{"nctId":3488,"briefTitle":3489,"status":226,"phases":3993,"primaryCompletion":3491,"completion":3491,"start":3492,"conditions":3994,"interventions":3995},[90],[3494],[3496,958,2608,1607,960],{"nctId":3997,"briefTitle":3998,"status":343,"phases":3999,"primaryCompletion":3274,"completion":4000,"start":4001,"enrollment":102,"conditions":4002,"interventions":4003},"NCT04466475","Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma",[90],"2027-09-30","2024-01-27",[536],[702,491],{"nctId":3271,"briefTitle":3272,"status":343,"phases":4005,"primaryCompletion":3274,"completion":293,"start":3275,"enrollment":102,"conditions":4006,"interventions":4007},[90],[248,258,259,249,3277,252,261,262,253,3278],[1290,373,692,3280,491],{"nctId":3498,"briefTitle":3499,"status":226,"phases":4009,"primaryCompletion":999,"completion":999,"start":3501,"enrollment":1510,"conditions":4010,"interventions":4011},[90],[3503],[674,1118,958,960],{"nctId":950,"briefTitle":951,"status":226,"phases":4013,"completion":953,"start":954,"conditions":4014,"interventions":4015},[90],[956],[674,673,958,959,960],{"nctId":3510,"briefTitle":3511,"status":226,"phases":4017,"primaryCompletion":953,"start":3513,"enrollment":3514,"conditions":4018,"interventions":4019},[90],[3494],[674,958,960],{"trials":4021,"activeCount":3454,"soonestReadout":71},[4022,4026,4033,4037,4041,4045,4049,4053,4057,4061,4065,4069,4073,4079,4085,4089,4093,4097,4101],{"nctId":3316,"briefTitle":3317,"status":226,"phases":4023,"primaryCompletion":3319,"completion":3320,"start":3321,"enrollment":317,"conditions":4024,"interventions":4025},[91],[2170,3323,531,533,516,1473],[2052,1290,373,692,491,505,1206],{"nctId":4027,"briefTitle":4028,"status":226,"phases":4029,"completion":2492,"start":4030,"enrollment":463,"conditions":4031,"interventions":4032},"NCT00248430","Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer",[90,91],"2003-08",[1137,15,797,1096],[719,1812,958],{"nctId":1159,"briefTitle":1160,"status":226,"phases":4034,"primaryCompletion":1162,"completion":76,"start":1163,"enrollment":1164,"conditions":4035,"interventions":4036},[91],[488,489],[87,57,504,491,442,376,417,441],{"nctId":3365,"briefTitle":3366,"status":226,"phases":4038,"primaryCompletion":3368,"completion":3369,"start":3370,"enrollment":463,"conditions":4039,"interventions":4040},[90,91],[247,1150,24,1471,251,1233,1309,3372],[1290,373,692,491],{"nctId":84,"briefTitle":85,"status":126,"phases":4042,"primaryCompletion":86,"completion":484,"start":485,"enrollment":486,"conditions":4043,"interventions":4044},[91],[488,489],[87,57,204,491,442,376,417,441],{"nctId":2020,"briefTitle":2021,"status":226,"phases":4046,"primaryCompletion":2023,"start":2024,"enrollment":598,"conditions":4047,"interventions":4048},[90,91],[700,1905,1017,1027],[958,479,481,1812],{"nctId":1275,"briefTitle":1276,"status":226,"phases":4050,"primaryCompletion":772,"completion":1278,"start":1279,"enrollment":1280,"conditions":4051,"interventions":4052},[90,91],[537,1009,1282,1283,1148,1284,21,1285,27,1233,1286,563,1287,1288],[1290,57,82,373,692,504,491,376,1291],{"nctId":2045,"briefTitle":2046,"status":226,"phases":4054,"primaryCompletion":1198,"completion":1198,"start":2048,"enrollment":2049,"conditions":4055,"interventions":4056},[91],[234],[2052,82,82,504,491,376],{"nctId":1408,"briefTitle":1409,"status":226,"phases":4058,"completion":1182,"start":1411,"conditions":4059,"interventions":4060},[91],[797,956,1413],[719,674,1415,1118,673,958,959,960],{"nctId":3556,"briefTitle":3557,"status":226,"phases":4062,"primaryCompletion":3559,"completion":3559,"start":3560,"conditions":4063,"interventions":4064},[91],[1096],[1118,958,960],{"nctId":2105,"briefTitle":2106,"status":226,"phases":4066,"primaryCompletion":2108,"completion":2109,"start":1135,"enrollment":1510,"conditions":4067,"interventions":4068},[90,91],[700],[937,958,481,479],{"nctId":3568,"briefTitle":3569,"status":226,"phases":4070,"primaryCompletion":1297,"completion":1297,"start":3560,"enrollment":475,"conditions":4071,"interventions":4072},[91],[3572,3573,3574,3575,3576,3577,3578,3579],[1607,1118,960,958,719,1415],{"nctId":4074,"briefTitle":4075,"status":226,"phases":4076,"primaryCompletion":2448,"completion":2448,"start":2126,"enrollment":22,"conditions":4077,"interventions":4078},"NCT00006244","Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma",[91],[700,1905,1017,1027],[958,2003,719],{"nctId":4080,"briefTitle":4081,"status":226,"phases":4082,"completion":1241,"start":2605,"conditions":4083,"interventions":4084},"NCT00004158","Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma",[90,91],[1096],[958],{"nctId":605,"briefTitle":606,"status":213,"phases":4086,"primaryCompletion":608,"completion":608,"start":609,"enrollment":475,"conditions":4087,"interventions":4088},[91],[390,488,489],[417,87,57,204,612,491,442,441],{"nctId":1505,"briefTitle":1506,"status":226,"phases":4090,"primaryCompletion":1508,"completion":1508,"start":1509,"enrollment":1510,"conditions":4091,"interventions":4092},[91],[1512,1513,1514,1515,1516,1009,1517,1282,1283,1148,233,21,1285,27,1286,234,563,1518,1519,1288,1234],[1290,57,373,692,504,491,376,441],{"nctId":3209,"briefTitle":3210,"status":226,"phases":4094,"primaryCompletion":2492,"start":1980,"enrollment":463,"conditions":4095,"interventions":4096},[91],[1096],[1118,958,811,1043],{"nctId":614,"briefTitle":615,"status":213,"phases":4098,"primaryCompletion":617,"completion":618,"start":619,"enrollment":463,"conditions":4099,"interventions":4100},[91],[488,489],[57,612,204,468,491,376,441],{"nctId":69,"briefTitle":70,"status":126,"phases":4102,"primaryCompletion":71,"completion":3427,"start":3428,"enrollment":486,"conditions":4103,"interventions":4104},[91],[3430,3431,3432,3433,3434,3435,3436,3437,3438,3439,3440,3441,3442,3443,3444,3445,3446,3447,3448],[72,1290,373,692,491,691],{"trials":4106,"activeCount":102},[4107,4116,4123],{"nctId":4108,"briefTitle":4109,"status":226,"phases":4110,"primaryCompletion":4111,"start":4112,"enrollment":2032,"conditions":4113,"interventions":4114},"NCT00217438","Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma",[92],"2012-10","2005-07",[700,1017,1027],[958,4115,1044],"amifostine trihydrate",{"nctId":4117,"briefTitle":4118,"status":226,"phases":4119,"completion":1612,"start":4120,"conditions":4121,"interventions":4122},"NCT00008229","Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma",[92],"2000-08",[1096],[674,958],{"nctId":1597,"briefTitle":1598,"status":226,"phases":4124,"primaryCompletion":1600,"completion":1600,"start":1601,"enrollment":1602,"conditions":4125,"interventions":4126},[92],[1604],[674,1415,1118,1606,673,958,959,1607,960],{"trials":4128,"activeCount":102},[],{"trials":4130,"activeCount":102},[4131],{"nctId":3462,"briefTitle":3463,"status":343,"phases":4132,"primaryCompletion":3465,"start":2116,"enrollment":102,"conditions":4133,"interventions":4134},[94],[873,2311,2312,2313,2314,2315,2316,2318,558,1001,1002,710,1004,2322,1005,711,1114,1006,899,500,900,1008,901,1009,902,903,1010,1012,712,713,908,24,714,1013,21,1759,1016,715,3467,3468,3469,3470,1775,1041,716],[3472,2194,958,948,3473],{"intervention":3288,"totalTrials":334,"cells":4136},{"EARLY_PHASE1":4137,"PHASE1":4139,"PHASE2":4153,"PHASE3":4180,"PHASE4":4182,"NA":4184},{"trials":4138,"activeCount":102},[],{"trials":4140,"activeCount":98,"soonestReadout":383},[4141,4145,4149],{"nctId":3282,"briefTitle":3283,"status":226,"phases":4142,"completion":3285,"start":2369,"conditions":4143,"interventions":4144},[90],[15],[2194,3288,3289],{"nctId":354,"briefTitle":355,"status":213,"phases":4146,"primaryCompletion":357,"completion":358,"start":359,"enrollment":360,"conditions":4147,"interventions":4148},[90],[362,363,364,365,366,367,368,369,370],[372,57,82,373,374,375,376,377,378,204,373],{"nctId":380,"briefTitle":381,"status":126,"phases":4150,"primaryCompletion":383,"completion":384,"start":385,"enrollment":282,"conditions":4151,"interventions":4152},[90],[387,388,389,390,391],[373,204,393,378,394],{"trials":4154,"activeCount":98,"soonestReadout":460},[4155,4159,4163,4167,4176],{"nctId":3307,"briefTitle":3308,"status":114,"phases":4156,"primaryCompletion":865,"completion":829,"start":3310,"enrollment":3311,"conditions":4157,"interventions":4158},[91],[1108,2013,2014,2015,2016,29,35,32,872,2017,1109,1110,898,18,737],[3314,3288,2194],{"nctId":3326,"briefTitle":3327,"status":226,"phases":4160,"completion":3329,"start":1981,"conditions":4161,"interventions":4162},[91],[1126],[674,1118,2194,3288],{"nctId":444,"briefTitle":445,"status":213,"phases":4164,"primaryCompletion":447,"completion":448,"start":449,"enrollment":22,"conditions":4165,"interventions":4166},[90,91],[387,429,388,362,451,363,452,364,365,370,366,367,368,453],[455,373,374,204,378],{"nctId":4168,"briefTitle":4169,"status":226,"phases":4170,"primaryCompletion":4171,"completion":4171,"start":1870,"enrollment":4172,"conditions":4173,"interventions":4174},"NCT01141725","Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS",[90,91],"2012-11",39,[29,870,35,871,32,872,890,1592,1638],[4175,3288],"bendamustine hydrochloride",{"nctId":457,"briefTitle":458,"status":213,"phases":4177,"primaryCompletion":460,"completion":461,"start":462,"enrollment":463,"conditions":4178,"interventions":4179},[91],[428,387,465,389],[373,204,378,467,468],{"trials":4181,"activeCount":102},[],{"trials":4183,"activeCount":102},[],{"trials":4185,"activeCount":102},[4186],{"nctId":3475,"briefTitle":3476,"status":226,"phases":4187,"primaryCompletion":2116,"completion":772,"start":3478,"enrollment":217,"conditions":4188,"interventions":4189},[94],[1108,2012,2013,2014,2015,2016,29,870,35,32,872,2017,1109,1110,465,890,1593,737,1638],[2877,3288,2194],{"intervention":418,"totalTrials":296,"cells":4191},{"EARLY_PHASE1":4192,"PHASE1":4194,"PHASE2":4196,"PHASE3":4245,"PHASE4":4251,"NA":4253},{"trials":4193,"activeCount":102},[],{"trials":4195,"activeCount":102},[],{"trials":4197,"activeCount":2616,"soonestReadout":81},[4198,4202,4206,4210,4214,4218,4222,4226,4230,4234,4238],{"nctId":1140,"briefTitle":1141,"status":114,"phases":4199,"primaryCompletion":1143,"completion":1143,"start":1144,"enrollment":1145,"conditions":4200,"interventions":4201},[91],[404,387,1147,529,685,533,389,390,537,1148,1149,1150,233,21,1151,1152,431],[57,82,376,418],{"nctId":79,"briefTitle":80,"status":126,"phases":4203,"primaryCompletion":81,"completion":412,"start":413,"enrollment":135,"conditions":4204,"interventions":4205},[91],[415],[82,204,393,376,417,418],{"nctId":1179,"briefTitle":1180,"status":226,"phases":4207,"primaryCompletion":1182,"start":1183,"enrollment":475,"conditions":4208,"interventions":4209},[91],[15,797,798],[673,479,811,481,1186,1043],{"nctId":2887,"briefTitle":2888,"status":343,"phases":4211,"start":1565,"enrollment":102,"conditions":4212,"interventions":4213},[90,91],[1137,15,798],[479,811,1186],{"nctId":1208,"briefTitle":1209,"status":114,"phases":4215,"primaryCompletion":1211,"completion":1212,"start":1213,"enrollment":1214,"conditions":4216,"interventions":4217},[91],[1216,1217,1218],[57,504,376,418,441],{"nctId":3167,"briefTitle":3168,"status":226,"phases":4219,"primaryCompletion":1733,"completion":1733,"start":1263,"conditions":4220,"interventions":4221},[90,91],[1126,1137,15,797,1096,798,799],[811,1186,1043],{"nctId":583,"briefTitle":584,"status":213,"phases":4223,"primaryCompletion":586,"completion":587,"start":588,"enrollment":360,"conditions":4224,"interventions":4225},[91],[427,404,387,389,391],[409,204,441,591,442,57,467,82,418,87],{"nctId":593,"briefTitle":594,"status":213,"phases":4227,"primaryCompletion":596,"completion":596,"start":597,"enrollment":598,"conditions":4228,"interventions":4229},[90,91],[600],[602,204,57,603,376,418],{"nctId":2161,"briefTitle":2162,"status":226,"phases":4231,"primaryCompletion":2164,"completion":2165,"start":2166,"enrollment":1642,"conditions":4232,"interventions":4233},[91],[2168,2169,2170,2171,2172,1147,2173,2174,2175,1843,2176,529,2177,530,406,533,536,537,1148,27,1288,1234,248,1150],[82,504,376,418],{"nctId":2196,"briefTitle":2197,"status":226,"phases":4235,"primaryCompletion":2199,"completion":2200,"start":2201,"enrollment":2202,"conditions":4236,"interventions":4237},[91],[1593,736,27,234,1234,1556,733,734,2204,2205,2206,2207,1862,1558,874,875,876,2136,878,2208,1843,2209,2210,2211,2212,2213,2214,2215,2216,2217,2218,2219,2220,2221,2222,2223,2224,2225,2226,2227,2228,1204,246,18,899,500,900,1008,1009,2229,903,1116,298,904,906,907,2230,712,713,908,24,714,21,1282,1149,2231,911,912,913,2232,915,1761,1762,916,2233,1902,1903,917,918,1904,1202,1765,919,2234,920,921,922,1018,2235,924,1768,1769,925,2236,1024,1025,926,927,1026,1029,928,929,930,1030,2237,932,1771,1772,933,2238,1036,1037,934,935,1038,1040],[504,441,376,418],{"nctId":4239,"briefTitle":4240,"status":226,"phases":4241,"primaryCompletion":1740,"completion":4242,"start":2010,"enrollment":1792,"conditions":4243,"interventions":4244},"NCT00079183","Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior Treatment",[91],"2010-06-10",[1137],[1186],{"trials":4246,"activeCount":102},[4247],{"nctId":2252,"briefTitle":2253,"status":226,"phases":4248,"primaryCompletion":2255,"completion":2256,"start":2257,"enrollment":2258,"conditions":4249,"interventions":4250},[92],[404,387,1147,529,685,406,1470,533,389,391,537,1148,233,27,2260,1233,538,1287,1234],[82,504,376,418],{"trials":4252,"activeCount":102},[],{"trials":4254,"activeCount":102},[],{"intervention":547,"totalTrials":2248,"cells":4256},{"EARLY_PHASE1":4257,"PHASE1":4259,"PHASE2":4261,"PHASE3":4295,"PHASE4":4297,"NA":4299},{"trials":4258,"activeCount":102},[],{"trials":4260,"activeCount":102},[],{"trials":4262,"activeCount":2616,"soonestReadout":76},[4263,4267,4271,4275,4279,4283,4287,4291],{"nctId":2456,"briefTitle":2457,"status":226,"phases":4264,"primaryCompletion":2459,"completion":2459,"start":2460,"enrollment":598,"conditions":4265,"interventions":4266},[91],[2462,2463,2464,2465,1863,2466,2467,2468,2469],[547,504,441,442,603],{"nctId":2480,"briefTitle":2481,"status":226,"phases":4268,"primaryCompletion":2483,"start":1573,"enrollment":2484,"conditions":4269,"interventions":4270},[91],[868,733,734,29,870,35,871,32,872,1111,874,875,877,880,465,890,898,246,18,1116,298,910,1778,1779],[2487,937,1043,811],{"nctId":2531,"briefTitle":2532,"status":1090,"phases":4272,"primaryCompletion":2534,"completion":2535,"start":2536,"enrollment":2537,"conditions":4273,"interventions":4274},[91],[1433,465,2539,389,390,1593],[504,547],{"nctId":2028,"briefTitle":2029,"status":226,"phases":4276,"primaryCompletion":333,"completion":333,"start":2031,"enrollment":2032,"conditions":4277,"interventions":4278},[91],[403,1446,1433,433,405,530,2034],[82,504,376,547],{"nctId":74,"briefTitle":75,"status":126,"phases":4280,"primaryCompletion":76,"completion":542,"start":543,"enrollment":544,"conditions":4281,"interventions":4282},[91],[387,389],[77,204,547],{"nctId":549,"briefTitle":550,"status":213,"phases":4284,"primaryCompletion":552,"completion":553,"start":554,"enrollment":555,"conditions":4285,"interventions":4286},[91],[427,404,387,557,558,528,559,465,560,438,532,533,388,389,537,27,561,562,563],[57,82,374,204,376,377,547],{"nctId":2659,"briefTitle":2660,"status":213,"phases":4288,"primaryCompletion":2662,"completion":2662,"start":2663,"enrollment":598,"conditions":4289,"interventions":4290},[91],[2665],[409,547,504,2667],{"nctId":2143,"briefTitle":2144,"status":226,"phases":4292,"primaryCompletion":2146,"completion":2146,"start":2147,"enrollment":2148,"conditions":4293,"interventions":4294},[91],[2150],[72,82,504,442,376,441,547],{"trials":4296,"activeCount":102},[],{"trials":4298,"activeCount":102},[],{"trials":4300,"activeCount":102},[],{"intervention":417,"totalTrials":3454,"cells":4302},{"EARLY_PHASE1":4303,"PHASE1":4305,"PHASE2":4307,"PHASE3":4325,"PHASE4":4327,"NA":4329},{"trials":4304,"activeCount":102},[],{"trials":4306,"activeCount":102},[],{"trials":4308,"activeCount":2616,"soonestReadout":81},[4309,4313,4317,4321],{"nctId":79,"briefTitle":80,"status":126,"phases":4310,"primaryCompletion":81,"completion":412,"start":413,"enrollment":135,"conditions":4311,"interventions":4312},[91],[415],[82,204,393,376,417,418],{"nctId":1159,"briefTitle":1160,"status":226,"phases":4314,"primaryCompletion":1162,"completion":76,"start":1163,"enrollment":1164,"conditions":4315,"interventions":4316},[91],[488,489],[87,57,504,491,442,376,417,441],{"nctId":84,"briefTitle":85,"status":126,"phases":4318,"primaryCompletion":86,"completion":484,"start":485,"enrollment":486,"conditions":4319,"interventions":4320},[91],[488,489],[87,57,204,491,442,376,417,441],{"nctId":605,"briefTitle":606,"status":213,"phases":4322,"primaryCompletion":608,"completion":608,"start":609,"enrollment":475,"conditions":4323,"interventions":4324},[91],[390,488,489],[417,87,57,204,612,491,442,441],{"trials":4326,"activeCount":102},[],{"trials":4328,"activeCount":102},[],{"trials":4330,"activeCount":102},[],{"intervention":325,"totalTrials":2616,"cells":4332},{"EARLY_PHASE1":4333,"PHASE1":4335,"PHASE2":4341,"PHASE3":4367,"PHASE4":4369,"NA":4371},{"trials":4334,"activeCount":102},[],{"trials":4336,"activeCount":135,"soonestReadout":56},[4337],{"nctId":54,"briefTitle":55,"status":126,"phases":4338,"primaryCompletion":56,"completion":315,"start":316,"enrollment":317,"conditions":4339,"interventions":4340},[90],[248,258,319,320,252,261,321,322,323],[57,204,325,326],{"trials":4342,"activeCount":98,"soonestReadout":1530},[4343,4353],{"nctId":4344,"briefTitle":4345,"status":213,"phases":4346,"primaryCompletion":1530,"completion":1530,"start":4347,"enrollment":463,"conditions":4348,"interventions":4351},"NCT07194980","Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed\u002FRefractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[91],"2026-05-29",[4349,4350],"Recurrent Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma","Refractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[4352,325],"Nemtabrutinib",{"nctId":4354,"briefTitle":4355,"status":213,"phases":4356,"primaryCompletion":4357,"completion":4358,"start":4359,"enrollment":33,"conditions":4360,"interventions":4365},"NCT07098364","ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed\u002FRefractory Large B-Cell Lymphoma",[90,91],"2030-10-04","2043-10-04","2025-12-27",[248,258,319,4361,4362,320,252,261,321,4363,4364,322],"Recurrent High-Grade B-Cell Lymphoma","Recurrent Indolent B-Cell Non-Hodgkin Lymphoma","Refractory High-Grade B-Cell Lymphoma","Refractory Indolent B-Cell Non-Hodgkin Lymphoma",[4366,325],"Vevoctadekin",{"trials":4368,"activeCount":102},[],{"trials":4370,"activeCount":102},[],{"trials":4372,"activeCount":102},[],{"intervention":674,"totalTrials":9,"cells":4374},{"EARLY_PHASE1":4375,"PHASE1":4377,"PHASE2":4432,"PHASE3":4530,"PHASE4":4540,"NA":4542},{"trials":4376,"activeCount":102},[],{"trials":4378,"activeCount":135,"soonestReadout":357},[4379,4389,4393,4408,4412,4416,4420,4424,4428],{"nctId":4380,"briefTitle":4381,"status":114,"phases":4382,"primaryCompletion":4383,"completion":4383,"start":4384,"enrollment":2616,"conditions":4385,"interventions":4386},"NCT01331018","Gene Therapy for Fanconi Anemia",[90],"2024-02-15","2012-02-22",[809],[374,4387,4388,1546,691],"Genetically Engineered Hematopoietic Stem Progenitor Cells","Methylprednisolone",{"nctId":665,"briefTitle":666,"status":226,"phases":4390,"start":668,"enrollment":25,"conditions":4391,"interventions":4392},[90],[670],[672,673,674,675],{"nctId":4394,"briefTitle":4395,"status":343,"phases":4396,"primaryCompletion":4397,"start":4398,"enrollment":102,"conditions":4399,"interventions":4405},"NCT02343666","HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection",[90],"2020-08-01","2016-08-15",[4400,2327,4401,2329,4402,1019,4403,1031,4404],"Human Immunodeficiency Virus 1 Positive","Stage I Adult Non-Hodgkin Lymphoma","Stage II Adult Non-Hodgkin Lymphoma","Stage III Adult Non-Hodgkin Lymphoma","Stage IV Adult Non-Hodgkin Lymphoma",[4406,1290,374,4407,1546],"C46\u002FCCR5\u002FP140K Lentiviral Vector-transduced Autologous HSPCs","O6-Benzylguanine",{"nctId":939,"briefTitle":940,"status":226,"phases":4409,"completion":942,"start":943,"enrollment":944,"conditions":4410,"interventions":4411},[90],[15],[674,673,947,948],{"nctId":3498,"briefTitle":3499,"status":226,"phases":4413,"primaryCompletion":999,"completion":999,"start":3501,"enrollment":1510,"conditions":4414,"interventions":4415},[90],[3503],[674,1118,958,960],{"nctId":950,"briefTitle":951,"status":226,"phases":4417,"completion":953,"start":954,"conditions":4418,"interventions":4419},[90],[956],[674,673,958,959,960],{"nctId":354,"briefTitle":355,"status":213,"phases":4421,"primaryCompletion":357,"completion":358,"start":359,"enrollment":360,"conditions":4422,"interventions":4423},[90],[362,363,364,365,366,367,368,369,370],[372,57,82,373,374,375,376,377,378,204,373],{"nctId":3510,"briefTitle":3511,"status":226,"phases":4425,"primaryCompletion":953,"start":3513,"enrollment":3514,"conditions":4426,"interventions":4427},[90],[3494],[674,958,960],{"nctId":979,"briefTitle":980,"status":114,"phases":4429,"primaryCompletion":982,"start":983,"enrollment":282,"conditions":4430,"interventions":4431},[90],[415],[673,672,479,481,986,674],{"trials":4433,"activeCount":98,"soonestReadout":552},[4434,4444,4448,4452,4456,4468,4472,4476,4487,4493,4497,4504,4508,4512,4516,4520,4526],{"nctId":4435,"briefTitle":4436,"status":226,"phases":4437,"primaryCompletion":829,"completion":4438,"start":4439,"enrollment":463,"conditions":4440,"interventions":4441},"NCT01097057","Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells",[91],"2017-12-26","2010-11-09",[516],[4442,692,374,4443,1546,505],"Carboplatin","Ifosfamide",{"nctId":3326,"briefTitle":3327,"status":226,"phases":4445,"completion":3329,"start":1981,"conditions":4446,"interventions":4447},[91],[1126],[674,1118,2194,3288],{"nctId":3340,"briefTitle":3341,"status":226,"phases":4449,"primaryCompletion":3343,"completion":3344,"start":3345,"enrollment":3346,"conditions":4450,"interventions":4451},[90,91],[403,1434,736,18,1638,453],[372,373,374,3349],{"nctId":444,"briefTitle":445,"status":213,"phases":4453,"primaryCompletion":447,"completion":448,"start":449,"enrollment":22,"conditions":4454,"interventions":4455},[90,91],[387,429,388,362,451,363,452,364,365,370,366,367,368,453],[455,373,374,204,378],{"nctId":4457,"briefTitle":4458,"status":114,"phases":4459,"primaryCompletion":4460,"completion":4461,"start":4462,"enrollment":296,"conditions":4463,"interventions":4466},"NCT00669669","O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas",[90,91],"2018-07-06","2021-01-20","2009-02-25",[4464,4465],"Glioblastoma","Gliosarcoma",[1290,374,4407,1546,4467],"Temozolomide",{"nctId":549,"briefTitle":550,"status":213,"phases":4469,"primaryCompletion":552,"completion":553,"start":554,"enrollment":555,"conditions":4470,"interventions":4471},[91],[427,404,387,557,558,528,559,465,560,438,532,533,388,389,537,27,561,562,563],[57,82,374,204,376,377,547],{"nctId":2602,"briefTitle":2603,"status":226,"phases":4473,"primaryCompletion":1404,"completion":1404,"start":2605,"conditions":4474,"interventions":4475},[90,91],[15],[719,674,1812,2194,948,937,811,2608,2609],{"nctId":4477,"briefTitle":4478,"status":226,"phases":4479,"primaryCompletion":2010,"completion":2010,"start":4120,"conditions":4480,"interventions":4485},"NCT00004157","Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors",[91],[1604,4481,4482,797,4483,3494,3503,4484],"Gestational Trophoblastic Tumor","Kidney Cancer","Neuroblastoma","Testicular Germ Cell Tumor",[674,4486],"recombinant interleukin-11",{"nctId":4488,"briefTitle":4489,"status":226,"phases":4490,"completion":1340,"start":3409,"conditions":4491,"interventions":4492},"NCT00006241","Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Low- or Intermediate-Grade Non-Hodgkin's Lymphoma",[91],[797],[674,2287],{"nctId":1383,"briefTitle":1384,"status":226,"phases":4494,"primaryCompletion":1386,"completion":1386,"start":1387,"enrollment":1388,"conditions":4495,"interventions":4496},[91],[15,797,798,799],[672,674,1118,673,1391],{"nctId":4498,"briefTitle":4499,"status":226,"phases":4500,"completion":4501,"start":4030,"conditions":4502,"interventions":4503},"NCT00118326","Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease",[90,91],"2007-05",[4482,15,797,798,4483,3503],[674],{"nctId":1408,"briefTitle":1409,"status":226,"phases":4505,"completion":1182,"start":1411,"conditions":4506,"interventions":4507},[91],[797,956,1413],[719,674,1415,1118,673,958,959,960],{"nctId":3396,"briefTitle":3397,"status":226,"phases":4509,"primaryCompletion":3399,"completion":3399,"start":3400,"enrollment":231,"conditions":4510,"interventions":4511},[90,91],[388,736,18,3402,365,3403,1638],[372,373,455,374,3349],{"nctId":1437,"briefTitle":1438,"status":114,"phases":4513,"primaryCompletion":1440,"completion":1440,"start":1441,"enrollment":1442,"conditions":4514,"interventions":4515},[91],[403,1444,1445,1446,1447,1433,1448,1449,1450,1451,429,1452,1453,1454,528,1455,1456,1457,389,1458,433,1306,1150,24,714,233,234,453,1459,1364],[57,374,504,376,441],{"nctId":3406,"briefTitle":3407,"status":226,"phases":4517,"primaryCompletion":3409,"completion":3409,"start":3410,"enrollment":282,"conditions":4518,"interventions":4519},[91],[15],[674,2194,948,3413,2608],{"nctId":4521,"briefTitle":4522,"status":226,"phases":4523,"primaryCompletion":4501,"completion":773,"start":1124,"enrollment":807,"conditions":4524,"interventions":4525},"NCT00073931","Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",[91],[797],[674,1415],{"nctId":1537,"briefTitle":1538,"status":226,"phases":4527,"primaryCompletion":1540,"completion":1541,"start":1542,"enrollment":1053,"conditions":4528,"interventions":4529},[91],[1544],[72,57,374,376,1546],{"trials":4531,"activeCount":102},[4532,4536],{"nctId":4117,"briefTitle":4118,"status":226,"phases":4533,"completion":1612,"start":4120,"conditions":4534,"interventions":4535},[92],[1096],[674,958],{"nctId":1597,"briefTitle":1598,"status":226,"phases":4537,"primaryCompletion":1600,"completion":1600,"start":1601,"enrollment":1602,"conditions":4538,"interventions":4539},[92],[1604],[674,1415,1118,1606,673,958,959,1607,960],{"trials":4541,"activeCount":102},[],{"trials":4543,"activeCount":102},[4544],{"nctId":4545,"briefTitle":4546,"status":114,"phases":4547,"primaryCompletion":4548,"completion":4549,"start":4550,"enrollment":135,"conditions":4551,"interventions":4553},"NCT01076270","Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies",[94],"2011-01","2011-02","2010-06",[868,733,734,29,35,871,32,872,4552,1111,882,890,710,1593,711,891,892,893,1895,894,895,1896,1897,896,897,1898,1899,898,246,18,899,500,900,1008,1009,902,903,1012,712,713,908,24,714,1013,21,27,1759,700,1015,453,910,715,1905,1017,920,921,922,1018,1019,923,924,1022,1024,1025,926,927,1026,1027,1029,928,929,930,1030,1031,931,932,1034,1036,1037,934,935,1038,1040],"Atypical Chronic Myeloid Leukemia, BCR-ABL Negative",[4554,674],"plerixafor",{"intervention":372,"totalTrials":2308,"cells":4556},{"EARLY_PHASE1":4557,"PHASE1":4559,"PHASE2":4565,"PHASE3":4583,"PHASE4":4585,"NA":4587},{"trials":4558,"activeCount":102},[],{"trials":4560,"activeCount":135,"soonestReadout":357},[4561],{"nctId":354,"briefTitle":355,"status":213,"phases":4562,"primaryCompletion":357,"completion":358,"start":359,"enrollment":360,"conditions":4563,"interventions":4564},[90],[362,363,364,365,366,367,368,369,370],[372,57,82,373,374,375,376,377,378,204,373],{"trials":4566,"activeCount":135,"soonestReadout":46},[4567,4571,4575,4579],{"nctId":44,"briefTitle":45,"status":126,"phases":4568,"primaryCompletion":46,"completion":586,"start":3302,"enrollment":555,"conditions":4569,"interventions":4570},[91],[387,3304],[47,372,373,468,375],{"nctId":3340,"briefTitle":3341,"status":226,"phases":4572,"primaryCompletion":3343,"completion":3344,"start":3345,"enrollment":3346,"conditions":4573,"interventions":4574},[90,91],[403,1434,736,18,1638,453],[372,373,374,3349],{"nctId":3351,"briefTitle":3352,"status":226,"phases":4576,"primaryCompletion":3354,"completion":3355,"start":3356,"enrollment":2100,"conditions":4577,"interventions":4578},[90,91],[387],[372,373,3359,468,3349],{"nctId":3396,"briefTitle":3397,"status":226,"phases":4580,"primaryCompletion":3399,"completion":3399,"start":3400,"enrollment":231,"conditions":4581,"interventions":4582},[90,91],[388,736,18,3402,365,3403,1638],[372,373,455,374,3349],{"trials":4584,"activeCount":102},[],{"trials":4586,"activeCount":102},[],{"trials":4588,"activeCount":102},[],{"intervention":221,"totalTrials":3454,"cells":4590},{"EARLY_PHASE1":4591,"PHASE1":4593,"PHASE2":4607,"PHASE3":4619,"PHASE4":4621,"NA":4623},{"trials":4592,"activeCount":102},[],{"trials":4594,"activeCount":135,"soonestReadout":215},[4595,4599,4603],{"nctId":211,"briefTitle":212,"status":213,"phases":4596,"primaryCompletion":215,"completion":215,"start":216,"enrollment":217,"conditions":4597,"interventions":4598},[90],[219],[221,57,204,222],{"nctId":328,"briefTitle":329,"status":114,"phases":4600,"primaryCompletion":331,"completion":332,"start":333,"enrollment":334,"conditions":4601,"interventions":4602},[90],[336,337],[339,57,204,221],{"nctId":341,"briefTitle":342,"status":343,"phases":4604,"primaryCompletion":345,"completion":345,"start":346,"enrollment":102,"conditions":4605,"interventions":4606},[90],[348,349,350,351],[221,57,204,222],{"trials":4608,"activeCount":135,"soonestReadout":4613},[4609],{"nctId":4610,"briefTitle":4611,"status":213,"phases":4612,"primaryCompletion":4613,"completion":4614,"start":4615,"enrollment":475,"conditions":4616,"interventions":4617},"NCT07225985","Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma",[90,91],"2030-09-30","2030-11-15","2026-04-27",[1471,3372],[221,4618],"Pralatrexate",{"trials":4620,"activeCount":102},[],{"trials":4622,"activeCount":102},[],{"trials":4624,"activeCount":102},[],{"intervention":4626,"totalTrials":98,"cells":4627},"Nivolumab",{"EARLY_PHASE1":4628,"PHASE1":4630,"PHASE2":4664,"PHASE3":4704,"PHASE4":4706,"NA":4708},{"trials":4629,"activeCount":102},[],{"trials":4631,"activeCount":135,"soonestReadout":4636},[4632],{"nctId":4633,"briefTitle":4634,"status":213,"phases":4635,"primaryCompletion":4636,"completion":4637,"start":4638,"enrollment":807,"conditions":4639,"interventions":4661},"NCT05098210","Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer",[90],"2027-11-01","2028-11-01","2022-06-09",[573,4640,4641,4642,4643,4644,4645,4646,4647,574,219,4648,4649,4650,4651,4652,4653,4654,4655,4656,577,4657,4658,4659,4660],"Clinical Stage IV Cutaneous Melanoma AJCC v8","Locally Advanced Cutaneous Melanoma","Locally Advanced Mucosal Melanoma","Metastatic Acral Melanoma","Metastatic Conjunctival Melanoma","Metastatic Cutaneous Melanoma","Metastatic HER2-Negative Breast Carcinoma","Metastatic Hormone Receptor-Positive Breast Carcinoma","Metastatic Mucosal Melanoma","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Pathologic Stage IIID Cutaneous Melanoma AJCC v8","Recurrent Cutaneous Melanoma","Recurrent HER2-Negative Breast Carcinoma","Recurrent Hormone Receptor-Positive Breast Carcinoma","Recurrent Lung Non-Small Cell Carcinoma","Recurrent Mucosal Melanoma","Stage III Lung Cancer AJCC v8","Unresectable Acral Melanoma","Unresectable Cutaneous Melanoma","Unresectable Lung Non-Small Cell Carcinoma","Unresectable Mucosal Melanoma",[4662,4626,4663],"Neoantigen Peptide Vaccine","Poly ICLC",{"trials":4665,"activeCount":135,"soonestReadout":618},[4666],{"nctId":4667,"briefTitle":4668,"status":152,"phases":4669,"primaryCompletion":618,"completion":618,"start":4670,"enrollment":475,"conditions":4671,"interventions":4703},"NCT07576725","Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial",[91],"2026-09-01",[4672,4673,4640,4674,560,4675,4676,4677,4678,4679,4680,4645,4681,4682,574,219,4683,4648,4684,576,4685,4686,4687,4656,4688,4689,4690,4691,577,4692,4693,4694,4695,4696,4697,4658,4698,4659,4699,4700,4660,4701,4702],"Clinical Stage III Cutaneous Melanoma AJCC v8","Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8","Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8","Kaposi Sarcoma","Metastatic Acral Lentiginous Melanoma","Metastatic Basal Cell Carcinoma","Metastatic Cervical Carcinoma","Metastatic Clear Cell Renal Cell Carcinoma","Metastatic Colorectal Carcinoma","Metastatic Head and Neck Squamous Cell Carcinoma","Metastatic Kaposi Sarcoma","Metastatic Merkel Cell Carcinoma","Metastatic Skin Squamous Cell Carcinoma","Stage III Cervical Cancer AJCC v8","Stage III Colorectal Cancer AJCC v8","Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8","Stage III Renal Cell Cancer AJCC v8","Stage IV Cervical Cancer AJCC v8","Stage IV Colorectal Cancer AJCC v8","Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8","Stage IV Renal Cell Cancer AJCC v8","Unresectable Acral Lentiginous Melanoma","Unresectable Basal Cell Carcinoma","Unresectable Cervical Carcinoma","Unresectable Clear Cell Renal Cell Carcinoma","Unresectable Colorectal Carcinoma","Unresectable Head and Neck Squamous Cell Carcinoma","Unresectable Malignant Solid Neoplasm","Unresectable Merkel Cell Carcinoma","Unresectable Skin Squamous Cell Carcinoma","Unresectable Urothelial Carcinoma",[4626],{"trials":4705,"activeCount":102},[],{"trials":4707,"activeCount":102},[],{"trials":4709,"activeCount":102},[],{"intervention":375,"totalTrials":98,"cells":4711},{"EARLY_PHASE1":4712,"PHASE1":4714,"PHASE2":4720,"PHASE3":4726,"PHASE4":4728,"NA":4730},{"trials":4713,"activeCount":102},[],{"trials":4715,"activeCount":135,"soonestReadout":357},[4716],{"nctId":354,"briefTitle":355,"status":213,"phases":4717,"primaryCompletion":357,"completion":358,"start":359,"enrollment":360,"conditions":4718,"interventions":4719},[90],[362,363,364,365,366,367,368,369,370],[372,57,82,373,374,375,376,377,378,204,373],{"trials":4721,"activeCount":135,"soonestReadout":46},[4722],{"nctId":44,"briefTitle":45,"status":126,"phases":4723,"primaryCompletion":46,"completion":586,"start":3302,"enrollment":555,"conditions":4724,"interventions":4725},[91],[387,3304],[47,372,373,468,375],{"trials":4727,"activeCount":102},[],{"trials":4729,"activeCount":102},[],{"trials":4731,"activeCount":102},[],{"intervention":4733,"totalTrials":98,"cells":4734},"Fecal Microbiota Transplantation",{"EARLY_PHASE1":4735,"PHASE1":4737,"PHASE2":4748,"PHASE3":4761,"PHASE4":4763,"NA":4765},{"trials":4736,"activeCount":102},[],{"trials":4738,"activeCount":135,"soonestReadout":586},[4739],{"nctId":4740,"briefTitle":4741,"status":213,"phases":4742,"primaryCompletion":586,"completion":586,"start":4743,"enrollment":4744,"conditions":4745,"interventions":4747},"NCT05067595","Fecal Microbiota Transplant and Dietary Fiber Supplementation for the Treatment of Gut Graft Versus Host Disease",[90],"2025-01-24",72,[4746],"Intestinal Graft Versus Host Disease",[4733,4733],{"trials":4749,"activeCount":135,"soonestReadout":4754},[4750],{"nctId":4751,"briefTitle":4752,"status":126,"phases":4753,"primaryCompletion":4754,"completion":4755,"start":4756,"enrollment":4757,"conditions":4758,"interventions":4760},"NCT06026371","Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation",[91],"2026-09-30","2027-03-31","2023-12-12",138,[4759,1352],"Acute Graft Versus Host Disease",[4733],{"trials":4762,"activeCount":102},[],{"trials":4764,"activeCount":102},[],{"trials":4766,"activeCount":102},[],{"intervention":393,"totalTrials":98,"cells":4768},{"EARLY_PHASE1":4769,"PHASE1":4771,"PHASE2":4777,"PHASE3":4783,"PHASE4":4785,"NA":4787},{"trials":4770,"activeCount":102},[],{"trials":4772,"activeCount":135,"soonestReadout":383},[4773],{"nctId":380,"briefTitle":381,"status":126,"phases":4774,"primaryCompletion":383,"completion":384,"start":385,"enrollment":282,"conditions":4775,"interventions":4776},[90],[387,388,389,390,391],[373,204,393,378,394],{"trials":4778,"activeCount":135,"soonestReadout":81},[4779],{"nctId":79,"briefTitle":80,"status":126,"phases":4780,"primaryCompletion":81,"completion":412,"start":413,"enrollment":135,"conditions":4781,"interventions":4782},[91],[415],[82,204,393,376,417,418],{"trials":4784,"activeCount":102},[],{"trials":4786,"activeCount":102},[],{"trials":4788,"activeCount":102},[],{"intervention":467,"totalTrials":98,"cells":4790},{"EARLY_PHASE1":4791,"PHASE1":4793,"PHASE2":4795,"PHASE3":4805,"PHASE4":4807,"NA":4809},{"trials":4792,"activeCount":102},[],{"trials":4794,"activeCount":102},[],{"trials":4796,"activeCount":98,"soonestReadout":460},[4797,4801],{"nctId":457,"briefTitle":458,"status":213,"phases":4798,"primaryCompletion":460,"completion":461,"start":462,"enrollment":463,"conditions":4799,"interventions":4800},[91],[428,387,465,389],[373,204,378,467,468],{"nctId":583,"briefTitle":584,"status":213,"phases":4802,"primaryCompletion":586,"completion":587,"start":588,"enrollment":360,"conditions":4803,"interventions":4804},[91],[427,404,387,389,391],[409,204,441,591,442,57,467,82,418,87],{"trials":4806,"activeCount":102},[],{"trials":4808,"activeCount":102},[],{"trials":4810,"activeCount":102},[],{"intervention":377,"totalTrials":98,"cells":4812},{"EARLY_PHASE1":4813,"PHASE1":4815,"PHASE2":4821,"PHASE3":4827,"PHASE4":4829,"NA":4831},{"trials":4814,"activeCount":102},[],{"trials":4816,"activeCount":135,"soonestReadout":357},[4817],{"nctId":354,"briefTitle":355,"status":213,"phases":4818,"primaryCompletion":357,"completion":358,"start":359,"enrollment":360,"conditions":4819,"interventions":4820},[90],[362,363,364,365,366,367,368,369,370],[372,57,82,373,374,375,376,377,378,204,373],{"trials":4822,"activeCount":135,"soonestReadout":552},[4823],{"nctId":549,"briefTitle":550,"status":213,"phases":4824,"primaryCompletion":552,"completion":553,"start":554,"enrollment":555,"conditions":4825,"interventions":4826},[91],[427,404,387,557,558,528,559,465,560,438,532,533,388,389,537,27,561,562,563],[57,82,374,204,376,377,547],{"trials":4828,"activeCount":102},[],{"trials":4830,"activeCount":102},[],{"trials":4832,"activeCount":102},[],{"intervention":62,"totalTrials":98,"cells":4834},{"EARLY_PHASE1":4835,"PHASE1":4837,"PHASE2":4839,"PHASE3":4858,"PHASE4":4860,"NA":4862},{"trials":4836,"activeCount":102},[],{"trials":4838,"activeCount":102},[],{"trials":4840,"activeCount":98,"soonestReadout":61},[4841,4848],{"nctId":59,"briefTitle":60,"status":126,"phases":4842,"primaryCompletion":61,"completion":617,"start":4843,"enrollment":4844,"conditions":4845,"interventions":4847},[91],"2020-12-11",51,[4846,406],"Recurrent Moderate-Severe Chronic Graft Versus Host Disease",[62],{"nctId":4849,"briefTitle":4850,"status":213,"phases":4851,"primaryCompletion":4852,"completion":4853,"start":4854,"enrollment":463,"conditions":4855,"interventions":4856},"NCT04941716","Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial",[91],"2027-08-10","2031-08-10","2023-05-31",[1148,21,27,563],[62,4857],"Venetoclax",{"trials":4859,"activeCount":102},[],{"trials":4861,"activeCount":102},[],{"trials":4863,"activeCount":102},[],{"intervention":602,"totalTrials":98,"cells":4865},{"EARLY_PHASE1":4866,"PHASE1":4868,"PHASE2":4870,"PHASE3":4880,"PHASE4":4882,"NA":4884},{"trials":4867,"activeCount":102},[],{"trials":4869,"activeCount":102},[],{"trials":4871,"activeCount":98,"soonestReadout":596},[4872,4876],{"nctId":593,"briefTitle":594,"status":213,"phases":4873,"primaryCompletion":596,"completion":596,"start":597,"enrollment":598,"conditions":4874,"interventions":4875},[90,91],[600],[602,204,57,603,376,418],{"nctId":1526,"briefTitle":1527,"status":213,"phases":4877,"primaryCompletion":1529,"completion":1530,"start":1531,"enrollment":282,"conditions":4878,"interventions":4879},[90,91],[1446,732,1433,465,407,1533,362,1534,365,452,367,406],[602,57,376,468,504,441],{"trials":4881,"activeCount":102},[],{"trials":4883,"activeCount":102},[],{"trials":4885,"activeCount":102},[],{"intervention":612,"totalTrials":98,"cells":4887},{"EARLY_PHASE1":4888,"PHASE1":4890,"PHASE2":4892,"PHASE3":4902,"PHASE4":4904,"NA":4906},{"trials":4889,"activeCount":102},[],{"trials":4891,"activeCount":102},[],{"trials":4893,"activeCount":98,"soonestReadout":617},[4894,4898],{"nctId":605,"briefTitle":606,"status":213,"phases":4895,"primaryCompletion":608,"completion":608,"start":609,"enrollment":475,"conditions":4896,"interventions":4897},[91],[390,488,489],[417,87,57,204,612,491,442,441],{"nctId":614,"briefTitle":615,"status":213,"phases":4899,"primaryCompletion":617,"completion":618,"start":619,"enrollment":463,"conditions":4900,"interventions":4901},[91],[488,489],[57,612,204,468,491,376,441],{"trials":4903,"activeCount":102},[],{"trials":4905,"activeCount":102},[],{"trials":4907,"activeCount":102},[],{"intervention":675,"totalTrials":2248,"cells":4909},{"EARLY_PHASE1":4910,"PHASE1":4912,"PHASE2":4930,"PHASE3":4947,"PHASE4":4957,"NA":4959},{"trials":4911,"activeCount":102},[],{"trials":4913,"activeCount":102},[4914,4918,4922,4926],{"nctId":4380,"briefTitle":4381,"status":114,"phases":4915,"primaryCompletion":4383,"completion":4383,"start":4384,"enrollment":2616,"conditions":4916,"interventions":4917},[90],[809],[374,4387,4388,1546,691],{"nctId":665,"briefTitle":666,"status":226,"phases":4919,"start":668,"enrollment":25,"conditions":4920,"interventions":4921},[90],[670],[672,673,674,675],{"nctId":677,"briefTitle":678,"status":114,"phases":4923,"primaryCompletion":680,"completion":680,"start":681,"enrollment":682,"conditions":4924,"interventions":4925},[90],[528,684,685],[687,57,688,442,689,690,691,692,505],{"nctId":970,"briefTitle":971,"status":226,"phases":4927,"completion":973,"start":974,"enrollment":296,"conditions":4928,"interventions":4929},[90],[15,797],[719,718,673,675,977],{"trials":4931,"activeCount":135,"soonestReadout":71},[4932,4936,4943],{"nctId":3694,"briefTitle":3695,"status":226,"phases":4933,"primaryCompletion":473,"start":1827,"enrollment":486,"conditions":4934,"interventions":4935},[91],[3698],[811,1391,675],{"nctId":4937,"briefTitle":4938,"status":226,"phases":4939,"primaryCompletion":4940,"start":1999,"enrollment":486,"conditions":4941,"interventions":4942},"NCT00410657","Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant",[91],"2006-11",[1604,1126,4481,1137,15,797,1096,798,799,4483,3494,4484],[1499,1391,675],{"nctId":69,"briefTitle":70,"status":126,"phases":4944,"primaryCompletion":71,"completion":3427,"start":3428,"enrollment":486,"conditions":4945,"interventions":4946},[91],[3430,3431,3432,3433,3434,3435,3436,3437,3438,3439,3440,3441,3442,3443,3444,3445,3446,3447,3448],[72,1290,373,692,491,691],{"trials":4948,"activeCount":102},[4949],{"nctId":4950,"briefTitle":4951,"status":226,"phases":4952,"primaryCompletion":865,"completion":4953,"start":1199,"enrollment":4954,"conditions":4955,"interventions":4956},"NCT00929695","Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease",[92],"2015-12-14",164,[1137,246],[675,1391],{"trials":4958,"activeCount":102},[],{"trials":4960,"activeCount":102},[],{"intervention":672,"totalTrials":1510,"cells":4962},{"EARLY_PHASE1":4963,"PHASE1":4965,"PHASE2":4975,"PHASE3":5043,"PHASE4":5045,"NA":5047},{"trials":4964,"activeCount":102},[],{"trials":4966,"activeCount":102},[4967,4971],{"nctId":665,"briefTitle":666,"status":226,"phases":4968,"start":668,"enrollment":25,"conditions":4969,"interventions":4970},[90],[670],[672,673,674,675],{"nctId":979,"briefTitle":980,"status":114,"phases":4972,"primaryCompletion":982,"start":983,"enrollment":282,"conditions":4973,"interventions":4974},[90],[415],[673,672,479,481,986,674],{"trials":4976,"activeCount":135,"soonestReadout":71},[4977,4981,4985,4989,4996,5000,5007,5011,5015,5019,5027,5031,5035,5039],{"nctId":1048,"briefTitle":1049,"status":226,"phases":4978,"primaryCompletion":1051,"completion":1052,"start":983,"enrollment":1053,"conditions":4979,"interventions":4980},[91],[415],[673,672,479,811,986,1045],{"nctId":1131,"briefTitle":1132,"status":226,"phases":4982,"completion":1134,"start":1135,"conditions":4983,"interventions":4984},[90,91],[1126,1137,15,798,799],[672,1118,673,479,811],{"nctId":2445,"briefTitle":2446,"status":226,"phases":4986,"primaryCompletion":1386,"completion":2448,"start":1839,"enrollment":544,"conditions":4987,"interventions":4988},[91],[868,734,29,870,35,871,32,872,1111,875,877,880,882,890,1003,1593,898,18,298,1015],[937,1118,672,1043,811],{"nctId":4990,"briefTitle":4991,"status":226,"phases":4992,"completion":4993,"start":1298,"enrollment":296,"conditions":4994,"interventions":4995},"NCT00378768","Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple Myeloma",[91],"2007-06",[1096],[672],{"nctId":2516,"briefTitle":2517,"status":226,"phases":4997,"completion":1182,"start":2519,"enrollment":598,"conditions":4998,"interventions":4999},[91],[1126,1137,15,798,799],[672,1118,937,811,1043],{"nctId":5001,"briefTitle":5002,"status":226,"phases":5003,"primaryCompletion":1386,"completion":1386,"start":474,"conditions":5004,"interventions":5005},"NCT00005853","Biological Therapy in Treating Patients With Myelodysplastic Syndrome",[91],[15,798],[672,5006],"etanercept",{"nctId":1293,"briefTitle":1294,"status":114,"phases":5008,"primaryCompletion":1296,"completion":1297,"start":1298,"enrollment":636,"conditions":5009,"interventions":5010},[91],[15,797,1096,798,799],[672,673,479,937,481],{"nctId":1383,"briefTitle":1384,"status":226,"phases":5012,"primaryCompletion":1386,"completion":1386,"start":1387,"enrollment":1388,"conditions":5013,"interventions":5014},[91],[15,797,798,799],[672,674,1118,673,1391],{"nctId":1476,"briefTitle":1477,"status":343,"phases":5016,"primaryCompletion":1479,"completion":1479,"start":1480,"enrollment":102,"conditions":5017,"interventions":5018},[91],[1446,732,465,530,1482,389,535,391,362,1150,1284,365,1362],[72,87,57,82,504,442,441],{"nctId":5020,"briefTitle":5021,"status":226,"phases":5022,"primaryCompletion":5023,"start":5024,"enrollment":282,"conditions":5025,"interventions":5026},"NCT00217386","Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes",[91],"2007-12","2004-03",[15,798,799],[672,5006],{"nctId":1485,"briefTitle":1486,"status":226,"phases":5028,"start":1488,"enrollment":463,"conditions":5029,"interventions":5030},[91],[1490],[672,673],{"nctId":2143,"briefTitle":2144,"status":226,"phases":5032,"primaryCompletion":2146,"completion":2146,"start":2147,"enrollment":2148,"conditions":5033,"interventions":5034},[91],[2150],[72,82,504,442,376,441,547],{"nctId":69,"briefTitle":70,"status":126,"phases":5036,"primaryCompletion":71,"completion":3427,"start":3428,"enrollment":486,"conditions":5037,"interventions":5038},[91],[3430,3431,3432,3433,3434,3435,3436,3437,3438,3439,3440,3441,3442,3443,3444,3445,3446,3447,3448],[72,1290,373,692,491,691],{"nctId":1537,"briefTitle":1538,"status":226,"phases":5040,"primaryCompletion":1540,"completion":1541,"start":1542,"enrollment":1053,"conditions":5041,"interventions":5042},[91],[1544],[72,57,374,376,1546],{"trials":5044,"activeCount":102},[],{"trials":5046,"activeCount":102},[],{"trials":5048,"activeCount":102},[],{"intervention":505,"totalTrials":636,"cells":5050},{"EARLY_PHASE1":5051,"PHASE1":5053,"PHASE2":5059,"PHASE3":5133,"PHASE4":5135,"NA":5137},{"trials":5052,"activeCount":102},[],{"trials":5054,"activeCount":102},[5055],{"nctId":677,"briefTitle":678,"status":114,"phases":5056,"primaryCompletion":680,"completion":680,"start":681,"enrollment":682,"conditions":5057,"interventions":5058},[90],[528,684,685],[687,57,688,442,689,690,691,692,505],{"trials":5060,"activeCount":135,"soonestReadout":5120},[5061,5065,5069,5078,5082,5089,5097,5101,5105,5112,5116,5127],{"nctId":1737,"briefTitle":1738,"status":226,"phases":5062,"primaryCompletion":1740,"completion":1741,"start":1742,"enrollment":1743,"conditions":5063,"interventions":5064},[91],[709,711,899,500,900,1008,901,902,903,712,713,908,24,714,21,715,716],[1746,479,937,481],{"nctId":4435,"briefTitle":4436,"status":226,"phases":5066,"primaryCompletion":829,"completion":4438,"start":4439,"enrollment":463,"conditions":5067,"interventions":5068},[91],[516],[4442,692,374,4443,1546,505],{"nctId":5070,"briefTitle":5071,"status":226,"phases":5072,"primaryCompletion":1962,"completion":5073,"start":1573,"enrollment":2284,"conditions":5074,"interventions":5077},"NCT00867529","Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma",[91],"2015-03-26",[5075,5076,709,876,878,879,1002,710,1005,711,1007,246,899,500,900,1008,901,1009,902,903,1116,905,906,907,1011,712,713,908,24,714,21,1014,27,1759,1016,715,1041,716],"B-cell Adult Acute Lymphoblastic Leukemia","B-cell Childhood Acute Lymphoblastic Leukemia",[1746],{"nctId":3316,"briefTitle":3317,"status":226,"phases":5079,"primaryCompletion":3319,"completion":3320,"start":3321,"enrollment":317,"conditions":5080,"interventions":5081},[91],[2170,3323,531,533,516,1473],[2052,1290,373,692,491,505,1206],{"nctId":5083,"briefTitle":5084,"status":226,"phases":5085,"primaryCompletion":1092,"completion":5086,"start":3024,"enrollment":2049,"conditions":5087,"interventions":5088},"NCT00244855","Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma",[91],"2011-08-29",[1891,1892,1893,1002,710,711,1896,1897,1898,712,713,714,715,1902,1903,1904,1024,1025,1026,1036,1037,1038,1234],[1746,947],{"nctId":5090,"briefTitle":5091,"status":226,"phases":5092,"primaryCompletion":5093,"completion":2536,"start":4030,"enrollment":244,"conditions":5094,"interventions":5095},"NCT00072514","Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies",[91],"2008-07",[873,558,1001,1002,710,1004,1005,711,1114,1006,899,500,900,1008,901,1009,902,903,1010,1012,712,713,908,24,714,1013,21,1016,715,1041,1234],[5096,1606,947,1746],"gemcitabine hydrochloride",{"nctId":1195,"briefTitle":1196,"status":226,"phases":5098,"primaryCompletion":1198,"completion":1198,"start":1199,"enrollment":598,"conditions":5099,"interventions":5100},[90,91],[529,1201,1202,1203,1204,1022,1029,1034,1040],[504,57,505,1206],{"nctId":493,"briefTitle":494,"status":114,"phases":5102,"primaryCompletion":496,"completion":496,"start":497,"enrollment":463,"conditions":5103,"interventions":5104},[91],[499,500,247,501,251,502,252],[82,504,376,505,204],{"nctId":5106,"briefTitle":5107,"status":114,"phases":5108,"primaryCompletion":829,"start":1051,"enrollment":2616,"conditions":5109,"interventions":5110},"NCT01419795","Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant",[91],[873,558,1001,1002,710,1004,1005,711,1114,1006,537,899,500,900,1008,901,902,903,1010,1012,712,713,908,24,714,1013,21,27,1759,1016,715,1775,1041,716],[5111,1746],"lenalidomide",{"nctId":2095,"briefTitle":2096,"status":226,"phases":5113,"primaryCompletion":2098,"completion":2098,"start":2099,"enrollment":2100,"conditions":5114,"interventions":5115},[91],[529,537,21,27,1022,1029,1034,1040,2102],[82,504,376,505],{"nctId":5117,"briefTitle":5118,"status":213,"phases":5119,"primaryCompletion":5120,"completion":5121,"start":5122,"enrollment":282,"conditions":5123,"interventions":5124},"NCT06839053","Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma",[91],"2028-08-01","2032-07-01","2025-06-02",[529,533,1148,24,21,27,1309,563,538],[505,5125,5126],"Sonrotoclax","Zanubrutinib",{"nctId":5128,"briefTitle":5129,"status":343,"phases":5130,"start":1573,"enrollment":102,"conditions":5131,"interventions":5132},"NCT00833534","Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant",[91],[15,797],[1746,5111],{"trials":5134,"activeCount":102},[],{"trials":5136,"activeCount":102},[],{"trials":5138,"activeCount":102},[],{"intervention":455,"totalTrials":395,"cells":5140},{"EARLY_PHASE1":5141,"PHASE1":5143,"PHASE2":5145,"PHASE3":5176,"PHASE4":5178,"NA":5180},{"trials":5142,"activeCount":102},[],{"trials":5144,"activeCount":102},[],{"trials":5146,"activeCount":135,"soonestReadout":447},[5147,5151,5160,5164,5168,5172],{"nctId":3307,"briefTitle":3308,"status":114,"phases":5148,"primaryCompletion":865,"completion":829,"start":3310,"enrollment":3311,"conditions":5149,"interventions":5150},[91],[1108,2013,2014,2015,2016,29,35,32,872,2017,1109,1110,898,18,737],[3314,3288,2194],{"nctId":5152,"briefTitle":5153,"status":226,"phases":5154,"primaryCompletion":5155,"completion":5155,"start":5156,"enrollment":475,"conditions":5157,"interventions":5158},"NCT01812252","Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant",[91],"2022-10-26","2013-08-19",[465,1434,389,2231],[5159,455],"Azacitidine",{"nctId":3333,"briefTitle":3334,"status":226,"phases":5161,"primaryCompletion":1431,"completion":1431,"start":1051,"enrollment":30,"conditions":5162,"interventions":5163},[91],[1450,29,870,871,890,898,453,910,1638],[3338,2194,3314],{"nctId":444,"briefTitle":445,"status":213,"phases":5165,"primaryCompletion":447,"completion":448,"start":449,"enrollment":22,"conditions":5166,"interventions":5167},[90,91],[387,429,388,362,451,363,452,364,365,370,366,367,368,453],[455,373,374,204,378],{"nctId":3387,"briefTitle":3388,"status":226,"phases":5169,"primaryCompletion":3390,"completion":3391,"start":3392,"enrollment":1634,"conditions":5170,"interventions":5171},[90,91],[736,18],[373,455,692,3349],{"nctId":3396,"briefTitle":3397,"status":226,"phases":5173,"primaryCompletion":3399,"completion":3399,"start":3400,"enrollment":231,"conditions":5174,"interventions":5175},[90,91],[388,736,18,3402,365,3403,1638],[372,373,455,374,3349],{"trials":5177,"activeCount":102},[],{"trials":5179,"activeCount":102},[],{"trials":5181,"activeCount":102},[],{"intervention":1206,"totalTrials":2308,"cells":5183},{"EARLY_PHASE1":5184,"PHASE1":5186,"PHASE2":5188,"PHASE3":5224,"PHASE4":5226,"NA":5228},{"trials":5185,"activeCount":102},[],{"trials":5187,"activeCount":102},[],{"trials":5189,"activeCount":135,"soonestReadout":5210},[5190,5194,5198,5206,5216],{"nctId":3316,"briefTitle":3317,"status":226,"phases":5191,"primaryCompletion":3319,"completion":3320,"start":3321,"enrollment":317,"conditions":5192,"interventions":5193},[91],[2170,3323,531,533,516,1473],[2052,1290,373,692,491,505,1206],{"nctId":1195,"briefTitle":1196,"status":226,"phases":5195,"primaryCompletion":1198,"completion":1198,"start":1199,"enrollment":598,"conditions":5196,"interventions":5197},[90,91],[529,1201,1202,1203,1204,1022,1029,1034,1040],[504,57,505,1206],{"nctId":5199,"briefTitle":5200,"status":226,"phases":5201,"primaryCompletion":1052,"completion":5202,"start":1573,"enrollment":36,"conditions":5203,"interventions":5205},"NCT00839956","Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant",[91],"2017-03-31",[5204,1456,1457],"DS Stage I Plasma Cell Myeloma",[2052,1206],{"nctId":5207,"briefTitle":5208,"status":213,"phases":5209,"primaryCompletion":5210,"completion":5211,"start":5212,"enrollment":944,"conditions":5213,"interventions":5214},"NCT06145633","Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer",[91],"2026-12-30","2027-12-30","2024-09-18",[630,631,632],[5215,1206],"Lutetium Lu 177 Vipivotide Tetraxetan",{"nctId":5217,"briefTitle":5218,"status":114,"phases":5219,"primaryCompletion":1082,"start":5220,"enrollment":36,"conditions":5221,"interventions":5222},"NCT00673153","Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia",[91],"2008-03",[1108,2012,2013,2014,2015,2016,29,870,35,32,872,2017,1109,1110,1638],[1994,5223],"vorinostat",{"trials":5225,"activeCount":102},[],{"trials":5227,"activeCount":102},[],{"trials":5229,"activeCount":102},[],{"intervention":77,"totalTrials":2616,"cells":5231},{"EARLY_PHASE1":5232,"PHASE1":5234,"PHASE2":5236,"PHASE3":5250,"PHASE4":5252,"NA":5254},{"trials":5233,"activeCount":102},[],{"trials":5235,"activeCount":102},[],{"trials":5237,"activeCount":135,"soonestReadout":76},[5238,5242,5246],{"nctId":1786,"briefTitle":1787,"status":226,"phases":5239,"primaryCompletion":1789,"completion":1790,"start":1791,"enrollment":1792,"conditions":5240,"interventions":5241},[91],[387],[77,82,376],{"nctId":74,"briefTitle":75,"status":126,"phases":5243,"primaryCompletion":76,"completion":542,"start":543,"enrollment":544,"conditions":5244,"interventions":5245},[91],[387,389],[77,204,547],{"nctId":3415,"briefTitle":3416,"status":226,"phases":5247,"primaryCompletion":847,"completion":847,"start":1296,"enrollment":25,"conditions":5248,"interventions":5249},[90,91],[29,870,35,32,872,1592,898,18],[3420,2194],{"trials":5251,"activeCount":102},[],{"trials":5253,"activeCount":102},[],{"trials":5255,"activeCount":102},[],{"intervention":52,"totalTrials":98,"cells":5257},{"EARLY_PHASE1":5258,"PHASE1":5260,"PHASE2":5262,"PHASE3":5272,"PHASE4":5274,"NA":5276},{"trials":5259,"activeCount":102},[],{"trials":5261,"activeCount":102},[],{"trials":5263,"activeCount":135,"soonestReadout":51},[5264,5268],{"nctId":49,"briefTitle":50,"status":126,"phases":5265,"primaryCompletion":51,"completion":400,"start":401,"enrollment":36,"conditions":5266,"interventions":5267},[91],[403,404,405,406,389,407],[52,57,204,409],{"nctId":507,"briefTitle":508,"status":114,"phases":5269,"primaryCompletion":510,"completion":511,"start":512,"enrollment":135,"conditions":5270,"interventions":5271},[91],[514,404,515,387,405,406,133,389,407,516,517],[204,57,409,52],{"trials":5273,"activeCount":102},[],{"trials":5275,"activeCount":102},[],{"trials":5277,"activeCount":102},[],{"intervention":47,"totalTrials":98,"cells":5279},{"EARLY_PHASE1":5280,"PHASE1":5282,"PHASE2":5284,"PHASE3":5298,"PHASE4":5300,"NA":5302},{"trials":5281,"activeCount":102},[],{"trials":5283,"activeCount":102},[],{"trials":5285,"activeCount":135,"soonestReadout":46},[5286,5290],{"nctId":44,"briefTitle":45,"status":126,"phases":5287,"primaryCompletion":46,"completion":586,"start":3302,"enrollment":555,"conditions":5288,"interventions":5289},[91],[387,3304],[47,372,373,468,375],{"nctId":5291,"briefTitle":5292,"status":114,"phases":5293,"primaryCompletion":5294,"completion":5294,"start":5295,"enrollment":135,"conditions":5296,"interventions":5297},"NCT04526288","CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease",[91],"2023-08-27","2021-08-09",[387,1559,3304],[47],{"trials":5299,"activeCount":102},[],{"trials":5301,"activeCount":102},[],{"trials":5303,"activeCount":102},[],{"intervention":603,"totalTrials":98,"cells":5305},{"EARLY_PHASE1":5306,"PHASE1":5308,"PHASE2":5310,"PHASE3":5320,"PHASE4":5322,"NA":5324},{"trials":5307,"activeCount":102},[],{"trials":5309,"activeCount":102},[],{"trials":5311,"activeCount":135,"soonestReadout":596},[5312,5316],{"nctId":2456,"briefTitle":2457,"status":226,"phases":5313,"primaryCompletion":2459,"completion":2459,"start":2460,"enrollment":598,"conditions":5314,"interventions":5315},[91],[2462,2463,2464,2465,1863,2466,2467,2468,2469],[547,504,441,442,603],{"nctId":593,"briefTitle":594,"status":213,"phases":5317,"primaryCompletion":596,"completion":596,"start":597,"enrollment":598,"conditions":5318,"interventions":5319},[90,91],[600],[602,204,57,603,376,418],{"trials":5321,"activeCount":102},[],{"trials":5323,"activeCount":102},[],{"trials":5325,"activeCount":102},[],{"intervention":4618,"totalTrials":135,"cells":5327},{"EARLY_PHASE1":5328,"PHASE1":5330,"PHASE2":5332,"PHASE3":5338,"PHASE4":5340,"NA":5342},{"trials":5329,"activeCount":102},[],{"trials":5331,"activeCount":102},[],{"trials":5333,"activeCount":135,"soonestReadout":4613},[5334],{"nctId":4610,"briefTitle":4611,"status":213,"phases":5335,"primaryCompletion":4613,"completion":4614,"start":4615,"enrollment":475,"conditions":5336,"interventions":5337},[90,91],[1471,3372],[221,4618],{"trials":5339,"activeCount":102},[],{"trials":5341,"activeCount":102},[],{"trials":5343,"activeCount":102},[],{"intervention":5345,"totalTrials":135,"cells":5346},"Belumosudil",{"EARLY_PHASE1":5347,"PHASE1":5349,"PHASE2":5351,"PHASE3":5364,"PHASE4":5366,"NA":5368},{"trials":5348,"activeCount":102},[],{"trials":5350,"activeCount":102},[],{"trials":5352,"activeCount":135,"soonestReadout":5357},[5353],{"nctId":5354,"briefTitle":5355,"status":213,"phases":5356,"primaryCompletion":5357,"completion":5358,"start":5359,"enrollment":5360,"conditions":5361,"interventions":5363},"NCT05996627","Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease",[91],"2028-04-30","2028-11-30","2023-12-06",82,[5362],"Chronic Graft Versus Host Disease",[5345],{"trials":5365,"activeCount":102},[],{"trials":5367,"activeCount":102},[],{"trials":5369,"activeCount":102},[],{"intervention":5371,"totalTrials":135,"cells":5372},"Axatilimab",{"EARLY_PHASE1":5373,"PHASE1":5375,"PHASE2":5377,"PHASE3":5388,"PHASE4":5390,"NA":5392},{"trials":5374,"activeCount":102},[],{"trials":5376,"activeCount":102},[],{"trials":5378,"activeCount":135,"soonestReadout":5383},[5379],{"nctId":5380,"briefTitle":5381,"status":213,"phases":5382,"primaryCompletion":5383,"completion":5384,"start":5385,"enrollment":475,"conditions":5386,"interventions":5387},"NCT07011810","Axatilimab for Sclerotic Chronic Graft-versus-Host Disease",[91],"2028-08-10","2030-02-10","2025-08-06",[5362],[5371],{"trials":5389,"activeCount":102},[],{"trials":5391,"activeCount":102},[],{"trials":5393,"activeCount":102},[],{"intervention":5395,"totalTrials":135,"cells":5396},"Immune Globulin Infusion (Human), 10% Solution",{"EARLY_PHASE1":5397,"PHASE1":5399,"PHASE2":5401,"PHASE3":5413,"PHASE4":5415,"NA":5417},{"trials":5398,"activeCount":102},[],{"trials":5400,"activeCount":102},[],{"trials":5402,"activeCount":135,"soonestReadout":5407},[5403],{"nctId":5404,"briefTitle":5405,"status":213,"phases":5406,"primaryCompletion":5407,"completion":5407,"start":5408,"enrollment":1145,"conditions":5409,"interventions":5411},"NCT05952804","IVIG for Infection Prevention After CAR-T-Cell Therapy",[91],"2028-07-31","2024-06-10",[5410],"Hematologic Malignancies",[5395,5412],"Anti-CD19 CAR T Cells Preparation",{"trials":5414,"activeCount":102},[],{"trials":5416,"activeCount":102},[],{"trials":5418,"activeCount":102},[],{"intervention":5412,"totalTrials":135,"cells":5420},{"EARLY_PHASE1":5421,"PHASE1":5423,"PHASE2":5425,"PHASE3":5431,"PHASE4":5433,"NA":5435},{"trials":5422,"activeCount":102},[],{"trials":5424,"activeCount":102},[],{"trials":5426,"activeCount":135,"soonestReadout":5407},[5427],{"nctId":5404,"briefTitle":5405,"status":213,"phases":5428,"primaryCompletion":5407,"completion":5407,"start":5408,"enrollment":1145,"conditions":5429,"interventions":5430},[91],[5410],[5395,5412],{"trials":5432,"activeCount":102},[],{"trials":5434,"activeCount":102},[],{"trials":5436,"activeCount":102},[],{"intervention":5438,"totalTrials":135,"cells":5439},"Linvoseltamab",{"EARLY_PHASE1":5440,"PHASE1":5442,"PHASE2":5444,"PHASE3":5454,"PHASE4":5456,"NA":5458},{"trials":5441,"activeCount":102},[],{"trials":5443,"activeCount":102},[],{"trials":5445,"activeCount":135,"soonestReadout":5450},[5446],{"nctId":5447,"briefTitle":5448,"status":213,"phases":5449,"primaryCompletion":5450,"completion":5450,"start":5451,"enrollment":282,"conditions":5452,"interventions":5453},"NCT07181941","Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed\u002FRefractory Multiple Myeloma",[90,91],"2028-06-30","2026-03-24",[699,700],[5438],{"trials":5455,"activeCount":102},[],{"trials":5457,"activeCount":102},[],{"trials":5459,"activeCount":102},[],{"intervention":4352,"totalTrials":135,"cells":5461},{"EARLY_PHASE1":5462,"PHASE1":5464,"PHASE2":5466,"PHASE3":5472,"PHASE4":5474,"NA":5476},{"trials":5463,"activeCount":102},[],{"trials":5465,"activeCount":102},[],{"trials":5467,"activeCount":135,"soonestReadout":1530},[5468],{"nctId":4344,"briefTitle":4345,"status":213,"phases":5469,"primaryCompletion":1530,"completion":1530,"start":4347,"enrollment":463,"conditions":5470,"interventions":5471},[91],[4349,4350],[4352,325],{"trials":5473,"activeCount":102},[],{"trials":5475,"activeCount":102},[],{"trials":5477,"activeCount":102},[],{"intervention":67,"totalTrials":135,"cells":5479},{"EARLY_PHASE1":5480,"PHASE1":5482,"PHASE2":5484,"PHASE3":5492,"PHASE4":5494,"NA":5496},{"trials":5481,"activeCount":102},[],{"trials":5483,"activeCount":102},[],{"trials":5485,"activeCount":135,"soonestReadout":66},[5486],{"nctId":64,"briefTitle":65,"status":126,"phases":5487,"primaryCompletion":66,"completion":460,"start":5488,"enrollment":5489,"conditions":5490,"interventions":5491},[91],"2021-05-14",116,[1152,1482],[67],{"trials":5493,"activeCount":102},[],{"trials":5495,"activeCount":102},[],{"trials":5497,"activeCount":102},[],{"intervention":42,"totalTrials":135,"cells":5499},{"EARLY_PHASE1":5500,"PHASE1":5502,"PHASE2":5504,"PHASE3":5510,"PHASE4":5512,"NA":5514},{"trials":5501,"activeCount":102},[],{"trials":5503,"activeCount":102},[],{"trials":5505,"activeCount":135,"soonestReadout":41},[5506],{"nctId":39,"briefTitle":40,"status":126,"phases":5507,"primaryCompletion":41,"completion":1303,"start":1304,"enrollment":486,"conditions":5508,"interventions":5509},[90,91],[247,1148,248,1306,1307,24,714,251,252,561,1308,1309,1310,1311,1312,562,1313,1314,21,27,563,1315,1316],[42,57,504],{"trials":5511,"activeCount":102},[],{"trials":5513,"activeCount":102},[],{"trials":5515,"activeCount":102},[],{"intervention":5517,"totalTrials":135,"cells":5518},"SARS-CoV-2 mRNA Vaccine ARCT-021",{"EARLY_PHASE1":5519,"PHASE1":5521,"PHASE2":5523,"PHASE3":5535,"PHASE4":5537,"NA":5539},{"trials":5520,"activeCount":102},[],{"trials":5522,"activeCount":102},[],{"trials":5524,"activeCount":135,"soonestReadout":5529},[5525],{"nctId":5526,"briefTitle":5527,"status":152,"phases":5528,"primaryCompletion":5529,"completion":5530,"start":4670,"enrollment":5531,"conditions":5532,"interventions":5533},"NCT07390968","Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients",[91],"2028-09-01","2029-01-01",56,[1352],[5517,5534],"Tozinameran",{"trials":5536,"activeCount":102},[],{"trials":5538,"activeCount":102},[],{"trials":5540,"activeCount":102},[],{"intervention":5534,"totalTrials":135,"cells":5542},{"EARLY_PHASE1":5543,"PHASE1":5545,"PHASE2":5547,"PHASE3":5553,"PHASE4":5555,"NA":5557},{"trials":5544,"activeCount":102},[],{"trials":5546,"activeCount":102},[],{"trials":5548,"activeCount":135,"soonestReadout":5529},[5549],{"nctId":5526,"briefTitle":5527,"status":152,"phases":5550,"primaryCompletion":5529,"completion":5530,"start":4670,"enrollment":5531,"conditions":5551,"interventions":5552},[91],[1352],[5517,5534],{"trials":5554,"activeCount":102},[],{"trials":5556,"activeCount":102},[],{"trials":5558,"activeCount":102},[],{"intervention":5560,"totalTrials":135,"cells":5561},"Remdesivir",{"EARLY_PHASE1":5562,"PHASE1":5564,"PHASE2":5566,"PHASE3":5577,"PHASE4":5579,"NA":5581},{"trials":5563,"activeCount":102},[],{"trials":5565,"activeCount":102},[],{"trials":5567,"activeCount":135,"soonestReadout":5572},[5568],{"nctId":5569,"briefTitle":5570,"status":213,"phases":5571,"primaryCompletion":5572,"completion":5572,"start":5573,"enrollment":555,"conditions":5574,"interventions":5576},"NCT06817889","Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals",[91],"2027-11-30","2025-12-23",[1352,3430,5575],"Respiratory Syncytial Virus Infection",[5560],{"trials":5578,"activeCount":102},[],{"trials":5580,"activeCount":102},[],{"trials":5582,"activeCount":102},[],{"intervention":591,"totalTrials":135,"cells":5584},{"EARLY_PHASE1":5585,"PHASE1":5587,"PHASE2":5589,"PHASE3":5595,"PHASE4":5597,"NA":5599},{"trials":5586,"activeCount":102},[],{"trials":5588,"activeCount":102},[],{"trials":5590,"activeCount":135,"soonestReadout":586},[5591],{"nctId":583,"briefTitle":584,"status":213,"phases":5592,"primaryCompletion":586,"completion":587,"start":588,"enrollment":360,"conditions":5593,"interventions":5594},[91],[427,404,387,389,391],[409,204,441,591,442,57,467,82,418,87],{"trials":5596,"activeCount":102},[],{"trials":5598,"activeCount":102},[],{"trials":5600,"activeCount":102},[],{"intervention":4857,"totalTrials":135,"cells":5602},{"EARLY_PHASE1":5603,"PHASE1":5605,"PHASE2":5607,"PHASE3":5613,"PHASE4":5615,"NA":5617},{"trials":5604,"activeCount":102},[],{"trials":5606,"activeCount":102},[],{"trials":5608,"activeCount":135,"soonestReadout":4852},[5609],{"nctId":4849,"briefTitle":4850,"status":213,"phases":5610,"primaryCompletion":4852,"completion":4853,"start":4854,"enrollment":463,"conditions":5611,"interventions":5612},[91],[1148,21,27,563],[62,4857],{"trials":5614,"activeCount":102},[],{"trials":5616,"activeCount":102},[],{"trials":5618,"activeCount":102},[],{"intervention":5215,"totalTrials":135,"cells":5620},{"EARLY_PHASE1":5621,"PHASE1":5623,"PHASE2":5625,"PHASE3":5631,"PHASE4":5633,"NA":5635},{"trials":5622,"activeCount":102},[],{"trials":5624,"activeCount":102},[],{"trials":5626,"activeCount":135,"soonestReadout":5210},[5627],{"nctId":5207,"briefTitle":5208,"status":213,"phases":5628,"primaryCompletion":5210,"completion":5211,"start":5212,"enrollment":944,"conditions":5629,"interventions":5630},[91],[630,631,632],[5215,1206],{"trials":5632,"activeCount":102},[],{"trials":5634,"activeCount":102},[],{"trials":5636,"activeCount":102},[],{"intervention":5125,"totalTrials":135,"cells":5638},{"EARLY_PHASE1":5639,"PHASE1":5641,"PHASE2":5643,"PHASE3":5649,"PHASE4":5651,"NA":5653},{"trials":5640,"activeCount":102},[],{"trials":5642,"activeCount":102},[],{"trials":5644,"activeCount":135,"soonestReadout":5120},[5645],{"nctId":5117,"briefTitle":5118,"status":213,"phases":5646,"primaryCompletion":5120,"completion":5121,"start":5122,"enrollment":282,"conditions":5647,"interventions":5648},[91],[529,533,1148,24,21,27,1309,563,538],[505,5125,5126],{"trials":5650,"activeCount":102},[],{"trials":5652,"activeCount":102},[],{"trials":5654,"activeCount":102},[],{"intervention":5126,"totalTrials":135,"cells":5656},{"EARLY_PHASE1":5657,"PHASE1":5659,"PHASE2":5661,"PHASE3":5667,"PHASE4":5669,"NA":5671},{"trials":5658,"activeCount":102},[],{"trials":5660,"activeCount":102},[],{"trials":5662,"activeCount":135,"soonestReadout":5120},[5663],{"nctId":5117,"briefTitle":5118,"status":213,"phases":5664,"primaryCompletion":5120,"completion":5121,"start":5122,"enrollment":282,"conditions":5665,"interventions":5666},[91],[529,533,1148,24,21,27,1309,563,538],[505,5125,5126],{"trials":5668,"activeCount":102},[],{"trials":5670,"activeCount":102},[],{"trials":5672,"activeCount":102},[],{"intervention":4366,"totalTrials":135,"cells":5674},{"EARLY_PHASE1":5675,"PHASE1":5677,"PHASE2":5679,"PHASE3":5685,"PHASE4":5687,"NA":5689},{"trials":5676,"activeCount":102},[],{"trials":5678,"activeCount":102},[],{"trials":5680,"activeCount":135,"soonestReadout":4357},[5681],{"nctId":4354,"briefTitle":4355,"status":213,"phases":5682,"primaryCompletion":4357,"completion":4358,"start":4359,"enrollment":33,"conditions":5683,"interventions":5684},[90,91],[248,258,319,4361,4362,320,252,261,321,4363,4364,322],[4366,325],{"trials":5686,"activeCount":102},[],{"trials":5688,"activeCount":102},[],{"trials":5690,"activeCount":102},[],{"intervention":5692,"totalTrials":135,"cells":5693},"Rifaximin",{"EARLY_PHASE1":5694,"PHASE1":5696,"PHASE2":5698,"PHASE3":5708,"PHASE4":5710,"NA":5712},{"trials":5695,"activeCount":102},[],{"trials":5697,"activeCount":102},[],{"trials":5699,"activeCount":135,"soonestReadout":5704},[5700],{"nctId":5701,"briefTitle":5702,"status":213,"phases":5703,"primaryCompletion":5704,"completion":5704,"start":76,"enrollment":475,"conditions":5705,"interventions":5707},"NCT07209371","Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance",[91],"2028-05-01",[5706],"IgA Monoclonal Gammopathy of Undetermined Significance",[5692],{"trials":5709,"activeCount":102},[],{"trials":5711,"activeCount":102},[],{"trials":5713,"activeCount":102},[],{"intervention":2667,"totalTrials":135,"cells":5715},{"EARLY_PHASE1":5716,"PHASE1":5718,"PHASE2":5720,"PHASE3":5726,"PHASE4":5728,"NA":5730},{"trials":5717,"activeCount":102},[],{"trials":5719,"activeCount":102},[],{"trials":5721,"activeCount":135,"soonestReadout":2662},[5722],{"nctId":2659,"briefTitle":2660,"status":213,"phases":5723,"primaryCompletion":2662,"completion":2662,"start":2663,"enrollment":598,"conditions":5724,"interventions":5725},[91],[2665],[409,547,504,2667],{"trials":5727,"activeCount":102},[],{"trials":5729,"activeCount":102},[],{"trials":5731,"activeCount":102},[],{"intervention":634,"totalTrials":135,"cells":5733},{"EARLY_PHASE1":5734,"PHASE1":5736,"PHASE2":5738,"PHASE3":5744,"PHASE4":5746,"NA":5748},{"trials":5735,"activeCount":102},[],{"trials":5737,"activeCount":102},[],{"trials":5739,"activeCount":135,"soonestReadout":626},[5740],{"nctId":623,"briefTitle":624,"status":213,"phases":5741,"primaryCompletion":626,"completion":626,"start":627,"enrollment":628,"conditions":5742,"interventions":5743},[90,91],[630,631,632],[634,57,635,204],{"trials":5745,"activeCount":102},[],{"trials":5747,"activeCount":102},[],{"trials":5749,"activeCount":102},[],{"intervention":635,"totalTrials":135,"cells":5751},{"EARLY_PHASE1":5752,"PHASE1":5754,"PHASE2":5756,"PHASE3":5762,"PHASE4":5764,"NA":5766},{"trials":5753,"activeCount":102},[],{"trials":5755,"activeCount":102},[],{"trials":5757,"activeCount":135,"soonestReadout":626},[5758],{"nctId":623,"briefTitle":624,"status":213,"phases":5759,"primaryCompletion":626,"completion":626,"start":627,"enrollment":628,"conditions":5760,"interventions":5761},[90,91],[630,631,632],[634,57,635,204],{"trials":5763,"activeCount":102},[],{"trials":5765,"activeCount":102},[],{"trials":5767,"activeCount":102},[],{"intervention":692,"totalTrials":271,"cells":5769},{"EARLY_PHASE1":5770,"PHASE1":5772,"PHASE2":5794,"PHASE3":5848,"PHASE4":5850,"NA":5852},{"trials":5771,"activeCount":102},[],{"trials":5773,"activeCount":102},[5774,5778,5782,5786,5790],{"nctId":677,"briefTitle":678,"status":114,"phases":5775,"primaryCompletion":680,"completion":680,"start":681,"enrollment":682,"conditions":5776,"interventions":5777},[90],[528,684,685],[687,57,688,442,689,690,691,692,505],{"nctId":3251,"briefTitle":3252,"status":226,"phases":5779,"primaryCompletion":3254,"start":1387,"conditions":5780,"interventions":5781},[90],[15,798],[719,1812,718,2194,948,2608],{"nctId":3258,"briefTitle":3259,"status":114,"phases":5783,"primaryCompletion":3261,"completion":3262,"start":3263,"enrollment":2616,"conditions":5784,"interventions":5785},[90],[528,3265,685,1470,533,247,3266],[3268,1290,3269,373,692,491],{"nctId":3271,"briefTitle":3272,"status":343,"phases":5787,"primaryCompletion":3274,"completion":293,"start":3275,"enrollment":102,"conditions":5788,"interventions":5789},[90],[248,258,259,249,3277,252,261,262,253,3278],[1290,373,692,3280,491],{"nctId":939,"briefTitle":940,"status":226,"phases":5791,"completion":942,"start":943,"enrollment":944,"conditions":5792,"interventions":5793},[90],[15],[674,673,947,948],{"trials":5795,"activeCount":135,"soonestReadout":71},[5796,5800,5804,5808,5812,5816,5820,5824,5828,5832,5836,5840,5844],{"nctId":4435,"briefTitle":4436,"status":226,"phases":5797,"primaryCompletion":829,"completion":4438,"start":4439,"enrollment":463,"conditions":5798,"interventions":5799},[91],[516],[4442,692,374,4443,1546,505],{"nctId":3316,"briefTitle":3317,"status":226,"phases":5801,"primaryCompletion":3319,"completion":3320,"start":3321,"enrollment":317,"conditions":5802,"interventions":5803},[91],[2170,3323,531,533,516,1473],[2052,1290,373,692,491,505,1206],{"nctId":3365,"briefTitle":3366,"status":226,"phases":5805,"primaryCompletion":3368,"completion":3369,"start":3370,"enrollment":463,"conditions":5806,"interventions":5807},[90,91],[247,1150,24,1471,251,1233,1309,3372],[1290,373,692,491],{"nctId":2871,"briefTitle":2872,"status":114,"phases":5809,"primaryCompletion":848,"completion":848,"start":2874,"enrollment":395,"conditions":5810,"interventions":5811},[90,91],[1108,2012,2013,2014,2015,2016,29,870,35,32,872,2017,1109,1110,18],[479,2877,2608,948],{"nctId":3883,"briefTitle":3884,"status":226,"phases":5813,"primaryCompletion":3886,"completion":3886,"start":3887,"enrollment":282,"conditions":5814,"interventions":5815},[91],[734,29,870,871,32,875,18,298],[1118,948,719],{"nctId":1275,"briefTitle":1276,"status":226,"phases":5817,"primaryCompletion":772,"completion":1278,"start":1279,"enrollment":1280,"conditions":5818,"interventions":5819},[90,91],[537,1009,1282,1283,1148,1284,21,1285,27,1233,1286,563,1287,1288],[1290,57,82,373,692,504,491,376,1291],{"nctId":3911,"briefTitle":3912,"status":343,"phases":5821,"primaryCompletion":3914,"completion":3915,"start":3916,"enrollment":102,"conditions":5822,"interventions":5823},[91],[387,3918],[87,692],{"nctId":2602,"briefTitle":2603,"status":226,"phases":5825,"primaryCompletion":1404,"completion":1404,"start":2605,"conditions":5826,"interventions":5827},[90,91],[15],[719,674,1812,2194,948,937,811,2608,2609],{"nctId":3387,"briefTitle":3388,"status":226,"phases":5829,"primaryCompletion":3390,"completion":3391,"start":3392,"enrollment":1634,"conditions":5830,"interventions":5831},[90,91],[736,18],[373,455,692,3349],{"nctId":1393,"briefTitle":1394,"status":226,"phases":5833,"primaryCompletion":1396,"completion":1396,"start":1371,"enrollment":1397,"conditions":5834,"interventions":5835},[91],[558,1002,710,711,899,500,900,1008,902,903,712,713,908,24,714,715,716],[673,948],{"nctId":3406,"briefTitle":3407,"status":226,"phases":5837,"primaryCompletion":3409,"completion":3409,"start":3410,"enrollment":282,"conditions":5838,"interventions":5839},[91],[15],[674,2194,948,3413,2608],{"nctId":1505,"briefTitle":1506,"status":226,"phases":5841,"primaryCompletion":1508,"completion":1508,"start":1509,"enrollment":1510,"conditions":5842,"interventions":5843},[91],[1512,1513,1514,1515,1516,1009,1517,1282,1283,1148,233,21,1285,27,1286,234,563,1518,1519,1288,1234],[1290,57,373,692,504,491,376,441],{"nctId":69,"briefTitle":70,"status":126,"phases":5845,"primaryCompletion":71,"completion":3427,"start":3428,"enrollment":486,"conditions":5846,"interventions":5847},[91],[3430,3431,3432,3433,3434,3435,3436,3437,3438,3439,3440,3441,3442,3443,3444,3445,3446,3447,3448],[72,1290,373,692,491,691],{"trials":5849,"activeCount":102},[],{"trials":5851,"activeCount":102},[],{"trials":5853,"activeCount":102},[5854],{"nctId":3462,"briefTitle":3463,"status":343,"phases":5855,"primaryCompletion":3465,"start":2116,"enrollment":102,"conditions":5856,"interventions":5857},[94],[873,2311,2312,2313,2314,2315,2316,2318,558,1001,1002,710,1004,2322,1005,711,1114,1006,899,500,900,1008,901,1009,902,903,1010,1012,712,713,908,24,714,1013,21,1759,1016,715,3467,3468,3469,3470,1775,1041,716],[3472,2194,958,948,3473],{"intervention":1290,"totalTrials":1084,"cells":5859},{"EARLY_PHASE1":5860,"PHASE1":5862,"PHASE2":5876,"PHASE3":5902,"PHASE4":5904,"NA":5906},{"trials":5861,"activeCount":102},[],{"trials":5863,"activeCount":102},[5864,5868,5872],{"nctId":3258,"briefTitle":3259,"status":114,"phases":5865,"primaryCompletion":3261,"completion":3262,"start":3263,"enrollment":2616,"conditions":5866,"interventions":5867},[90],[528,3265,685,1470,533,247,3266],[3268,1290,3269,373,692,491],{"nctId":3271,"briefTitle":3272,"status":343,"phases":5869,"primaryCompletion":3274,"completion":293,"start":3275,"enrollment":102,"conditions":5870,"interventions":5871},[90],[248,258,259,249,3277,252,261,262,253,3278],[1290,373,692,3280,491],{"nctId":4394,"briefTitle":4395,"status":343,"phases":5873,"primaryCompletion":4397,"start":4398,"enrollment":102,"conditions":5874,"interventions":5875},[90],[4400,2327,4401,2329,4402,1019,4403,1031,4404],[4406,1290,374,4407,1546],{"trials":5877,"activeCount":135,"soonestReadout":71},[5878,5882,5886,5890,5894,5898],{"nctId":3316,"briefTitle":3317,"status":226,"phases":5879,"primaryCompletion":3319,"completion":3320,"start":3321,"enrollment":317,"conditions":5880,"interventions":5881},[91],[2170,3323,531,533,516,1473],[2052,1290,373,692,491,505,1206],{"nctId":3365,"briefTitle":3366,"status":226,"phases":5883,"primaryCompletion":3368,"completion":3369,"start":3370,"enrollment":463,"conditions":5884,"interventions":5885},[90,91],[247,1150,24,1471,251,1233,1309,3372],[1290,373,692,491],{"nctId":4457,"briefTitle":4458,"status":114,"phases":5887,"primaryCompletion":4460,"completion":4461,"start":4462,"enrollment":296,"conditions":5888,"interventions":5889},[90,91],[4464,4465],[1290,374,4407,1546,4467],{"nctId":1275,"briefTitle":1276,"status":226,"phases":5891,"primaryCompletion":772,"completion":1278,"start":1279,"enrollment":1280,"conditions":5892,"interventions":5893},[90,91],[537,1009,1282,1283,1148,1284,21,1285,27,1233,1286,563,1287,1288],[1290,57,82,373,692,504,491,376,1291],{"nctId":1505,"briefTitle":1506,"status":226,"phases":5895,"primaryCompletion":1508,"completion":1508,"start":1509,"enrollment":1510,"conditions":5896,"interventions":5897},[91],[1512,1513,1514,1515,1516,1009,1517,1282,1283,1148,233,21,1285,27,1286,234,563,1518,1519,1288,1234],[1290,57,373,692,504,491,376,441],{"nctId":69,"briefTitle":70,"status":126,"phases":5899,"primaryCompletion":71,"completion":3427,"start":3428,"enrollment":486,"conditions":5900,"interventions":5901},[91],[3430,3431,3432,3433,3434,3435,3436,3437,3438,3439,3440,3441,3442,3443,3444,3445,3446,3447,3448],[72,1290,373,692,491,691],{"trials":5903,"activeCount":102},[],{"trials":5905,"activeCount":102},[],{"trials":5907,"activeCount":102},[5908],{"nctId":3462,"briefTitle":3463,"status":343,"phases":5909,"primaryCompletion":3465,"start":2116,"enrollment":102,"conditions":5910,"interventions":5911},[94],[873,2311,2312,2313,2314,2315,2316,2318,558,1001,1002,710,1004,2322,1005,711,1114,1006,899,500,900,1008,901,1009,902,903,1010,1012,712,713,908,24,714,1013,21,1759,1016,715,3467,3468,3469,3470,1775,1041,716],[3472,2194,958,948,3473],{"intervention":222,"totalTrials":98,"cells":5913},{"EARLY_PHASE1":5914,"PHASE1":5916,"PHASE2":5926,"PHASE3":5928,"PHASE4":5930,"NA":5932},{"trials":5915,"activeCount":102},[],{"trials":5917,"activeCount":135,"soonestReadout":215},[5918,5922],{"nctId":211,"briefTitle":212,"status":213,"phases":5919,"primaryCompletion":215,"completion":215,"start":216,"enrollment":217,"conditions":5920,"interventions":5921},[90],[219],[221,57,204,222],{"nctId":341,"briefTitle":342,"status":343,"phases":5923,"primaryCompletion":345,"completion":345,"start":346,"enrollment":102,"conditions":5924,"interventions":5925},[90],[348,349,350,351],[221,57,204,222],{"trials":5927,"activeCount":102},[],{"trials":5929,"activeCount":102},[],{"trials":5931,"activeCount":102},[],{"trials":5933,"activeCount":102},[],{"intervention":702,"totalTrials":98,"cells":5935},{"EARLY_PHASE1":5936,"PHASE1":5938,"PHASE2":5948,"PHASE3":5950,"PHASE4":5952,"NA":5954},{"trials":5937,"activeCount":102},[],{"trials":5939,"activeCount":135,"soonestReadout":586},[5940,5944],{"nctId":694,"briefTitle":695,"status":152,"phases":5941,"primaryCompletion":586,"completion":423,"start":156,"enrollment":282,"conditions":5942,"interventions":5943},[90],[698,699,700],[702,57,504],{"nctId":3997,"briefTitle":3998,"status":343,"phases":5945,"primaryCompletion":3274,"completion":4000,"start":4001,"enrollment":102,"conditions":5946,"interventions":5947},[90],[536],[702,491],{"trials":5949,"activeCount":102},[],{"trials":5951,"activeCount":102},[],{"trials":5953,"activeCount":102},[],{"trials":5955,"activeCount":102},[],{"intervention":4662,"totalTrials":135,"cells":5957},{"EARLY_PHASE1":5958,"PHASE1":5960,"PHASE2":5966,"PHASE3":5968,"PHASE4":5970,"NA":5972},{"trials":5959,"activeCount":102},[],{"trials":5961,"activeCount":135,"soonestReadout":4636},[5962],{"nctId":4633,"briefTitle":4634,"status":213,"phases":5963,"primaryCompletion":4636,"completion":4637,"start":4638,"enrollment":807,"conditions":5964,"interventions":5965},[90],[573,4640,4641,4642,4643,4644,4645,4646,4647,574,219,4648,4649,4650,4651,4652,4653,4654,4655,4656,577,4657,4658,4659,4660],[4662,4626,4663],{"trials":5967,"activeCount":102},[],{"trials":5969,"activeCount":102},[],{"trials":5971,"activeCount":102},[],{"trials":5973,"activeCount":102},[],{"intervention":4663,"totalTrials":135,"cells":5975},{"EARLY_PHASE1":5976,"PHASE1":5978,"PHASE2":5984,"PHASE3":5986,"PHASE4":5988,"NA":5990},{"trials":5977,"activeCount":102},[],{"trials":5979,"activeCount":135,"soonestReadout":4636},[5980],{"nctId":4633,"briefTitle":4634,"status":213,"phases":5981,"primaryCompletion":4636,"completion":4637,"start":4638,"enrollment":807,"conditions":5982,"interventions":5983},[90],[573,4640,4641,4642,4643,4644,4645,4646,4647,574,219,4648,4649,4650,4651,4652,4653,4654,4655,4656,577,4657,4658,4659,4660],[4662,4626,4663],{"trials":5985,"activeCount":102},[],{"trials":5987,"activeCount":102},[],{"trials":5989,"activeCount":102},[],{"trials":5991,"activeCount":102},[],{"intervention":288,"totalTrials":135,"cells":5993},{"EARLY_PHASE1":5994,"PHASE1":5996,"PHASE2":6002,"PHASE3":6004,"PHASE4":6006,"NA":6008},{"trials":5995,"activeCount":102},[],{"trials":5997,"activeCount":135,"soonestReadout":280},[5998],{"nctId":277,"briefTitle":278,"status":213,"phases":5999,"primaryCompletion":280,"completion":280,"start":281,"enrollment":282,"conditions":6000,"interventions":6001},[90],[284,285,286],[288,204,57],{"trials":6003,"activeCount":102},[],{"trials":6005,"activeCount":102},[],{"trials":6007,"activeCount":102},[],{"trials":6009,"activeCount":102},[],{"intervention":6011,"totalTrials":135,"cells":6012},"CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR",{"EARLY_PHASE1":6013,"PHASE1":6015,"PHASE2":6033,"PHASE3":6035,"PHASE4":6037,"NA":6039},{"trials":6014,"activeCount":102},[],{"trials":6016,"activeCount":135,"soonestReadout":6021},[6017],{"nctId":6018,"briefTitle":6019,"status":213,"phases":6020,"primaryCompletion":6021,"completion":6022,"start":6023,"enrollment":217,"conditions":6024,"interventions":6032},"NCT03326921","HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant",[90],"2027-10-16","2028-07-16","2018-02-23",[1757,6025,451,1116,298,1534,250,6026,6027,364,6028,368,429,388,6029,6030,1533,362,389,387,404,403,6031,465,2539,363,452,15,559],"Recurrent Acute Biphenotypic Leukemia","Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm","Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive","Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive","Chronic Myeloid Leukemia",[6011],{"trials":6034,"activeCount":102},[],{"trials":6036,"activeCount":102},[],{"trials":6038,"activeCount":102},[],{"trials":6040,"activeCount":102},[],{"intervention":301,"totalTrials":135,"cells":6042},{"EARLY_PHASE1":6043,"PHASE1":6045,"PHASE2":6051,"PHASE3":6053,"PHASE4":6055,"NA":6057},{"trials":6044,"activeCount":102},[],{"trials":6046,"activeCount":135,"soonestReadout":293},[6047],{"nctId":290,"briefTitle":291,"status":213,"phases":6048,"primaryCompletion":293,"completion":294,"start":295,"enrollment":296,"conditions":6049,"interventions":6050},[90],[298,299],[301,57,204],{"trials":6052,"activeCount":102},[],{"trials":6054,"activeCount":102},[],{"trials":6056,"activeCount":102},[],{"trials":6058,"activeCount":102},[],{"intervention":326,"totalTrials":135,"cells":6060},{"EARLY_PHASE1":6061,"PHASE1":6063,"PHASE2":6069,"PHASE3":6071,"PHASE4":6073,"NA":6075},{"trials":6062,"activeCount":102},[],{"trials":6064,"activeCount":135,"soonestReadout":56},[6065],{"nctId":54,"briefTitle":55,"status":126,"phases":6066,"primaryCompletion":56,"completion":315,"start":316,"enrollment":317,"conditions":6067,"interventions":6068},[90],[248,258,319,320,252,261,321,322,323],[57,204,325,326],{"trials":6070,"activeCount":102},[],{"trials":6072,"activeCount":102},[],{"trials":6074,"activeCount":102},[],{"trials":6076,"activeCount":102},[],{"intervention":394,"totalTrials":135,"cells":6078},{"EARLY_PHASE1":6079,"PHASE1":6081,"PHASE2":6087,"PHASE3":6089,"PHASE4":6091,"NA":6093},{"trials":6080,"activeCount":102},[],{"trials":6082,"activeCount":135,"soonestReadout":383},[6083],{"nctId":380,"briefTitle":381,"status":126,"phases":6084,"primaryCompletion":383,"completion":384,"start":385,"enrollment":282,"conditions":6085,"interventions":6086},[90],[387,388,389,390,391],[373,204,393,378,394],{"trials":6088,"activeCount":102},[],{"trials":6090,"activeCount":102},[],{"trials":6092,"activeCount":102},[],{"trials":6094,"activeCount":102},[],{"intervention":1607,"totalTrials":3454,"cells":6096},{"EARLY_PHASE1":6097,"PHASE1":6099,"PHASE2":6105,"PHASE3":6111,"PHASE4":6117,"NA":6137},{"trials":6098,"activeCount":102},[],{"trials":6100,"activeCount":102},[6101],{"nctId":3488,"briefTitle":3489,"status":226,"phases":6102,"primaryCompletion":3491,"completion":3491,"start":3492,"conditions":6103,"interventions":6104},[90],[3494],[3496,958,2608,1607,960],{"trials":6106,"activeCount":102},[6107],{"nctId":3568,"briefTitle":3569,"status":226,"phases":6108,"primaryCompletion":1297,"completion":1297,"start":3560,"enrollment":475,"conditions":6109,"interventions":6110},[91],[3572,3573,3574,3575,3576,3577,3578,3579],[1607,1118,960,958,719,1415],{"trials":6112,"activeCount":102},[6113],{"nctId":1597,"briefTitle":1598,"status":226,"phases":6114,"primaryCompletion":1600,"completion":1600,"start":1601,"enrollment":1602,"conditions":6115,"interventions":6116},[92],[1604],[674,1415,1118,1606,673,958,959,1607,960],{"trials":6118,"activeCount":102},[6119],{"nctId":6120,"briefTitle":6121,"status":343,"phases":6122,"primaryCompletion":6123,"completion":6124,"start":6125,"enrollment":102,"conditions":6126,"interventions":6131},"NCT03238703","Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer",[93],"2023-03-14","2025-03-14","2018-09-01",[6127,756,6128,6129,6130],"HER2\u002FNeu Negative","Postmenopausal","Stage 0 Breast Cancer","Stage IA Breast Cancer",[6132,6133,6134,6135,6136],"Anastrozole","Exemestane","Letrozole","Tamoxifen Citrate","Toremifene Citrate",{"trials":6138,"activeCount":102},[],{"intervention":6140,"totalTrials":135,"cells":6141},"Hepatitis B vaccine",{"EARLY_PHASE1":6142,"PHASE1":6144,"PHASE2":6146,"PHASE3":6148,"PHASE4":6150,"NA":6162},{"trials":6143,"activeCount":102},[],{"trials":6145,"activeCount":102},[],{"trials":6147,"activeCount":102},[],{"trials":6149,"activeCount":102},[],{"trials":6151,"activeCount":102},[6152],{"nctId":6153,"briefTitle":6154,"status":226,"phases":6155,"primaryCompletion":6156,"completion":6156,"start":6157,"enrollment":6158,"conditions":6159,"interventions":6161},"NCT02316444","Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda",[93],"2017-04-28","2015-11",132,[6160],"HIV\u002FAIDS and Infections",[6140],{"trials":6163,"activeCount":102},[],{"intervention":6165,"totalTrials":135,"cells":6166},"Beta Carotene and Retinol",{"EARLY_PHASE1":6167,"PHASE1":6169,"PHASE2":6171,"PHASE3":6173,"PHASE4":6175,"NA":6186},{"trials":6168,"activeCount":102},[],{"trials":6170,"activeCount":102},[],{"trials":6172,"activeCount":102},[],{"trials":6174,"activeCount":102},[],{"trials":6176,"activeCount":102},[6177],{"nctId":6178,"briefTitle":6179,"status":226,"phases":6180,"primaryCompletion":2099,"completion":1817,"start":6181,"enrollment":6182,"conditions":6183,"interventions":6185},"NCT00712647","Carotene and Retinol Efficacy Trial",[93],"1985-05",18314,[6184],"Lung Cancer",[6165],{"trials":6187,"activeCount":102},[],{"intervention":6189,"totalTrials":135,"cells":6190},"Atripla or Stribild",{"EARLY_PHASE1":6191,"PHASE1":6193,"PHASE2":6195,"PHASE3":6197,"PHASE4":6199,"NA":6211},{"trials":6192,"activeCount":102},[],{"trials":6194,"activeCount":102},[],{"trials":6196,"activeCount":102},[],{"trials":6198,"activeCount":102},[],{"trials":6200,"activeCount":102},[6201],{"nctId":6202,"briefTitle":6203,"status":226,"phases":6204,"primaryCompletion":6205,"completion":6206,"start":865,"enrollment":6207,"conditions":6208,"interventions":6210},"NCT01815580","HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women",[93],"2020-11-30","2021-06-30",225,[6209],"HIV",[6189],{"trials":6212,"activeCount":102},[],{"intervention":6132,"totalTrials":135,"cells":6214},{"EARLY_PHASE1":6215,"PHASE1":6217,"PHASE2":6219,"PHASE3":6221,"PHASE4":6223,"NA":6229},{"trials":6216,"activeCount":102},[],{"trials":6218,"activeCount":102},[],{"trials":6220,"activeCount":102},[],{"trials":6222,"activeCount":102},[],{"trials":6224,"activeCount":102},[6225],{"nctId":6120,"briefTitle":6121,"status":343,"phases":6226,"primaryCompletion":6123,"completion":6124,"start":6125,"enrollment":102,"conditions":6227,"interventions":6228},[93],[6127,756,6128,6129,6130],[6132,6133,6134,6135,6136],{"trials":6230,"activeCount":102},[],{"intervention":6133,"totalTrials":135,"cells":6232},{"EARLY_PHASE1":6233,"PHASE1":6235,"PHASE2":6237,"PHASE3":6239,"PHASE4":6241,"NA":6247},{"trials":6234,"activeCount":102},[],{"trials":6236,"activeCount":102},[],{"trials":6238,"activeCount":102},[],{"trials":6240,"activeCount":102},[],{"trials":6242,"activeCount":102},[6243],{"nctId":6120,"briefTitle":6121,"status":343,"phases":6244,"primaryCompletion":6123,"completion":6124,"start":6125,"enrollment":102,"conditions":6245,"interventions":6246},[93],[6127,756,6128,6129,6130],[6132,6133,6134,6135,6136],{"trials":6248,"activeCount":102},[],{"intervention":6134,"totalTrials":135,"cells":6250},{"EARLY_PHASE1":6251,"PHASE1":6253,"PHASE2":6255,"PHASE3":6257,"PHASE4":6259,"NA":6265},{"trials":6252,"activeCount":102},[],{"trials":6254,"activeCount":102},[],{"trials":6256,"activeCount":102},[],{"trials":6258,"activeCount":102},[],{"trials":6260,"activeCount":102},[6261],{"nctId":6120,"briefTitle":6121,"status":343,"phases":6262,"primaryCompletion":6123,"completion":6124,"start":6125,"enrollment":102,"conditions":6263,"interventions":6264},[93],[6127,756,6128,6129,6130],[6132,6133,6134,6135,6136],{"trials":6266,"activeCount":102},[],{"intervention":6136,"totalTrials":135,"cells":6268},{"EARLY_PHASE1":6269,"PHASE1":6271,"PHASE2":6273,"PHASE3":6275,"PHASE4":6277,"NA":6283},{"trials":6270,"activeCount":102},[],{"trials":6272,"activeCount":102},[],{"trials":6274,"activeCount":102},[],{"trials":6276,"activeCount":102},[],{"trials":6278,"activeCount":102},[6279],{"nctId":6120,"briefTitle":6121,"status":343,"phases":6280,"primaryCompletion":6123,"completion":6124,"start":6125,"enrollment":102,"conditions":6281,"interventions":6282},[93],[6127,756,6128,6129,6130],[6132,6133,6134,6135,6136],{"trials":6284,"activeCount":102},[],{"intervention":6286,"totalTrials":135,"cells":6287},"oral naltrexone",{"EARLY_PHASE1":6288,"PHASE1":6290,"PHASE2":6292,"PHASE3":6294,"PHASE4":6296,"NA":6309},{"trials":6289,"activeCount":102},[],{"trials":6291,"activeCount":102},[],{"trials":6293,"activeCount":102},[],{"trials":6295,"activeCount":102},[],{"trials":6297,"activeCount":102},[6298],{"nctId":6299,"briefTitle":6300,"status":226,"phases":6301,"primaryCompletion":6302,"completion":6303,"start":6304,"enrollment":6305,"conditions":6306,"interventions":6308},"NCT01377168","Naltrexone for Medication Compliance Among HIV-infected Men With Alcohol Use Disorder",[93],"2016-06","2017-06","2014-05",159,[6209,6307],"Alcohol Use Disorder",[6286],{"trials":6310,"activeCount":102},[],{"intervention":6312,"totalTrials":135,"cells":6313},"oxycodone",{"EARLY_PHASE1":6314,"PHASE1":6316,"PHASE2":6318,"PHASE3":6320,"PHASE4":6322,"NA":6332},{"trials":6315,"activeCount":102},[],{"trials":6317,"activeCount":102},[],{"trials":6319,"activeCount":102},[],{"trials":6321,"activeCount":102},[],{"trials":6323,"activeCount":102},[6324],{"nctId":6325,"briefTitle":6326,"status":226,"phases":6327,"primaryCompletion":6328,"completion":6328,"start":4940,"enrollment":944,"conditions":6329,"interventions":6331},"NCT00499460","Effects of Garlic Supplements on Opioids in Healthy Volunteers",[93],"2008-08",[6330],"Healthy, No Evidence of Disease",[6312],{"trials":6333,"activeCount":102},[],{"intervention":1391,"totalTrials":2308,"cells":6335},{"EARLY_PHASE1":6336,"PHASE1":6338,"PHASE2":6344,"PHASE3":6358,"PHASE4":6364,"NA":6366},{"trials":6337,"activeCount":102},[],{"trials":6339,"activeCount":102},[6340],{"nctId":4380,"briefTitle":4381,"status":114,"phases":6341,"primaryCompletion":4383,"completion":4383,"start":4384,"enrollment":2616,"conditions":6342,"interventions":6343},[90],[809],[374,4387,4388,1546,691],{"trials":6345,"activeCount":102},[6346,6350,6354],{"nctId":3694,"briefTitle":3695,"status":226,"phases":6347,"primaryCompletion":473,"start":1827,"enrollment":486,"conditions":6348,"interventions":6349},[91],[3698],[811,1391,675],{"nctId":1383,"briefTitle":1384,"status":226,"phases":6351,"primaryCompletion":1386,"completion":1386,"start":1387,"enrollment":1388,"conditions":6352,"interventions":6353},[91],[15,797,798,799],[672,674,1118,673,1391],{"nctId":4937,"briefTitle":4938,"status":226,"phases":6355,"primaryCompletion":4940,"start":1999,"enrollment":486,"conditions":6356,"interventions":6357},[91],[1604,1126,4481,1137,15,797,1096,798,799,4483,3494,4484],[1499,1391,675],{"trials":6359,"activeCount":102},[6360],{"nctId":4950,"briefTitle":4951,"status":226,"phases":6361,"primaryCompletion":865,"completion":4953,"start":1199,"enrollment":4954,"conditions":6362,"interventions":6363},[92],[1137,246],[675,1391],{"trials":6365,"activeCount":102},[],{"trials":6367,"activeCount":102},[],{"intervention":1606,"totalTrials":2308,"cells":6369},{"EARLY_PHASE1":6370,"PHASE1":6372,"PHASE2":6374,"PHASE3":6401,"PHASE4":6407,"NA":6409},{"trials":6371,"activeCount":102},[],{"trials":6373,"activeCount":102},[],{"trials":6375,"activeCount":102},[6376,6380,6384,6395],{"nctId":4435,"briefTitle":4436,"status":226,"phases":6377,"primaryCompletion":829,"completion":4438,"start":4439,"enrollment":463,"conditions":6378,"interventions":6379},[91],[516],[4442,692,374,4443,1546,505],{"nctId":5090,"briefTitle":5091,"status":226,"phases":6381,"primaryCompletion":5093,"completion":2536,"start":4030,"enrollment":244,"conditions":6382,"interventions":6383},[91],[873,558,1001,1002,710,1004,1005,711,1114,1006,899,500,900,1008,901,1009,902,903,1010,1012,712,713,908,24,714,1013,21,1016,715,1041,1234],[5096,1606,947,1746],{"nctId":6385,"briefTitle":6386,"status":226,"phases":6387,"primaryCompletion":1298,"start":1742,"conditions":6388,"interventions":6391},"NCT00217529","Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",[90,91],[6389,3494,6390],"Fallopian Tube Cancer","Peritoneal Cavity Cancer",[6392,1606,6393,6394],"pegfilgrastim","docetaxel","erlotinib hydrochloride",{"nctId":6396,"briefTitle":6397,"status":226,"phases":6398,"primaryCompletion":2519,"start":1183,"conditions":6399,"interventions":6400},"NCT00217568","Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer",[91],[3494,6390],[6392,1606,6393],{"trials":6402,"activeCount":102},[6403],{"nctId":1597,"briefTitle":1598,"status":226,"phases":6404,"primaryCompletion":1600,"completion":1600,"start":1601,"enrollment":1602,"conditions":6405,"interventions":6406},[92],[1604],[674,1415,1118,1606,673,958,959,1607,960],{"trials":6408,"activeCount":102},[],{"trials":6410,"activeCount":102},[],{"intervention":1415,"totalTrials":2308,"cells":6412},{"EARLY_PHASE1":6413,"PHASE1":6415,"PHASE2":6417,"PHASE3":6435,"PHASE4":6441,"NA":6443},{"trials":6414,"activeCount":102},[],{"trials":6416,"activeCount":102},[],{"trials":6418,"activeCount":102},[6419,6423,6427,6431],{"nctId":3855,"briefTitle":3856,"status":226,"phases":6420,"primaryCompletion":2425,"completion":2425,"start":1665,"conditions":6421,"interventions":6422},[91],[15],[719,2003,1415,1118],{"nctId":1408,"briefTitle":1409,"status":226,"phases":6424,"completion":1182,"start":1411,"conditions":6425,"interventions":6426},[91],[797,956,1413],[719,674,1415,1118,673,958,959,960],{"nctId":3568,"briefTitle":3569,"status":226,"phases":6428,"primaryCompletion":1297,"completion":1297,"start":3560,"enrollment":475,"conditions":6429,"interventions":6430},[91],[3572,3573,3574,3575,3576,3577,3578,3579],[1607,1118,960,958,719,1415],{"nctId":4521,"briefTitle":4522,"status":226,"phases":6432,"primaryCompletion":4501,"completion":773,"start":1124,"enrollment":807,"conditions":6433,"interventions":6434},[91],[797],[674,1415],{"trials":6436,"activeCount":102},[6437],{"nctId":1597,"briefTitle":1598,"status":226,"phases":6438,"primaryCompletion":1600,"completion":1600,"start":1601,"enrollment":1602,"conditions":6439,"interventions":6440},[92],[1604],[674,1415,1118,1606,673,958,959,1607,960],{"trials":6442,"activeCount":102},[],{"trials":6444,"activeCount":102},[],{"intervention":959,"totalTrials":3454,"cells":6446},{"EARLY_PHASE1":6447,"PHASE1":6449,"PHASE2":6455,"PHASE3":6468,"PHASE4":6474,"NA":6476},{"trials":6448,"activeCount":102},[],{"trials":6450,"activeCount":102},[6451],{"nctId":950,"briefTitle":951,"status":226,"phases":6452,"completion":953,"start":954,"conditions":6453,"interventions":6454},[90],[956],[674,673,958,959,960],{"trials":6456,"activeCount":102},[6457,6461],{"nctId":1408,"briefTitle":1409,"status":226,"phases":6458,"completion":1182,"start":1411,"conditions":6459,"interventions":6460},[91],[797,956,1413],[719,674,1415,1118,673,958,959,960],{"nctId":6462,"briefTitle":6463,"status":226,"phases":6464,"primaryCompletion":2425,"completion":2425,"start":954,"enrollment":555,"conditions":6465,"interventions":6466},"NCT00004013","Paclitaxel With or Without Trastuzumab Following Peripheral Stem Cell Transplantation in Treating Patients With Refractory Stage IV Breast Cancer",[91],[1604],[6467,959],"trastuzumab",{"trials":6469,"activeCount":102},[6470],{"nctId":1597,"briefTitle":1598,"status":226,"phases":6471,"primaryCompletion":1600,"completion":1600,"start":1601,"enrollment":1602,"conditions":6472,"interventions":6473},[92],[1604],[674,1415,1118,1606,673,958,959,1607,960],{"trials":6475,"activeCount":102},[],{"trials":6477,"activeCount":102},[],{"intervention":1044,"totalTrials":2616,"cells":6479},{"EARLY_PHASE1":6480,"PHASE1":6482,"PHASE2":6484,"PHASE3":6490,"PHASE4":6500,"NA":6502},{"trials":6481,"activeCount":102},[],{"trials":6483,"activeCount":102},[],{"trials":6485,"activeCount":102},[6486],{"nctId":994,"briefTitle":995,"status":226,"phases":6487,"primaryCompletion":997,"completion":998,"start":999,"enrollment":486,"conditions":6488,"interventions":6489},[91],[868,733,734,29,870,35,871,32,872,873,558,1001,874,875,876,877,880,881,1002,890,710,1003,1004,1005,711,1006,1007,898,899,500,900,1008,901,1009,902,903,1010,904,905,906,907,1011,1012,712,713,908,24,714,1013,21,1014,27,700,1015,910,1016,715,1017,920,921,922,1018,1019,923,924,1020,1021,1022,1023,1024,1025,926,927,1026,1027,1028,1029,928,929,930,1030,1031,931,932,1032,1033,1034,1035,1036,1037,934,935,1038,1039,1040,1041,716],[673,937,1043,481,720,1044,1045,1046],{"trials":6491,"activeCount":102},[6492,6496],{"nctId":4108,"briefTitle":4109,"status":226,"phases":6493,"primaryCompletion":4111,"start":4112,"enrollment":2032,"conditions":6494,"interventions":6495},[92],[700,1017,1027],[958,4115,1044],{"nctId":1585,"briefTitle":1586,"status":226,"phases":6497,"primaryCompletion":1588,"completion":1589,"start":1241,"enrollment":807,"conditions":6498,"interventions":6499},[92],[869,1591,734,29,870,35,871,32,872,875,880,890,1592,1593,898,18,298,453,910],[673,481,1118,479,937,1595,1044,1045,1043,811],{"trials":6501,"activeCount":102},[],{"trials":6503,"activeCount":102},[],{"intervention":1045,"totalTrials":2616,"cells":6505},{"EARLY_PHASE1":6506,"PHASE1":6508,"PHASE2":6510,"PHASE3":6520,"PHASE4":6526,"NA":6528},{"trials":6507,"activeCount":102},[],{"trials":6509,"activeCount":102},[],{"trials":6511,"activeCount":102},[6512,6516],{"nctId":994,"briefTitle":995,"status":226,"phases":6513,"primaryCompletion":997,"completion":998,"start":999,"enrollment":486,"conditions":6514,"interventions":6515},[91],[868,733,734,29,870,35,871,32,872,873,558,1001,874,875,876,877,880,881,1002,890,710,1003,1004,1005,711,1006,1007,898,899,500,900,1008,901,1009,902,903,1010,904,905,906,907,1011,1012,712,713,908,24,714,1013,21,1014,27,700,1015,910,1016,715,1017,920,921,922,1018,1019,923,924,1020,1021,1022,1023,1024,1025,926,927,1026,1027,1028,1029,928,929,930,1030,1031,931,932,1032,1033,1034,1035,1036,1037,934,935,1038,1039,1040,1041,716],[673,937,1043,481,720,1044,1045,1046],{"nctId":1048,"briefTitle":1049,"status":226,"phases":6517,"primaryCompletion":1051,"completion":1052,"start":983,"enrollment":1053,"conditions":6518,"interventions":6519},[91],[415],[673,672,479,811,986,1045],{"trials":6521,"activeCount":102},[6522],{"nctId":1585,"briefTitle":1586,"status":226,"phases":6523,"primaryCompletion":1588,"completion":1589,"start":1241,"enrollment":807,"conditions":6524,"interventions":6525},[92],[869,1591,734,29,870,35,871,32,872,875,880,890,1592,1593,898,18,298,453,910],[673,481,1118,479,937,1595,1044,1045,1043,811],{"trials":6527,"activeCount":102},[],{"trials":6529,"activeCount":102},[],{"intervention":6531,"totalTrials":2616,"cells":6532},"Acyclovir",{"EARLY_PHASE1":6533,"PHASE1":6535,"PHASE2":6537,"PHASE3":6539,"PHASE4":6567,"NA":6569},{"trials":6534,"activeCount":102},[],{"trials":6536,"activeCount":102},[],{"trials":6538,"activeCount":102},[],{"trials":6540,"activeCount":102},[6541,6549,6557],{"nctId":6542,"briefTitle":6543,"status":226,"phases":6544,"completion":794,"start":6545,"enrollment":360,"conditions":6546,"interventions":6548},"NCT00209352","Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant",[92],"1985-06",[6547],"VZV Infection After Bone Marrow Transplantation",[6531],{"nctId":6550,"briefTitle":6551,"status":226,"phases":6552,"completion":647,"start":1404,"enrollment":598,"conditions":6553,"interventions":6556},"NCT00209313","Usage of Acyclovir for Suppression of HIV-1 and HSV-2 Coinfected Persons in Cameroon",[91,92],[6554,6555],"HIV-1 and HSV-2 Coinfection","HIV Infections",[6531],{"nctId":6558,"briefTitle":6559,"status":226,"phases":6560,"completion":6561,"start":2010,"conditions":6562,"interventions":6563},"NCT00045292","Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation",[92],"2004-10",[3698],[6564,6565,6566],"acyclovir","acyclovir sodium","valacyclovir",{"trials":6568,"activeCount":102},[],{"trials":6570,"activeCount":102},[],{"intervention":6572,"totalTrials":98,"cells":6573},"ribavirin",{"EARLY_PHASE1":6574,"PHASE1":6576,"PHASE2":6578,"PHASE3":6580,"PHASE4":6596,"NA":6598},{"trials":6575,"activeCount":102},[],{"trials":6577,"activeCount":102},[],{"trials":6579,"activeCount":102},[],{"trials":6581,"activeCount":102},[6582,6589],{"nctId":6583,"briefTitle":6584,"status":226,"phases":6585,"primaryCompletion":1600,"completion":1600,"start":3501,"conditions":6586,"interventions":6588},"NCT00016081","Ribavirin Compared With Standard Care in Treating Patients With Respiratory Syncytial Virus Following Stem Cell Transplantation",[92],[6587],"Infection",[6572],{"nctId":6590,"briefTitle":6591,"status":226,"phases":6592,"primaryCompletion":2425,"completion":2425,"start":1371,"conditions":6593,"interventions":6594},"NCT00014391","Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation",[92],[3698],[6595,6572],"palivizumab",{"trials":6597,"activeCount":102},[],{"trials":6599,"activeCount":102},[],{"intervention":6601,"totalTrials":98,"cells":6602},"IV Ganciclovir",{"EARLY_PHASE1":6603,"PHASE1":6605,"PHASE2":6607,"PHASE3":6621,"PHASE4":6635,"NA":6637},{"trials":6604,"activeCount":102},[],{"trials":6606,"activeCount":102},[],{"trials":6608,"activeCount":102},[6609],{"nctId":6610,"briefTitle":6611,"status":226,"phases":6612,"primaryCompletion":6613,"completion":6614,"start":6615,"enrollment":2293,"conditions":6616,"interventions":6620},"NCT01335932","Ganciclovir\u002FValganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure",[91],"2016-06-17","2016-10-28","2011-03-10",[6617,6618,6619],"Acute Lung Injury","Acute Respiratory Distress Syndrome","Respiratory Failure",[6601],{"trials":6622,"activeCount":102},[6623],{"nctId":6624,"briefTitle":6625,"status":114,"phases":6626,"primaryCompletion":6627,"completion":6628,"start":6629,"enrollment":6630,"conditions":6631,"interventions":6633},"NCT04706507","Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis",[92],"2024-10-25","2025-04-08","2021-06-29",205,[6632],"Acute Respiratory Failure",[6601,6634],"Normal saline",{"trials":6636,"activeCount":102},[],{"trials":6638,"activeCount":102},[],{"intervention":6640,"totalTrials":98,"cells":6641},"Valacyclovir",{"EARLY_PHASE1":6642,"PHASE1":6644,"PHASE2":6655,"PHASE3":6657,"PHASE4":6663,"NA":6665},{"trials":6643,"activeCount":102},[],{"trials":6645,"activeCount":102},[6646],{"nctId":6647,"briefTitle":6648,"status":226,"phases":6649,"primaryCompletion":6650,"completion":6650,"start":6157,"enrollment":1084,"conditions":6651,"interventions":6653},"NCT02571166","HSV529 Vaccine in HSV-2 Seropositive Adults",[90],"2018-12-01",[6652],"Herpes Simplex Virus 2",[6654,6640],"HSV529",{"trials":6656,"activeCount":102},[],{"trials":6658,"activeCount":102},[6659],{"nctId":6558,"briefTitle":6559,"status":226,"phases":6660,"completion":6561,"start":2010,"conditions":6661,"interventions":6662},[92],[3698],[6564,6565,6566],{"trials":6664,"activeCount":102},[],{"trials":6666,"activeCount":102},[],{"intervention":6668,"totalTrials":98,"cells":6669},"ganciclovir",{"EARLY_PHASE1":6670,"PHASE1":6672,"PHASE2":6680,"PHASE3":6682,"PHASE4":6692,"NA":6694},{"trials":6671,"activeCount":102},[],{"trials":6673,"activeCount":102},[6674],{"nctId":6675,"briefTitle":6676,"status":226,"phases":6677,"completion":1404,"start":1981,"conditions":6678,"interventions":6679},"NCT00006480","Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma",[90],[4483],[719,718,2287,6668],{"trials":6681,"activeCount":102},[],{"trials":6683,"activeCount":102},[6684],{"nctId":6685,"briefTitle":6686,"status":226,"phases":6687,"completion":1083,"start":6688,"enrollment":12,"conditions":6689,"interventions":6690},"NCT00016068","Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation",[92],"2001-01",[6587],[6668,6691],"valganciclovir",{"trials":6693,"activeCount":102},[],{"trials":6695,"activeCount":102},[],{"intervention":4115,"totalTrials":135,"cells":6697},{"EARLY_PHASE1":6698,"PHASE1":6700,"PHASE2":6702,"PHASE3":6704,"PHASE4":6710,"NA":6712},{"trials":6699,"activeCount":102},[],{"trials":6701,"activeCount":102},[],{"trials":6703,"activeCount":102},[],{"trials":6705,"activeCount":102},[6706],{"nctId":4108,"briefTitle":4109,"status":226,"phases":6707,"primaryCompletion":4111,"start":4112,"enrollment":2032,"conditions":6708,"interventions":6709},[92],[700,1017,1027],[958,4115,1044],{"trials":6711,"activeCount":102},[],{"trials":6713,"activeCount":102},[],{"intervention":6715,"totalTrials":135,"cells":6716},"Vagifem",{"EARLY_PHASE1":6717,"PHASE1":6719,"PHASE2":6721,"PHASE3":6723,"PHASE4":6736,"NA":6738},{"trials":6718,"activeCount":102},[],{"trials":6720,"activeCount":102},[],{"trials":6722,"activeCount":102},[],{"trials":6724,"activeCount":102},[6725],{"nctId":6726,"briefTitle":6727,"status":226,"phases":6728,"primaryCompletion":1228,"completion":6729,"start":2448,"enrollment":6730,"conditions":6731,"interventions":6735},"NCT02516202","The Vaginal Health Trial",[92],"2017-07",302,[6732,6733,6734],"Atrophy of Vagina","Menopause","Dyspareunia (Female)",[6715],{"trials":6737,"activeCount":102},[],{"trials":6739,"activeCount":102},[],{"intervention":6634,"totalTrials":135,"cells":6741},{"EARLY_PHASE1":6742,"PHASE1":6744,"PHASE2":6746,"PHASE3":6748,"PHASE4":6754,"NA":6756},{"trials":6743,"activeCount":102},[],{"trials":6745,"activeCount":102},[],{"trials":6747,"activeCount":102},[],{"trials":6749,"activeCount":102},[6750],{"nctId":6624,"briefTitle":6625,"status":114,"phases":6751,"primaryCompletion":6627,"completion":6628,"start":6629,"enrollment":6630,"conditions":6752,"interventions":6753},[92],[6632],[6601,6634],{"trials":6755,"activeCount":102},[],{"trials":6757,"activeCount":102},[],{"intervention":6759,"totalTrials":135,"cells":6760},"fluconazole",{"EARLY_PHASE1":6761,"PHASE1":6763,"PHASE2":6765,"PHASE3":6767,"PHASE4":6778,"NA":6780},{"trials":6762,"activeCount":102},[],{"trials":6764,"activeCount":102},[],{"trials":6766,"activeCount":102},[],{"trials":6768,"activeCount":102},[6769],{"nctId":6770,"briefTitle":6771,"status":226,"phases":6772,"primaryCompletion":1991,"completion":1991,"start":6773,"enrollment":6774,"conditions":6775,"interventions":6776},"NCT00003883","Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation",[92],"1998-10",578,[3698],[6759,6777],"itraconazole",{"trials":6779,"activeCount":102},[],{"trials":6781,"activeCount":102},[],{"intervention":6777,"totalTrials":135,"cells":6783},{"EARLY_PHASE1":6784,"PHASE1":6786,"PHASE2":6788,"PHASE3":6790,"PHASE4":6796,"NA":6798},{"trials":6785,"activeCount":102},[],{"trials":6787,"activeCount":102},[],{"trials":6789,"activeCount":102},[],{"trials":6791,"activeCount":102},[6792],{"nctId":6770,"briefTitle":6771,"status":226,"phases":6793,"primaryCompletion":1991,"completion":1991,"start":6773,"enrollment":6774,"conditions":6794,"interventions":6795},[92],[3698],[6759,6777],{"trials":6797,"activeCount":102},[],{"trials":6799,"activeCount":102},[],{"intervention":6691,"totalTrials":135,"cells":6801},{"EARLY_PHASE1":6802,"PHASE1":6804,"PHASE2":6806,"PHASE3":6808,"PHASE4":6814,"NA":6816},{"trials":6803,"activeCount":102},[],{"trials":6805,"activeCount":102},[],{"trials":6807,"activeCount":102},[],{"trials":6809,"activeCount":102},[6810],{"nctId":6685,"briefTitle":6686,"status":226,"phases":6811,"completion":1083,"start":6688,"enrollment":12,"conditions":6812,"interventions":6813},[92],[6587],[6668,6691],{"trials":6815,"activeCount":102},[],{"trials":6817,"activeCount":102},[],{"intervention":6565,"totalTrials":135,"cells":6819},{"EARLY_PHASE1":6820,"PHASE1":6822,"PHASE2":6824,"PHASE3":6826,"PHASE4":6832,"NA":6834},{"trials":6821,"activeCount":102},[],{"trials":6823,"activeCount":102},[],{"trials":6825,"activeCount":102},[],{"trials":6827,"activeCount":102},[6828],{"nctId":6558,"briefTitle":6559,"status":226,"phases":6829,"completion":6561,"start":2010,"conditions":6830,"interventions":6831},[92],[3698],[6564,6565,6566],{"trials":6833,"activeCount":102},[],{"trials":6835,"activeCount":102},[],{"intervention":6595,"totalTrials":135,"cells":6837},{"EARLY_PHASE1":6838,"PHASE1":6840,"PHASE2":6842,"PHASE3":6844,"PHASE4":6850,"NA":6852},{"trials":6839,"activeCount":102},[],{"trials":6841,"activeCount":102},[],{"trials":6843,"activeCount":102},[],{"trials":6845,"activeCount":102},[6846],{"nctId":6590,"briefTitle":6591,"status":226,"phases":6847,"primaryCompletion":2425,"completion":2425,"start":1371,"conditions":6848,"interventions":6849},[92],[3698],[6595,6572],{"trials":6851,"activeCount":102},[],{"trials":6853,"activeCount":102},[],{"intervention":2608,"totalTrials":334,"cells":6855},{"EARLY_PHASE1":6856,"PHASE1":6858,"PHASE2":6868,"PHASE3":6898,"PHASE4":6900,"NA":6902},{"trials":6857,"activeCount":102},[],{"trials":6859,"activeCount":102},[6860,6864],{"nctId":3251,"briefTitle":3252,"status":226,"phases":6861,"primaryCompletion":3254,"start":1387,"conditions":6862,"interventions":6863},[90],[15,798],[719,1812,718,2194,948,2608],{"nctId":3488,"briefTitle":3489,"status":226,"phases":6865,"primaryCompletion":3491,"completion":3491,"start":3492,"conditions":6866,"interventions":6867},[90],[3494],[3496,958,2608,1607,960],{"trials":6869,"activeCount":102},[6870,6874,6878,6882,6886,6890,6894],{"nctId":3340,"briefTitle":3341,"status":226,"phases":6871,"primaryCompletion":3343,"completion":3344,"start":3345,"enrollment":3346,"conditions":6872,"interventions":6873},[90,91],[403,1434,736,18,1638,453],[372,373,374,3349],{"nctId":3351,"briefTitle":3352,"status":226,"phases":6875,"primaryCompletion":3354,"completion":3355,"start":3356,"enrollment":2100,"conditions":6876,"interventions":6877},[90,91],[387],[372,373,3359,468,3349],{"nctId":2871,"briefTitle":2872,"status":114,"phases":6879,"primaryCompletion":848,"completion":848,"start":2874,"enrollment":395,"conditions":6880,"interventions":6881},[90,91],[1108,2012,2013,2014,2015,2016,29,870,35,32,872,2017,1109,1110,18],[479,2877,2608,948],{"nctId":2602,"briefTitle":2603,"status":226,"phases":6883,"primaryCompletion":1404,"completion":1404,"start":2605,"conditions":6884,"interventions":6885},[90,91],[15],[719,674,1812,2194,948,937,811,2608,2609],{"nctId":3387,"briefTitle":3388,"status":226,"phases":6887,"primaryCompletion":3390,"completion":3391,"start":3392,"enrollment":1634,"conditions":6888,"interventions":6889},[90,91],[736,18],[373,455,692,3349],{"nctId":3396,"briefTitle":3397,"status":226,"phases":6891,"primaryCompletion":3399,"completion":3399,"start":3400,"enrollment":231,"conditions":6892,"interventions":6893},[90,91],[388,736,18,3402,365,3403,1638],[372,373,455,374,3349],{"nctId":3406,"briefTitle":3407,"status":226,"phases":6895,"primaryCompletion":3409,"completion":3409,"start":3410,"enrollment":282,"conditions":6896,"interventions":6897},[91],[15],[674,2194,948,3413,2608],{"trials":6899,"activeCount":102},[],{"trials":6901,"activeCount":102},[],{"trials":6903,"activeCount":102},[],{"intervention":720,"totalTrials":2248,"cells":6905},{"EARLY_PHASE1":6906,"PHASE1":6908,"PHASE2":6922,"PHASE3":6952,"PHASE4":6954,"NA":6956},{"trials":6907,"activeCount":102},[],{"trials":6909,"activeCount":102},[6910,6914,6918],{"nctId":704,"briefTitle":705,"status":226,"phases":6911,"primaryCompletion":707,"start":473,"enrollment":296,"conditions":6912,"interventions":6913},[90],[709,710,711,712,713,24,714,21,27,715,716],[718,673,719,720,721,722],{"nctId":2366,"briefTitle":2367,"status":226,"phases":6915,"primaryCompletion":1632,"start":2369,"enrollment":2370,"conditions":6916,"interventions":6917},[90],[710,711,899,500,900,1008,902,903,712,713,908,24,714,715,716],[937,720],{"nctId":844,"briefTitle":845,"status":226,"phases":6919,"primaryCompletion":847,"start":848,"enrollment":296,"conditions":6920,"interventions":6921},[90],[850,823],[673,719,852,720,718],{"trials":6923,"activeCount":102},[6924,6928,6932,6940,6948],{"nctId":994,"briefTitle":995,"status":226,"phases":6925,"primaryCompletion":997,"completion":998,"start":999,"enrollment":486,"conditions":6926,"interventions":6927},[91],[868,733,734,29,870,35,871,32,872,873,558,1001,874,875,876,877,880,881,1002,890,710,1003,1004,1005,711,1006,1007,898,899,500,900,1008,901,1009,902,903,1010,904,905,906,907,1011,1012,712,713,908,24,714,1013,21,1014,27,700,1015,910,1016,715,1017,920,921,922,1018,1019,923,924,1020,1021,1022,1023,1024,1025,926,927,1026,1027,1028,1029,928,929,930,1030,1031,931,932,1032,1033,1034,1035,1036,1037,934,935,1038,1039,1040,1041,716],[673,937,1043,481,720,1044,1045,1046],{"nctId":1079,"briefTitle":1080,"status":226,"phases":6929,"primaryCompletion":1082,"completion":848,"start":1083,"enrollment":1084,"conditions":6930,"interventions":6931},[90,91],[850,823],[718,719,673,720],{"nctId":6933,"briefTitle":6934,"status":226,"phases":6935,"primaryCompletion":2874,"completion":1431,"start":942,"enrollment":19,"conditions":6936,"interventions":6939},"NCT00052520","Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation",[90,91],[29,35,871,32,872,5075,5076,877,880,465,1636,1637,898,246,18,1116,298,737,909,1015,453,6937,6938],"T-cell Adult Acute Lymphoblastic Leukemia","T-cell Childhood Acute Lymphoblastic Leukemia",[1812,719,1046,720,1595],{"nctId":6941,"briefTitle":6942,"status":114,"phases":6943,"primaryCompletion":4548,"completion":4548,"start":1740,"enrollment":2616,"conditions":6944,"interventions":6946},"NCT00945269","Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma",[90,91],[850,6945,823],"Stage III Melanoma",[718,719,6947,720],"denileukin diftitox",{"nctId":1569,"briefTitle":1570,"status":226,"phases":6949,"primaryCompletion":829,"completion":1572,"start":1573,"enrollment":1084,"conditions":6950,"interventions":6951},[90,91],[850,823],[1576,673,719,720,1577],{"trials":6953,"activeCount":102},[],{"trials":6955,"activeCount":102},[],{"trials":6957,"activeCount":102},[],{"intervention":947,"totalTrials":395,"cells":6959},{"EARLY_PHASE1":6960,"PHASE1":6962,"PHASE2":6968,"PHASE3":7000,"PHASE4":7002,"NA":7004},{"trials":6961,"activeCount":102},[],{"trials":6963,"activeCount":102},[6964],{"nctId":939,"briefTitle":940,"status":226,"phases":6965,"completion":942,"start":943,"enrollment":944,"conditions":6966,"interventions":6967},[90],[15],[674,673,947,948],{"trials":6969,"activeCount":102},[6970,6974,6978,6982,6989],{"nctId":1088,"briefTitle":1089,"status":1090,"phases":6971,"primaryCompletion":1092,"start":1093,"enrollment":1094,"conditions":6972,"interventions":6973},[91],[1096],[1098,673,947,1099],{"nctId":5083,"briefTitle":5084,"status":226,"phases":6975,"primaryCompletion":1092,"completion":5086,"start":3024,"enrollment":2049,"conditions":6976,"interventions":6977},[91],[1891,1892,1893,1002,710,711,1896,1897,1898,712,713,714,715,1902,1903,1904,1024,1025,1026,1036,1037,1038,1234],[1746,947],{"nctId":5090,"briefTitle":5091,"status":226,"phases":6979,"primaryCompletion":5093,"completion":2536,"start":4030,"enrollment":244,"conditions":6980,"interventions":6981},[91],[873,558,1001,1002,710,1004,1005,711,1114,1006,899,500,900,1008,901,1009,902,903,1010,1012,712,713,908,24,714,1013,21,1016,715,1041,1234],[5096,1606,947,1746],{"nctId":6983,"briefTitle":6984,"status":226,"phases":6985,"primaryCompletion":647,"start":1263,"enrollment":282,"conditions":6986,"interventions":6987},"NCT00182663","Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant",[91],[700,1905,1017,1027],[6988,1099,947],"clarithromycin",{"nctId":6990,"briefTitle":6991,"status":226,"phases":6992,"primaryCompletion":6993,"completion":6993,"start":6994,"enrollment":2049,"conditions":6995,"interventions":6996},"NCT00445692","Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma",[91],"2017-04-24","2007-01-10",[5204,1456,1457,234],[6997,6998,6999],"Clarithromycin","Dexamethasone","Lenalidomide",{"trials":7001,"activeCount":102},[],{"trials":7003,"activeCount":102},[],{"trials":7005,"activeCount":102},[],{"intervention":5111,"totalTrials":2308,"cells":7007},{"EARLY_PHASE1":7008,"PHASE1":7010,"PHASE2":7012,"PHASE3":7045,"PHASE4":7047,"NA":7049},{"trials":7009,"activeCount":102},[],{"trials":7011,"activeCount":102},[],{"trials":7013,"activeCount":102},[7014,7025,7033,7037,7041],{"nctId":7015,"briefTitle":7016,"status":226,"phases":7017,"primaryCompletion":7018,"completion":7019,"start":7020,"enrollment":282,"conditions":7021,"interventions":7023},"NCT02619682","Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma",[91],"2022-06-01","2025-10-24","2015-12-30",[536,7022],"Transplant-Related Carcinoma",[7024,6999],"Ixazomib Citrate",{"nctId":7026,"briefTitle":7027,"status":226,"phases":7028,"primaryCompletion":2117,"completion":7029,"start":7030,"enrollment":682,"conditions":7031,"interventions":7032},"NCT00619684","Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant",[91],"2015-09","2008-02",[700,1905,1017,1027],[5111],{"nctId":5106,"briefTitle":5107,"status":114,"phases":7034,"primaryCompletion":829,"start":1051,"enrollment":2616,"conditions":7035,"interventions":7036},[91],[873,558,1001,1002,710,1004,1005,711,1114,1006,537,899,500,900,1008,901,902,903,1010,1012,712,713,908,24,714,1013,21,27,1759,1016,715,1775,1041,716],[5111,1746],{"nctId":5128,"briefTitle":5129,"status":343,"phases":7038,"start":1573,"enrollment":102,"conditions":7039,"interventions":7040},[91],[15,797],[1746,5111],{"nctId":6990,"briefTitle":6991,"status":226,"phases":7042,"primaryCompletion":6993,"completion":6993,"start":6994,"enrollment":2049,"conditions":7043,"interventions":7044},[91],[5204,1456,1457,234],[6997,6998,6999],{"trials":7046,"activeCount":102},[],{"trials":7048,"activeCount":102},[],{"trials":7050,"activeCount":102},[],{"intervention":2052,"totalTrials":2308,"cells":7052},{"EARLY_PHASE1":7053,"PHASE1":7055,"PHASE2":7057,"PHASE3":7084,"PHASE4":7086,"NA":7088},{"trials":7054,"activeCount":102},[],{"trials":7056,"activeCount":102},[],{"trials":7058,"activeCount":102},[7059,7063,7067,7076,7080],{"nctId":1088,"briefTitle":1089,"status":1090,"phases":7060,"primaryCompletion":1092,"start":1093,"enrollment":1094,"conditions":7061,"interventions":7062},[91],[1096],[1098,673,947,1099],{"nctId":3316,"briefTitle":3317,"status":226,"phases":7064,"primaryCompletion":3319,"completion":3320,"start":3321,"enrollment":317,"conditions":7065,"interventions":7066},[91],[2170,3323,531,533,516,1473],[2052,1290,373,692,491,505,1206],{"nctId":7068,"briefTitle":7069,"status":114,"phases":7070,"primaryCompletion":7071,"completion":7072,"start":820,"enrollment":395,"conditions":7073,"interventions":7075},"NCT01465386","Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission",[91],"2014-01-28","2015-03-02",[869,2012,2016,734,29,870,871,32,7074,1109,1110,453],"Adult Acute Promyelocytic Leukemia (M3)",[1098],{"nctId":2045,"briefTitle":2046,"status":226,"phases":7077,"primaryCompletion":1198,"completion":1198,"start":2048,"enrollment":2049,"conditions":7078,"interventions":7079},[91],[234],[2052,82,82,504,491,376],{"nctId":5199,"briefTitle":5200,"status":226,"phases":7081,"primaryCompletion":1052,"completion":5202,"start":1573,"enrollment":36,"conditions":7082,"interventions":7083},[91],[5204,1456,1457],[2052,1206],{"trials":7085,"activeCount":102},[],{"trials":7087,"activeCount":102},[],{"trials":7089,"activeCount":102},[],{"intervention":1499,"totalTrials":2308,"cells":7091},{"EARLY_PHASE1":7092,"PHASE1":7094,"PHASE2":7096,"PHASE3":7118,"PHASE4":7120,"NA":7122},{"trials":7093,"activeCount":102},[],{"trials":7095,"activeCount":102},[],{"trials":7097,"activeCount":102},[7098,7102,7106,7110,7114],{"nctId":1917,"briefTitle":1918,"status":226,"phases":7099,"primaryCompletion":1297,"completion":1297,"start":953,"enrollment":555,"conditions":7100,"interventions":7101},[91],[29,870,35,871,32,872,873,558,1001,876,877,878,879,881,882,1890,1891,1892,1893,1894,710,1004,1593,711,1895,1896,1897,1898,1899,1006,898,1921,18,899,500,900,1008,901,1009,902,903,1010,1116,298,904,906,907,1011,1012,712,713,908,24,714,1013,21,1014,27,1759,700,1015,715,1900,1761,1762,1901,1902,1903,918,1904,1922,1202,1765,1766,1908,1923,921,1018,1768,1769,1023,1024,1025,927,1026,1028,1029,929,1030,1771,1772,1035,1036,1037,935,1038,1039,1040,1775,716],[1499,937,481,479],{"nctId":1959,"briefTitle":1960,"status":226,"phases":7103,"primaryCompletion":1962,"start":1963,"enrollment":9,"conditions":7104,"interventions":7105},[91],[1216,1965],[1967,82,504,376],{"nctId":4937,"briefTitle":4938,"status":226,"phases":7107,"primaryCompletion":4940,"start":1999,"enrollment":486,"conditions":7108,"interventions":7109},[91],[1604,1126,4481,1137,15,797,1096,798,799,4483,3494,4484],[1499,1391,675],{"nctId":1493,"briefTitle":1494,"status":114,"phases":7111,"primaryCompletion":1496,"start":1083,"enrollment":135,"conditions":7112,"interventions":7113},[90,91],[1137,15,798,799],[1499,1118,673,811,1043],{"nctId":2153,"briefTitle":2154,"status":226,"phases":7115,"primaryCompletion":973,"completion":2156,"start":1404,"enrollment":296,"conditions":7116,"interventions":7117},[91],[429,733,734,873,558,1001,1862,874,875,876,877,878,879,880,881,465,882,1002,710,1004,1005,1757,439,1593,711,1114,1006,898,246,18,899,500,900,1008,901,1009,902,903,1010,1116,298,904,905,906,907,1011,1012,712,713,908,24,714,1013,21,1014,27,1759,700,1015,910,1016,715,1041,716],[1499,937,479,481,2159],{"trials":7119,"activeCount":102},[],{"trials":7121,"activeCount":102},[],{"trials":7123,"activeCount":102},[],{"intervention":2003,"totalTrials":3454,"cells":7125},{"EARLY_PHASE1":7126,"PHASE1":7128,"PHASE2":7130,"PHASE3":7148,"PHASE4":7150,"NA":7152},{"trials":7127,"activeCount":102},[],{"trials":7129,"activeCount":102},[],{"trials":7131,"activeCount":102},[7132,7136,7140,7144],{"nctId":3855,"briefTitle":3856,"status":226,"phases":7133,"primaryCompletion":2425,"completion":2425,"start":1665,"conditions":7134,"interventions":7135},[91],[15],[719,2003,1415,1118],{"nctId":3865,"briefTitle":3866,"status":226,"phases":7137,"completion":648,"start":668,"conditions":7138,"interventions":7139},[91],[1096],[2003,1118],{"nctId":1996,"briefTitle":1997,"status":226,"phases":7141,"completion":1999,"start":2000,"enrollment":598,"conditions":7142,"interventions":7143},[91],[15],[2003,1812,479,937,2004,481],{"nctId":4074,"briefTitle":4075,"status":226,"phases":7145,"primaryCompletion":2448,"completion":2448,"start":2126,"enrollment":22,"conditions":7146,"interventions":7147},[91],[700,1905,1017,1027],[958,2003,719],{"trials":7149,"activeCount":102},[],{"trials":7151,"activeCount":102},[],{"trials":7153,"activeCount":102},[],{"intervention":1994,"totalTrials":3454,"cells":7155},{"EARLY_PHASE1":7156,"PHASE1":7158,"PHASE2":7160,"PHASE3":7178,"PHASE4":7180,"NA":7182},{"trials":7157,"activeCount":102},[],{"trials":7159,"activeCount":102},[],{"trials":7161,"activeCount":102},[7162,7166,7170,7174],{"nctId":3351,"briefTitle":3352,"status":226,"phases":7163,"primaryCompletion":3354,"completion":3355,"start":3356,"enrollment":2100,"conditions":7164,"interventions":7165},[90,91],[387],[372,373,3359,468,3349],{"nctId":1988,"briefTitle":1989,"status":226,"phases":7167,"primaryCompletion":1991,"completion":1991,"start":1340,"conditions":7168,"interventions":7169},[91],[15,798],[479,937,1994,811,481],{"nctId":5217,"briefTitle":5218,"status":114,"phases":7171,"primaryCompletion":1082,"start":5220,"enrollment":36,"conditions":7172,"interventions":7173},[91],[1108,2012,2013,2014,2015,2016,29,870,35,32,872,2017,1109,1110,1638],[1994,5223],{"nctId":3021,"briefTitle":3022,"status":226,"phases":7175,"completion":2519,"start":3024,"conditions":7176,"interventions":7177},[91],[15],[479,1994],{"trials":7179,"activeCount":102},[],{"trials":7181,"activeCount":102},[],{"trials":7183,"activeCount":102},[],{"intervention":5006,"totalTrials":3454,"cells":7185},{"EARLY_PHASE1":7186,"PHASE1":7188,"PHASE2":7190,"PHASE3":7214,"PHASE4":7216,"NA":7218},{"trials":7187,"activeCount":102},[],{"trials":7189,"activeCount":102},[],{"trials":7191,"activeCount":102},[7192,7199,7206,7210],{"nctId":7193,"briefTitle":7194,"status":226,"phases":7195,"primaryCompletion":2048,"start":1733,"enrollment":2049,"conditions":7196,"interventions":7197},"NCT00118287","Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes",[90,91],[890,898,910],[7198,5006],"azacitidine",{"nctId":7200,"briefTitle":7201,"status":226,"phases":7202,"completion":1999,"start":1742,"enrollment":2049,"conditions":7203,"interventions":7204},"NCT00093366","Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes",[90,91],[15,798,799],[5006,7205],"arsenic trioxide",{"nctId":5001,"briefTitle":5002,"status":226,"phases":7207,"primaryCompletion":1386,"completion":1386,"start":474,"conditions":7208,"interventions":7209},[91],[15,798],[672,5006],{"nctId":5020,"briefTitle":5021,"status":226,"phases":7211,"primaryCompletion":5023,"start":5024,"enrollment":282,"conditions":7212,"interventions":7213},[91],[15,798,799],[672,5006],{"trials":7215,"activeCount":102},[],{"trials":7217,"activeCount":102},[],{"trials":7219,"activeCount":102},[],{"intervention":2004,"totalTrials":3454,"cells":7221},{"EARLY_PHASE1":7222,"PHASE1":7224,"PHASE2":7226,"PHASE3":7254,"PHASE4":7256,"NA":7258},{"trials":7223,"activeCount":102},[],{"trials":7225,"activeCount":102},[],{"trials":7227,"activeCount":102},[7228,7232,7236,7248],{"nctId":1926,"briefTitle":1927,"status":226,"phases":7229,"primaryCompletion":773,"completion":1929,"start":1930,"enrollment":231,"conditions":7230,"interventions":7231},[91],[733,1932,1933,874,1934,405,1935,246,1116,1936],[82,1938,504,1939,376,1940,1941],{"nctId":1996,"briefTitle":1997,"status":226,"phases":7233,"completion":1999,"start":2000,"enrollment":598,"conditions":7234,"interventions":7235},[91],[15],[2003,1812,479,937,2004,481],{"nctId":7237,"briefTitle":7238,"status":226,"phases":7239,"primaryCompletion":7240,"completion":7241,"start":7242,"enrollment":598,"conditions":7243,"interventions":7246},"NCT00702403","Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML",[90,91],"2013-12","2013-12-01","2008-08-14",[868,733,1111,874,877,405,882,7244,7245,246,1116,1015,1778,1779],"Philadelphia Positive Adult Acute Lymphoblastic Leukemia","Philadelphia Positive Childhood Acute Lymphoblastic Leukemia",[7247,2004],"nilotinib",{"nctId":7249,"briefTitle":7250,"status":226,"phases":7251,"completion":473,"start":3329,"conditions":7252,"interventions":7253},"NCT00244829","Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia",[90,91],[15],[2004],{"trials":7255,"activeCount":102},[],{"trials":7257,"activeCount":102},[],{"trials":7259,"activeCount":102},[],{"intervention":7261,"totalTrials":2616,"cells":7262},"therapeutic tumor infiltrating lymphocytes",{"EARLY_PHASE1":7263,"PHASE1":7265,"PHASE2":7273,"PHASE3":7284,"PHASE4":7286,"NA":7288},{"trials":7264,"activeCount":102},[],{"trials":7266,"activeCount":102},[7267],{"nctId":7268,"briefTitle":7269,"status":226,"phases":7270,"completion":1817,"start":1135,"conditions":7271,"interventions":7272},"NCT00045149","Biological Therapy in Treating Patients With Metastatic Melanoma",[90],[1626],[719,7261],{"trials":7274,"activeCount":102},[7275,7280],{"nctId":7276,"briefTitle":7269,"status":226,"phases":7277,"completion":2519,"start":943,"enrollment":463,"conditions":7278,"interventions":7279},"NCT00002786",[90,91],[1626],[719,7261],{"nctId":1319,"briefTitle":1320,"status":226,"phases":7281,"primaryCompletion":1322,"completion":1322,"start":1323,"enrollment":1062,"conditions":7282,"interventions":7283},[91],[1325,1326,1327,1328,1329,1330],[1076,57,504,1332],{"trials":7285,"activeCount":102},[],{"trials":7287,"activeCount":102},[],{"trials":7289,"activeCount":102},[],{"intervention":7291,"totalTrials":2616,"cells":7292},"Avelumab",{"EARLY_PHASE1":7293,"PHASE1":7295,"PHASE2":7297,"PHASE3":7336,"PHASE4":7338,"NA":7340},{"trials":7294,"activeCount":102},[],{"trials":7296,"activeCount":102},[],{"trials":7298,"activeCount":102},[7299,7311,7323],{"nctId":7300,"briefTitle":7301,"status":114,"phases":7302,"primaryCompletion":7303,"completion":7303,"start":7304,"enrollment":2248,"conditions":7305,"interventions":7308},"NCT02584829","Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma",[90,91],"2018-12-18","2015-11-06",[7306,7307],"Merkel Cell Polyomavirus Infection","Stage IV Merkel Cell Carcinoma AJCC v7",[7291,7309,7310],"MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells","Recombinant Interferon Beta",{"nctId":7312,"briefTitle":7313,"status":114,"phases":7314,"primaryCompletion":7315,"completion":7315,"start":7316,"enrollment":3311,"conditions":7317,"interventions":7319},"NCT03747484","Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer",[90,91],"2024-01-09","2019-07-03",[7318],"Other Skin",[7320,7291,7321,7322],"Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR","Pembrolizumab","Interferon Gamma-1b",{"nctId":7324,"briefTitle":7325,"status":114,"phases":7326,"primaryCompletion":7327,"completion":7327,"start":7328,"enrollment":25,"conditions":7329,"interventions":7334},"NCT03074318","Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery",[90,91],"2020-11-15","2017-09-28",[7330,7331,7332,7333],"Metastatic Leiomyosarcoma","Metastatic Liposarcoma","Unresectable Leiomyosarcoma","Unresectable Liposarcoma",[7291,7335],"Trabectedin",{"trials":7337,"activeCount":102},[],{"trials":7339,"activeCount":102},[],{"trials":7341,"activeCount":102},[],{"intervention":1046,"totalTrials":2616,"cells":7343},{"EARLY_PHASE1":7344,"PHASE1":7346,"PHASE2":7348,"PHASE3":7362,"PHASE4":7364,"NA":7366},{"trials":7345,"activeCount":102},[],{"trials":7347,"activeCount":102},[],{"trials":7349,"activeCount":102},[7350,7354,7358],{"nctId":994,"briefTitle":995,"status":226,"phases":7351,"primaryCompletion":997,"completion":998,"start":999,"enrollment":486,"conditions":7352,"interventions":7353},[91],[868,733,734,29,870,35,871,32,872,873,558,1001,874,875,876,877,880,881,1002,890,710,1003,1004,1005,711,1006,1007,898,899,500,900,1008,901,1009,902,903,1010,904,905,906,907,1011,1012,712,713,908,24,714,1013,21,1014,27,700,1015,910,1016,715,1017,920,921,922,1018,1019,923,924,1020,1021,1022,1023,1024,1025,926,927,1026,1027,1028,1029,928,929,930,1030,1031,931,932,1032,1033,1034,1035,1036,1037,934,935,1038,1039,1040,1041,716],[673,937,1043,481,720,1044,1045,1046],{"nctId":6933,"briefTitle":6934,"status":226,"phases":7355,"primaryCompletion":2874,"completion":1431,"start":942,"enrollment":19,"conditions":7356,"interventions":7357},[90,91],[29,35,871,32,872,5075,5076,877,880,465,1636,1637,898,246,18,1116,298,737,909,1015,453,6937,6938],[1812,719,1046,720,1595],{"nctId":2709,"briefTitle":2710,"status":114,"phases":7359,"primaryCompletion":973,"completion":973,"start":1633,"enrollment":135,"conditions":7360,"interventions":7361},[91],[1137,15,798],[2714,2715,937,811,960,1046],{"trials":7363,"activeCount":102},[],{"trials":7365,"activeCount":102},[],{"trials":7367,"activeCount":102},[],{"intervention":7198,"totalTrials":2616,"cells":7369},{"EARLY_PHASE1":7370,"PHASE1":7372,"PHASE2":7374,"PHASE3":7390,"PHASE4":7392,"NA":7394},{"trials":7371,"activeCount":102},[],{"trials":7373,"activeCount":102},[],{"trials":7375,"activeCount":102},[7376,7380,7384],{"nctId":5152,"briefTitle":5153,"status":226,"phases":7377,"primaryCompletion":5155,"completion":5155,"start":5156,"enrollment":475,"conditions":7378,"interventions":7379},[91],[465,1434,389,2231],[5159,455],{"nctId":7193,"briefTitle":7194,"status":226,"phases":7381,"primaryCompletion":2048,"start":1733,"enrollment":2049,"conditions":7382,"interventions":7383},[90,91],[890,898,910],[7198,5006],{"nctId":7385,"briefTitle":7386,"status":226,"phases":7387,"primaryCompletion":7240,"start":821,"enrollment":1094,"conditions":7388,"interventions":7389},"NCT01083706","Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant",[91],[29,870,35,871,32,872,880,465,898,18,298,910],[7198],{"trials":7391,"activeCount":102},[],{"trials":7393,"activeCount":102},[],{"trials":7395,"activeCount":102},[],{"intervention":7321,"totalTrials":2616,"cells":7397},{"EARLY_PHASE1":7398,"PHASE1":7400,"PHASE2":7402,"PHASE3":7428,"PHASE4":7430,"NA":7432},{"trials":7399,"activeCount":102},[],{"trials":7401,"activeCount":102},[],{"trials":7403,"activeCount":102},[7404,7415,7419],{"nctId":7405,"briefTitle":7406,"status":226,"phases":7407,"primaryCompletion":7408,"completion":7409,"start":7410,"enrollment":317,"conditions":7411,"interventions":7414},"NCT03338959","Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma",[90,91],"2023-06-08","2023-08-04","2018-03-28",[7412,7413],"Soft Tissue Sarcoma","Recurrent Soft Tissue Sarcoma",[7321],{"nctId":7312,"briefTitle":7313,"status":114,"phases":7416,"primaryCompletion":7315,"completion":7315,"start":7316,"enrollment":3311,"conditions":7417,"interventions":7418},[90,91],[7318],[7320,7291,7321,7322],{"nctId":7420,"briefTitle":7421,"status":226,"phases":7422,"primaryCompletion":7423,"completion":7424,"start":7425,"enrollment":19,"conditions":7426,"interventions":7427},"NCT02888665","Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery",[90,91],"2020-03-17","2020-10-09","2016-12-05",[3503],[690,7321],{"trials":7429,"activeCount":102},[],{"trials":7431,"activeCount":102},[],{"trials":7433,"activeCount":102},[],{"intervention":7309,"totalTrials":98,"cells":7435},{"EARLY_PHASE1":7436,"PHASE1":7438,"PHASE2":7440,"PHASE3":7455,"PHASE4":7457,"NA":7459},{"trials":7437,"activeCount":102},[],{"trials":7439,"activeCount":102},[],{"trials":7441,"activeCount":102},[7442,7446],{"nctId":7300,"briefTitle":7301,"status":114,"phases":7443,"primaryCompletion":7303,"completion":7303,"start":7304,"enrollment":2248,"conditions":7444,"interventions":7445},[90,91],[7306,7307],[7291,7309,7310],{"nctId":7447,"briefTitle":7448,"status":114,"phases":7449,"primaryCompletion":7450,"completion":7450,"start":2483,"enrollment":3454,"conditions":7451,"interventions":7454},"NCT01758458","Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma",[90,91],"2016-05",[7452,7453],"Recurrent Merkel Cell Carcinoma","Stage IV Merkel Cell Carcinoma",[1076,7309,7310],{"trials":7456,"activeCount":102},[],{"trials":7458,"activeCount":102},[],{"trials":7460,"activeCount":102},[],{"intervention":7310,"totalTrials":98,"cells":7462},{"EARLY_PHASE1":7463,"PHASE1":7465,"PHASE2":7467,"PHASE3":7477,"PHASE4":7479,"NA":7481},{"trials":7464,"activeCount":102},[],{"trials":7466,"activeCount":102},[],{"trials":7468,"activeCount":102},[7469,7473],{"nctId":7300,"briefTitle":7301,"status":114,"phases":7470,"primaryCompletion":7303,"completion":7303,"start":7304,"enrollment":2248,"conditions":7471,"interventions":7472},[90,91],[7306,7307],[7291,7309,7310],{"nctId":7447,"briefTitle":7448,"status":114,"phases":7474,"primaryCompletion":7450,"completion":7450,"start":2483,"enrollment":3454,"conditions":7475,"interventions":7476},[90,91],[7452,7453],[1076,7309,7310],{"trials":7478,"activeCount":102},[],{"trials":7480,"activeCount":102},[],{"trials":7482,"activeCount":102},[],{"intervention":986,"totalTrials":98,"cells":7484},{"EARLY_PHASE1":7485,"PHASE1":7487,"PHASE2":7493,"PHASE3":7499,"PHASE4":7501,"NA":7503},{"trials":7486,"activeCount":102},[],{"trials":7488,"activeCount":102},[7489],{"nctId":979,"briefTitle":980,"status":114,"phases":7490,"primaryCompletion":982,"start":983,"enrollment":282,"conditions":7491,"interventions":7492},[90],[415],[673,672,479,481,986,674],{"trials":7494,"activeCount":102},[7495],{"nctId":1048,"briefTitle":1049,"status":226,"phases":7496,"primaryCompletion":1051,"completion":1052,"start":983,"enrollment":1053,"conditions":7497,"interventions":7498},[91],[415],[673,672,479,811,986,1045],{"trials":7500,"activeCount":102},[],{"trials":7502,"activeCount":102},[],{"trials":7504,"activeCount":102},[],{"intervention":2416,"totalTrials":98,"cells":7506},{"EARLY_PHASE1":7507,"PHASE1":7509,"PHASE2":7511,"PHASE3":7521,"PHASE4":7523,"NA":7525},{"trials":7508,"activeCount":102},[],{"trials":7510,"activeCount":102},[],{"trials":7512,"activeCount":102},[7513,7517],{"nctId":2408,"briefTitle":2409,"status":114,"phases":7514,"primaryCompletion":2411,"completion":2412,"start":2413,"enrollment":1230,"conditions":7515,"interventions":7516},[91],[1137,15,798],[504,441,409,2416],{"nctId":2645,"briefTitle":2646,"status":226,"phases":7518,"primaryCompletion":2648,"completion":2649,"start":2650,"enrollment":463,"conditions":7519,"interventions":7520},[91],[1556,403,428,429,733,734,1558,874,875,405,434,1559,246,18,1116,298,250,2652],[504,442,2416,441,409],{"trials":7522,"activeCount":102},[],{"trials":7524,"activeCount":102},[],{"trials":7526,"activeCount":102},[],{"intervention":1077,"totalTrials":98,"cells":7528},{"EARLY_PHASE1":7529,"PHASE1":7531,"PHASE2":7533,"PHASE3":7549,"PHASE4":7551,"NA":7553},{"trials":7530,"activeCount":102},[],{"trials":7532,"activeCount":102},[],{"trials":7534,"activeCount":102},[7535,7539],{"nctId":1057,"briefTitle":1058,"status":114,"phases":7536,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":1062,"conditions":7537,"interventions":7538},[90,91],[1064,1065,1066,1067,1068,1069,1070,1071,1072,1073,1074],[1076,1077,57],{"nctId":7540,"briefTitle":7541,"status":114,"phases":7542,"primaryCompletion":7543,"completion":7543,"start":7544,"enrollment":334,"conditions":7545,"interventions":7548},"NCT02770820","Laboratory-Treated (Central Memory\u002FNaive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia",[90,91],"2020-06-01","2017-11-06",[387,7546,1065,433,7547],"EBV-Positive Neoplastic Cells Present","Elevated WT1",[1076,1077],{"trials":7550,"activeCount":102},[],{"trials":7552,"activeCount":102},[],{"trials":7554,"activeCount":102},[],{"intervention":1804,"totalTrials":98,"cells":7556},{"EARLY_PHASE1":7557,"PHASE1":7559,"PHASE2":7561,"PHASE3":7576,"PHASE4":7578,"NA":7580},{"trials":7558,"activeCount":102},[],{"trials":7560,"activeCount":102},[],{"trials":7562,"activeCount":102},[7563,7567],{"nctId":1796,"briefTitle":1797,"status":226,"phases":7564,"primaryCompletion":1278,"completion":1799,"start":1800,"enrollment":1360,"conditions":7565,"interventions":7566},[91],[1147,433,529,1514,390,516,537,246,18,1802,1116,298,1148,1149,248,1150,24,1284,233,21,1234],[1804,82,504,376],{"nctId":7568,"briefTitle":7569,"status":226,"phases":7570,"primaryCompletion":7029,"completion":7571,"start":1051,"enrollment":7572,"conditions":7573,"interventions":7575},"NCT01525407","Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation",[91],"2016-02",83,[7574],"Malignant Neoplasm",[1804],{"trials":7577,"activeCount":102},[],{"trials":7579,"activeCount":102},[],{"trials":7581,"activeCount":102},[],{"intervention":7024,"totalTrials":98,"cells":7583},{"EARLY_PHASE1":7584,"PHASE1":7586,"PHASE2":7588,"PHASE3":7603,"PHASE4":7605,"NA":7607},{"trials":7585,"activeCount":102},[],{"trials":7587,"activeCount":102},[],{"trials":7589,"activeCount":102},[7590,7594],{"nctId":7015,"briefTitle":7016,"status":226,"phases":7591,"primaryCompletion":7018,"completion":7019,"start":7020,"enrollment":282,"conditions":7592,"interventions":7593},[91],[536,7022],[7024,6999],{"nctId":7595,"briefTitle":7596,"status":226,"phases":7597,"primaryCompletion":7598,"completion":7599,"start":7600,"enrollment":475,"conditions":7601,"interventions":7602},"NCT02513498","Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease",[91],"2018-01-05","2018-06-27","2015-12-08",[5362],[7024],{"trials":7604,"activeCount":102},[],{"trials":7606,"activeCount":102},[],{"trials":7608,"activeCount":102},[],{"intervention":690,"totalTrials":98,"cells":7610},{"EARLY_PHASE1":7611,"PHASE1":7613,"PHASE2":7619,"PHASE3":7625,"PHASE4":7627,"NA":7629},{"trials":7612,"activeCount":102},[],{"trials":7614,"activeCount":102},[7615],{"nctId":677,"briefTitle":678,"status":114,"phases":7616,"primaryCompletion":680,"completion":680,"start":681,"enrollment":682,"conditions":7617,"interventions":7618},[90],[528,684,685],[687,57,688,442,689,690,691,692,505],{"trials":7620,"activeCount":102},[7621],{"nctId":7420,"briefTitle":7421,"status":226,"phases":7622,"primaryCompletion":7423,"completion":7424,"start":7425,"enrollment":19,"conditions":7623,"interventions":7624},[90,91],[3503],[690,7321],{"trials":7626,"activeCount":102},[],{"trials":7628,"activeCount":102},[],{"trials":7630,"activeCount":102},[],{"intervention":1099,"totalTrials":98,"cells":7632},{"EARLY_PHASE1":7633,"PHASE1":7635,"PHASE2":7637,"PHASE3":7647,"PHASE4":7649,"NA":7651},{"trials":7634,"activeCount":102},[],{"trials":7636,"activeCount":102},[],{"trials":7638,"activeCount":102},[7639,7643],{"nctId":1088,"briefTitle":1089,"status":1090,"phases":7640,"primaryCompletion":1092,"start":1093,"enrollment":1094,"conditions":7641,"interventions":7642},[91],[1096],[1098,673,947,1099],{"nctId":6983,"briefTitle":6984,"status":226,"phases":7644,"primaryCompletion":647,"start":1263,"enrollment":282,"conditions":7645,"interventions":7646},[91],[700,1905,1017,1027],[6988,1099,947],{"trials":7648,"activeCount":102},[],{"trials":7650,"activeCount":102},[],{"trials":7652,"activeCount":102},[],{"intervention":1177,"totalTrials":98,"cells":7654},{"EARLY_PHASE1":7655,"PHASE1":7657,"PHASE2":7659,"PHASE3":7669,"PHASE4":7671,"NA":7673},{"trials":7656,"activeCount":102},[],{"trials":7658,"activeCount":102},[],{"trials":7660,"activeCount":102},[7661,7665],{"nctId":1168,"briefTitle":1169,"status":114,"phases":7662,"primaryCompletion":1171,"completion":1172,"start":1173,"enrollment":98,"conditions":7663,"interventions":7664},[91],[1175],[57,504,376,1177,441],{"nctId":2611,"briefTitle":2612,"status":226,"phases":7666,"primaryCompletion":2614,"completion":117,"start":2615,"enrollment":2616,"conditions":7667,"interventions":7668},[90,91],[1544,2618],[937,1177,1043],{"trials":7670,"activeCount":102},[],{"trials":7672,"activeCount":102},[],{"trials":7674,"activeCount":102},[],{"intervention":5096,"totalTrials":98,"cells":7676},{"EARLY_PHASE1":7677,"PHASE1":7679,"PHASE2":7681,"PHASE3":7694,"PHASE4":7696,"NA":7698},{"trials":7678,"activeCount":102},[],{"trials":7680,"activeCount":102},[],{"trials":7682,"activeCount":102},[7683,7687],{"nctId":5090,"briefTitle":5091,"status":226,"phases":7684,"primaryCompletion":5093,"completion":2536,"start":4030,"enrollment":244,"conditions":7685,"interventions":7686},[91],[873,558,1001,1002,710,1004,1005,711,1114,1006,899,500,900,1008,901,1009,902,903,1010,1012,712,713,908,24,714,1013,21,1016,715,1041,1234],[5096,1606,947,1746],{"nctId":7688,"briefTitle":7689,"status":226,"phases":7690,"primaryCompletion":983,"start":1991,"conditions":7691,"interventions":7692},"NCT00217555","Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer",[91],[6389,3494,6390],[5096,7693],"topotecan hydrochloride",{"trials":7695,"activeCount":102},[],{"trials":7697,"activeCount":102},[],{"trials":7699,"activeCount":102},[],{"intervention":3149,"totalTrials":98,"cells":7701},{"EARLY_PHASE1":7702,"PHASE1":7704,"PHASE2":7706,"PHASE3":7719,"PHASE4":7721,"NA":7723},{"trials":7703,"activeCount":102},[],{"trials":7705,"activeCount":102},[],{"trials":7707,"activeCount":102},[7708,7712],{"nctId":3141,"briefTitle":3142,"status":226,"phases":7709,"primaryCompletion":2257,"start":647,"enrollment":3144,"conditions":7710,"interventions":7711},[91],[1003,868,733,734,29,35,871,32,872,3146,1111,874,875,877,880,2319,465,2320,882,883,884,885,1890,886,887,1891,1892,888,889,1893,1894,890,1636,2321,710,1137,2323,1757,2324,3147,711,891,892,1895,894,895,1896,1897,896,897,1898,1899,898,488,246,18,899,500,900,1008,901,1009,903,1010,1012,712,713,908,24,714,1013,21,1014,27,1759,1015,910,911,912,913,1900,2327,914,915,1760,2328,1201,1901,1902,1903,917,918,1904,1905,1922,1202,2329,1764,1203,1908,1017,1923,920,921,922,1018,1019,923,924,1020,1022,1023,1024,1025,926,927,1026,1027,1028,1029,928,929,930,1030,1031,931,932,1032,1034,1035,1036,1037,934,1038,1039,1040],[3149,1043,811],{"nctId":7713,"briefTitle":7714,"status":226,"phases":7715,"primaryCompletion":1991,"completion":1991,"start":7716,"conditions":7717,"interventions":7718},"NCT00010283","Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon",[90,91],"2000-07",[1604,1126,4481,1137,4482,15,797,1096,798,4483,3494,4484],[3149],{"trials":7720,"activeCount":102},[],{"trials":7722,"activeCount":102},[],{"trials":7724,"activeCount":102},[],{"intervention":1940,"totalTrials":98,"cells":7726},{"EARLY_PHASE1":7727,"PHASE1":7729,"PHASE2":7731,"PHASE3":7741,"PHASE4":7743,"NA":7745},{"trials":7728,"activeCount":102},[],{"trials":7730,"activeCount":102},[],{"trials":7732,"activeCount":102},[7733,7737],{"nctId":1926,"briefTitle":1927,"status":226,"phases":7734,"primaryCompletion":773,"completion":1929,"start":1930,"enrollment":231,"conditions":7735,"interventions":7736},[91],[733,1932,1933,874,1934,405,1935,246,1116,1936],[82,1938,504,1939,376,1940,1941],{"nctId":7237,"briefTitle":7238,"status":226,"phases":7738,"primaryCompletion":7240,"completion":7241,"start":7242,"enrollment":598,"conditions":7739,"interventions":7740},[90,91],[868,733,1111,874,877,405,882,7244,7245,246,1116,1015,1778,1779],[7247,2004],{"trials":7742,"activeCount":102},[],{"trials":7744,"activeCount":102},[],{"trials":7746,"activeCount":102},[],{"intervention":1236,"totalTrials":98,"cells":7748},{"EARLY_PHASE1":7749,"PHASE1":7751,"PHASE2":7753,"PHASE3":7763,"PHASE4":7765,"NA":7767},{"trials":7750,"activeCount":102},[],{"trials":7752,"activeCount":102},[],{"trials":7754,"activeCount":102},[7755,7759],{"nctId":1225,"briefTitle":1226,"status":226,"phases":7756,"primaryCompletion":1228,"completion":1228,"start":1229,"enrollment":1230,"conditions":7757,"interventions":7758},[90,91],[404,387,1147,685,736,1148,1149,1232,24,233,21,27,1233,234,563,1234],[57,504,376,1236,441],{"nctId":2709,"briefTitle":2710,"status":114,"phases":7760,"primaryCompletion":973,"completion":973,"start":1633,"enrollment":135,"conditions":7761,"interventions":7762},[91],[1137,15,798],[2714,2715,937,811,960,1046],{"trials":7764,"activeCount":102},[],{"trials":7766,"activeCount":102},[],{"trials":7768,"activeCount":102},[],{"intervention":6392,"totalTrials":98,"cells":7770},{"EARLY_PHASE1":7771,"PHASE1":7773,"PHASE2":7775,"PHASE3":7785,"PHASE4":7787,"NA":7789},{"trials":7772,"activeCount":102},[],{"trials":7774,"activeCount":102},[],{"trials":7776,"activeCount":102},[7777,7781],{"nctId":6385,"briefTitle":6386,"status":226,"phases":7778,"primaryCompletion":1298,"start":1742,"conditions":7779,"interventions":7780},[90,91],[6389,3494,6390],[6392,1606,6393,6394],{"nctId":6396,"briefTitle":6397,"status":226,"phases":7782,"primaryCompletion":2519,"start":1183,"conditions":7783,"interventions":7784},[91],[3494,6390],[6392,1606,6393],{"trials":7786,"activeCount":102},[],{"trials":7788,"activeCount":102},[],{"trials":7790,"activeCount":102},[],{"intervention":6393,"totalTrials":98,"cells":7792},{"EARLY_PHASE1":7793,"PHASE1":7795,"PHASE2":7797,"PHASE3":7807,"PHASE4":7809,"NA":7811},{"trials":7794,"activeCount":102},[],{"trials":7796,"activeCount":102},[],{"trials":7798,"activeCount":102},[7799,7803],{"nctId":6385,"briefTitle":6386,"status":226,"phases":7800,"primaryCompletion":1298,"start":1742,"conditions":7801,"interventions":7802},[90,91],[6389,3494,6390],[6392,1606,6393,6394],{"nctId":6396,"briefTitle":6397,"status":226,"phases":7804,"primaryCompletion":2519,"start":1183,"conditions":7805,"interventions":7806},[91],[3494,6390],[6392,1606,6393],{"trials":7808,"activeCount":102},[],{"trials":7810,"activeCount":102},[],{"trials":7812,"activeCount":102},[],{"intervention":7335,"totalTrials":98,"cells":7814},{"EARLY_PHASE1":7815,"PHASE1":7817,"PHASE2":7819,"PHASE3":7840,"PHASE4":7842,"NA":7844},{"trials":7816,"activeCount":102},[],{"trials":7818,"activeCount":102},[],{"trials":7820,"activeCount":102},[7821,7825],{"nctId":7324,"briefTitle":7325,"status":114,"phases":7822,"primaryCompletion":7327,"completion":7327,"start":7328,"enrollment":25,"conditions":7823,"interventions":7824},[90,91],[7330,7331,7332,7333],[7291,7335],{"nctId":7826,"briefTitle":7827,"status":343,"phases":7828,"primaryCompletion":7829,"completion":7830,"start":7831,"enrollment":102,"conditions":7832,"interventions":7839},"NCT03397186","Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma",[91],"2021-01-01","2021-05-01","2018-06-19",[7833,7834,7835,7836,7837,7838],"Myxoid Liposarcoma","Round Cell Liposarcoma","Stage III Soft Tissue Sarcoma AJCC v7","Stage IV Soft Tissue Sarcoma AJCC v7","Metastatic Soft Tissue Sarcoma","Unresectable Soft Tissue Sarcoma",[7335],{"trials":7841,"activeCount":102},[],{"trials":7843,"activeCount":102},[],{"trials":7845,"activeCount":102},[],{"intervention":2159,"totalTrials":98,"cells":7847},{"EARLY_PHASE1":7848,"PHASE1":7850,"PHASE2":7852,"PHASE3":7867,"PHASE4":7869,"NA":7871},{"trials":7849,"activeCount":102},[],{"trials":7851,"activeCount":102},[],{"trials":7853,"activeCount":102},[7854,7863],{"nctId":7855,"briefTitle":7856,"status":226,"phases":7857,"primaryCompletion":1589,"completion":7858,"start":7859,"enrollment":463,"conditions":7860,"interventions":7862},"NCT01616056","Bandage Lenses in Treating Patients With Ocular Graft-Versus-Host Disease",[91],"2014-12","2012-06",[1137,7861],"Ophthalmologic Complications",[2159],{"nctId":2153,"briefTitle":2154,"status":226,"phases":7864,"primaryCompletion":973,"completion":2156,"start":1404,"enrollment":296,"conditions":7865,"interventions":7866},[91],[429,733,734,873,558,1001,1862,874,875,876,877,878,879,880,881,465,882,1002,710,1004,1005,1757,439,1593,711,1114,1006,898,246,18,899,500,900,1008,901,1009,902,903,1010,1116,298,904,905,906,907,1011,1012,712,713,908,24,714,1013,21,1014,27,1759,700,1015,910,1016,715,1041,716],[1499,937,479,481,2159],{"trials":7868,"activeCount":102},[],{"trials":7870,"activeCount":102},[],{"trials":7872,"activeCount":102},[],{"intervention":6988,"totalTrials":98,"cells":7874},{"EARLY_PHASE1":7875,"PHASE1":7877,"PHASE2":7879,"PHASE3":7889,"PHASE4":7891,"NA":7893},{"trials":7876,"activeCount":102},[],{"trials":7878,"activeCount":102},[],{"trials":7880,"activeCount":102},[7881,7885],{"nctId":6983,"briefTitle":6984,"status":226,"phases":7882,"primaryCompletion":647,"start":1263,"enrollment":282,"conditions":7883,"interventions":7884},[91],[700,1905,1017,1027],[6988,1099,947],{"nctId":6990,"briefTitle":6991,"status":226,"phases":7886,"primaryCompletion":6993,"completion":6993,"start":6994,"enrollment":2049,"conditions":7887,"interventions":7888},[91],[5204,1456,1457,234],[6997,6998,6999],{"trials":7890,"activeCount":102},[],{"trials":7892,"activeCount":102},[],{"trials":7894,"activeCount":102},[],{"intervention":7896,"totalTrials":135,"cells":7897},"ondansetron",{"EARLY_PHASE1":7898,"PHASE1":7900,"PHASE2":7902,"PHASE3":7926,"PHASE4":7928,"NA":7930},{"trials":7899,"activeCount":102},[],{"trials":7901,"activeCount":102},[],{"trials":7903,"activeCount":102},[7904],{"nctId":7905,"briefTitle":7906,"status":226,"phases":7907,"primaryCompletion":7908,"completion":7909,"start":7910,"enrollment":7911,"conditions":7912,"interventions":7925},"NCT00795769","Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant",[91],"2009-06-09","2009-06-10","2008-08-08",49,[868,733,734,29,35,871,32,872,4552,1111,2319,465,2320,882,890,7913,710,1593,711,891,892,893,1895,894,895,1896,1897,896,897,1898,1899,7914,898,488,246,18,899,500,900,1008,1009,902,903,906,907,1011,1012,712,713,908,7915,24,714,1013,7916,7917,7918,21,1014,27,1759,1015,453,910,715,1905,1017,7919,920,921,922,1018,1019,923,924,1022,1024,1025,926,7920,927,1026,1027,7921,1029,7922,3578,7923,928,929,930,1030,1031,931,932,3579,1034,1036,1037,934,935,1038,7924,1040],"Disseminated Neuroblastoma","Poor Prognosis Metastatic Gestational Trophoblastic Tumor","Recurrent Malignant Testicular Germ Cell Tumor","Recurrent Neuroblastoma","Recurrent Ovarian Epithelial Cancer","Recurrent Ovarian Germ Cell Tumor","Stage II Ovarian Epithelial Cancer","Stage III Malignant Testicular Germ Cell Tumor","Stage III Ovarian Epithelial Cancer","Stage IIIA Breast Cancer","Stage IIIC Breast Cancer","Stage IV Ovarian Epithelial Cancer",[7896],{"trials":7927,"activeCount":102},[],{"trials":7929,"activeCount":102},[],{"trials":7931,"activeCount":102},[],{"intervention":7933,"totalTrials":135,"cells":7934},"Tositumomab and Iodine I 131 Tositumomab",{"EARLY_PHASE1":7935,"PHASE1":7937,"PHASE2":7939,"PHASE3":7948,"PHASE4":7950,"NA":7952},{"trials":7936,"activeCount":102},[],{"trials":7938,"activeCount":102},[],{"trials":7940,"activeCount":102},[7941],{"nctId":7942,"briefTitle":7943,"status":226,"phases":7944,"primaryCompletion":2116,"completion":2116,"start":1424,"enrollment":1510,"conditions":7945,"interventions":7947},"NCT00476047","Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission",[91],[7946,1201,1203,1022,1029,1034,1040],"Lymphoid Leukemia in Remission",[7933],{"trials":7949,"activeCount":102},[],{"trials":7951,"activeCount":102},[],{"trials":7953,"activeCount":102},[],{"intervention":7955,"totalTrials":135,"cells":7956},"Interferon Beta-1A",{"EARLY_PHASE1":7957,"PHASE1":7959,"PHASE2":7961,"PHASE3":7970,"PHASE4":7972,"NA":7974},{"trials":7958,"activeCount":102},[],{"trials":7960,"activeCount":102},[],{"trials":7962,"activeCount":102},[7963],{"nctId":7964,"briefTitle":7965,"status":343,"phases":7966,"primaryCompletion":7967,"completion":7967,"start":1551,"enrollment":102,"conditions":7968,"interventions":7969},"NCT05936229","Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy",[90,91],"2027-10-30",[257,247,260,251,24,1309],[7955],{"trials":7971,"activeCount":102},[],{"trials":7973,"activeCount":102},[],{"trials":7975,"activeCount":102},[],{"intervention":4443,"totalTrials":135,"cells":7977},{"EARLY_PHASE1":7978,"PHASE1":7980,"PHASE2":7982,"PHASE3":7988,"PHASE4":7990,"NA":7992},{"trials":7979,"activeCount":102},[],{"trials":7981,"activeCount":102},[],{"trials":7983,"activeCount":102},[7984],{"nctId":4435,"briefTitle":4436,"status":226,"phases":7985,"primaryCompletion":829,"completion":4438,"start":4439,"enrollment":463,"conditions":7986,"interventions":7987},[91],[516],[4442,692,374,4443,1546,505],{"trials":7989,"activeCount":102},[],{"trials":7991,"activeCount":102},[],{"trials":7993,"activeCount":102},[],{"intervention":7995,"totalTrials":135,"cells":7996},"Ibrutinib",{"EARLY_PHASE1":7997,"PHASE1":7999,"PHASE2":8001,"PHASE3":8012,"PHASE4":8014,"NA":8016},{"trials":7998,"activeCount":102},[],{"trials":8000,"activeCount":102},[],{"trials":8002,"activeCount":102},[8003],{"nctId":8004,"briefTitle":8005,"status":343,"phases":8006,"primaryCompletion":8007,"start":8008,"enrollment":102,"conditions":8009,"interventions":8010},"NCT02662296","Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant",[91],"2022-02","2016-03",[537,1148,1284,21],[7995,8011],"Idelalisib",{"trials":8013,"activeCount":102},[],{"trials":8015,"activeCount":102},[],{"trials":8017,"activeCount":102},[],{"intervention":8011,"totalTrials":135,"cells":8019},{"EARLY_PHASE1":8020,"PHASE1":8022,"PHASE2":8024,"PHASE3":8030,"PHASE4":8032,"NA":8034},{"trials":8021,"activeCount":102},[],{"trials":8023,"activeCount":102},[],{"trials":8025,"activeCount":102},[8026],{"nctId":8004,"briefTitle":8005,"status":343,"phases":8027,"primaryCompletion":8007,"start":8008,"enrollment":102,"conditions":8028,"interventions":8029},[91],[537,1148,1284,21],[7995,8011],{"trials":8031,"activeCount":102},[],{"trials":8033,"activeCount":102},[],{"trials":8035,"activeCount":102},[],{"intervention":8037,"totalTrials":135,"cells":8038},"Deferasirox",{"EARLY_PHASE1":8039,"PHASE1":8041,"PHASE2":8043,"PHASE3":8054,"PHASE4":8056,"NA":8058},{"trials":8040,"activeCount":102},[],{"trials":8042,"activeCount":102},[],{"trials":8044,"activeCount":102},[8045],{"nctId":8046,"briefTitle":8047,"status":114,"phases":8048,"primaryCompletion":8049,"completion":8049,"start":8050,"enrollment":98,"conditions":8051,"interventions":8053},"NCT02943668","Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome",[91],"2018-12-17","2017-03-02",[8052,389],"Anemia",[8037],{"trials":8055,"activeCount":102},[],{"trials":8057,"activeCount":102},[],{"trials":8059,"activeCount":102},[],{"intervention":8061,"totalTrials":135,"cells":8062},"Immunosuppressive Therapy",{"EARLY_PHASE1":8063,"PHASE1":8065,"PHASE2":8067,"PHASE3":8077,"PHASE4":8079,"NA":8081},{"trials":8064,"activeCount":102},[],{"trials":8066,"activeCount":102},[],{"trials":8068,"activeCount":102},[8069],{"nctId":8070,"briefTitle":8071,"status":226,"phases":8072,"primaryCompletion":8073,"completion":8074,"start":747,"enrollment":1053,"conditions":8075,"interventions":8076},"NCT03483675","Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease",[91],"2020-05-14","2021-03-03",[5362],[8061,8061],{"trials":8078,"activeCount":102},[],{"trials":8080,"activeCount":102},[],{"trials":8082,"activeCount":102},[],{"intervention":8084,"totalTrials":135,"cells":8085},"Visilizumab",{"EARLY_PHASE1":8086,"PHASE1":8088,"PHASE2":8090,"PHASE3":8100,"PHASE4":8102,"NA":8104},{"trials":8087,"activeCount":102},[],{"trials":8089,"activeCount":102},[],{"trials":8091,"activeCount":102},[8092],{"nctId":8093,"briefTitle":8094,"status":1090,"phases":8095,"start":8096,"enrollment":2337,"conditions":8097,"interventions":8099},"NCT00032279","Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease",[91],"2002-03",[8098],"Graft-vs-Host Disease",[8084],{"trials":8101,"activeCount":102},[],{"trials":8103,"activeCount":102},[],{"trials":8105,"activeCount":102},[],{"intervention":8107,"totalTrials":135,"cells":8108},"Glasdegib",{"EARLY_PHASE1":8109,"PHASE1":8111,"PHASE2":8113,"PHASE3":8124,"PHASE4":8126,"NA":8128},{"trials":8110,"activeCount":102},[],{"trials":8112,"activeCount":102},[],{"trials":8114,"activeCount":102},[8115],{"nctId":8116,"briefTitle":8117,"status":114,"phases":8118,"primaryCompletion":8119,"completion":8119,"start":8120,"enrollment":944,"conditions":8121,"interventions":8123},"NCT04111497","Glasdegib for Chronic Graft-Versus-Host Disease",[90,91],"2023-08-23","2019-12-03",[5362,8122],"Fasciitis",[8107],{"trials":8125,"activeCount":102},[],{"trials":8127,"activeCount":102},[],{"trials":8129,"activeCount":102},[],{"intervention":8131,"totalTrials":135,"cells":8132},"allogeneic cytomegalovirus-specific cytotoxic T lymphocytes",{"EARLY_PHASE1":8133,"PHASE1":8135,"PHASE2":8137,"PHASE3":8148,"PHASE4":8150,"NA":8152},{"trials":8134,"activeCount":102},[],{"trials":8136,"activeCount":102},[],{"trials":8138,"activeCount":102},[8139],{"nctId":8140,"briefTitle":8141,"status":226,"phases":8142,"primaryCompletion":8143,"completion":773,"start":1588,"enrollment":135,"conditions":8144,"interventions":8147},"NCT01475058","CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant",[90,91],"2014-04",[8145,8146,246,500,902,24,27],"Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia","Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia",[8131],{"trials":8149,"activeCount":102},[],{"trials":8151,"activeCount":102},[],{"trials":8153,"activeCount":102},[],{"intervention":3338,"totalTrials":135,"cells":8155},{"EARLY_PHASE1":8156,"PHASE1":8158,"PHASE2":8160,"PHASE3":8166,"PHASE4":8168,"NA":8170},{"trials":8157,"activeCount":102},[],{"trials":8159,"activeCount":102},[],{"trials":8161,"activeCount":102},[8162],{"nctId":3333,"briefTitle":3334,"status":226,"phases":8163,"primaryCompletion":1431,"completion":1431,"start":1051,"enrollment":30,"conditions":8164,"interventions":8165},[91],[1450,29,870,871,890,898,453,910,1638],[3338,2194,3314],{"trials":8167,"activeCount":102},[],{"trials":8169,"activeCount":102},[],{"trials":8171,"activeCount":102},[],{"intervention":8173,"totalTrials":135,"cells":8174},"Platelet Transfusion",{"EARLY_PHASE1":8175,"PHASE1":8177,"PHASE2":8179,"PHASE3":8192,"PHASE4":8194,"NA":8196},{"trials":8176,"activeCount":102},[],{"trials":8178,"activeCount":102},[],{"trials":8180,"activeCount":102},[8181],{"nctId":8182,"briefTitle":8183,"status":114,"phases":8184,"primaryCompletion":8185,"completion":8185,"start":8186,"enrollment":3454,"conditions":8187,"interventions":8191},"NCT03195010","Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia",[91],"2018-12-21","2017-06-09",[403,404,387,3323,529,405,1152,8188,389,488,489,1473,8189,8190],"Hematopoietic Cell Transplantation Recipient","Thrombocytopenia","Venous Thromboembolism",[8173,8173],{"trials":8193,"activeCount":102},[],{"trials":8195,"activeCount":102},[],{"trials":8197,"activeCount":102},[],{"intervention":8199,"totalTrials":135,"cells":8200},"High Sulforaphane Extract",{"EARLY_PHASE1":8201,"PHASE1":8203,"PHASE2":8205,"PHASE3":8216,"PHASE4":8218,"NA":8220},{"trials":8202,"activeCount":102},[],{"trials":8204,"activeCount":102},[],{"trials":8206,"activeCount":102},[8207],{"nctId":8208,"briefTitle":8209,"status":226,"phases":8210,"primaryCompletion":6304,"completion":8211,"start":973,"enrollment":3514,"conditions":8212,"interventions":8214},"NCT00946309","Effects of Sulforaphane on Normal Prostate Tissue",[90,91],"2015-05",[8213],"Prostate Cancer",[8199,8215],"Microcrystalline Cellulose NF",{"trials":8217,"activeCount":102},[],{"trials":8219,"activeCount":102},[],{"trials":8221,"activeCount":102},[],{"intervention":8215,"totalTrials":135,"cells":8223},{"EARLY_PHASE1":8224,"PHASE1":8226,"PHASE2":8228,"PHASE3":8234,"PHASE4":8236,"NA":8238},{"trials":8225,"activeCount":102},[],{"trials":8227,"activeCount":102},[],{"trials":8229,"activeCount":102},[8230],{"nctId":8208,"briefTitle":8209,"status":226,"phases":8231,"primaryCompletion":6304,"completion":8211,"start":973,"enrollment":3514,"conditions":8232,"interventions":8233},[90,91],[8213],[8199,8215],{"trials":8235,"activeCount":102},[],{"trials":8237,"activeCount":102},[],{"trials":8239,"activeCount":102},[],{"intervention":7205,"totalTrials":135,"cells":8241},{"EARLY_PHASE1":8242,"PHASE1":8244,"PHASE2":8246,"PHASE3":8252,"PHASE4":8254,"NA":8256},{"trials":8243,"activeCount":102},[],{"trials":8245,"activeCount":102},[],{"trials":8247,"activeCount":102},[8248],{"nctId":7200,"briefTitle":7201,"status":226,"phases":8249,"completion":1999,"start":1742,"enrollment":2049,"conditions":8250,"interventions":8251},[90,91],[15,798,799],[5006,7205],{"trials":8253,"activeCount":102},[],{"trials":8255,"activeCount":102},[],{"trials":8257,"activeCount":102},[],{"intervention":4175,"totalTrials":135,"cells":8259},{"EARLY_PHASE1":8260,"PHASE1":8262,"PHASE2":8264,"PHASE3":8270,"PHASE4":8272,"NA":8274},{"trials":8261,"activeCount":102},[],{"trials":8263,"activeCount":102},[],{"trials":8265,"activeCount":102},[8266],{"nctId":4168,"briefTitle":4169,"status":226,"phases":8267,"primaryCompletion":4171,"completion":4171,"start":1870,"enrollment":4172,"conditions":8268,"interventions":8269},[90,91],[29,870,35,871,32,872,890,1592,1638],[4175,3288],{"trials":8271,"activeCount":102},[],{"trials":8273,"activeCount":102},[],{"trials":8275,"activeCount":102},[],{"intervention":8277,"totalTrials":135,"cells":8278},"Anakinra",{"EARLY_PHASE1":8279,"PHASE1":8281,"PHASE2":8283,"PHASE3":8294,"PHASE4":8296,"NA":8298},{"trials":8280,"activeCount":102},[],{"trials":8282,"activeCount":102},[],{"trials":8284,"activeCount":102},[8285],{"nctId":8286,"briefTitle":8287,"status":226,"phases":8288,"primaryCompletion":8289,"completion":8290,"start":8291,"enrollment":317,"conditions":8292,"interventions":8293},"NCT04359784","Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy",[91],"2024-10-01","2024-12-23","2021-12-27",[3323],[8277],{"trials":8295,"activeCount":102},[],{"trials":8297,"activeCount":102},[],{"trials":8299,"activeCount":102},[],{"intervention":1938,"totalTrials":135,"cells":8301},{"EARLY_PHASE1":8302,"PHASE1":8304,"PHASE2":8306,"PHASE3":8312,"PHASE4":8314,"NA":8316},{"trials":8303,"activeCount":102},[],{"trials":8305,"activeCount":102},[],{"trials":8307,"activeCount":102},[8308],{"nctId":1926,"briefTitle":1927,"status":226,"phases":8309,"primaryCompletion":773,"completion":1929,"start":1930,"enrollment":231,"conditions":8310,"interventions":8311},[91],[733,1932,1933,874,1934,405,1935,246,1116,1936],[82,1938,504,1939,376,1940,1941],{"trials":8313,"activeCount":102},[],{"trials":8315,"activeCount":102},[],{"trials":8317,"activeCount":102},[],{"intervention":8319,"totalTrials":135,"cells":8320},"Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]",{"EARLY_PHASE1":8321,"PHASE1":8323,"PHASE2":8325,"PHASE3":8336,"PHASE4":8338,"NA":8340},{"trials":8322,"activeCount":102},[],{"trials":8324,"activeCount":102},[],{"trials":8326,"activeCount":102},[8327],{"nctId":8328,"briefTitle":8329,"status":226,"phases":8330,"primaryCompletion":8331,"completion":8331,"start":8332,"enrollment":463,"conditions":8333,"interventions":8335},"NCT01523821","Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD)",[90,91],"2017-01-15","2013-10-11",[8334],"Graft-Versus-Host Disease (GVHD) Acute on Chronic",[8319],{"trials":8337,"activeCount":102},[],{"trials":8339,"activeCount":102},[],{"trials":8341,"activeCount":102},[],{"intervention":6394,"totalTrials":135,"cells":8343},{"EARLY_PHASE1":8344,"PHASE1":8346,"PHASE2":8348,"PHASE3":8354,"PHASE4":8356,"NA":8358},{"trials":8345,"activeCount":102},[],{"trials":8347,"activeCount":102},[],{"trials":8349,"activeCount":102},[8350],{"nctId":6385,"briefTitle":6386,"status":226,"phases":8351,"primaryCompletion":1298,"start":1742,"conditions":8352,"interventions":8353},[90,91],[6389,3494,6390],[6392,1606,6393,6394],{"trials":8355,"activeCount":102},[],{"trials":8357,"activeCount":102},[],{"trials":8359,"activeCount":102},[],{"intervention":1986,"totalTrials":135,"cells":8361},{"EARLY_PHASE1":8362,"PHASE1":8364,"PHASE2":8366,"PHASE3":8372,"PHASE4":8374,"NA":8376},{"trials":8363,"activeCount":102},[],{"trials":8365,"activeCount":102},[],{"trials":8367,"activeCount":102},[8368],{"nctId":1977,"briefTitle":1978,"status":226,"phases":8369,"primaryCompletion":1980,"start":1981,"enrollment":1053,"conditions":8370,"interventions":8371},[90,91],[429,873,558,1001,876,878,1754,879,880,881,465,1002,890,710,1004,1005,1757,439,1593,1983,711,1114,1006,1007,898,1984,246,18,899,500,900,1008,901,1009,902,903,1010,1116,298,904,905,906,907,1011,1012,712,713,908,24,714,1013,1758,21,1014,27,1759,700,1016,715,1017,1027,1775,1041,716],[937,479,481,1986],{"trials":8373,"activeCount":102},[],{"trials":8375,"activeCount":102},[],{"trials":8377,"activeCount":102},[],{"intervention":7320,"totalTrials":135,"cells":8379},{"EARLY_PHASE1":8380,"PHASE1":8382,"PHASE2":8384,"PHASE3":8390,"PHASE4":8392,"NA":8394},{"trials":8381,"activeCount":102},[],{"trials":8383,"activeCount":102},[],{"trials":8385,"activeCount":102},[8386],{"nctId":7312,"briefTitle":7313,"status":114,"phases":8387,"primaryCompletion":7315,"completion":7315,"start":7316,"enrollment":3311,"conditions":8388,"interventions":8389},[90,91],[7318],[7320,7291,7321,7322],{"trials":8391,"activeCount":102},[],{"trials":8393,"activeCount":102},[],{"trials":8395,"activeCount":102},[],{"intervention":7322,"totalTrials":135,"cells":8397},{"EARLY_PHASE1":8398,"PHASE1":8400,"PHASE2":8402,"PHASE3":8408,"PHASE4":8410,"NA":8412},{"trials":8399,"activeCount":102},[],{"trials":8401,"activeCount":102},[],{"trials":8403,"activeCount":102},[8404],{"nctId":7312,"briefTitle":7313,"status":114,"phases":8405,"primaryCompletion":7315,"completion":7315,"start":7316,"enrollment":3311,"conditions":8406,"interventions":8407},[90,91],[7318],[7320,7291,7321,7322],{"trials":8409,"activeCount":102},[],{"trials":8411,"activeCount":102},[],{"trials":8413,"activeCount":102},[],{"intervention":4467,"totalTrials":135,"cells":8415},{"EARLY_PHASE1":8416,"PHASE1":8418,"PHASE2":8420,"PHASE3":8426,"PHASE4":8428,"NA":8430},{"trials":8417,"activeCount":102},[],{"trials":8419,"activeCount":102},[],{"trials":8421,"activeCount":102},[8422],{"nctId":4457,"briefTitle":4458,"status":114,"phases":8423,"primaryCompletion":4460,"completion":4461,"start":4462,"enrollment":296,"conditions":8424,"interventions":8425},[90,91],[4464,4465],[1290,374,4407,1546,4467],{"trials":8427,"activeCount":102},[],{"trials":8429,"activeCount":102},[],{"trials":8431,"activeCount":102},[],{"intervention":8433,"totalTrials":135,"cells":8434},"Carfilzomib",{"EARLY_PHASE1":8435,"PHASE1":8437,"PHASE2":8439,"PHASE3":8450,"PHASE4":8452,"NA":8454},{"trials":8436,"activeCount":102},[],{"trials":8438,"activeCount":102},[],{"trials":8440,"activeCount":102},[8441],{"nctId":8442,"briefTitle":8443,"status":226,"phases":8444,"primaryCompletion":8445,"completion":8446,"start":8447,"enrollment":463,"conditions":8448,"interventions":8449},"NCT02491359","Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease",[91],"2018-02-19","2018-09-12","2015-11-12",[5362],[8433],{"trials":8451,"activeCount":102},[],{"trials":8453,"activeCount":102},[],{"trials":8455,"activeCount":102},[],{"intervention":8457,"totalTrials":135,"cells":8458},"tocilizumab",{"EARLY_PHASE1":8459,"PHASE1":8461,"PHASE2":8463,"PHASE3":8472,"PHASE4":8474,"NA":8476},{"trials":8460,"activeCount":102},[],{"trials":8462,"activeCount":102},[],{"trials":8464,"activeCount":102},[8465],{"nctId":8466,"briefTitle":8467,"status":343,"phases":8468,"primaryCompletion":8469,"start":7571,"enrollment":102,"conditions":8470,"interventions":8471},"NCT02174263","Tocilizumab for Chronic Graft-versus-Host Disease Treatment",[91],"2019-08",[1137],[8457],{"trials":8473,"activeCount":102},[],{"trials":8475,"activeCount":102},[],{"trials":8477,"activeCount":102},[],{"intervention":7693,"totalTrials":135,"cells":8479},{"EARLY_PHASE1":8480,"PHASE1":8482,"PHASE2":8484,"PHASE3":8490,"PHASE4":8492,"NA":8494},{"trials":8481,"activeCount":102},[],{"trials":8483,"activeCount":102},[],{"trials":8485,"activeCount":102},[8486],{"nctId":7688,"briefTitle":7689,"status":226,"phases":8487,"primaryCompletion":983,"start":1991,"conditions":8488,"interventions":8489},[91],[6389,3494,6390],[5096,7693],{"trials":8491,"activeCount":102},[],{"trials":8493,"activeCount":102},[],{"trials":8495,"activeCount":102},[],{"intervention":8497,"totalTrials":135,"cells":8498},"brentuximab vedotin",{"EARLY_PHASE1":8499,"PHASE1":8501,"PHASE2":8503,"PHASE3":8511,"PHASE4":8513,"NA":8515},{"trials":8500,"activeCount":102},[],{"trials":8502,"activeCount":102},[],{"trials":8504,"activeCount":102},[8505],{"nctId":8506,"briefTitle":8507,"status":343,"phases":8508,"primaryCompletion":8143,"start":1431,"enrollment":102,"conditions":8509,"interventions":8510},"NCT01620229","Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies",[90,91],[1003],[8497],{"trials":8512,"activeCount":102},[],{"trials":8514,"activeCount":102},[],{"trials":8516,"activeCount":102},[],{"intervention":1366,"totalTrials":135,"cells":8518},{"EARLY_PHASE1":8519,"PHASE1":8521,"PHASE2":8523,"PHASE3":8529,"PHASE4":8531,"NA":8533},{"trials":8520,"activeCount":102},[],{"trials":8522,"activeCount":102},[],{"trials":8524,"activeCount":102},[8525],{"nctId":1355,"briefTitle":1356,"status":114,"phases":8526,"primaryCompletion":1358,"completion":1358,"start":1359,"enrollment":1360,"conditions":8527,"interventions":8528},[90,91],[18,298,453,1362,1363,1364,1065,362],[1076,57,504,1366],{"trials":8530,"activeCount":102},[],{"trials":8532,"activeCount":102},[],{"trials":8534,"activeCount":102},[],{"intervention":2609,"totalTrials":135,"cells":8536},{"EARLY_PHASE1":8537,"PHASE1":8539,"PHASE2":8541,"PHASE3":8547,"PHASE4":8549,"NA":8551},{"trials":8538,"activeCount":102},[],{"trials":8540,"activeCount":102},[],{"trials":8542,"activeCount":102},[8543],{"nctId":2602,"briefTitle":2603,"status":226,"phases":8544,"primaryCompletion":1404,"completion":1404,"start":2605,"conditions":8545,"interventions":8546},[90,91],[15],[719,674,1812,2194,948,937,811,2608,2609],{"trials":8548,"activeCount":102},[],{"trials":8550,"activeCount":102},[],{"trials":8552,"activeCount":102},[],{"intervention":4486,"totalTrials":135,"cells":8554},{"EARLY_PHASE1":8555,"PHASE1":8557,"PHASE2":8559,"PHASE3":8565,"PHASE4":8567,"NA":8569},{"trials":8556,"activeCount":102},[],{"trials":8558,"activeCount":102},[],{"trials":8560,"activeCount":102},[8561],{"nctId":4477,"briefTitle":4478,"status":226,"phases":8562,"primaryCompletion":2010,"completion":2010,"start":4120,"conditions":8563,"interventions":8564},[91],[1604,4481,4482,797,4483,3494,3503,4484],[674,4486],{"trials":8566,"activeCount":102},[],{"trials":8568,"activeCount":102},[],{"trials":8570,"activeCount":102},[],{"intervention":579,"totalTrials":135,"cells":8572},{"EARLY_PHASE1":8573,"PHASE1":8575,"PHASE2":8577,"PHASE3":8583,"PHASE4":8585,"NA":8587},{"trials":8574,"activeCount":102},[],{"trials":8576,"activeCount":102},[],{"trials":8578,"activeCount":102},[8579],{"nctId":566,"briefTitle":567,"status":114,"phases":8580,"primaryCompletion":569,"completion":570,"start":571,"enrollment":135,"conditions":8581,"interventions":8582},[90,91],[573,574,219,575,576,577],[579,57,204,580,581],{"trials":8584,"activeCount":102},[],{"trials":8586,"activeCount":102},[],{"trials":8588,"activeCount":102},[],{"intervention":580,"totalTrials":135,"cells":8590},{"EARLY_PHASE1":8591,"PHASE1":8593,"PHASE2":8595,"PHASE3":8601,"PHASE4":8603,"NA":8605},{"trials":8592,"activeCount":102},[],{"trials":8594,"activeCount":102},[],{"trials":8596,"activeCount":102},[8597],{"nctId":566,"briefTitle":567,"status":114,"phases":8598,"primaryCompletion":569,"completion":570,"start":571,"enrollment":135,"conditions":8599,"interventions":8600},[90,91],[573,574,219,575,576,577],[579,57,204,580,581],{"trials":8602,"activeCount":102},[],{"trials":8604,"activeCount":102},[],{"trials":8606,"activeCount":102},[],{"intervention":581,"totalTrials":135,"cells":8608},{"EARLY_PHASE1":8609,"PHASE1":8611,"PHASE2":8613,"PHASE3":8619,"PHASE4":8621,"NA":8623},{"trials":8610,"activeCount":102},[],{"trials":8612,"activeCount":102},[],{"trials":8614,"activeCount":102},[8615],{"nctId":566,"briefTitle":567,"status":114,"phases":8616,"primaryCompletion":569,"completion":570,"start":571,"enrollment":135,"conditions":8617,"interventions":8618},[90,91],[573,574,219,575,576,577],[579,57,204,580,581],{"trials":8620,"activeCount":102},[],{"trials":8622,"activeCount":102},[],{"trials":8624,"activeCount":102},[],{"intervention":8626,"totalTrials":135,"cells":8627},"monoclonal antibody CD19",{"EARLY_PHASE1":8628,"PHASE1":8630,"PHASE2":8632,"PHASE3":8641,"PHASE4":8643,"NA":8645},{"trials":8629,"activeCount":102},[],{"trials":8631,"activeCount":102},[],{"trials":8633,"activeCount":102},[8634],{"nctId":8635,"briefTitle":8636,"status":226,"phases":8637,"completion":1612,"start":1371,"conditions":8638,"interventions":8639},"NCT00003874","Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia",[90,91],[15,797],[8626,8640],"monoclonal antibody CD20",{"trials":8642,"activeCount":102},[],{"trials":8644,"activeCount":102},[],{"trials":8646,"activeCount":102},[],{"intervention":8640,"totalTrials":135,"cells":8648},{"EARLY_PHASE1":8649,"PHASE1":8651,"PHASE2":8653,"PHASE3":8659,"PHASE4":8661,"NA":8663},{"trials":8650,"activeCount":102},[],{"trials":8652,"activeCount":102},[],{"trials":8654,"activeCount":102},[8655],{"nctId":8635,"briefTitle":8636,"status":226,"phases":8656,"completion":1612,"start":1371,"conditions":8657,"interventions":8658},[90,91],[15,797],[8626,8640],{"trials":8660,"activeCount":102},[],{"trials":8662,"activeCount":102},[],{"trials":8664,"activeCount":102},[],{"intervention":8666,"totalTrials":135,"cells":8667},"Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes",{"EARLY_PHASE1":8668,"PHASE1":8670,"PHASE2":8672,"PHASE3":8684,"PHASE4":8686,"NA":8688},{"trials":8669,"activeCount":102},[],{"trials":8671,"activeCount":102},[],{"trials":8673,"activeCount":102},[8674],{"nctId":8675,"briefTitle":8676,"status":226,"phases":8677,"primaryCompletion":8678,"completion":8678,"start":8679,"enrollment":8680,"conditions":8681,"interventions":8683},"NCT01865617","Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia",[90,91],"2021-03-26","2013-05-22",204,[8682,246,1148,248,24,1284,21,1534,27,252,1309,1286,563],"CD19-Positive Neoplastic Cells Present",[8666],{"trials":8685,"activeCount":102},[],{"trials":8687,"activeCount":102},[],{"trials":8689,"activeCount":102},[],{"intervention":8691,"totalTrials":135,"cells":8692},"peripheral blood lymphocyte therapy",{"EARLY_PHASE1":8693,"PHASE1":8695,"PHASE2":8697,"PHASE3":8707,"PHASE4":8709,"NA":8711},{"trials":8694,"activeCount":102},[],{"trials":8696,"activeCount":102},[],{"trials":8698,"activeCount":102},[8699],{"nctId":8700,"briefTitle":8701,"status":226,"phases":8702,"completion":8703,"start":8704,"conditions":8705,"interventions":8706},"NCT00003887","Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation",[91],"2003-02","1998-08",[1604,1126,4481,4482,15,797,1096,798,4483,3494,3503,4484],[8691],{"trials":8708,"activeCount":102},[],{"trials":8710,"activeCount":102},[],{"trials":8712,"activeCount":102},[],{"intervention":6467,"totalTrials":135,"cells":8714},{"EARLY_PHASE1":8715,"PHASE1":8717,"PHASE2":8719,"PHASE3":8725,"PHASE4":8727,"NA":8729},{"trials":8716,"activeCount":102},[],{"trials":8718,"activeCount":102},[],{"trials":8720,"activeCount":102},[8721],{"nctId":6462,"briefTitle":6463,"status":226,"phases":8722,"primaryCompletion":2425,"completion":2425,"start":954,"enrollment":555,"conditions":8723,"interventions":8724},[91],[1604],[6467,959],{"trials":8726,"activeCount":102},[],{"trials":8728,"activeCount":102},[],{"trials":8730,"activeCount":102},[],{"intervention":8732,"totalTrials":135,"cells":8733},"BCG Solution",{"EARLY_PHASE1":8734,"PHASE1":8736,"PHASE2":8738,"PHASE3":8754,"PHASE4":8756,"NA":8758},{"trials":8735,"activeCount":102},[],{"trials":8737,"activeCount":102},[],{"trials":8739,"activeCount":102},[8740],{"nctId":8741,"briefTitle":8742,"status":226,"phases":8743,"primaryCompletion":570,"completion":8744,"start":8745,"enrollment":3514,"conditions":8746,"interventions":8753},"NCT04496219","Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer",[91],"2022-08-23","2021-01-22",[8747,8748,8749,8750,8751,8752],"Bladder Urothelial Carcinoma In Situ","Recurrent Bladder Urothelial Carcinoma","Stage 0a Bladder Cancer AJCC v8","Stage 0is Bladder Cancer AJCC v8","Stage I Bladder Cancer AJCC v8","Superficial Bladder Urothelial Carcinoma",[8732],{"trials":8755,"activeCount":102},[],{"trials":8757,"activeCount":102},[],{"trials":8759,"activeCount":102},[],{"intervention":3413,"totalTrials":135,"cells":8761},{"EARLY_PHASE1":8762,"PHASE1":8764,"PHASE2":8766,"PHASE3":8772,"PHASE4":8774,"NA":8776},{"trials":8763,"activeCount":102},[],{"trials":8765,"activeCount":102},[],{"trials":8767,"activeCount":102},[8768],{"nctId":3406,"briefTitle":3407,"status":226,"phases":8769,"primaryCompletion":3409,"completion":3409,"start":3410,"enrollment":282,"conditions":8770,"interventions":8771},[91],[15],[674,2194,948,3413,2608],{"trials":8773,"activeCount":102},[],{"trials":8775,"activeCount":102},[],{"trials":8777,"activeCount":102},[],{"intervention":8779,"totalTrials":135,"cells":8780},"TCAD",{"EARLY_PHASE1":8781,"PHASE1":8783,"PHASE2":8785,"PHASE3":8797,"PHASE4":8799,"NA":8801},{"trials":8782,"activeCount":102},[],{"trials":8784,"activeCount":102},[],{"trials":8786,"activeCount":102},[8787],{"nctId":8788,"briefTitle":8789,"status":226,"phases":8790,"primaryCompletion":3254,"completion":8791,"start":8792,"enrollment":3311,"conditions":8793,"interventions":8795},"NCT00867139","TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients",[90,91],"2010-01","2009-03",[8794],"Influenza",[8779,8796],"Zanamivir or Oseltamivir",{"trials":8798,"activeCount":102},[],{"trials":8800,"activeCount":102},[],{"trials":8802,"activeCount":102},[],{"intervention":8796,"totalTrials":135,"cells":8804},{"EARLY_PHASE1":8805,"PHASE1":8807,"PHASE2":8809,"PHASE3":8815,"PHASE4":8817,"NA":8819},{"trials":8806,"activeCount":102},[],{"trials":8808,"activeCount":102},[],{"trials":8810,"activeCount":102},[8811],{"nctId":8788,"briefTitle":8789,"status":226,"phases":8812,"primaryCompletion":3254,"completion":8791,"start":8792,"enrollment":3311,"conditions":8813,"interventions":8814},[90,91],[8794],[8779,8796],{"trials":8816,"activeCount":102},[],{"trials":8818,"activeCount":102},[],{"trials":8820,"activeCount":102},[],{"intervention":8822,"totalTrials":135,"cells":8823},"Glycosylated Recombinant Human Interleukin-7",{"EARLY_PHASE1":8824,"PHASE1":8826,"PHASE2":8828,"PHASE3":8842,"PHASE4":8844,"NA":8846},{"trials":8825,"activeCount":102},[],{"trials":8827,"activeCount":102},[],{"trials":8829,"activeCount":102},[8830],{"nctId":8831,"briefTitle":8832,"status":226,"phases":8833,"primaryCompletion":8834,"completion":8835,"start":8836,"enrollment":1350,"conditions":8837,"interventions":8841},"NCT01881867","CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer",[91],"2017-05-15","2018-01-02","2013-09-10",[8838,630,8839,8840],"Castration Levels of Testosterone","Metastatic Prostate Carcinoma","Stage IV Prostate Cancer",[8822],{"trials":8843,"activeCount":102},[],{"trials":8845,"activeCount":102},[],{"trials":8847,"activeCount":102},[],{"intervention":2120,"totalTrials":135,"cells":8849},{"EARLY_PHASE1":8850,"PHASE1":8852,"PHASE2":8854,"PHASE3":8860,"PHASE4":8862,"NA":8864},{"trials":8851,"activeCount":102},[],{"trials":8853,"activeCount":102},[],{"trials":8855,"activeCount":102},[8856],{"nctId":2113,"briefTitle":2114,"status":226,"phases":8857,"primaryCompletion":2116,"completion":2117,"start":2075,"enrollment":22,"conditions":8858,"interventions":8859},[91],[404,387,529,405,1137,560,390,516,536,1234],[82,376,2120,1941],{"trials":8861,"activeCount":102},[],{"trials":8863,"activeCount":102},[],{"trials":8865,"activeCount":102},[],{"intervention":8867,"totalTrials":135,"cells":8868},"Epacadostat",{"EARLY_PHASE1":8869,"PHASE1":8871,"PHASE2":8873,"PHASE3":8895,"PHASE4":8897,"NA":8899},{"trials":8870,"activeCount":102},[],{"trials":8872,"activeCount":102},[],{"trials":8874,"activeCount":102},[8875],{"nctId":8876,"briefTitle":8877,"status":226,"phases":8878,"primaryCompletion":8879,"completion":8880,"start":8881,"enrollment":1062,"conditions":8882,"interventions":8893},"NCT01961115","Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma",[91],"2016-10-31","2017-05-18","2013-09-13",[8883,850,8884,8885,8886,8887,8888,8889,8890,8891,8892],"Mucosal Melanoma","Recurrent Uveal Melanoma","Stage IIIA Skin Melanoma","Stage IIIA Uveal Melanoma","Stage IIIB Skin Melanoma","Stage IIIB Uveal Melanoma","Stage IIIC Skin Melanoma","Stage IIIC Uveal Melanoma","Stage IV Skin Melanoma","Stage IV Uveal Melanoma",[8867,8894],"MELITAC 12.1 Peptide Vaccine",{"trials":8896,"activeCount":102},[],{"trials":8898,"activeCount":102},[],{"trials":8900,"activeCount":102},[],{"intervention":8894,"totalTrials":135,"cells":8902},{"EARLY_PHASE1":8903,"PHASE1":8905,"PHASE2":8907,"PHASE3":8913,"PHASE4":8915,"NA":8917},{"trials":8904,"activeCount":102},[],{"trials":8906,"activeCount":102},[],{"trials":8908,"activeCount":102},[8909],{"nctId":8876,"briefTitle":8877,"status":226,"phases":8910,"primaryCompletion":8879,"completion":8880,"start":8881,"enrollment":1062,"conditions":8911,"interventions":8912},[91],[8883,850,8884,8885,8886,8887,8888,8889,8890,8891,8892],[8867,8894],{"trials":8914,"activeCount":102},[],{"trials":8916,"activeCount":102},[],{"trials":8918,"activeCount":102},[],{"intervention":6947,"totalTrials":135,"cells":8920},{"EARLY_PHASE1":8921,"PHASE1":8923,"PHASE2":8925,"PHASE3":8931,"PHASE4":8933,"NA":8935},{"trials":8922,"activeCount":102},[],{"trials":8924,"activeCount":102},[],{"trials":8926,"activeCount":102},[8927],{"nctId":6941,"briefTitle":6942,"status":114,"phases":8928,"primaryCompletion":4548,"completion":4548,"start":1740,"enrollment":2616,"conditions":8929,"interventions":8930},[90,91],[850,6945,823],[718,719,6947,720],{"trials":8932,"activeCount":102},[],{"trials":8934,"activeCount":102},[],{"trials":8936,"activeCount":102},[],{"intervention":8938,"totalTrials":135,"cells":8939},"Mycophenolate Mofetil 500Mg Tab",{"EARLY_PHASE1":8940,"PHASE1":8942,"PHASE2":8944,"PHASE3":8955,"PHASE4":8957,"NA":8959},{"trials":8941,"activeCount":102},[],{"trials":8943,"activeCount":102},[],{"trials":8945,"activeCount":102},[8946],{"nctId":8947,"briefTitle":8948,"status":226,"phases":8949,"primaryCompletion":8950,"completion":8950,"start":8951,"enrollment":2308,"conditions":8952,"interventions":8954},"NCT03262441","MMF for HIV Reservoir Reduction",[91],"2019-08-31","2018-02-12",[8953],"Human Immunodeficiency Virus I Infection",[8938],{"trials":8956,"activeCount":102},[],{"trials":8958,"activeCount":102},[],{"trials":8960,"activeCount":102},[],{"intervention":2714,"totalTrials":135,"cells":8962},{"EARLY_PHASE1":8963,"PHASE1":8965,"PHASE2":8967,"PHASE3":8973,"PHASE4":8975,"NA":8977},{"trials":8964,"activeCount":102},[],{"trials":8966,"activeCount":102},[],{"trials":8968,"activeCount":102},[8969],{"nctId":2709,"briefTitle":2710,"status":114,"phases":8970,"primaryCompletion":973,"completion":973,"start":1633,"enrollment":135,"conditions":8971,"interventions":8972},[91],[1137,15,798],[2714,2715,937,811,960,1046],{"trials":8974,"activeCount":102},[],{"trials":8976,"activeCount":102},[],{"trials":8978,"activeCount":102},[],{"intervention":1576,"totalTrials":135,"cells":8980},{"EARLY_PHASE1":8981,"PHASE1":8983,"PHASE2":8985,"PHASE3":8991,"PHASE4":8993,"NA":8995},{"trials":8982,"activeCount":102},[],{"trials":8984,"activeCount":102},[],{"trials":8986,"activeCount":102},[8987],{"nctId":1569,"briefTitle":1570,"status":226,"phases":8988,"primaryCompletion":829,"completion":1572,"start":1573,"enrollment":1084,"conditions":8989,"interventions":8990},[90,91],[850,823],[1576,673,719,720,1577],{"trials":8992,"activeCount":102},[],{"trials":8994,"activeCount":102},[],{"trials":8996,"activeCount":102},[],{"intervention":1577,"totalTrials":135,"cells":8998},{"EARLY_PHASE1":8999,"PHASE1":9001,"PHASE2":9003,"PHASE3":9009,"PHASE4":9011,"NA":9013},{"trials":9000,"activeCount":102},[],{"trials":9002,"activeCount":102},[],{"trials":9004,"activeCount":102},[9005],{"nctId":1569,"briefTitle":1570,"status":226,"phases":9006,"primaryCompletion":829,"completion":1572,"start":1573,"enrollment":1084,"conditions":9007,"interventions":9008},[90,91],[850,823],[1576,673,719,720,1577],{"trials":9010,"activeCount":102},[],{"trials":9012,"activeCount":102},[],{"trials":9014,"activeCount":102},[],{"intervention":781,"totalTrials":98,"cells":9016},{"EARLY_PHASE1":9017,"PHASE1":9019,"PHASE2":9032,"PHASE3":9034,"PHASE4":9036,"NA":9038},{"trials":9018,"activeCount":102},[],{"trials":9020,"activeCount":102},[9021,9025],{"nctId":769,"briefTitle":770,"status":343,"phases":9022,"primaryCompletion":772,"completion":772,"start":773,"enrollment":102,"conditions":9023,"interventions":9024},[90],[775,776,777,778,779],[781,57],{"nctId":9026,"briefTitle":9027,"status":226,"phases":9028,"primaryCompletion":9029,"start":1688,"enrollment":98,"conditions":9030,"interventions":9031},"NCT02319824","NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy",[90],"2015-06",[3503],[781],{"trials":9033,"activeCount":102},[],{"trials":9035,"activeCount":102},[],{"trials":9037,"activeCount":102},[],{"trials":9039,"activeCount":102},[],{"intervention":9041,"totalTrials":98,"cells":9042},"indium In 111 anti-CD45 monoclonal antibody BC8",{"EARLY_PHASE1":9043,"PHASE1":9045,"PHASE2":9059,"PHASE3":9061,"PHASE4":9063,"NA":9065},{"trials":9044,"activeCount":102},[],{"trials":9046,"activeCount":102},[9047,9055],{"nctId":9048,"briefTitle":9049,"status":114,"phases":9050,"primaryCompletion":9051,"completion":2125,"start":9052,"enrollment":98,"conditions":9053,"interventions":9054},"NCT01678443","Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies",[90],"2013-09-21","1999-09-01",[873,558,1001,1002,710,1004,1005,711,1114,1006,899,500,900,1008,901,1009,902,903,1010,1012,712,713,908,24,714,1013,21,1759,1016,715,1775,1041,716],[9041],{"nctId":1708,"briefTitle":1709,"status":226,"phases":9056,"primaryCompletion":1711,"completion":1712,"start":830,"enrollment":1510,"conditions":9057,"interventions":9058},[90],[465,736,246,18,737,453],[82,504,1715,376],{"trials":9060,"activeCount":102},[],{"trials":9062,"activeCount":102},[],{"trials":9064,"activeCount":102},[],{"trials":9066,"activeCount":102},[],{"intervention":9068,"totalTrials":135,"cells":9069},"Sotrovimab",{"EARLY_PHASE1":9070,"PHASE1":9072,"PHASE2":9085,"PHASE3":9087,"PHASE4":9089,"NA":9091},{"trials":9071,"activeCount":102},[],{"trials":9073,"activeCount":102},[9074],{"nctId":9075,"briefTitle":9076,"status":114,"phases":9077,"primaryCompletion":9078,"completion":9079,"start":9080,"enrollment":463,"conditions":9081,"interventions":9084},"NCT05135650","Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study",[90],"2022-10-18","2023-01-10","2022-01-25",[9082,406,9083],"COVID-19 Infection","Malignant Solid Neoplasm",[9068],{"trials":9086,"activeCount":102},[],{"trials":9088,"activeCount":102},[],{"trials":9090,"activeCount":102},[],{"trials":9092,"activeCount":102},[],{"intervention":4387,"totalTrials":135,"cells":9094},{"EARLY_PHASE1":9095,"PHASE1":9097,"PHASE2":9103,"PHASE3":9105,"PHASE4":9107,"NA":9109},{"trials":9096,"activeCount":102},[],{"trials":9098,"activeCount":102},[9099],{"nctId":4380,"briefTitle":4381,"status":114,"phases":9100,"primaryCompletion":4383,"completion":4383,"start":4384,"enrollment":2616,"conditions":9101,"interventions":9102},[90],[809],[374,4387,4388,1546,691],{"trials":9104,"activeCount":102},[],{"trials":9106,"activeCount":102},[],{"trials":9108,"activeCount":102},[],{"trials":9110,"activeCount":102},[],{"intervention":9112,"totalTrials":135,"cells":9113},"TLR4 Agonist GLA-SE",{"EARLY_PHASE1":9114,"PHASE1":9116,"PHASE2":9126,"PHASE3":9128,"PHASE4":9130,"NA":9132},{"trials":9115,"activeCount":102},[],{"trials":9117,"activeCount":102},[9118],{"nctId":9119,"briefTitle":9120,"status":226,"phases":9121,"primaryCompletion":9122,"completion":9122,"start":9123,"enrollment":1510,"conditions":9124,"interventions":9125},"NCT02180698","TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery",[90],"2016-10-07","2014-11-17",[778,779],[9112],{"trials":9127,"activeCount":102},[],{"trials":9129,"activeCount":102},[],{"trials":9131,"activeCount":102},[],{"trials":9133,"activeCount":102},[],{"intervention":687,"totalTrials":135,"cells":9135},{"EARLY_PHASE1":9136,"PHASE1":9138,"PHASE2":9144,"PHASE3":9146,"PHASE4":9148,"NA":9150},{"trials":9137,"activeCount":102},[],{"trials":9139,"activeCount":102},[9140],{"nctId":677,"briefTitle":678,"status":114,"phases":9141,"primaryCompletion":680,"completion":680,"start":681,"enrollment":682,"conditions":9142,"interventions":9143},[90],[528,684,685],[687,57,688,442,689,690,691,692,505],{"trials":9145,"activeCount":102},[],{"trials":9147,"activeCount":102},[],{"trials":9149,"activeCount":102},[],{"trials":9151,"activeCount":102},[],{"intervention":688,"totalTrials":135,"cells":9153},{"EARLY_PHASE1":9154,"PHASE1":9156,"PHASE2":9162,"PHASE3":9164,"PHASE4":9166,"NA":9168},{"trials":9155,"activeCount":102},[],{"trials":9157,"activeCount":102},[9158],{"nctId":677,"briefTitle":678,"status":114,"phases":9159,"primaryCompletion":680,"completion":680,"start":681,"enrollment":682,"conditions":9160,"interventions":9161},[90],[528,684,685],[687,57,688,442,689,690,691,692,505],{"trials":9163,"activeCount":102},[],{"trials":9165,"activeCount":102},[],{"trials":9167,"activeCount":102},[],{"trials":9169,"activeCount":102},[],{"intervention":689,"totalTrials":135,"cells":9171},{"EARLY_PHASE1":9172,"PHASE1":9174,"PHASE2":9180,"PHASE3":9182,"PHASE4":9184,"NA":9186},{"trials":9173,"activeCount":102},[],{"trials":9175,"activeCount":102},[9176],{"nctId":677,"briefTitle":678,"status":114,"phases":9177,"primaryCompletion":680,"completion":680,"start":681,"enrollment":682,"conditions":9178,"interventions":9179},[90],[528,684,685],[687,57,688,442,689,690,691,692,505],{"trials":9181,"activeCount":102},[],{"trials":9183,"activeCount":102},[],{"trials":9185,"activeCount":102},[],{"trials":9187,"activeCount":102},[],{"intervention":721,"totalTrials":135,"cells":9189},{"EARLY_PHASE1":9190,"PHASE1":9192,"PHASE2":9198,"PHASE3":9200,"PHASE4":9202,"NA":9204},{"trials":9191,"activeCount":102},[],{"trials":9193,"activeCount":102},[9194],{"nctId":704,"briefTitle":705,"status":226,"phases":9195,"primaryCompletion":707,"start":473,"enrollment":296,"conditions":9196,"interventions":9197},[90],[709,710,711,712,713,24,714,21,27,715,716],[718,673,719,720,721,722],{"trials":9199,"activeCount":102},[],{"trials":9201,"activeCount":102},[],{"trials":9203,"activeCount":102},[],{"trials":9205,"activeCount":102},[],{"intervention":722,"totalTrials":135,"cells":9207},{"EARLY_PHASE1":9208,"PHASE1":9210,"PHASE2":9216,"PHASE3":9218,"PHASE4":9220,"NA":9222},{"trials":9209,"activeCount":102},[],{"trials":9211,"activeCount":102},[9212],{"nctId":704,"briefTitle":705,"status":226,"phases":9213,"primaryCompletion":707,"start":473,"enrollment":296,"conditions":9214,"interventions":9215},[90],[709,710,711,712,713,24,714,21,27,715,716],[718,673,719,720,721,722],{"trials":9217,"activeCount":102},[],{"trials":9219,"activeCount":102},[],{"trials":9221,"activeCount":102},[],{"trials":9223,"activeCount":102},[],{"intervention":763,"totalTrials":135,"cells":9225},{"EARLY_PHASE1":9226,"PHASE1":9228,"PHASE2":9234,"PHASE3":9236,"PHASE4":9238,"NA":9240},{"trials":9227,"activeCount":102},[],{"trials":9229,"activeCount":102},[9230],{"nctId":743,"briefTitle":744,"status":226,"phases":9231,"primaryCompletion":746,"completion":746,"start":747,"enrollment":748,"conditions":9232,"interventions":9233},[90],[750,751,752,753,754,755,756,757,758,759,760,761],[57,442,763],{"trials":9235,"activeCount":102},[],{"trials":9237,"activeCount":102},[],{"trials":9239,"activeCount":102},[],{"trials":9241,"activeCount":102},[],{"intervention":236,"totalTrials":135,"cells":9243},{"EARLY_PHASE1":9244,"PHASE1":9246,"PHASE2":9252,"PHASE3":9254,"PHASE4":9256,"NA":9258},{"trials":9245,"activeCount":102},[],{"trials":9247,"activeCount":102},[9248],{"nctId":224,"briefTitle":225,"status":226,"phases":9249,"primaryCompletion":228,"completion":229,"start":230,"enrollment":231,"conditions":9250,"interventions":9251},[90],[233,234],[236,57,204],{"trials":9253,"activeCount":102},[],{"trials":9255,"activeCount":102},[],{"trials":9257,"activeCount":102},[],{"trials":9259,"activeCount":102},[],{"intervention":9261,"totalTrials":135,"cells":9262},"Rivogenlecleucel",{"EARLY_PHASE1":9263,"PHASE1":9265,"PHASE2":9278,"PHASE3":9280,"PHASE4":9282,"NA":9284},{"trials":9264,"activeCount":102},[],{"trials":9266,"activeCount":102},[9267],{"nctId":9268,"briefTitle":9269,"status":343,"phases":9270,"primaryCompletion":9271,"completion":9272,"start":9273,"enrollment":102,"conditions":9274,"interventions":9276},"NCT03807063","Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant",[90],"2020-12-31","2021-12-31","2020-01-02",[9275,390,1593,391,6025,1533,362,6027,1148,1149,363,364],"Acute Bilineal Leukemia",[9261,9277],"Rimiducid",{"trials":9279,"activeCount":102},[],{"trials":9281,"activeCount":102},[],{"trials":9283,"activeCount":102},[],{"trials":9285,"activeCount":102},[],{"intervention":9277,"totalTrials":135,"cells":9287},{"EARLY_PHASE1":9288,"PHASE1":9290,"PHASE2":9296,"PHASE3":9298,"PHASE4":9300,"NA":9302},{"trials":9289,"activeCount":102},[],{"trials":9291,"activeCount":102},[9292],{"nctId":9268,"briefTitle":9269,"status":343,"phases":9293,"primaryCompletion":9271,"completion":9272,"start":9273,"enrollment":102,"conditions":9294,"interventions":9295},[90],[9275,390,1593,391,6025,1533,362,6027,1148,1149,363,364],[9261,9277],{"trials":9297,"activeCount":102},[],{"trials":9299,"activeCount":102},[],{"trials":9301,"activeCount":102},[],{"trials":9303,"activeCount":102},[],{"intervention":264,"totalTrials":135,"cells":9305},{"EARLY_PHASE1":9306,"PHASE1":9308,"PHASE2":9314,"PHASE3":9316,"PHASE4":9318,"NA":9320},{"trials":9307,"activeCount":102},[],{"trials":9309,"activeCount":102},[9310],{"nctId":238,"briefTitle":239,"status":114,"phases":9311,"primaryCompletion":241,"completion":242,"start":243,"enrollment":244,"conditions":9312,"interventions":9313},[90],[246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262],[264,57,204],{"trials":9315,"activeCount":102},[],{"trials":9317,"activeCount":102},[],{"trials":9319,"activeCount":102},[],{"trials":9321,"activeCount":102},[],{"intervention":274,"totalTrials":135,"cells":9323},{"EARLY_PHASE1":9324,"PHASE1":9326,"PHASE2":9332,"PHASE3":9334,"PHASE4":9336,"NA":9338},{"trials":9325,"activeCount":102},[],{"trials":9327,"activeCount":102},[9328],{"nctId":266,"briefTitle":267,"status":114,"phases":9329,"primaryCompletion":269,"completion":269,"start":270,"enrollment":271,"conditions":9330,"interventions":9331},[90],[233,234],[274,57,204,275],{"trials":9333,"activeCount":102},[],{"trials":9335,"activeCount":102},[],{"trials":9337,"activeCount":102},[],{"trials":9339,"activeCount":102},[],{"intervention":275,"totalTrials":135,"cells":9341},{"EARLY_PHASE1":9342,"PHASE1":9344,"PHASE2":9350,"PHASE3":9352,"PHASE4":9354,"NA":9356},{"trials":9343,"activeCount":102},[],{"trials":9345,"activeCount":102},[9346],{"nctId":266,"briefTitle":267,"status":114,"phases":9347,"primaryCompletion":269,"completion":269,"start":270,"enrollment":271,"conditions":9348,"interventions":9349},[90],[233,234],[274,57,204,275],{"trials":9351,"activeCount":102},[],{"trials":9353,"activeCount":102},[],{"trials":9355,"activeCount":102},[],{"trials":9357,"activeCount":102},[],{"intervention":9359,"totalTrials":135,"cells":9360},"Nozin",{"EARLY_PHASE1":9361,"PHASE1":9363,"PHASE2":9374,"PHASE3":9376,"PHASE4":9378,"NA":9380},{"trials":9362,"activeCount":102},[],{"trials":9364,"activeCount":102},[9365],{"nctId":9366,"briefTitle":9367,"status":114,"phases":9368,"primaryCompletion":9369,"completion":9369,"start":9370,"enrollment":1084,"conditions":9371,"interventions":9373},"NCT04060849","Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY",[90],"2020-04-12","2019-09-03",[406,9083,9372],"Solid Neoplasm",[9359],{"trials":9375,"activeCount":102},[],{"trials":9377,"activeCount":102},[],{"trials":9379,"activeCount":102},[],{"trials":9381,"activeCount":102},[],{"intervention":3268,"totalTrials":135,"cells":9383},{"EARLY_PHASE1":9384,"PHASE1":9386,"PHASE2":9392,"PHASE3":9394,"PHASE4":9396,"NA":9398},{"trials":9385,"activeCount":102},[],{"trials":9387,"activeCount":102},[9388],{"nctId":3258,"briefTitle":3259,"status":114,"phases":9389,"primaryCompletion":3261,"completion":3262,"start":3263,"enrollment":2616,"conditions":9390,"interventions":9391},[90],[528,3265,685,1470,533,247,3266],[3268,1290,3269,373,692,491],{"trials":9393,"activeCount":102},[],{"trials":9395,"activeCount":102},[],{"trials":9397,"activeCount":102},[],{"trials":9399,"activeCount":102},[],{"intervention":3269,"totalTrials":135,"cells":9401},{"EARLY_PHASE1":9402,"PHASE1":9404,"PHASE2":9410,"PHASE3":9412,"PHASE4":9414,"NA":9416},{"trials":9403,"activeCount":102},[],{"trials":9405,"activeCount":102},[9406],{"nctId":3258,"briefTitle":3259,"status":114,"phases":9407,"primaryCompletion":3261,"completion":3262,"start":3263,"enrollment":2616,"conditions":9408,"interventions":9409},[90],[528,3265,685,1470,533,247,3266],[3268,1290,3269,373,692,491],{"trials":9411,"activeCount":102},[],{"trials":9413,"activeCount":102},[],{"trials":9415,"activeCount":102},[],{"trials":9417,"activeCount":102},[],{"intervention":9419,"totalTrials":135,"cells":9420},"Wistar Rabies Virus Strain PM-1503-3M Vaccine",{"EARLY_PHASE1":9421,"PHASE1":9423,"PHASE2":9435,"PHASE3":9437,"PHASE4":9439,"NA":9441},{"trials":9422,"activeCount":102},[],{"trials":9424,"activeCount":102},[9425],{"nctId":9426,"briefTitle":9427,"status":226,"phases":9428,"primaryCompletion":9429,"completion":9430,"start":9431,"enrollment":7911,"conditions":9432,"interventions":9434},"NCT04410900","Vaccine Responsiveness After CAR-T Cell Therapy",[90],"2025-04-28","2025-08-31","2020-08-03",[9433],"B-Cell Neoplasm",[9419],{"trials":9436,"activeCount":102},[],{"trials":9438,"activeCount":102},[],{"trials":9440,"activeCount":102},[],{"trials":9442,"activeCount":102},[],{"intervention":9444,"totalTrials":135,"cells":9445},"BCG Vaccine USP",{"EARLY_PHASE1":9446,"PHASE1":9448,"PHASE2":9461,"PHASE3":9463,"PHASE4":9465,"NA":9467},{"trials":9447,"activeCount":102},[],{"trials":9449,"activeCount":102},[9450],{"nctId":9451,"briefTitle":9452,"status":226,"phases":9453,"primaryCompletion":8119,"completion":9454,"start":9455,"enrollment":463,"conditions":9456,"interventions":9458},"NCT05592223","Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines",[90],"2023-12-01","2022-12-06",[9457],"Tuberculosis",[9444,9459,9460],"Isoniazid","Rifampin",{"trials":9462,"activeCount":102},[],{"trials":9464,"activeCount":102},[],{"trials":9466,"activeCount":102},[],{"trials":9468,"activeCount":102},[],{"intervention":9459,"totalTrials":135,"cells":9470},{"EARLY_PHASE1":9471,"PHASE1":9473,"PHASE2":9479,"PHASE3":9481,"PHASE4":9483,"NA":9485},{"trials":9472,"activeCount":102},[],{"trials":9474,"activeCount":102},[9475],{"nctId":9451,"briefTitle":9452,"status":226,"phases":9476,"primaryCompletion":8119,"completion":9454,"start":9455,"enrollment":463,"conditions":9477,"interventions":9478},[90],[9457],[9444,9459,9460],{"trials":9480,"activeCount":102},[],{"trials":9482,"activeCount":102},[],{"trials":9484,"activeCount":102},[],{"trials":9486,"activeCount":102},[],{"intervention":9460,"totalTrials":135,"cells":9488},{"EARLY_PHASE1":9489,"PHASE1":9491,"PHASE2":9497,"PHASE3":9499,"PHASE4":9501,"NA":9503},{"trials":9490,"activeCount":102},[],{"trials":9492,"activeCount":102},[9493],{"nctId":9451,"briefTitle":9452,"status":226,"phases":9494,"primaryCompletion":8119,"completion":9454,"start":9455,"enrollment":463,"conditions":9495,"interventions":9496},[90],[9457],[9444,9459,9460],{"trials":9498,"activeCount":102},[],{"trials":9500,"activeCount":102},[],{"trials":9502,"activeCount":102},[],{"trials":9504,"activeCount":102},[],{"intervention":3496,"totalTrials":135,"cells":9506},{"EARLY_PHASE1":9507,"PHASE1":9509,"PHASE2":9515,"PHASE3":9517,"PHASE4":9519,"NA":9521},{"trials":9508,"activeCount":102},[],{"trials":9510,"activeCount":102},[9511],{"nctId":3488,"briefTitle":3489,"status":226,"phases":9512,"primaryCompletion":3491,"completion":3491,"start":3492,"conditions":9513,"interventions":9514},[90],[3494],[3496,958,2608,1607,960],{"trials":9516,"activeCount":102},[],{"trials":9518,"activeCount":102},[],{"trials":9520,"activeCount":102},[],{"trials":9522,"activeCount":102},[],{"intervention":834,"totalTrials":135,"cells":9524},{"EARLY_PHASE1":9525,"PHASE1":9527,"PHASE2":9533,"PHASE3":9535,"PHASE4":9537,"NA":9539},{"trials":9526,"activeCount":102},[],{"trials":9528,"activeCount":102},[9529],{"nctId":826,"briefTitle":827,"status":226,"phases":9530,"primaryCompletion":829,"start":830,"enrollment":395,"conditions":9531,"interventions":9532},[90],[832,775,777,778,779],[673,834],{"trials":9534,"activeCount":102},[],{"trials":9536,"activeCount":102},[],{"trials":9538,"activeCount":102},[],{"trials":9540,"activeCount":102},[],{"intervention":311,"totalTrials":135,"cells":9542},{"EARLY_PHASE1":9543,"PHASE1":9545,"PHASE2":9551,"PHASE3":9553,"PHASE4":9555,"NA":9557},{"trials":9544,"activeCount":102},[],{"trials":9546,"activeCount":102},[9547],{"nctId":303,"briefTitle":304,"status":114,"phases":9548,"primaryCompletion":306,"completion":306,"start":307,"enrollment":282,"conditions":9549,"interventions":9550},[90],[309,248,249,252,256,253],[311,57,312,204],{"trials":9552,"activeCount":102},[],{"trials":9554,"activeCount":102},[],{"trials":9556,"activeCount":102},[],{"trials":9558,"activeCount":102},[],{"intervention":312,"totalTrials":135,"cells":9560},{"EARLY_PHASE1":9561,"PHASE1":9563,"PHASE2":9569,"PHASE3":9571,"PHASE4":9573,"NA":9575},{"trials":9562,"activeCount":102},[],{"trials":9564,"activeCount":102},[9565],{"nctId":303,"briefTitle":304,"status":114,"phases":9566,"primaryCompletion":306,"completion":306,"start":307,"enrollment":282,"conditions":9567,"interventions":9568},[90],[309,248,249,252,256,253],[311,57,312,204],{"trials":9570,"activeCount":102},[],{"trials":9572,"activeCount":102},[],{"trials":9574,"activeCount":102},[],{"trials":9576,"activeCount":102},[],{"intervention":852,"totalTrials":135,"cells":9578},{"EARLY_PHASE1":9579,"PHASE1":9581,"PHASE2":9587,"PHASE3":9589,"PHASE4":9591,"NA":9593},{"trials":9580,"activeCount":102},[],{"trials":9582,"activeCount":102},[9583],{"nctId":844,"briefTitle":845,"status":226,"phases":9584,"primaryCompletion":847,"start":848,"enrollment":296,"conditions":9585,"interventions":9586},[90],[850,823],[673,719,852,720,718],{"trials":9588,"activeCount":102},[],{"trials":9590,"activeCount":102},[],{"trials":9592,"activeCount":102},[],{"trials":9594,"activeCount":102},[],{"intervention":6654,"totalTrials":135,"cells":9596},{"EARLY_PHASE1":9597,"PHASE1":9599,"PHASE2":9605,"PHASE3":9607,"PHASE4":9609,"NA":9611},{"trials":9598,"activeCount":102},[],{"trials":9600,"activeCount":102},[9601],{"nctId":6647,"briefTitle":6648,"status":226,"phases":9602,"primaryCompletion":6650,"completion":6650,"start":6157,"enrollment":1084,"conditions":9603,"interventions":9604},[90],[6652],[6654,6640],{"trials":9606,"activeCount":102},[],{"trials":9608,"activeCount":102},[],{"trials":9610,"activeCount":102},[],{"trials":9612,"activeCount":102},[],{"intervention":9614,"totalTrials":135,"cells":9615},"Gene-Modified HIV-Protected Hematopoietic Stem Cells",{"EARLY_PHASE1":9616,"PHASE1":9618,"PHASE2":9630,"PHASE3":9632,"PHASE4":9634,"NA":9636},{"trials":9617,"activeCount":102},[],{"trials":9619,"activeCount":102},[9620],{"nctId":9621,"briefTitle":9622,"status":343,"phases":9623,"primaryCompletion":9624,"completion":9624,"start":9625,"enrollment":102,"conditions":9626,"interventions":9629},"NCT02378922","Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma",[90],"2019-06-15","2016-06-22",[9627,9628,133,1150,1284],"AIDS-Related Hodgkin Lymphoma","AIDS-Related Non-Hodgkin Lymphoma",[9614],{"trials":9631,"activeCount":102},[],{"trials":9633,"activeCount":102},[],{"trials":9635,"activeCount":102},[],{"trials":9637,"activeCount":102},[],{"intervention":339,"totalTrials":135,"cells":9639},{"EARLY_PHASE1":9640,"PHASE1":9642,"PHASE2":9648,"PHASE3":9650,"PHASE4":9652,"NA":9654},{"trials":9641,"activeCount":102},[],{"trials":9643,"activeCount":102},[9644],{"nctId":328,"briefTitle":329,"status":114,"phases":9645,"primaryCompletion":331,"completion":332,"start":333,"enrollment":334,"conditions":9646,"interventions":9647},[90],[336,337],[339,57,204,221],{"trials":9649,"activeCount":102},[],{"trials":9651,"activeCount":102},[],{"trials":9653,"activeCount":102},[],{"trials":9655,"activeCount":102},[],{"intervention":1694,"totalTrials":135,"cells":9657},{"EARLY_PHASE1":9658,"PHASE1":9660,"PHASE2":9666,"PHASE3":9668,"PHASE4":9670,"NA":9672},{"trials":9659,"activeCount":102},[],{"trials":9661,"activeCount":102},[9662],{"nctId":1685,"briefTitle":1686,"status":226,"phases":9663,"primaryCompletion":1688,"start":1689,"enrollment":1690,"conditions":9664,"interventions":9665},[90],[465,1593,736,246,18,737,739,1692,453],[1694,82,376,504],{"trials":9667,"activeCount":102},[],{"trials":9669,"activeCount":102},[],{"trials":9671,"activeCount":102},[],{"trials":9673,"activeCount":102},[],{"intervention":9675,"totalTrials":135,"cells":9676},"Decoy-resistant interleukin-18",{"EARLY_PHASE1":9677,"PHASE1":9679,"PHASE2":9690,"PHASE3":9692,"PHASE4":9694,"NA":9696},{"trials":9678,"activeCount":102},[],{"trials":9680,"activeCount":102},[9681],{"nctId":9682,"briefTitle":9683,"status":9684,"phases":9685,"primaryCompletion":293,"completion":9686,"start":9687,"enrollment":463,"conditions":9688,"interventions":9689},"NCT06492707","DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hematopoietic Cell Transplantation, the DR. DREAM Trial","SUSPENDED",[90],"2028-10-01","2024-09-23",[387,389,362,364],[9675],{"trials":9691,"activeCount":102},[],{"trials":9693,"activeCount":102},[],{"trials":9695,"activeCount":102},[],{"trials":9697,"activeCount":102},[],{"intervention":3280,"totalTrials":135,"cells":9699},{"EARLY_PHASE1":9700,"PHASE1":9702,"PHASE2":9708,"PHASE3":9710,"PHASE4":9712,"NA":9714},{"trials":9701,"activeCount":102},[],{"trials":9703,"activeCount":102},[9704],{"nctId":3271,"briefTitle":3272,"status":343,"phases":9705,"primaryCompletion":3274,"completion":293,"start":3275,"enrollment":102,"conditions":9706,"interventions":9707},[90],[248,258,259,249,3277,252,261,262,253,3278],[1290,373,692,3280,491],{"trials":9709,"activeCount":102},[],{"trials":9711,"activeCount":102},[],{"trials":9713,"activeCount":102},[],{"trials":9715,"activeCount":102},[],{"intervention":4406,"totalTrials":135,"cells":9717},{"EARLY_PHASE1":9718,"PHASE1":9720,"PHASE2":9726,"PHASE3":9728,"PHASE4":9730,"NA":9732},{"trials":9719,"activeCount":102},[],{"trials":9721,"activeCount":102},[9722],{"nctId":4394,"briefTitle":4395,"status":343,"phases":9723,"primaryCompletion":4397,"start":4398,"enrollment":102,"conditions":9724,"interventions":9725},[90],[4400,2327,4401,2329,4402,1019,4403,1031,4404],[4406,1290,374,4407,1546],{"trials":9727,"activeCount":102},[],{"trials":9729,"activeCount":102},[],{"trials":9731,"activeCount":102},[],{"trials":9733,"activeCount":102},[],{"intervention":3289,"totalTrials":135,"cells":9735},{"EARLY_PHASE1":9736,"PHASE1":9738,"PHASE2":9744,"PHASE3":9746,"PHASE4":9748,"NA":9750},{"trials":9737,"activeCount":102},[],{"trials":9739,"activeCount":102},[9740],{"nctId":3282,"briefTitle":3283,"status":226,"phases":9741,"completion":3285,"start":2369,"conditions":9742,"interventions":9743},[90],[15],[2194,3288,3289],{"trials":9745,"activeCount":102},[],{"trials":9747,"activeCount":102},[],{"trials":9749,"activeCount":102},[],{"trials":9751,"activeCount":102},[],{"intervention":9753,"totalTrials":135,"cells":9754},"Efineptakin alfa",{"EARLY_PHASE1":9755,"PHASE1":9757,"PHASE2":9767,"PHASE3":9769,"PHASE4":9771,"NA":9773},{"trials":9756,"activeCount":102},[],{"trials":9758,"activeCount":102},[9759],{"nctId":9760,"briefTitle":9761,"status":114,"phases":9762,"primaryCompletion":216,"completion":216,"start":9763,"enrollment":2248,"conditions":9764,"interventions":9766},"NCT04893018","NT-I7 for Kaposi Sarcoma in Patients With or Without HIV",[90],"2022-05-23",[9765,133,4675],"AIDS-Related Kaposi Sarcoma",[9753],{"trials":9768,"activeCount":102},[],{"trials":9770,"activeCount":102},[],{"trials":9772,"activeCount":102},[],{"trials":9774,"activeCount":102},[],{"intervention":9776,"totalTrials":135,"cells":9777},"Itacitinib",{"EARLY_PHASE1":9778,"PHASE1":9780,"PHASE2":9807,"PHASE3":9809,"PHASE4":9811,"NA":9813},{"trials":9779,"activeCount":102},[],{"trials":9781,"activeCount":102},[9782],{"nctId":9783,"briefTitle":9784,"status":114,"phases":9785,"primaryCompletion":9786,"completion":9787,"start":9788,"enrollment":317,"conditions":9789,"interventions":9806},"NCT03670069","Itacitinib in Treating Patients With Refractory Metastatic\u002FAdvanced Sarcomas",[90],"2023-03-04","2024-05-06","2019-09-30",[7330,9790,9791,9792,9793,9794,9795,7837,9796,9797,9798,9799,9800,9801,9802,9803,9804,9805],"Metastatic Synovial Sarcoma","Metastatic Undifferentiated Pleomorphic Sarcoma","Advanced Myxoid Liposarcoma","Advanced Soft Tissue Sarcoma","Metastatic Myxoid Liposarcoma","Metastatic Round Cell Liposarcoma","Refractory Leiomyosarcoma","Refractory Myxoid Liposarcoma","Refractory Round Cell Liposarcoma","Refractory Soft Tissue Sarcoma","Refractory Synovial Sarcoma","Refractory Undifferentiated Pleomorphic Sarcoma","Advanced Leiomyosarcoma","Advanced Synovial Sarcoma","Advanced Undifferentiated Pleomorphic Sarcoma","Metastatic Chondrosarcoma",[9776],{"trials":9808,"activeCount":102},[],{"trials":9810,"activeCount":102},[],{"trials":9812,"activeCount":102},[],{"trials":9814,"activeCount":102},[],{"intervention":977,"totalTrials":135,"cells":9816},{"EARLY_PHASE1":9817,"PHASE1":9819,"PHASE2":9825,"PHASE3":9827,"PHASE4":9829,"NA":9831},{"trials":9818,"activeCount":102},[],{"trials":9820,"activeCount":102},[9821],{"nctId":970,"briefTitle":971,"status":226,"phases":9822,"completion":973,"start":974,"enrollment":296,"conditions":9823,"interventions":9824},[90],[15,797],[719,718,673,675,977],{"trials":9826,"activeCount":102},[],{"trials":9828,"activeCount":102},[],{"trials":9830,"activeCount":102},[],{"trials":9832,"activeCount":102},[],{"intervention":9834,"totalTrials":135,"cells":9835},"ROR1 CAR-specific Autologous T-Lymphocytes",{"EARLY_PHASE1":9836,"PHASE1":9838,"PHASE2":9854,"PHASE3":9856,"PHASE4":9858,"NA":9860},{"trials":9837,"activeCount":102},[],{"trials":9839,"activeCount":102},[9840],{"nctId":9841,"briefTitle":9842,"status":114,"phases":9843,"primaryCompletion":9844,"completion":9845,"start":9846,"enrollment":1053,"conditions":9847,"interventions":9853},"NCT02706392","Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies",[90],"2021-05-17","2021-09-28","2016-03-16",[406,9083,574,575,1533,24,27,9848,9849,9850,9851,9852,4659],"Stage III Lung Non-Small Cell Cancer AJCC v7","Stage IIIA Lung Non-Small Cell Cancer AJCC v7","Stage IIIB Lung Non-Small Cell Cancer AJCC v7","Stage IV Breast Cancer AJCC v6 and v7","Stage IV Lung Non-Small Cell Cancer AJCC v7",[9834],{"trials":9855,"activeCount":102},[],{"trials":9857,"activeCount":102},[],{"trials":9859,"activeCount":102},[],{"trials":9861,"activeCount":102},[],{"intervention":9863,"totalTrials":135,"cells":9864},"Recombinant Interferon Gamma",{"EARLY_PHASE1":9865,"PHASE1":9876,"PHASE2":9878,"PHASE3":9880,"PHASE4":9882,"NA":9884},{"trials":9866,"activeCount":102},[9867],{"nctId":9868,"briefTitle":9869,"status":114,"phases":9870,"primaryCompletion":9871,"completion":9871,"start":9872,"enrollment":2248,"conditions":9873,"interventions":9875},"NCT01957709","Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma",[89],"2018-06-01","2013-09-25",[7833,7834,9874],"Synovial Sarcoma",[9863],{"trials":9877,"activeCount":102},[],{"trials":9879,"activeCount":102},[],{"trials":9881,"activeCount":102},[],{"trials":9883,"activeCount":102},[],{"trials":9885,"activeCount":102},[],{"intervention":719,"totalTrials":730,"cells":9887},{"EARLY_PHASE1":9888,"PHASE1":9890,"PHASE2":9920,"PHASE3":9997,"PHASE4":9999,"NA":10001},{"trials":9889,"activeCount":102},[],{"trials":9891,"activeCount":102},[9892,9896,9900,9904,9908,9912,9916],{"nctId":7268,"briefTitle":7269,"status":226,"phases":9893,"completion":1817,"start":1135,"conditions":9894,"interventions":9895},[90],[1626],[719,7261],{"nctId":704,"briefTitle":705,"status":226,"phases":9897,"primaryCompletion":707,"start":473,"enrollment":296,"conditions":9898,"interventions":9899},[90],[709,710,711,712,713,24,714,21,27,715,716],[718,673,719,720,721,722],{"nctId":3251,"briefTitle":3252,"status":226,"phases":9901,"primaryCompletion":3254,"start":1387,"conditions":9902,"interventions":9903},[90],[15,798],[719,1812,718,2194,948,2608],{"nctId":817,"briefTitle":818,"status":114,"phases":9905,"primaryCompletion":820,"start":821,"enrollment":296,"conditions":9906,"interventions":9907},[90],[823],[718,719,673],{"nctId":844,"briefTitle":845,"status":226,"phases":9909,"primaryCompletion":847,"start":848,"enrollment":296,"conditions":9910,"interventions":9911},[90],[850,823],[673,719,852,720,718],{"nctId":6675,"briefTitle":6676,"status":226,"phases":9913,"completion":1404,"start":1981,"conditions":9914,"interventions":9915},[90],[4483],[719,718,2287,6668],{"nctId":970,"briefTitle":971,"status":226,"phases":9917,"completion":973,"start":974,"enrollment":296,"conditions":9918,"interventions":9919},[90],[15,797],[719,718,673,675,977],{"trials":9921,"activeCount":102},[9922,9929,9933,9937,9941,9945,9949,9953,9957,9961,9965,9969,9973,9977,9981,9985,9989,9993],{"nctId":9923,"briefTitle":9924,"status":114,"phases":9925,"primaryCompletion":9926,"completion":1632,"start":942,"enrollment":3311,"conditions":9927,"interventions":9928},"NCT00052598","Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant",[90,91],"2009-11",[868,869,29,870,35,871,32,872,1111,877,880,18,298,1015,453],[1812,719],{"nctId":1057,"briefTitle":1058,"status":114,"phases":9930,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":1062,"conditions":9931,"interventions":9932},[90,91],[1064,1065,1066,1067,1068,1069,1070,1071,1072,1073,1074],[1076,1077,57],{"nctId":1079,"briefTitle":1080,"status":226,"phases":9934,"primaryCompletion":1082,"completion":848,"start":1083,"enrollment":1084,"conditions":9935,"interventions":9936},[90,91],[850,823],[718,719,673,720],{"nctId":6933,"briefTitle":6934,"status":226,"phases":9938,"primaryCompletion":2874,"completion":1431,"start":942,"enrollment":19,"conditions":9939,"interventions":9940},[90,91],[29,35,871,32,872,5075,5076,877,880,465,1636,1637,898,246,18,1116,298,737,909,1015,453,6937,6938],[1812,719,1046,720,1595],{"nctId":4027,"briefTitle":4028,"status":226,"phases":9942,"completion":2492,"start":4030,"enrollment":463,"conditions":9943,"interventions":9944},[90,91],[1137,15,797,1096],[719,1812,958],{"nctId":3855,"briefTitle":3856,"status":226,"phases":9946,"primaryCompletion":2425,"completion":2425,"start":1665,"conditions":9947,"interventions":9948},[91],[15],[719,2003,1415,1118],{"nctId":7276,"briefTitle":7269,"status":226,"phases":9950,"completion":2519,"start":943,"enrollment":463,"conditions":9951,"interventions":9952},[90,91],[1626],[719,7261],{"nctId":3883,"briefTitle":3884,"status":226,"phases":9954,"primaryCompletion":3886,"completion":3886,"start":3887,"enrollment":282,"conditions":9955,"interventions":9956},[91],[734,29,870,871,32,875,18,298],[1118,948,719],{"nctId":1319,"briefTitle":1320,"status":226,"phases":9958,"primaryCompletion":1322,"completion":1322,"start":1323,"enrollment":1062,"conditions":9959,"interventions":9960},[91],[1325,1326,1327,1328,1329,1330],[1076,57,504,1332],{"nctId":7540,"briefTitle":7541,"status":114,"phases":9962,"primaryCompletion":7543,"completion":7543,"start":7544,"enrollment":334,"conditions":9963,"interventions":9964},[90,91],[387,7546,1065,433,7547],[1076,1077],{"nctId":1355,"briefTitle":1356,"status":114,"phases":9966,"primaryCompletion":1358,"completion":1358,"start":1359,"enrollment":1360,"conditions":9967,"interventions":9968},[90,91],[18,298,453,1362,1363,1364,1065,362],[1076,57,504,1366],{"nctId":2602,"briefTitle":2603,"status":226,"phases":9970,"primaryCompletion":1404,"completion":1404,"start":2605,"conditions":9971,"interventions":9972},[90,91],[15],[719,674,1812,2194,948,937,811,2608,2609],{"nctId":7447,"briefTitle":7448,"status":114,"phases":9974,"primaryCompletion":7450,"completion":7450,"start":2483,"enrollment":3454,"conditions":9975,"interventions":9976},[90,91],[7452,7453],[1076,7309,7310],{"nctId":1408,"briefTitle":1409,"status":226,"phases":9978,"completion":1182,"start":1411,"conditions":9979,"interventions":9980},[91],[797,956,1413],[719,674,1415,1118,673,958,959,960],{"nctId":3568,"briefTitle":3569,"status":226,"phases":9982,"primaryCompletion":1297,"completion":1297,"start":3560,"enrollment":475,"conditions":9983,"interventions":9984},[91],[3572,3573,3574,3575,3576,3577,3578,3579],[1607,1118,960,958,719,1415],{"nctId":4074,"briefTitle":4075,"status":226,"phases":9986,"primaryCompletion":2448,"completion":2448,"start":2126,"enrollment":22,"conditions":9987,"interventions":9988},[91],[700,1905,1017,1027],[958,2003,719],{"nctId":6941,"briefTitle":6942,"status":114,"phases":9990,"primaryCompletion":4548,"completion":4548,"start":1740,"enrollment":2616,"conditions":9991,"interventions":9992},[90,91],[850,6945,823],[718,719,6947,720],{"nctId":1569,"briefTitle":1570,"status":226,"phases":9994,"primaryCompletion":829,"completion":1572,"start":1573,"enrollment":1084,"conditions":9995,"interventions":9996},[90,91],[850,823],[1576,673,719,720,1577],{"trials":9998,"activeCount":102},[],{"trials":10000,"activeCount":102},[],{"trials":10002,"activeCount":102},[10003],{"nctId":1621,"briefTitle":1622,"status":1623,"phases":10004,"primaryCompletion":1496,"start":1199,"conditions":10005,"interventions":10006},[],[1626],[719,718,673],{"intervention":1812,"totalTrials":682,"cells":10008},{"EARLY_PHASE1":10009,"PHASE1":10011,"PHASE2":10017,"PHASE3":10078,"PHASE4":10080,"NA":10082},{"trials":10010,"activeCount":102},[],{"trials":10012,"activeCount":102},[10013],{"nctId":3251,"briefTitle":3252,"status":226,"phases":10014,"primaryCompletion":3254,"start":1387,"conditions":10015,"interventions":10016},[90],[15,798],[719,1812,718,2194,948,2608],{"trials":10018,"activeCount":102},[10019,10023,10027,10031,10035,10039,10046,10050,10054,10058,10062,10066,10070,10074],{"nctId":9923,"briefTitle":9924,"status":114,"phases":10020,"primaryCompletion":9926,"completion":1632,"start":942,"enrollment":3311,"conditions":10021,"interventions":10022},[90,91],[868,869,29,870,35,871,32,872,1111,877,880,18,298,1015,453],[1812,719],{"nctId":1806,"briefTitle":1807,"status":226,"phases":10024,"completion":1809,"start":1665,"conditions":10025,"interventions":10026},[91],[1626],[1812,479,937,481],{"nctId":1814,"briefTitle":1815,"status":226,"phases":10028,"primaryCompletion":1817,"completion":1817,"start":1818,"conditions":10029,"interventions":10030},[91],[1820,1821],[1812,479,937,481],{"nctId":6933,"briefTitle":6934,"status":226,"phases":10032,"primaryCompletion":2874,"completion":1431,"start":942,"enrollment":19,"conditions":10033,"interventions":10034},[90,91],[29,35,871,32,872,5075,5076,877,880,465,1636,1637,898,246,18,1116,298,737,909,1015,453,6937,6938],[1812,719,1046,720,1595],{"nctId":4027,"briefTitle":4028,"status":226,"phases":10036,"completion":2492,"start":4030,"enrollment":463,"conditions":10037,"interventions":10038},[90,91],[1137,15,797,1096],[719,1812,958],{"nctId":10040,"briefTitle":10041,"status":226,"phases":10042,"primaryCompletion":10043,"completion":10043,"start":2075,"enrollment":25,"conditions":10044,"interventions":10045},"NCT00068718","Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant",[90,91],"2013-04",[1558,246,18,1150,1284,233],[1941],{"nctId":1926,"briefTitle":1927,"status":226,"phases":10047,"primaryCompletion":773,"completion":1929,"start":1930,"enrollment":231,"conditions":10048,"interventions":10049},[91],[733,1932,1933,874,1934,405,1935,246,1116,1936],[82,1938,504,1939,376,1940,1941],{"nctId":1996,"briefTitle":1997,"status":226,"phases":10051,"completion":1999,"start":2000,"enrollment":598,"conditions":10052,"interventions":10053},[91],[15],[2003,1812,479,937,2004,481],{"nctId":2020,"briefTitle":2021,"status":226,"phases":10055,"primaryCompletion":2023,"start":2024,"enrollment":598,"conditions":10056,"interventions":10057},[90,91],[700,1905,1017,1027],[958,479,481,1812],{"nctId":2602,"briefTitle":2603,"status":226,"phases":10059,"primaryCompletion":1404,"completion":1404,"start":2605,"conditions":10060,"interventions":10061},[90,91],[15],[719,674,1812,2194,948,937,811,2608,2609],{"nctId":2113,"briefTitle":2114,"status":226,"phases":10063,"primaryCompletion":2116,"completion":2117,"start":2075,"enrollment":22,"conditions":10064,"interventions":10065},[91],[404,387,529,405,1137,560,390,516,536,1234],[82,376,2120,1941],{"nctId":2122,"briefTitle":2123,"status":226,"phases":10067,"primaryCompletion":794,"completion":2125,"start":2126,"enrollment":1062,"conditions":10068,"interventions":10069},[90,91],[1758,1774],[937,479,481,1812],{"nctId":2130,"briefTitle":2131,"status":226,"phases":10071,"primaryCompletion":1404,"start":2133,"enrollment":682,"conditions":10072,"interventions":10073},[91],[2135,2136,405,1935,1936],[504,82,376,1941],{"nctId":2188,"briefTitle":2189,"status":226,"phases":10075,"completion":794,"start":2191,"conditions":10076,"interventions":10077},[90,91],[15],[1812,479,2194,937,811,481],{"trials":10079,"activeCount":102},[],{"trials":10081,"activeCount":102},[],{"trials":10083,"activeCount":102},[10084,10090,10094],{"nctId":10085,"briefTitle":10086,"status":1623,"phases":10087,"primaryCompletion":847,"start":1083,"conditions":10088,"interventions":10089},"NCT00547235","Emergency Use of Adoptive Immunotherapy With CMV-Specific T Cells After Donor Bone Marrow Transplant of an Infant With Immunodeficiency Syndrome and CMV Infection",[],[6587,1127],[1812],{"nctId":2280,"briefTitle":2281,"status":226,"phases":10091,"primaryCompletion":2010,"completion":2010,"start":2283,"enrollment":2284,"conditions":10092,"interventions":10093},[94],[873,558,1001,1002,710,1004,1005,711,1114,1006,246,899,500,900,1008,901,902,903,1010,1012,712,713,908,24,714,1013,21,27,1759,700,1016,715,1017,1027,1041,716],[2287,479,481,1812],{"nctId":2297,"briefTitle":2298,"status":226,"phases":10095,"primaryCompletion":1991,"start":1818,"enrollment":244,"conditions":10096,"interventions":10097},[94],[868,733,734,29,870,35,871,32,872,709,874,875,877,880,1755,882,1756,890,710,711,898,246,18,1008,1009,1116,298,1012,712,713,714,1013,21,1014,27,1759,700,1015,715,2301,1774,1775,1776,1777,716],[937,1812,479,481],{"intervention":718,"totalTrials":636,"cells":10099},{"EARLY_PHASE1":10100,"PHASE1":10102,"PHASE2":10144,"PHASE3":10158,"PHASE4":10160,"NA":10162},{"trials":10101,"activeCount":102},[],{"trials":10103,"activeCount":102},[10104,10108,10115,10119,10123,10127,10131,10135,10139],{"nctId":704,"briefTitle":705,"status":226,"phases":10105,"primaryCompletion":707,"start":473,"enrollment":296,"conditions":10106,"interventions":10107},[90],[709,710,711,712,713,24,714,21,27,715,716],[718,673,719,720,721,722],{"nctId":10109,"briefTitle":10110,"status":226,"phases":10111,"completion":10112,"start":6561,"enrollment":682,"conditions":10113,"interventions":10114},"NCT00101257","Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer",[90],"2010-03",[3494,6390],[718],{"nctId":3251,"briefTitle":3252,"status":226,"phases":10116,"primaryCompletion":3254,"start":1387,"conditions":10117,"interventions":10118},[90],[15,798],[719,1812,718,2194,948,2608],{"nctId":2360,"briefTitle":2361,"status":226,"phases":10120,"completion":2048,"start":2075,"enrollment":296,"conditions":10121,"interventions":10122},[90],[1626],[718,937],{"nctId":817,"briefTitle":818,"status":114,"phases":10124,"primaryCompletion":820,"start":821,"enrollment":296,"conditions":10125,"interventions":10126},[90],[823],[718,719,673],{"nctId":844,"briefTitle":845,"status":226,"phases":10128,"primaryCompletion":847,"start":848,"enrollment":296,"conditions":10129,"interventions":10130},[90],[850,823],[673,719,852,720,718],{"nctId":6675,"briefTitle":6676,"status":226,"phases":10132,"completion":1404,"start":1981,"conditions":10133,"interventions":10134},[90],[4483],[719,718,2287,6668],{"nctId":970,"briefTitle":971,"status":226,"phases":10136,"completion":973,"start":974,"enrollment":296,"conditions":10137,"interventions":10138},[90],[15,797],[719,718,673,675,977],{"nctId":10140,"briefTitle":7269,"status":226,"phases":10141,"completion":6328,"start":953,"enrollment":682,"conditions":10142,"interventions":10143},"NCT00045357",[90],[1626],[718],{"trials":10145,"activeCount":102},[10146,10150,10154],{"nctId":1079,"briefTitle":1080,"status":226,"phases":10147,"primaryCompletion":1082,"completion":848,"start":1083,"enrollment":1084,"conditions":10148,"interventions":10149},[90,91],[850,823],[718,719,673,720],{"nctId":1275,"briefTitle":1276,"status":226,"phases":10151,"primaryCompletion":772,"completion":1278,"start":1279,"enrollment":1280,"conditions":10152,"interventions":10153},[90,91],[537,1009,1282,1283,1148,1284,21,1285,27,1233,1286,563,1287,1288],[1290,57,82,373,692,504,491,376,1291],{"nctId":6941,"briefTitle":6942,"status":114,"phases":10155,"primaryCompletion":4548,"completion":4548,"start":1740,"enrollment":2616,"conditions":10156,"interventions":10157},[90,91],[850,6945,823],[718,719,6947,720],{"trials":10159,"activeCount":102},[],{"trials":10161,"activeCount":102},[],{"trials":10163,"activeCount":102},[10164],{"nctId":1621,"briefTitle":1622,"status":1623,"phases":10165,"primaryCompletion":1496,"start":1199,"conditions":10166,"interventions":10167},[],[1626],[719,718,673],{"intervention":1546,"totalTrials":395,"cells":10169},{"EARLY_PHASE1":10170,"PHASE1":10172,"PHASE2":10182,"PHASE3":10196,"PHASE4":10198,"NA":10200},{"trials":10171,"activeCount":102},[],{"trials":10173,"activeCount":102},[10174,10178],{"nctId":4380,"briefTitle":4381,"status":114,"phases":10175,"primaryCompletion":4383,"completion":4383,"start":4384,"enrollment":2616,"conditions":10176,"interventions":10177},[90],[809],[374,4387,4388,1546,691],{"nctId":4394,"briefTitle":4395,"status":343,"phases":10179,"primaryCompletion":4397,"start":4398,"enrollment":102,"conditions":10180,"interventions":10181},[90],[4400,2327,4401,2329,4402,1019,4403,1031,4404],[4406,1290,374,4407,1546],{"trials":10183,"activeCount":102},[10184,10188,10192],{"nctId":4435,"briefTitle":4436,"status":226,"phases":10185,"primaryCompletion":829,"completion":4438,"start":4439,"enrollment":463,"conditions":10186,"interventions":10187},[91],[516],[4442,692,374,4443,1546,505],{"nctId":4457,"briefTitle":4458,"status":114,"phases":10189,"primaryCompletion":4460,"completion":4461,"start":4462,"enrollment":296,"conditions":10190,"interventions":10191},[90,91],[4464,4465],[1290,374,4407,1546,4467],{"nctId":1537,"briefTitle":1538,"status":226,"phases":10193,"primaryCompletion":1540,"completion":1541,"start":1542,"enrollment":1053,"conditions":10194,"interventions":10195},[91],[1544],[72,57,374,376,1546],{"trials":10197,"activeCount":102},[],{"trials":10199,"activeCount":102},[],{"trials":10201,"activeCount":102},[10202],{"nctId":4545,"briefTitle":4546,"status":114,"phases":10203,"primaryCompletion":4548,"completion":4549,"start":4550,"enrollment":135,"conditions":10204,"interventions":10205},[94],[868,733,734,29,35,871,32,872,4552,1111,882,890,710,1593,711,891,892,893,1895,894,895,1896,1897,896,897,1898,1899,898,246,18,899,500,900,1008,1009,902,903,1012,712,713,908,24,714,1013,21,27,1759,700,1015,453,910,715,1905,1017,920,921,922,1018,1019,923,924,1022,1024,1025,926,927,1026,1027,1029,928,929,930,1030,1031,931,932,1034,1036,1037,934,935,1038,1040],[4554,674],{"intervention":2287,"totalTrials":2616,"cells":10207},{"EARLY_PHASE1":10208,"PHASE1":10210,"PHASE2":10216,"PHASE3":10222,"PHASE4":10224,"NA":10226},{"trials":10209,"activeCount":102},[],{"trials":10211,"activeCount":102},[10212],{"nctId":6675,"briefTitle":6676,"status":226,"phases":10213,"completion":1404,"start":1981,"conditions":10214,"interventions":10215},[90],[4483],[719,718,2287,6668],{"trials":10217,"activeCount":102},[10218],{"nctId":4488,"briefTitle":4489,"status":226,"phases":10219,"completion":1340,"start":3409,"conditions":10220,"interventions":10221},[91],[797],[674,2287],{"trials":10223,"activeCount":102},[],{"trials":10225,"activeCount":102},[],{"trials":10227,"activeCount":102},[10228],{"nctId":2280,"briefTitle":2281,"status":226,"phases":10229,"primaryCompletion":2010,"completion":2010,"start":2283,"enrollment":2284,"conditions":10230,"interventions":10231},[94],[873,558,1001,1002,710,1004,1005,711,1114,1006,246,899,500,900,1008,901,902,903,1010,1012,712,713,908,24,714,1013,21,27,1759,700,1016,715,1017,1027,1041,716],[2287,479,481,1812],{"intervention":1595,"totalTrials":2616,"cells":10233},{"EARLY_PHASE1":10234,"PHASE1":10236,"PHASE2":10238,"PHASE3":10244,"PHASE4":10250,"NA":10252},{"trials":10235,"activeCount":102},[],{"trials":10237,"activeCount":102},[],{"trials":10239,"activeCount":102},[10240],{"nctId":6933,"briefTitle":6934,"status":226,"phases":10241,"primaryCompletion":2874,"completion":1431,"start":942,"enrollment":19,"conditions":10242,"interventions":10243},[90,91],[29,35,871,32,872,5075,5076,877,880,465,1636,1637,898,246,18,1116,298,737,909,1015,453,6937,6938],[1812,719,1046,720,1595],{"trials":10245,"activeCount":102},[10246],{"nctId":1585,"briefTitle":1586,"status":226,"phases":10247,"primaryCompletion":1588,"completion":1589,"start":1241,"enrollment":807,"conditions":10248,"interventions":10249},[92],[869,1591,734,29,870,35,871,32,872,875,880,890,1592,1593,898,18,298,453,910],[673,481,1118,479,937,1595,1044,1045,1043,811],{"trials":10251,"activeCount":102},[],{"trials":10253,"activeCount":102},[10254],{"nctId":1629,"briefTitle":1630,"status":226,"phases":10255,"primaryCompletion":1632,"completion":1431,"start":1633,"enrollment":1634,"conditions":10256,"interventions":10257},[94],[734,29,870,35,871,32,872,875,880,890,1636,1592,1637,898,488,18,298,453,910,489,1638,1639],[673,1118,1043,811,1595],{"intervention":4407,"totalTrials":2616,"cells":10259},{"EARLY_PHASE1":10260,"PHASE1":10262,"PHASE2":10268,"PHASE3":10274,"PHASE4":10276,"NA":10278},{"trials":10261,"activeCount":102},[],{"trials":10263,"activeCount":102},[10264],{"nctId":4394,"briefTitle":4395,"status":343,"phases":10265,"primaryCompletion":4397,"start":4398,"enrollment":102,"conditions":10266,"interventions":10267},[90],[4400,2327,4401,2329,4402,1019,4403,1031,4404],[4406,1290,374,4407,1546],{"trials":10269,"activeCount":102},[10270],{"nctId":4457,"briefTitle":4458,"status":114,"phases":10271,"primaryCompletion":4460,"completion":4461,"start":4462,"enrollment":296,"conditions":10272,"interventions":10273},[90,91],[4464,4465],[1290,374,4407,1546,4467],{"trials":10275,"activeCount":102},[],{"trials":10277,"activeCount":102},[],{"trials":10279,"activeCount":102},[10280],{"nctId":3462,"briefTitle":3463,"status":343,"phases":10281,"primaryCompletion":3465,"start":2116,"enrollment":102,"conditions":10282,"interventions":10283},[94],[873,2311,2312,2313,2314,2315,2316,2318,558,1001,1002,710,1004,2322,1005,711,1114,1006,899,500,900,1008,901,1009,902,903,1010,1012,712,713,908,24,714,1013,21,1759,1016,715,3467,3468,3469,3470,1775,1041,716],[3472,2194,958,948,3473],{"intervention":2877,"totalTrials":98,"cells":10285},{"EARLY_PHASE1":10286,"PHASE1":10288,"PHASE2":10290,"PHASE3":10296,"PHASE4":10298,"NA":10300},{"trials":10287,"activeCount":102},[],{"trials":10289,"activeCount":102},[],{"trials":10291,"activeCount":102},[10292],{"nctId":2871,"briefTitle":2872,"status":114,"phases":10293,"primaryCompletion":848,"completion":848,"start":2874,"enrollment":395,"conditions":10294,"interventions":10295},[90,91],[1108,2012,2013,2014,2015,2016,29,870,35,32,872,2017,1109,1110,18],[479,2877,2608,948],{"trials":10297,"activeCount":102},[],{"trials":10299,"activeCount":102},[],{"trials":10301,"activeCount":102},[10302],{"nctId":3475,"briefTitle":3476,"status":226,"phases":10303,"primaryCompletion":2116,"completion":772,"start":3478,"enrollment":217,"conditions":10304,"interventions":10305},[94],[1108,2012,2013,2014,2015,2016,29,870,35,32,872,2017,1109,1110,465,890,1593,737,1638],[2877,3288,2194],{"intervention":10307,"totalTrials":135,"cells":10308},"lithium carbonate",{"EARLY_PHASE1":10309,"PHASE1":10311,"PHASE2":10313,"PHASE3":10315,"PHASE4":10317,"NA":10319},{"trials":10310,"activeCount":102},[],{"trials":10312,"activeCount":102},[],{"trials":10314,"activeCount":102},[],{"trials":10316,"activeCount":102},[],{"trials":10318,"activeCount":102},[],{"trials":10320,"activeCount":102},[10321],{"nctId":10322,"briefTitle":10323,"status":226,"phases":10324,"primaryCompletion":2257,"completion":10325,"start":1963,"enrollment":463,"conditions":10326,"interventions":10332},"NCT00408681","Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant",[94],"2015-05-01",[868,733,734,29,35,871,32,872,10327,1111,874,875,877,880,2319,465,2320,882,890,7913,710,10328,1757,1593,711,891,892,893,1895,894,895,1896,1897,896,897,1898,1899,7914,10329,488,246,18,899,500,900,1008,1009,902,903,1116,298,906,907,10330,1011,1012,712,713,908,7915,24,714,1013,7916,7917,7918,21,10331,1014,27,1759,1015,453,910,715,1905,1017,7919,920,921,922,1018,1019,923,924,1022,1024,1025,926,7920,927,1026,1027,7921,1029,7922,3578,7923,928,929,930,1030,1031,931,932,3579,1034,1036,1037,934,935,1038,7924,1040],"Atypical Chronic Myeloid Leukemia, Breakpoint Cluster Region-abl Translocation (BCR-ABL) Negative","Gastrointestinal Complications","Previously Treated Childhood Rhabdomyosarcoma","Recurrent Childhood Rhabdomyosarcoma","Recurrent Wilms Tumor and Other Childhood Kidney Tumors",[10307],{"intervention":10334,"totalTrials":135,"cells":10335},"Low-dose 17-ß-estradiol with progesterone taper",{"EARLY_PHASE1":10336,"PHASE1":10338,"PHASE2":10340,"PHASE3":10342,"PHASE4":10344,"NA":10346},{"trials":10337,"activeCount":102},[],{"trials":10339,"activeCount":102},[],{"trials":10341,"activeCount":102},[],{"trials":10343,"activeCount":102},[],{"trials":10345,"activeCount":102},[],{"trials":10347,"activeCount":102},[10348],{"nctId":10349,"briefTitle":10350,"status":226,"phases":10351,"primaryCompletion":10352,"completion":10352,"start":820,"enrollment":10353,"conditions":10354,"interventions":10357},"NCT01418209","MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms",[94],"2013-01",339,[10355,6733,10356],"Hot Flashes","Vasomotor Disturbance",[10334,10358],"Venlafaxine XR",{"intervention":10358,"totalTrials":135,"cells":10360},{"EARLY_PHASE1":10361,"PHASE1":10363,"PHASE2":10365,"PHASE3":10367,"PHASE4":10369,"NA":10371},{"trials":10362,"activeCount":102},[],{"trials":10364,"activeCount":102},[],{"trials":10366,"activeCount":102},[],{"trials":10368,"activeCount":102},[],{"trials":10370,"activeCount":102},[],{"trials":10372,"activeCount":102},[10373],{"nctId":10349,"briefTitle":10350,"status":226,"phases":10374,"primaryCompletion":10352,"completion":10352,"start":820,"enrollment":10353,"conditions":10375,"interventions":10376},[94],[10355,6733,10356],[10334,10358],{"intervention":10378,"totalTrials":135,"cells":10379},"Garlic powder with high allicin content",{"EARLY_PHASE1":10380,"PHASE1":10382,"PHASE2":10384,"PHASE3":10386,"PHASE4":10388,"NA":10390},{"trials":10381,"activeCount":102},[],{"trials":10383,"activeCount":102},[],{"trials":10385,"activeCount":102},[],{"trials":10387,"activeCount":102},[],{"trials":10389,"activeCount":102},[],{"trials":10391,"activeCount":102},[10392],{"nctId":10393,"briefTitle":10394,"status":226,"phases":10395,"completion":8792,"start":4112,"enrollment":2337,"conditions":10396,"interventions":10398},"NCT00122889","Effects of Garlic Supplements on Drug Metabolism",[],[10397],"Healthy",[10378,10399,10400,10401],"Garlic powder with low allicin content","Garlic oil","Aged garlic",{"intervention":10399,"totalTrials":135,"cells":10403},{"EARLY_PHASE1":10404,"PHASE1":10406,"PHASE2":10408,"PHASE3":10410,"PHASE4":10412,"NA":10414},{"trials":10405,"activeCount":102},[],{"trials":10407,"activeCount":102},[],{"trials":10409,"activeCount":102},[],{"trials":10411,"activeCount":102},[],{"trials":10413,"activeCount":102},[],{"trials":10415,"activeCount":102},[10416],{"nctId":10393,"briefTitle":10394,"status":226,"phases":10417,"completion":8792,"start":4112,"enrollment":2337,"conditions":10418,"interventions":10419},[],[10397],[10378,10399,10400,10401],{"intervention":10400,"totalTrials":135,"cells":10421},{"EARLY_PHASE1":10422,"PHASE1":10424,"PHASE2":10426,"PHASE3":10428,"PHASE4":10430,"NA":10432},{"trials":10423,"activeCount":102},[],{"trials":10425,"activeCount":102},[],{"trials":10427,"activeCount":102},[],{"trials":10429,"activeCount":102},[],{"trials":10431,"activeCount":102},[],{"trials":10433,"activeCount":102},[10434],{"nctId":10393,"briefTitle":10394,"status":226,"phases":10435,"completion":8792,"start":4112,"enrollment":2337,"conditions":10436,"interventions":10437},[],[10397],[10378,10399,10400,10401],{"intervention":10401,"totalTrials":135,"cells":10439},{"EARLY_PHASE1":10440,"PHASE1":10442,"PHASE2":10444,"PHASE3":10446,"PHASE4":10448,"NA":10450},{"trials":10441,"activeCount":102},[],{"trials":10443,"activeCount":102},[],{"trials":10445,"activeCount":102},[],{"trials":10447,"activeCount":102},[],{"trials":10449,"activeCount":102},[],{"trials":10451,"activeCount":102},[10452],{"nctId":10393,"briefTitle":10394,"status":226,"phases":10453,"completion":8792,"start":4112,"enrollment":2337,"conditions":10454,"interventions":10455},[],[10397],[10378,10399,10400,10401],{"intervention":10457,"totalTrials":135,"cells":10458},"ART initiation at time of HIV diagnosis",{"EARLY_PHASE1":10459,"PHASE1":10461,"PHASE2":10463,"PHASE3":10465,"PHASE4":10467,"NA":10469},{"trials":10460,"activeCount":102},[],{"trials":10462,"activeCount":102},[],{"trials":10464,"activeCount":102},[],{"trials":10466,"activeCount":102},[],{"trials":10468,"activeCount":102},[],{"trials":10470,"activeCount":102},[10471],{"nctId":10472,"briefTitle":10473,"status":226,"phases":10474,"primaryCompletion":6205,"completion":6205,"start":10475,"enrollment":10476,"conditions":10477,"interventions":10478},"NCT02744040","Modulating the Impact of Critical Events in Early HIV Infection: Effect of ART Initiation and Alcohol Use",[94],"2017-08-28",151,[133],[10457,10479],"ART at 24 weeks",{"intervention":10479,"totalTrials":135,"cells":10481},{"EARLY_PHASE1":10482,"PHASE1":10484,"PHASE2":10486,"PHASE3":10488,"PHASE4":10490,"NA":10492},{"trials":10483,"activeCount":102},[],{"trials":10485,"activeCount":102},[],{"trials":10487,"activeCount":102},[],{"trials":10489,"activeCount":102},[],{"trials":10491,"activeCount":102},[],{"trials":10493,"activeCount":102},[10494],{"nctId":10472,"briefTitle":10473,"status":226,"phases":10495,"primaryCompletion":6205,"completion":6205,"start":10475,"enrollment":10476,"conditions":10496,"interventions":10497},[94],[133],[10457,10479],{"intervention":10499,"totalTrials":135,"cells":10500},"chemoprotection",{"EARLY_PHASE1":10501,"PHASE1":10503,"PHASE2":10505,"PHASE3":10507,"PHASE4":10509,"NA":10511},{"trials":10502,"activeCount":102},[],{"trials":10504,"activeCount":102},[],{"trials":10506,"activeCount":102},[],{"trials":10508,"activeCount":102},[],{"trials":10510,"activeCount":102},[],{"trials":10512,"activeCount":102},[10513],{"nctId":10514,"briefTitle":10515,"status":226,"phases":10516,"primaryCompletion":1827,"completion":1827,"start":805,"enrollment":1230,"conditions":10517,"interventions":10519},"NCT00118339","Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma",[94],[698,10518],"Plasma Cell Neoplasm",[10499],{"intervention":10521,"totalTrials":135,"cells":10522},"Aspirin",{"EARLY_PHASE1":10523,"PHASE1":10525,"PHASE2":10527,"PHASE3":10529,"PHASE4":10531,"NA":10533},{"trials":10524,"activeCount":102},[],{"trials":10526,"activeCount":102},[],{"trials":10528,"activeCount":102},[],{"trials":10530,"activeCount":102},[],{"trials":10532,"activeCount":102},[],{"trials":10534,"activeCount":102},[10535],{"nctId":10536,"briefTitle":10537,"status":226,"phases":10538,"primaryCompletion":4993,"completion":2492,"start":1298,"enrollment":10539,"conditions":10540,"interventions":10542},"NCT00470561","Effect of Aspirin on Mammogram Density in Healthy Postmenopausal Women With a Moderate or High Level of Breast Density",[94],144,[10541],"Mammographic Breast Density",[10521],{"intervention":10544,"totalTrials":135,"cells":10545},"Escitalopram",{"EARLY_PHASE1":10546,"PHASE1":10548,"PHASE2":10550,"PHASE3":10552,"PHASE4":10554,"NA":10556},{"trials":10547,"activeCount":102},[],{"trials":10549,"activeCount":102},[],{"trials":10551,"activeCount":102},[],{"trials":10553,"activeCount":102},[],{"trials":10555,"activeCount":102},[],{"trials":10557,"activeCount":102},[10558],{"nctId":10559,"briefTitle":10560,"status":226,"phases":10561,"primaryCompletion":4550,"completion":4550,"start":1740,"enrollment":6630,"conditions":10562,"interventions":10564},"NCT00894543","MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women",[94],[10355,6733,10563],"Vasomotor Symptoms",[10544],{"intervention":10566,"totalTrials":135,"cells":10567},"Liposomal Cytarabine-Daunorubicin CPX-351",{"EARLY_PHASE1":10568,"PHASE1":10570,"PHASE2":10572,"PHASE3":10574,"PHASE4":10576,"NA":10578},{"trials":10569,"activeCount":102},[],{"trials":10571,"activeCount":102},[],{"trials":10573,"activeCount":102},[],{"trials":10575,"activeCount":102},[],{"trials":10577,"activeCount":102},[],{"trials":10579,"activeCount":102},[10580],{"nctId":10581,"briefTitle":10582,"status":226,"phases":10583,"primaryCompletion":10584,"completion":10584,"start":10585,"enrollment":628,"conditions":10586,"interventions":10587},"NCT01804101","Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia",[94],"2017-01-10","2013-05-07",[403,387,389,1638],[10566]]